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Abstract
The synthesis of inositol phosphates and novel analogues is described. Their effects at 
inositol 1,4,5-trisphosphate receptors and metabolising enzymes of the phosphoinositide 
pathway is reported. The enantiomers of myoinositol 1,3,4-trisphosphate were prepared by 
a novel route from myo-inositol involving the optical resolution of DL-2,4,5-tri-0-benzyl-l-
0-/?-methoxybenzyl-myoinositol. lD-Ins(l,3,4)P3 was shown to be essentially inactive at 
Ins(l,4,5)P3 receptors, whereas lL-Ins(l,3,4)P3 was able to mobilise intracellular Ca2+, in 
accordance with arguments based on structure-activity principles. The first five-membered 
ring mimic of Ins(l,4,5)P3 [(1R, 2R, 35, 4R, 55)-3-hydroxy-l,2,4-trisphospho-5- 
vinylcyclopentane] was synthesised by a strategy involving zirconium-mediated 
diastereoselective ring contraction of a protected vinyl carbohydrate. A conformationally 
restrained cyclic phosphate analogue of Ins(l,4,5)P3 [DL-6-deoxy-6-hydroxymethyl-s,cy//o 
inositol l:7-cyclic,2,4-trisphosphate] was synthesised from myoinositol orthoformate via a 
versatile intermediate [2,4,6/3,5-pentahydroxy-3,5-di-0-p-methoxybenzyl-2,4,6-<9- 
methylidene-cyclohexanone], and appeared to behave as a weak full agonist at Ins(l,4,5)P3
Q 1
receptors. Potentiometric and P NMR studies showed the analogue to have markedly 
different acid-base properties to Ins(l,4,5)P3. A scy//oinositol-based analogue of 
Ins(l,4,5)P3 [DL-6-deoxy-6-hydroxymethyl-.scy//oinositol-l,2,4-trisphosphate] bearing an 
hydroxymethyl group at a position analogous to that of this structure in adenophostin A. 
was synthesised and found to be equipotent to Ins(l,4,5)P3 itself. The first disaccharide 
based Ca2+-mobilising Ins(l,4,5)P3 mimic, the C2-symmetrical a,a-trehalose 3,4,3',4'- 
tetrakisphosphate, was synthesised from a,a-trehalose by a route involving the 
simultaneous regioselective reduction of two benzylidene acetals. lL-myoinositol 1,3,4- 
trisphosphorothioate was synthesised and shown to be a very low intrinsic activity partial 
agonist at the Ins(l,4,5)P3 receptors of platelets, and was able to inhibit Ins(l,4,5)P3 - 
induced Ca2+ release in a dose-dependent manner. A novel symmetrical analogue of inositol
1,3,4,5-tetrakisphosphate [scy//oinositol 1,2,3,5-tetrakisphosphate], intended for structure- 
activity investigations into the properties of Ins(l,3,4,5)P4 binding proteins, was 
synthesised. A new rapid route to lD-Ins(l,3,4,5)P4 and its unnatural enantiomer 1l- 
Ins(l,3,4,5)P4, via diastereoisomeric bis-(-)-fi>camphanate esters of myo-inositol 
orthoformate was developed, and the absolute configurations of the products proved by an 
X-ray crystallographic study of the intermediate Id-2,6-di-0-[(-)-fit>camphanoyl]-1,3,5-0- 
methy li dene-my oinositol.
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1 Introduction
1.1 First and Second Messengers
This thesis is primarily concerned with lD-myoinositol 1,4,5-trisphosphate 





Figure 1.1 lD-raye>-inositol 1,4,5-trisphosphate.
The cells in a multicellular organism must be able to communicate with one 
another in order to regulate their function, their growth and division, and their 
organisation into tissues. This intercellular communication is conducted by a range of 
extracellular signalling molecules or first messengers, which include hormones, 
neurotransmitters, and local mediators. Small hydrophobic signalling molecules, such as 
steroids and thyroid hormones, are able to pass through the cell membrane and activate 
receptor proteins within the cell, but the vast majority of signalling molecules are 
hydrophilic, and are denied entry to the cell by the lipid bilayer of the plasma 
membrane. Instead, they bind to receptors on the cell surface, and this interaction with 
the receptor somehow causes the production or release within the cell of a second 







Figure 1.2 First and second messengers.
1.2 Calcium Signalling
The most common second messenger in cells, ranging from the simplest bacteria to the 
specialised neurones of the vertebrate nervous system , 1 is ionised calcium; Ca2+. The 
reason for this choice of ion may be related to the changing compositions of the oceans
1
during the early stages of the evolution of life on Earth. When life first evolved, it is 
likely that the oceans were more alkaline than they are today and the concentration of
Oxdissolved Ca was therefore low. As organisms proliferated, the accumulation of 
carbon dioxide and other acidic metabolites caused the pH to fall, and the solubility of 
Ca2+ increased.2 Cells would have been unable to tolerate high levels of intracellular 
Ca2+ since it precipitates phosphate, which was already established as an energy 
currency. They were therefore forced to develop mechanisms to control intracellular 
Ca2+ concentrations, either by pumping Ca2+ out of the cell or sequestering it in some 
way. Having created transmembrane Ca2+ gradients out of the need to avoid the toxic 
effects of Ca2+, cells later evolved ways of exploiting these gradients. Mechanisms
Oxdeveloped that could allow small amounts of Ca to flow back into the cytosol, either 
from outside or from intracellular sequestering compartments, under the control of 
variables such as changes in membrane potential or extracellular stimuli. Proteins that
O xoriginally functioned as Ca buffers took on more specialised signal-transducing roles, 
involving conformational changes triggered by the binding of Ca2+, and Ca2+-binding 
motifs became incorporated into many different proteins.
O xIt is now known that the complex mechanisms that have evolved for Ca release 
from intracellular stores and for Ca2+ entry across the plasma membrane lead to an 
inherently oscillatory system.4 The Ca2+ signals that are generated in response to 
external stimuli are not uniform, but pulsatile in nature, and take the form of repetitive 
spikes or waves which encode information by frequency modulation. Complex wave 
patterns with spherical, spiral and planar waves have been observed, and detailed 
mathematical models have been proposed to account for these.5
1.3 Calcium Channels
The flow of Ca2+, either from the extracellular space or from internal stores is controlled
O xby various types of Ca channel (Figure 1.3). Entry from the outside is controlled by 
voltage-operated channels or receptor-operated channels (e.g. NMDA receptors). There 
are also calcium-release activated channels (CRAC) which are somehow triggered by 
emptying of the intracellular stores (Section 1.6) and there may be calcium influx 
channels gated by Ins(l,4 ,5)P3 or other second messengers such as D-rayo-inositol
O x  _1,3,4,5-tetrakisphosphate [Ins(l,3,4 ,5)P4], or by Ca itself. Two main families of 
intracellular Ca2+ channels are known; ryanodine receptors and Ins(l,4 ,5)P3 receptors, 
and they share many similarities. A third type of intracellular Ca2+ channel, gated by
2
sphingolipids has recently been characterised.6 The natural ligand may be sphingosine-










Figure 1.3 Calcium channels. DHPR = dihydropyridine receptor, VOC = voltage- 
operated channel, ROC = receptor-operated channel, SMOC = second messenger- 
operated channel, CRAC = calcium release-activated channel, RYR1 = type 1 
ryanodine receptor, RYR2 = type 2 ryanodine receptor, IP3R = D-myo-inositol 1,4,5- 
trisphosphate receptor, IP3 = D-myo-inositol 1,4,5-trisphosphate, IP4 = D-myo-inositol
1,3,4,5-tetrakisphosphate, CICR = calcium-induced calcium release.
Ryanodine receptors were first identified through their high-affinity binding for 
the plant alkaloid ryanodine. Several subtypes have been found. The type 1 isoform 
(RYR1), predominantly found in skeletal muscle, is activated by depolarisation of 
transverse tubules (T-tubules), and this is an important step in excitation-contraction 
coupling of skeletal muscle. The bulbous head of RYR1 seems to interact through 
conformational coupling with the dihydropyridine receptor, which is the voltage sensor 
of the T-tubule membrane. RYR2, found in cardiac muscle, can also be opened by 
depolarisation of the cell membrane, but in this case the interaction is less direct, in that 
it is stimulated by a pulse of Ca2+. Note that in this case, Ca2+ triggers its own release; 
an example of positive feedback. This process of calcium-induced calcium release 
(CICR) is of central importance in Ca2+ signalling, and it is a property of both ryanodine 
and Ins(l,4,5)P3 receptors. A single mutation in RYR1 (Arg 615 —» Cys) seems to be 
responsible for malignant hyperthermia, in which over-sensitivity of the receptor to Ca2+
3
leads to uncontrolled CICR, with spasm of the muscles and potentially fatal 
overheating.8
Some cells express only ryanodine or only Ins(l,4 ,5)P3 receptors, while others
express both. Within an individual cell, individual Ca2+ stores may express only one of
the receptors, both, or neither. As the phenomenon of CICR is increasingly seen as
fundamental to the whole process of Ca signalling, it may be more instructive to
regard Ins(l,4 ,5)P3 receptors and ryanodine receptors as two related families of CICR
channels, the first of which is known to be modulated by Ins(l,4 ,5)P3. Cyclic adenosine
diphosphate ribose (cADPR, Figure 1.4),9,10 a naturally occurring metabolite of
nicotinamide adenine dinucleotide (NAD+), triggers Ca2+ release through ryanodine
receptors by sensitising them to CICR, and this molecule and/or its 2'-phosphaten may
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Figure 1.4 Cyclic ADP-ribose (X = OH) and its 2'-phosphate (X = OPO32 )
Finally, there is a recent report of intracellular Ca2+ release in Xenopus oocytes
in response to microinjection of cytidine-5'-diphosphate-D-glucose (CDPG, Figure 
111.5) The site of action is currently unknown, but appears to be quite specific in its 
structural requirements. The closely-related uridine-glucose conjugate UDPG, for 
example, was less active and other nucleotide-glucose conjugates were inactive. The 









Figure 1.5 Cytidine 5'-diphosphate-D-glucose.
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It is interesting to note a kind of family resemblance between cADPR (or its 2'- 
phosphate), CDGP and the adenophostins (Section 1.7). Whether this is a reflection of 
corresponding evolutionary relationships between their respective target proteins 
remains to be seen.
The rest of this thesis will be concerned with Ins(l,4 ,5 )P3 and other inositol 
phosphates. Ins(l,4,5)P3 receptors will be discussed in Section 1.5. but first we will 
describe the origin of Ins(l,4,5)P3, and how its production may be controlled by 
extracellular messengers.
1.4 Origin of Ins(l,4,5)P3
Ins(l,4,5)P3 is produced when the minor membrane phospholipid phosphatidylinositol
4,5-bisphosphate [PtdIns(4,5)P2] is cleaved by a phosphodiesterase of the phospholipase 
C (PLC) type (Figure 1.6). Recent evidence suggests an additional source for 
Ins(l,4,5)P3 (see Section 1.9.2) but the significance of this is unknown at present.
Fatty acid chains in 
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Figure 1.6 Hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase C 
produces inositol 1,4,5-trisphosphate and diacylglycerol.
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PLCs are classified into three types (PLC-/3, PLC-y and PLC-<5) and each type 
contains more than one subtype. Two main types of cell-surface receptor are able to 
initiate the production of Ins(l,4 ,5 )P3 by activating particular PLC isoforms. These are 
the G protein-coupled receptors and the tyrosine kinase-coupled receptors (Figure 1.7).
Figure 1.7 Tyrosine kinase-linked and G protein-linked receptors. EGF = epidermal 
growth factor, PDGF = platelet-derived growth factor, PLC = phospholipase C.
cell-surface G-protein coupled receptors. Many of this large family of receptors, which 
all have seven transmembrane domains, are able to activate PLC-/3j via G q/ n  subunits of 
their associated heterotrimeric G-proteins. The tyrosine kinase-linked receptors are 
simpler, having a single transmembrane domain, and relay information through a direct 
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Many extracellular signals cause release of intracellular Ca2+ by interacting with
6
dimerise and phosphorylate one another on tyrosine, creating docking sites for PLC-yi. 
PLC-yi then binds to the receptor and is pulled onto the membrane, where it meets its 
substrate, PtdIns(4 ,5)P2. The hydrophilic head-group of PtdIns(4 ,5)P2 released by both 
these mechanisms is Ins(l,4 ,5)P3, which then diffuses into the cytoplasm and causes the 
release of Ca2+ from intracellular stores by interacting with Ins(l,4 ,5)P3 receptors. In 
general, the tyrosine-kinase-activated PLC-'js increase Ca2+ more slowly and for longer 
durations than do the G protein-mediated PLC-/3s. It is important to stress that tyrosine 
kinase-linked receptors also activate other effectors such as phosphatidylinositol-3- 
kinase (Section 1.9.5), and GTPase-activator protein (GAP, Section 1.10.4). These other 
signalling pathways have been omitted from Figure 1.7 for the sake of clarity.
Via PLC-P Via PLC-y
Adrenoceptors ocia. 0Cib ,(Xid Epidermal growth factor receptor
Angiotensin ATi Fibroblast growth factor receptor
Bombesin BBj, BB2 Platelet-derived growth factor receptor
i Bradykinin Bi, B2 T cell antigen receptor
! Cholecystokinin CCKa, CCKb








Metabotropic glutamate mGlui, mGlus
Muscarinic Mi ,M3, M5,
Oxytocin
Platelet-activating factor
Prostanoid EPi, EP3, FP, TP
Purinoceptors P2Y, P2U




Vasopressin V ia , V ib
Table 1.1 Plasma membrane receptors activating phospholipase C.
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Finally, IgM receptors in B-lymphocytes and the T-cell antigen receptor CD3 
can also stimulate the production of Ins(l,4 ,5 )P3 . They lack tyrosine kinase activity of 
their own but recruit members of the src proto-oncogene family such as the protein 
tyrosine kinases fyn  and lek . Table 1.1 lists some of the plasma membrane receptors that 
are coupled to hydrolysis of PtdIns(4 ,5 )P2, either through activation of PLC-/3 or PLC-7 . 
The other product of hydrolysis of PtdIns(4 ,5 )P2 by PLCs is the lipophilic 1,2-di-O-acyl 
glycerol (DAG). DAG remains in the membrane, and can activate a family of protein 
kinase C isoenzymes, which catalyse protein phosphorylation. This part of the pathway 
is not shown in Figure 1.7. Many of the actions of DAG are mimicked by the phorbol 
esters, products of the Euphorbaciae family of higher plants.
1.5 Inositol 1,4,5-trisphosphate Receptors
The Ins(l,4 ,5 )P3 receptor is a tetramer, composed of four subunits surrounding a 
cationic pore which behaves as an ion channel. Each subunit binds one molecule of 
Ins(l,4 ,5 )P3 at a positively-charged domain close to the N-terminal. The transmembrane 
topology is thought to be as shown in Figure 1.8. Each subunit has six transmembrane 














Figure 1.8 Cross-section of a generalised inositol 1,4,5-trisphosphate receptor, showing 
proposed site of action of antagonists.
The two domains are coupled by a large regulatory domain which contains sites for 
phosphorylation by many different protein kinases, and also two putative ATP binding 
sites. Note that Figure 1.8 represents a cross-section through a generalised Ins(l,4,5)P3 
receptor and therefore shows only two of the four subunits. There are at least three types 
of Ins(l,4 ,5)P3 receptor subunits, derived from distinct genes and designated type 1 
(IP3R-I), type 2 (IP3R-2) and type 3 (IP3R-3), all of which share significant similarity to 
each other, partial homology with the ryanodine receptor and no significant homology 
with voltage-gated calcium channels. It is likely that this list will expand in the future. 
The distribution of isoforms differs considerably between tissues.14 IP3R -I, for example, 
is particularly enriched in cerebellum. Mutant mice lacking IP3R-I usually die in utero, 
and bom animals have severe ataxia and epileptic seizures.15 IP3R-3 is expressed most 
abundantly in gastrointestinal tract and kidney16 and is also the predominant isoform 
expressed in adult pancreatic islets. It may be responsible for mediating the effects of 
Ins(l,4 ,5)P3 on insulin secretion.17 For a recent review on the Ins(l,4 ,5)P3 receptor 
family see Joseph (1996)18
It was originally thought that Ins(l,4 ,5)P3 receptors were located only in the 
membranes of the endoplasmic reticulum, but more recently they have been found in the 
plasma membranes of various cells (e.g. lymphocytes19,20). This could indicate that, at 
least in some cell-types, Ins(l,4 ,5)P3 receptors may have a role in Ca entry from the 
extracellular space. Until very recently Ins(l,4 ,5)P3 receptors were assumed to be 
homotetramers, composed of identical subunits, but evidence is now emerging that 
distinct types of subunits may assemble to form heterotetramers.21,22 
Heteroligomerisation of isoforms might provide a mechanism for generating greater 
diversity of Ins(l,4 ,5)P3 receptors. The mixing of just two types of subunits, for 
example, would produce five kinds of Ins(l,4 ,5)P3 receptor, i.e. two homotetramers and 
three kinds of heterotetramer. A mathematical model based on the random association 
of subunits with high and low affinities for Ins(l,4 ,5)P3 in this way has been used to 
describe the kinetics of Ca2+ release from rat basophilic leukaemia cells and has been
2+ 23proposed as an explanation for the phenomenon of quantal Ca release (see below).
1.6 Capacitative Calcium Entry
The binding of Ins(l,4 ,5)P3 to its receptor results in the release of Ca2+ stored in the 
endoplasmic reticulum (ER). Submaximal concentrations of Ins(l,4 ,5)P3 release only a 
fraction of the Ins(l,4 ,5)P3-sensitive Ca store, and further increases in Ins(l,4 ,5)P3
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concentration can mobilise more Ca2+. This phenomenon, which may also be a property 
of ryanodine receptors, is described as “quantal” Ca2+ release. The Ca2+ liberated by 
Ins(l,4 ,5)P3 can activate a range of calcium-dependent processes by inducing 
conformational changes in various Ca2+-binding proteins. Ca2+ is then pumped both out 
of the cell and back into the ER by Ca2+ ATPases. Thus there is a net loss of Ca2+ from 
the cell, and a small amount of extracellular Ca2+ must enter through the plasma 
membrane to make good this loss. This influx of Ca2+ from the environment is known as 
capacitative calcium entry, and it occurs regardless of whether the stores are emptied by 
Ins(l,4 ,5)P3 or by blockade of the endoplasmic reticulum Ca2+ pump. Besides 
replenishing the intracellular Ca2+ stores this mechanism maximises Ca2+ concentrations
2 i
near the plasma membrane, where specialised Ca -dependent proteins are found. There 
is a growing awareness that capacitative calcium entry plays a central role in the 
functioning of non-excitable cells, which lack voltage-gated Ca2+ channels. A currently 
unsolved mystery is why Ca2+ entry through the plasma membrane inevitably follows 
Ca2+ release from the endoplasmic reticulum. This question is now a subject of great 
controversy in the field of cellular signalling.24
A specific depletion-activated Ca2+ current has now been identified and is 
termed Icrac (calcium-release-activated calcium current). Icrac has been shown to be 
highly selective for Ca , not voltage-dependent, and is linked to depletion of 
intracellular Ca2+ stores, but neither Ins(l,4,5)P3 nor D-Ins(l,3,4 ,5)P4 are necessary for 
its activation.25 The CRAC channel itself has not yet been identified, although there has 
been considerable excitement generated by reports that CRAC may be activated by a 
novel diffusible factor, released from the Ca2+ stores and acting as a kind of reverse
Ofi 77messenger (Figure 1.9). ’ This putative messenger, now named calcium influx factor 
(CIF), was postulated to be a small anionic phosphorylated molecule and seemed to be 
present in extracts from cells in which the Ca2+ stores had been depleted. A more recent 
study, in which extracts from stimulated Jurkat T-lymphocytes caused Ca2+ influx in 
Xenopus oocytes suggests that the CIF activity may consist of at least two active 
components, one which can act from the outside and the other which works only when 
injected.28 However, little progress has been made in identifying CIF, and alternative 
models of capacitative Ca2+ entry, based on protein-protein interactions, have been 
gaining ground recently.24 It has been suggested, for example, that information is 
transmitted directly from Ins(l,4 ,5)P3 receptors to CRAC channels by a conformational 
coupling mechanism (analogous to that which is thought to exist between RYR1 and the
10
dihydropyridine receptor, and perhaps involving specific Ins(l,4,5)P3. receptor subtypes.
It has been found that over-expression of type-3 Ins(l,4,5)P3 receptors in Xenopus
oocytes has no effect on Ins( 1,4 ,5 )P3-induced Ca2+ release, but markedly enhances the
magnitude and duration of calcium influx.29 These two dominant theories of
capacitative calcium entry, conformational coupling and CIF are summarised
schematically in Figure 1.9. Either mechanism would be of interest to the medicinal
chemist, as they both offer the possibility of pharmacological intervention in
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Figure 1.9 Two theories of capacitative Ca2+ entry: conformational coupling and a 
diffusible calcium influx factor (CIF).
A recent study claims that LU52396 (Figure 1.10) is the first pharmacological 
tool that selectively inhibits capacitative Ca2+ influx (Kj around 2/xM in HeLa cells), 
although its selectivity is low, and it also inhibits Ca2+ fluxes through Ins(l,4 ,5 )P3 
receptors, ryanodine receptors and Ca2+-ATPases at higher concentrations.30 LU52396 
has three chiral centres, and the results were obtained with the mixture of eight 
stereoisomers, so there is the possibility that greater selectivity might be achieved when 
the individual isomers are synthesised and tested separately.
F
OH
Figure 1.10 LU52396; recently claimed to be an inhibitor of capacitative Ca2+ entry.
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1.7 Structure-Activity Relationships at Ins(l,4,5)P3 Receptors
Axial 2-hydroxyl
The least important part of 
lns(1 ,4,5)P3. Of only minimal 
importance for binding.
> Can be deleted, changed 
to equatorial or replaced with 
fluorine with only slight effect 
on activity.
> C-2 can be replaced with 
pyranoside oxygen.
> Bulky substituents or 
phosphate group are tolerated.
> Equatorial 2-OH together with 
phosphorothioates at 1,4,5 
and axial 3 or 6-OH gives low 
intrinsic activity partial agonists.
Equatorial 1-phosphate Equatorial 6-hydroxyl
Less important than the 4- 
and 5-phosphates. Enhances 
binding, but not essential. May 
have a long-range interaction 
with the receptor binding site.
> Deletion greatly reduces 
activity, but replacement with 
axial phosphate or a phosphate 
more distant from the ring
is tolerated.
> Large groups can be tolerated 
without major loss of activity.
> Replacement with 
phosphorothioate reduces 
activity only slightly.
Very important for binding. May 
have H-bond interactions with 
binding site and/or affect 
conformation / ionisation state 
of 5-phosphate, probably via 
hydroxyl hydrogen rather than 
lone pair electrons.
> Deletion or changing to axial 
greatly reduces activity, but
in combination with phosphoro­
thioate at 1,4,5 gives partial 
agonists.
> Bulky substituents, 
equatorial phosphate or 
replacement with fluorine 
gives greatly reduced 
activity.
Equatorial 3-hydroxyl
Enhances binding, but less 
important than 6-hydroxyl. May 
have H-bond interactions with 
binding site probably via 
oxygen lone pair electrons.
> Deletion or changing to axial 
reduces activity, but less so than 
for the 6-hydroxyl.
> Replacement with fluorine 
reduces activity only slightly.
> Axial hydroxyl together with 
phosphorothioates at 1,4,5 gives 
a partial agonist.
> Increasing molecular volume of 
equatorial substituents is thought 
to correlate inversely with potency, 
but se e  Chapter 5.
> Equatorial or axial phosphate 
gives greatly reduced potency.
4,5-bisphosphate
The most important part of lns(1,4,5)P3 and essential for activity. 
Can be replaced with a bisphosphorothioate. Linking the 4- and 5- 
phosphates to give a cyclic pyrophosphate abolishes activity.
Equatorial 4-phosphate
Information is lacking on 
analogues selectively modified 
at this position.
> Deletion abolishes activity, 
changing to axial greatly 
reduces activity.
> Replacement with 
phosphorothioate has less 
effect on potency than 
replacing the 5-phosphate.
Equatorial 5-phosphate
Ionisation state correlates with 
the affinity of lns(1,4,5)P3 for its 
receptor.
> Deletion abolishes activity, 
effect of axial not known.
> Can be replaced with 
methylenephosphonate or 
phosphorothioate, to give 
metabolically resistant analogues 
causing prolonged Ca2+ release.
Figure 1.11 Structure-activity relationships for Ins(l,4 ,5)P3 receptors.
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Since 1986 there has been considerable interest in the synthesis of inositol 
polyphosphates and in establishing structure-activity relationships for the Ins(l,4 ,5)P3 
receptor. As a result, we now have a reasonable idea of which molecular features are 
associated with agonist activity, and which modifications will increase or decrease 
potency. Structure-activity relationships for the various enzymes involved in the 
interconversion of inositol phosphates have also been studied, but are currently less 
well-defined. The contemporary state of knowledge of these relationships has been 
comprehensively documented in a recent review31 and there is no reason to reiterate it 
here. Instead, the important aspects of structure-activity relationships for the Ins(l,4 ,5)P3 
receptor are summarised in Figure 1.11, to which we will often return. The 
corresponding relationships for enzymes and other binding proteins will be discussed as 
they arise in the text.
The 4,5-bisphosphate appears to be the essential pharmacophore for activity at 
Ins(l,4 ,5)P3 receptors. These two phosphate groups are vicinal and diequatorial, and the 
torsion angle 0 4 -C 4 -C 5 -0 5  is negative (Figure 1.12). It may be possible for vicinal 
phosphate groups positioned elsewhere in the myo-inositol ring (or in other rings, or 
even in some conformations of acyclic molecules) to mimic the 4,5-bisphosphate to 




Figure 1.12 Definition of the term “4,5-bisphosphate”.
In 1994 the discovery was announced of adenophostins A and B (Figure 1.13) 
from the culture broth of a fungus, Penicillium brevicompactum. The adenophostins 
were reported to be astonishingly potent agonists at Ins(l,4 ,5)P3 receptors, 100-fold 
more potent than Ins(l,4,5)P3 itself. No compound had previously found to be more 
potent than Ins(l,4 ,5)P3 and most modifications of the Ins(l,4 ,5)P3 molecule had 
resulted in reduced potency. The publication of the structures of the adenophostins 
immediately confirmed most of the conclusions that had already been reached about the 
necessary features for Ins(l,4 ,5)P3 receptor ligands, and which are detailed in Figure
1.11 (e.g. a 4,5-bisphosphate together with a third phosphate close to position 1, a 6- 
hydroxyl group, etc.) and yet the adenophostins also have some additional features.
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At the time of writing, the significance of these additional components in the 
adenophostins, and the origin of their extreme potency is not understood. However, an 
explanation cannot be far away. The importance of the adenophostins is such that they 
are discussed separately, in Chapter 5.
Figure 1.13 Adenophostins A and B
The structure-activity principles outlined in Figure 1.11 are all derived from 
studies of analogues in which the 4,5-bisphosphate is on a six-membered ring. In 
Chapter 3 an excursion into new and uncharted territory is described: analogues based 
on a/zve-membered ring.
1.8 Antagonists at Ins(l,4,5)P3 Receptors
The polysulphated polysaccharide heparin has been shown to be a potent competitive
'JO
and reversible antagonist at Ins(l,4 ,5)P3 receptors, and it might seem likely that the 
anionic sulphate groups of heparin can somehow mimic the phosphate groups of 
Ins(l,4,5)P3 at the receptor binding site. However, myoinositol 1,4,5-trissulphate34 has 
been shown to be inactive at Ins(l,4 ,5)P3 receptors,35 as has the hexadeoxy-1,4,5- 
tris(methylenesulphonic acid) analogue of Ins(l,4,5)P3.36 The design of antagonists 
based on heparin is made difficult by the large and flexible nature of the heparin 
molecule, and the use of heparin in studies of intact cells is complicated by the fact that 
heparin is also a potent inhibitor of Ins(l,4,5)P3 3-kinase. Heparin has also been 
reported to interact with the ryanodine receptor, causing Ca2+ release.38 At millimolar 
concentrations, caffeine acts as an inhibitor of Ins(l,4,5)P3-induced calcium release, 
probably by acting at an ATP binding site present on the cytoplasmic coupling domain 
of the receptor, rather than at the ligand binding site, but like heparin, caffeine also 
interacts with ryanodine receptors.
RQ Adenophostin A R = H 
Adenophostin B R =COCH3
NH2
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It has recently been shown that physiological concentrations of polyamines can 
inhibit Ins(l,4 ,5)P3-induced Ca2+ release and their potency is directly related to the 
number of positive charges on the molecule.40 Furthermore, various 
tetraalkylammonium cations, particularly tetrahexylammonium ions (THA+) have a 
similar effect, (higher concentrations of THA+ (10-100jUM) can mobilise Ca2+)41 and 
may share a similar mechanism of action with polyamines, perhaps involving an 
interaction with negatively charged amino acids in the channel region of the receptor. It 
is not clear whether triethylammonium or cyclohexylammonium ions can have a 
significant effect on Ca2+ release, but as most of the compounds described in this thesis 
were isolated and used as the triethylammonium salts, the possibility must be bome in 
mind until experiments prove otherwise. It has also been reported that some reagents 
used as Ca2+ chelators may competitively antagonise binding of Ins(l,4 ,5)P3 to the 
receptor 42 This finding may be of importance, if only because these reagents (EDTA, 
EGTA, BAPTA, fura-2) are commonly used either to monitor or manipulate Ca2+ levels 
in biological studies of Ca2+ release, and may therefore give rise to experimental 
artefacts. Finally, the racemic 5-methylphosphonate analogue of Ins(l,4 ,5)P3 was 
reported to antagonise Ins(l,4 ,5)P3 -stimulated Ca2+ release in a pH-dependent manner 
in human platelets.43 This finding would be of major significance if it could be 
confirmed, but further biological data are not available.
1.8.1 Partial Agonists at Ins(l,4,5)P3 Receptors
It might be expected that Ins(l,4 ,5)P3 analogues would show greater selectivity for the 
Ins(l,4 ,5)P3 receptor than agents such as heparin, decavanadate or caffeine, and may 
therefore be better candidates as specific Ins(l,4,5)P3 antagonists. Unfortunately it 
appears that, in general, the inositol phosphate analogues that bind to Ins(l,4 ,5)P3 
receptors also cause Ca2+ release, and must therefore be classified as agonists.* 
However, it sometimes happens that, while an analogue can fully displace 
[3H ]Ins(l,4 ,5)P3 from its receptor, it induces only partial Ca2+ release compared to that 
releasable by Ins(l,4 ,5)P3 alone (Figure 1.14). These compounds may be classified as 
partial agonists (or alternatively, partial antagonists).
Evidence has recently been presented54 that the naturally-occurring Ins(l,3,4,5,6)P5 acts as a weak 
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Figure 1.14 Theoretical dose-response relationships for full and partial agonists.
At least under some conditions, the symmetrical inositol tetrakisphosphate 
Ins(l,3 ,4 ,6 )P4 (Figure 1.15) has been found to behave in this way, releasing around 80% 
of the Ca2+ mobilised by Ins(l,4 ,5 )P3 when tested in SH-SY5Y neuroblastoma cells.44 
Again working with SH-SY5Y cells, it has been shown that when the maximally 
effective Ca2+-releasing concentration of Ins(l,3,4,6)P4 is administered together with 
Ins(l,4 ,5 )P3, the EC50 of the latter is increased.44 This indicates that Ins(l,3,4,6)P4 and 
Ins(l,4 ,5 )P3 are competing for the same site, and is strong evidence that, in this assay, 
Ins(l,3,4,6)P4 is behaving as a true partial agonist. These observations were the stimulus 
for the synthesis of D-Ins(l,3,4)P3 and D-Ins(l,3,6)P3 [ = L-Ins(l,3,4)P3 ] described in 
Chapter 2, and also D-Ins( 1,4,6)P3 and D-Ins(3,4,6)P3 (carried out by a colleague), in a 
collaborative attempt to identify which features of Ins(l,3,4,6)P4 were responsible for its 
partial agonist properties. Ins(l,3,4,6)P4 has since been tested in permeabilised platelets, 
which is the assay system used to evaluate most of the analogues described in this 
thesis, and appears to behave as a full agonist under these conditions,45 further 
complicating the issue.* Unusual pH-dependent behaviour has been reported for d-3- 
amino-3 -deoxy-myo-Ins(l,4 ,5 )P3 (Fig. 1.15) again in SH-SY5Y cells. Apparently this 
compound behaved as a full agonist at pH 7.2 and 7.6, but as a high intrinsic activity 
partial agonist (releasing about 80% of the Ins(l,4 ,5 )P3 -sensitive Ca2+ pool) at pH 6 .8 . 46
However, the ability o f Ins( 1,3,4,6)P4 to displace [H3]In s(l,4 ,5 )P 3 from rat cerebellar membranes seem s 
to indicate a binding affinity higher than would be expected from its moderate potency in the rabbit 
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Two inositol phosphorothioates, L-c/»>0-inositol-2,3,5-trisphosphorothioate [l -  
c/iz>o-Ins(2,3,5)PS3] and D-6-deoxy-mye>-inositol-l,4,5-trisphosphorothioate [d -6 -  
deoxy-Ins(l,4,5)PS3] have been shown to act as low intrinsic activity partial agonists, 
releasing only 34% and 42% of Ins(l,4 ,5)P3-releasable Ca2+ respectively in SH-SY5Y 
cells.47 Significantly, L-c/nre>-Ins(2,3,5)P3 has now been tested in the rabbit platelet 
assay and shown to behave in a similar way, making it the first partial agonist at the 
platelet Ins(l,4 ,5)P3 receptor.45
Figure 1.15 Partial agonists at Ins(l,4,5)P3 receptors.
All the partial agonists discussed above can be seen as Ins(l,4 ,5)P3 analogues 
with modifications at C-3 or C-6 , sometimes together with phosphorothioate 
substitution. It was these observations that led us to consider the synthesis of two 
phosphorothioate analogues, L-myoinositol 1,3,4-trisphosphorothioate and DL-6-deoxy- 
6-hydroxymethyl-scy//0-inositol 1,2,5-trisphosphorothioate, described in Chapter 6, and 
also of DL-rayo-inositol-1,4,6-trisphosphorothioate.48’49
Very recently, a study of three D-3-deoxy-3-fluoro-myc>-Ins( 1,4,5)P3 
phosphorothioate analogues provided the significant observations that their order of 
potency was as shown in Figure 1.16 and that of the three, only the 4,5- 
bisphosphorothioate appeared to be a partial agonist (in SH-SY5Y cells).50 These results 
confirm the expectation that modification of the 5-phosphate is more perturbing for 
Ins(l,4 ,5)P3 receptor binding than a similar modification of the 4-phosphate (see 
Chapter 4), and show that in this series, phosphorothioate substitution at both C-4 and 
C-5 was necessary for partial agonism.
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Figure 1.16 Consequences of selective phosphorothioate substitution at the 4,5- 
bisphosphate for Ins(l,4 ,5)P3 receptor affinity and partial agonism. See Fauq et al. 
(1996)50
1.8.2 Antagonists and Partial Agonists: Conclusions
A major goal in the medicinal chemistry of inositol phosphates is the development of a 
specific competitive antagonist for Ins(l,4,5)P3 receptors (and then, subtype-selective 
analogues). Unfortunately it appears that, for small-molecule Ins(l,4 ,5)P3 receptor 
ligands, efficacy and affinity are difficult to disentangle, and it has not yet been possible 
to identify any structural feature that is related to one and not the other. Molecules that 
bind to the Ins(l,4 ,5)P3 receptor with reasonably high affinity and yet appear to behave 
as partial agonists are therefore important lead compounds in the search for specific 
Ins(l,4,5)P3 antagonists. However, it is becoming clear that Ins(l,4 ,5)P3 -induced Ca2+ 
release is a complex phenomenon, and it may be necessary to exercise some caution in 
using the simple criteria illustrated in Figure 1.14 to identify these leads. It is known for 
example, that Ins(l,4 ,5)P3 -sensitive Ca2+ stores can respond rapidly and transiently to a 
low concentration of agonist, and yet maintain the ability to release Ca in response to
•  ^i
higher concentrations (quantal Ca release). This complicates investigation of the 
relationship between Ins(l,4 ,5)P3 receptor occupation and Ca2+ release, and 
discrimination between agonists of different efficacy. Even a partial agonist may be 
able to deplete the Ca2+ stores given sufficient time,47 particularly if it is resistant to 
metabolism, and only partial agonists with very low intrinsic efficacy will give a dose 
response curve similar to that in Figure 1.14. Finally, there may be problems involved in 
the detection of antagonistic effects when permeabilised, rather than intact, cells are 
used.51
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1.9 Inositol Phosphate Metabolism
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Figure 1.17 Metabolism of receptor-generated Ins(l,4 ,5)P3 in mammalian cells.
Just as a cell must contain mechanisms for the generation of intracellular signals, 
it must also contain mechanisms for their termination. Cyclic nucleotides, (cAMP and 
cGMP), for example, are inactivated by the action of at least five classes of 
phosphodiesterase isoenzymes, and these enzymes are targets for therapeutic 
intervention in this signalling pathway. In a similar way, Ins(l,4 ,5)P3 is a substrate for 
various enzymes, whose function may be seen as that of terminating the Ins(l,4 ,5)P3 
signal. However, it is now becoming clear that the metabolism of Ins(l,4 ,5)P3 is 
complex, and the expanding number of metabolites, enzymes and isoenzymes reported
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in the literature have brought this possibly simplistic view into question. Nearly half of 
the 63 possible monoesterified phosphate derivatives of inositol have been found in 
eukaryotic cells, and it seems increasingly likely that some of these, particularly the 
higher inositol phosphates, will have important cellular functions of their own. Two of 
the most abundant inositol phosphates in cells are Ins(l,3,4,5,6)Ps and InsP6 for 
example, and many functions have been suggested for these highly charged 
molecules,52'54 including the theory that InsP6 may act as a binding site for iron, thus 
inhibiting iron-catalysed hydroxyl radical formation.55 A new class of pyrophosphate- 
containing inositol polyphosphates (PP-InsPn) has now been identified,56 and a total 
synthesis of the enantiomers of 1-PP-InsPs has recently been reported.57
The remainder of this section provides a highly selective account of some of the 
enzymes involved in phosphoinositide metabolism. It deals only with those that are 
potential targets for the compounds synthesised in this work. The currently established 
pathways of Ins(l,4 ,5)P3 metabolism in stimulated mammalian cells are diagrammed in 
Figure 1.17.
1.9.1 Inositol 1,4,5-trisphosphate 3-kinase
D-lns(1,4,5)P3 — 3'kln-ase- » D-lns(1,3,4,5)P4
The enzyme D-myo-inositol 1,4,5-trisphosphate 3-kinase catalyses the phosphorylation 
of Ins(l,4 ,5)P3 to Ins(l,3,4 ,5)P4. Two isoenzymes, 3-kinase A and 3-kinase B have been 
identified and recent evidence suggests that the human forms are specifically expressed
CO
in different tissues and cells. 3-Kinase seems to be highly selective for its substrates 
and there is increasing evidence that it is the key regulatory enzyme for Ins(l,4 ,5)P3 
metabolism. A number of mechanisms exist for the regulation of 3-kinase activity59 and 
the enzyme is a substrate for the calcium-activated proteolytic enzyme calpain, which 
might provide a mechanism for regulation of 3-kinase levels.60 Focal cerebral ischaemia 
in rats has been shown to result in a time-dependent irreversible decrease in 3-kinase 
activity, suggesting that 3-kinase is one of the target enzymes of cerebral ischaemia and 
that the resulting perturbation of Ins(l,4 ,5)P3 metabolism may be an important factor
2 . z |
underlying the changes in intracellular Ca that lead to neuronal cell death.
The specificity of 3-kinase poses problems for the design of inhibitors. Heparin 
inhibits the activity of bovine adrenal cortex cytosol 3-kinase in a non-competitive 
fashion37 but, as noted above, has many disadvantages as a pharmacological tool. The
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anthracycline antibiotic adriamycin, widely used in antineoplastic therapy has also been 
found to inhibit 3-kinase, but it too has numerous other biological effects.62 Some 3- 
position-modified analogues of Ins( 1,4,5)P3 act as 3-kinase inhibitors, but also release 
calcium. Unexpectedly, L-2,2-difluoro-2-deoxy-myo-inositol-l,4,5-trisphosphate is 
also a competitive inhibitor (Kj=l 1.9jUM)64 and a carbohydrate-based 3-kinase inhibitor 
(Kj=26.8^M) synthesised from mannose has also been reported.65 These two molecules 
are therefore important leads in the search for non-calcium releasing, small-molecule 
inhibitors of 3-kinase.
F OH
L-2,2-F2-lns(1 ,4 ,5)P 3 m annose-based  analogue
Figure 1.18 Small-molecule 3-kinase inhibitors
All the new compounds described in this thesis are currently being examined for 
their interaction with a purified 3-kinase preparation. In particular, an investigation is 
being carried out into the effect of 3-kinase on 6-deoxy-6-hydroxymethyl scy/Zo-inositol 
1,2,4-trisphosphate (Figure 1.19). The synthesis of this analogue is described in Chapter 
5.
_ 2  O a P O -y ^ -^ T ^ O H  
0 3PO—£ ^ " ^ ^ O P 0 32'
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Figure 1.19 6-deoxy-6-hydroxymethyl scyllo-inositol 1,2,4-trisphosphate.




Ins(l,3,4 ,5)P4 is a substrate for at least two metabolising enzymes, 5-phosphatase (see 
below) and a 3-phosphatase, both of which are potential targets for the design of 
inhibitors. The latter enzyme, (now re-named multiple inositol polyphosphate 
phosphatase, MIPP66 has been shown to be capable of hydrolysing the 6-phosphate of
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both Ins(l,3,4,5,6)Ps and Ins(l,4 ,5,6)P4, an observation which has been rationalised by 
considering the binding orientations in which these molecules can mimic Ins(l,3,4 ,5)P4. 
This finding suggests that pathways might exist for the synthesis of both Ins(l,4 ,5)P3 
and Ins(l,3,4 ,5)P4 independently of phospholipase C .67
Because Ins(l,3,4 ,5)P4 is converted into Ins(l,4 ,5)P3 in vivo by MIPP, it is 
possible that some effects apparently due to Ins(l,3,4 ,5)P4 may result from its 
conversion to Ins(l,4 ,5)P3. This problem has been addressed by the synthesis of the 
MIPP-resistant Ins(l,3,4,5)P4 analogue myo-inositol-l,4,5-trisphosphate-3- 
phosphorothioate (Ins(l,3,4 ,5)P4-3S).68 In SH-SY5Y cells, this analogue was found to 
be essentially equipotent to Ins(l,3,4 ,5)P4 in causing Ca2+ release,69’70 providing
9-i-evidence that, at least in this cell type, Ins(l,3,4,5)P4 may be able to mobilise Ca 
stores, independent of any conversion to Ins(l,4 ,5)P3.
ATP
x^3-kinase
Figure 1.20 The resistance of the 3-phosphorothioate analogue of Ins(l,3,4,5)P4 to the 
action of MIPP makes it a useful pharmacological tool.
In Chapter 7, a synthesis of the previously unknown scyllo-inositol analogue of 
Ins(l,3,4,5)P4, is described. This symmetrical molecule, in which the equivalent to the 
2-hydroxyl group is equatorial, rather than axial, should enable us to investigate the role 
of the 2-hydroxyl group in the mechanism of action of MIPP.
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Ptdlns(3,4,5)P3 ---------------------- ► Ptdlns(3,4)P2
Ins(l,4 ,5)P3 is dephosphorylated to the inactive D-Ins(l,4)P2 by a family of specific 5- 
phosphatases. This metabolic step is therefore a highly effective method of inactivating 
the Ins(l,4 ,5)P3 signal, as it removes the crucial 5-phosphate group, abolishing the 
pharmacophore in one step. There appear to be multiple types of 5-phosphatase, and 
both soluble, cytosolic forms and particulate, membrane-bound forms exist. For a 
review see Verjans et al. (1994).71
Three soluble, cytosolic 5-phosphatases have been identified and designated 
Type I 5-phosphatase. Type I 5-phosphatases have a mass of 40-45kDa and will 
hydrolyse both Ins(l,4 ,5)P3 and Ins(l,3,4,5)P4. A second, higher molecular mass group 
of cytosolic 5-phosphatases, which have reduced affinity for Ins(l,3,4 ,5)P4, have been 
named Type II 5-phosphatase. Less is known about the particulate forms, which make 
up the majority of 5-phosphatase activity within the cell, although one such enzyme
77from human placental membranes has been purified. Recently the cloning and 
expression of a cDNA encoding this enzyme has enabled its tissue distribution to be 
mapped, showing that this membrane-associated 5-phosphatase is predominantly 
expressed in heart, skeletal muscle and brain.73
A pattern seems to be emerging in which certain enzymes involved in the 
metabolism of inositol phosphates will also metabolise their inositol phospholipid 
counterparts. So for example, a Type II 75kDa 5-phosphatase from human platelets will 
also hydrolyse phosphatidylinositol 4,5-bisphosphate forming phosphatidylinositol 4- 
phosphate. The gene encoding this enzyme has been found to be highly homologous to 
the defective gene in Lowe’s oculocerebrorenal syndrome (OCRL), a disease of 
unknown pathogenesis featuring defective development of the eyes, brain and kidney. 
74,75 This discovery highlights the potential significance of the 5-phosphatases, and 
OCRL has become the first known example of an inborn defect in inositol 
polyphosphate metabolism.
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It has been reported that inositol polyphosphate metabolism is deranged in 
lymphocytes infected with the HIV virus, and that the effect can be reversed by AZT 
therapy.76 It seems that 5-phosphatase activity is reduced in patients infected with HIV, 
and that as the disease progresses, Ins(l,3,4,5)P4-3-phosphatase (MIPP) is also 
decreased. In the later stages both activities are completely lost. A study of 5- 
phosphatase in normal and malignant haemopoietic cells also found that 5-phosphatase 
activity was significantly reduced or completely absent in subpopulations of cells taken
77from patients with various leukaemias. The authors speculated that the half-life of 
Ins(l,4 ,5)P3 and Ins(l,3,4 ,5)P4 may be increased in these cells, resulting in prolongation 
of Ca signals. This might lead to aberrations in cellular regulatory processes, including 
those involved in cell proliferation and differentiation.
It has recently been reported that the 75kDa 5-phosphatase is also capable of 
hydrolysing phosphatidylinositol 3,4,5-trisphosphate, and growing evidence suggests 
that the potential signalling function of PtdIns(3,4,5)P3 may be terminated by such an 
enzyme.78 We can therefore imagine a pattern in which the initiation and termination of 
inositol phospholipid signals in the plasma membrane parallels that of inositol 
phosphate signals in the cytosol (Figure 1.21).
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Figure 1.21 Parallels between phospholipid and inositol phosphate metabolism.
Very recently, the central region of synaptojanin, a nerve terminal protein, has 
been shown to be highly homologous to both type I and II 5-phosphatases.79 The 
purified protein hydrolyses Ins(l,4 ,5)P3, Ins(l,3,4,5)P4 and PtdIns(4 ,5)P2. The N- 
terminal domain of the same protein is similar to the cytosolic domain of the yeast Sacl 
protein which is genetically implicated in inositol phospholipid metabolism. 
Synaptojanin therefore incorporates two separate domains which are linked to
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phosphoinositide metabolism (hence the name, from the Roman god with two faces, 
Janus). The C-terminal domain binds the SH3 domain of amphysin, which is also bound 
by dynamin, a presynaptic protein implicated in endocytosis. The fact that synaptojanin 
is highly concentrated at the nerve terminal provides strong evidence for a link between 
phosphoinositide metabolism and synaptic vesicle recycling.
In contrast to Ins(l,4 ,5)P3-3-kinase, it seems that 5-phosphatase is relatively non­
specific. A range of phenothiazines, including chlorpromazine and trifluoperazine
(which is also a potent calmodulin antagonist) inhibit both soluble and particulate 5-
80phosphatases, as does calmidazolinium chloride (another calmodulin antagonist), 
disulfiram, and several of its analogues.81
The most potent 5-phosphatase inhibitor yet discovered is L-chiro- 
Ins(2,3,5)PS3.82 However, this compound is also a 3-kinase inhibitor and a partial 
agonist at Ins(l,4 ,5)P3 receptors (see above). More selective inhibitors83 include L- 
Ins(l,4,5)PS3, the meso-compound Ins(l,3,5)PS3, and (lR,2R,4R)-cyclohexane-1,2,4- 
tris(methylenesulphonate)84 The most promising candidate so far in the search for a 
potent, selective 5-phosphatase inhibitor is L-c/uro-inositol 1,4,6-trisphosphorothioate [ 
L-chiro-lns( 1,4 ,6)PS3 ] which, with its two axial phosphorothioate groups, seems to be 
structurally quite different from the other analogues. A possible rationalisation for the 
potency of L-c/z/ro-Ins(l,4 ,6)PS3 is that its three phosphorothioate groups may mimic 
the phosphate groups of Ins(l,4,5)P3 if it were to bind with its ring orthogonal to the 
usual orientation. An alternative explanation may be that in solution under physiological 
conditions, a proportion of L-c/»>o-Ins(l,4 ,6)PS3 may exist in the alternative chair form 







Figure 1.22 Small-molecule 5-phosphatase inhibitors.
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1.9.4 Inositol 1,3,4-trisphosphate 5/6-kinase
D-lns(1,3,4)P3 5/6-kinase^ D-lns(1,3,4,6)P4 
D-lns(1,3,4,5)P4
In all vertebrate cells studied so far, D-Ins(l,3,4)P3 is phosphorylated to produce 
Ins(l,3,4,6)P4 and D-Ins(l,3,4,5)P4. It is not established at present whether these two 
tetrakisphosphates have signalling functions of their own, or whether their cellular role 
is as precursors of Ins(l,3,4,5,6)P5 and InsP6. The activity responsible for 
phosphorylating D-Ins(l,3,4)P3 has been purified and appears to be a single enzyme, 
which combines 6-kinase and 5-kinase activities in a ratio of roughly 5 :l .85 It is widely 
distributed and unaffected by Li+, Ca2+/calmodulin, protein kinase A or protein kinase 
C.86 The affinity of this enzyme for D-Ins(l,3,4)P3 is the highest yet determined for an 
inositol phosphate.
An initial structure-activity study of the interaction of the kinase with various
87inositol polyphosphates has been reported. It was found that several inositol 
trisphosphate isomers inhibited D-Ins(l,3,4)P3 kinase activity. They fell into two groups: 
InsP3 isomers having vicinal phosphate groups at positions 5 and 6 [D-Ins(l,5,6)P3 and 
D-Ins(3,5,6)P3] were moderately potent inhibitors, whilst InsP3 isomers containing a 
vicinal 4,5-bisphosphate were much weaker. Thus the essential pharmacophore for D- 
Ins(l,3,4)P3 kinase may be a 3,4-bisphosphate, (the role of the third phosphate is not yet 
clear) but a 5,6-bisphosphate may be able to mimic this to some extent. Structure- 
activity principles therefore become, to some extent analogous to those already 
developed for Ins(l,4,5)P3 analogues at the Ins(l,4,5)P3 receptor. The suggested L- 
Ins(l,3,4)P3 kinase pharmacophore is enantiomorphic with the minimal 4,5- 
bisphosphate pharmacophore identified for Ins(l,4,5)P3 receptor (Figure 1.23).
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Figure 1.23 Pharmacophores for recognition by the Ins(l,4,5)P3 receptor and by 
Ins(l,3,4)P3 6-kinase may be enantiomorphic
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This observation provides some justification for synthesising both enantiomers of novel 
polyphosphates, because, while one enantiomer may be recognised by the Ins(l,4,5)P3 
receptor, its non-calcium releasing antipode may be a D-Ins(l,3,4)P3 kinase ligand. An 
excellent example of this principle is the case of Ins(l,3,4)P3 itself (Chapter 2). The D- 
enantiomer has the highest affinity of any known molecule for the kinase and, as we will 
show, does not release calcium, while the L-enantiomer is an Ins(l,4,5)P3 receptor 
agonist and (preliminary results indicate) interacts only weakly with the kinase.
The most potent competitive inhibitors of D-Ins(l,3,4)P3 kinase were three 
inositol tetrakisphosphates; D-Ins(l,3,4,5)P4, Ins(l,3,4,6)P4 and D-Ins(3,4,5,6)P4.87 The 
first two are products of the kinase and may physiologically regulate its action through 
feedback inhibition. The third, and most potent of the three, D-Ins(3,4,5,6)P4, is also 
present in the cytosol at physiologically relevant concentrations. Note that this molecule 
has both a 3,4- and a 5,6-bisphosphate, and its resistance to phosphorylation might be 
rationalised by visualising four possible binding modes which retain the 3,4- 
bisphosphate structure of D-Ins(l,3,4)P3 (Figure 1.24). In each orientation, the area of 
the molecule corresponding to the site of action of the enzyme in Ins(l,3,4)P3 is either 
blocked by the presence of phosphates or has vicinal cw-hydroxyl groups rather than 
trans.
Figure 1.24 Possible binding modes of D-Ins(3,4,5,6)P4 to Ins(l,3,4)P3 6-kinase.
One can therefore imagine many potential inhibitors in which the recognition 
elements present in Ins(l,3,4)P3 are retained, but this part of the molecule is modified 
(e.g. by deletion of hydroxyls or replacement with fluorine). It might also be possible to
S ite  of ac tio n  
of 5 /6 -k in a se
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develop metabolically resistant, monosaccharide-based D-Ins(l,3,4)P3 mimics. All the 
compounds described in this thesis are currently under evaluation as part of a major 
investigation into structure-activity relationships for Ins(l,3,4)P3 5/6-kinase, and the 
synthesis of the natural substrate for this enzyme [ D-Ins(l,3,4)P3 ] is described in 
Chapter 2.
1.9.5 Phosphatidylinositol 3-kinase
P tdlns 3-k in ase
Ptdlns ----------------- ► Ptdlns(3)P
Ptdlns(4)P ----------------- ► Ptdlns(3,4)P2
Ptdlns(4,5)P2 ----------------- ► Ptdlns(3,4,5)P3
Phosphatidylinositol 3-kinase (Ptdlns 3-kinase) phosphorylates the D-3-position of the 
inositol head-groups of phosphatidylinositol (Ptdlns), phosphatidylinositol 4- 
monophosphate [PtdIns(4)P] and phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] 
giving D-3-phosphatidylinositol lipids, which are not substrates for phospholipase C. 
The enzyme is a heterodimer, comprising a 85kDa regulatory subunit and a llOkDa 
catalytic subunit. Evidence is accumulating that some or all of its 3-phosphorylated lipid 
products [and particularly PtdIns(3,4,5)P3] may have second messenger functions of 
their own. Any attempt to summarise the rapidly expanding field of phospholipid 
signalling is outside the scope of this work, which is primarily concerned with the
OQ
inositol phosphates, but the area has recently been reviewed.
Inhibitors of Ptdlns 3-kinase may help to clarify the role of this enzyme and its 
metabolic products in cells. The most widely used inhibitor at present is the fungal 
metabolite wortmannin, which is active at nanomolar concentrations, but also inhibits 
other enzymes (e.g. myosin light chain kinase and phospholipase D). The chromone 
derivative LY294002 (Figure 1.25) has recently been developed as the result of a
OQ . • . .  .
structure-activity study of several chromones and is claimed to be a specific inhibitor 




Figure 1.25 Inhibitors of Ptdlns 3-kinase currently in use as pharmacological tools.
In the light of the parallels that seem to exist between inositol phospholipid 
metabolism and the better-understood metabolism of the inositol phosphates, it might be 
instructive to examine the interaction of Ptdlns 3-kinase with inositol phosphates and 
their analogues, many of which are now available. Such a study has been carried out 
recently.90 Of the many analogues tested* most were inactive, but significantly, L-chiro- 
inositol 2,3,5-trisphosphate (and the corresponding trisphosphorothioate) were found to 
be inhibitors. Now L-c/i/ro-Ins(2,3,5)P3 can be considered as Ins(l,4,5)P3 in which the 
equatorial 3-position hydroxyl group is replaced by an axial hydroxyl group. It may not 
be surprising that a structural alteration at the d-3 position, which is the site of 
phosphorylation by Ptdlns 3-kinase, should have this effect, but D-Ins(l,4,6)P3 was not 
recognised. A comparison of the structures of D-Ins(l,4,6)P3 and L-c/i/roIns(2,3,5)P3 
(Figure 1.26) show that they differ only in the orientation of the hydroxyl group 
corresponding to the 2-hydroxyl of Ins(l,4,5)P3. Thus there seems to be a requirement 
for axial hydroxyl groups at both 2- and 3- positions for inositol phosphates to inhibit 
Ptdlns 3-kinase activity. One other analogue, benzene 1,2,4-trisphosphate (Bz(l,2,4)P3), 
in which the inositol ring is replaced by the planar benzene ring* with three phosphate 





L-c/7/ro-lns(2,3)5 )P 3 D-m yo-lns(1,4,6)P3
R ecognised Not R ecognised
Figure 1.26 The orientation of the 2-hydroxyl group appears to be important to the 
recognition of inositol phosphates by Ptdlns 3-kinase.*
* The syntheses of some of these are described in this thesis. Details are given in the appropriate chapters.
+ A molecular modelling study has shown that benzene may not be as rigid as is sometimes supposed, and 
for small torsional deformations (<15°) it is as flexible as cyclohexane.140
* An X-ray crystal structure of Ins(l,4,5)P3 bound to the PtdIns(4,5)P2 binding site of mammalian PLC-8 
has recently been published.141 The axial 2-OH group of Ins(l,4,5)P3 was seen to have a number of crucial
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1.10 Syntheses of Two Naturally Occurring Inositol Phosphates
Chapter 2 describes the synthesis of the enantiomers of myoinositol 1,3,4-trisphosphate, 
and in Chapter 7 a synthesis, strategically quite different, of the enantiomers of myo­
inositol 1,3,4,5-tetrakisphosphate will be described. In each case there has been 
controversy in the biological literature over the roles of the naturally-occurring D- 
enantiomers of these compounds.
1.10.1 my o-Inositol 1,3,4-trisphosphate
We were interested in the enantiomers of Ins(l,3,4)P3 (Figure 1.27) for two related 
reasons. First, there had been long-standing controversy in the literature as to the activity 
and role of the D-enantiomer, which is a major inositol phosphate in stimulated cells. 
Second, the previously unknown L-enantiomer has structural similarities to 
Ins(l,3,4,6)P4, which had recently been found to behave as a partial agonist in SH- 
SY5Y neuroblastoma cells (see Section 1.8.1 and Chapter 6).
[ = D-lns(1,3,6)P3]
Figure 1.27 Enantiomers of myo-inositol 1,3,4-trisphosphate
1.10.2 D-my o-Inositol 1,3,4-trisphosphate
D-Ins(l,3,4)P3 is well-established as one of the major inositol trisphosphates found in 
mammalian cells, and stands at a crucial branch-point in the metabolism of inositol 
phosphates. It has been isolated from biological sources and synthesised by various 
groups (see below). However, a survey of the literature presents us with a confusing, 
and sometimes contradictory, account of its biological activity (or lack of it) at 
Ins(l,4,5)P3 receptors. The important features of the various literature reports are 
summarised below as a chronological list, in an attempt to minimise this confusion. The 
contradictions will quickly become apparent.
interactions with amino acid residues at the active site (and also with one Ca2+ ion). Perhaps similar 
interactions explain the necessity for an axial 2-OH group in PtdIns(4,5)P2-3-kinase ligands.
OH OH
o p o 32‘
D-lns(1,3,4)P3 L-lns(1,3,4)P3
30
1986: D-Ins(l,3,4)P3 is obtained by incubation of D-Ins(l,3,4,5)P4 with human 
erythrocyte membranes. It is reported to release Ca2+ from Swiss 3T3 cells, with an EC50 
of 9fjmo\. Speculation follows that D-Ins(l,3,4)P3 may function to keep Ca2+ stores
91empty.
1988: Racemic Ins(l,3,4)P3 is synthesised. It releases Ca from permeabilised aortic 
smooth muscle cells. The authors conclude that D-Ins(l,3,4)P3 must be responsible.92
1988: Another group report that D-Ins(l,3,4)P3 does not release Ca2+ from GH3 or Swiss 
3T3 cells.93
1988: D-Ins(l,3,4)P3 is found to be active in depolarising the ventral photoreceptors of 
the horseshoe crab (Limulus polyphemus) when injected intracellularly. It is reported to 
be “about half as potent as Ins(l,4,5)P3 ” 94
1988: D-Ins(l,3,4)P3 is synthesised. It has a negative optical rotation.95
1988: [3H]-D-Ins(l,3,4)P3 and [3H]-L-Ins(l,3,4)P3 are synthesised. Neither shows 
binding displaceable by D-Ins(l,3,4)P3 to rat brain receptor proteins.96
1992: D-Ins(l,3,4)P3 is synthesised on a large scale by an enzymatic method.
It has a positive optical rotation. Authors comment on the discrepancy, but “ . . . no 
further information on optically active Ins(l,3,4)P3 is available”.97,98
1992: When injected into Limulus photoreceptors, some samples of D-Ins(l,3,4)P3 
(including commercially available material) release Ca2+. Others, produced by Gou and 
Chen, do not.99
While some of these contradictions might be explained by tissue-specific effects, 
or different experimental conditions, others, for example those involving Limulus 
photoreceptors, plainly cannot. It followed that some samples of D-Ins(l,3,4)P3 were 
different from others. The obvious explanation is that some samples of D-Ins(l,3,4)P3 
were impure and/or that mistakes had been made regarding the absolute configuration of 
synthetic D-Ins(l,3,4)P3. It was decided that the best way to provide a definitive solution 
to this problem would be to synthesise both enantiomers of Ins(l,3,4)P3 in highly pure 
form, prove their absolute configurations beyond doubt, and then test them under
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identical conditions in Limulus photoreceptors. In fact, these photoreceptors are 
sufficiently large that it would be possible to test both enantiomers in the same cell 
using a double-barrelled microelectrode.
1.10.3 L-myo-Inositol 1,3,4-trisphosphate: Relationship to Ins(l,3,4,6)P4
The L-enantiomer of Ins(l,3,4)P3 might also be useful in the search for partial agonists
at Ins(l,4,5)P3 receptors, because of its structural relationship to Ins(l,3,4,6)P4. Recall 
that a 4,5-bisphosphate system has been accepted as a necessary feature for binding to 
the Ins(l,4,5)P3 receptor (Section 1.7). Ins(l,3,4,6)P4 plainly does not possess this 
structure, and therefore should not bind. However, it is possible to imagine 
Ins(l,3,4,6)P4 in two different orientations relative to D-Ins(l,4,5)P35 in which two of the 
phosphate groups in Ins(l,3,4,6)P4 might mimic a 4,5-bisphosphate (a "pseudo-4,5- 
bisphosphate" arrangement100,101). The situation is best appreciated by the manipulation 
of computer-generated molecular graphics, but on paper, these orientations or binding 
modes can be represented as shown in Figure 1.28. In either one of the two binding 
modes shown, Ins(l,3,4,6)P4 may be capable of presenting three phosphate groups to the 
receptor binding site in a way that mimics the spatial arrangement of the three 
phosphates in D-Ins(l,4,5)P3. The extra phosphate now occupies a position analogous to 
position 2 in D-Ins(l,4,5)P3j normally occupied by an axial hydroxyl group. The 
important differences between the two putative binding modes lies in the two hydroxyl 
groups which flank the pseudo-4,5-bisphosphate moiety. In binding mode (b) the 
equatorial 3-OH of D-Ins(l,4,5)P3 is replaced by an axial OH group, while in (c) it is the 
6-OH whose orientation is changed. It is not obvious, however, which of the two 
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Figure 1.28 Possible binding orientations of Ins(l,3,4,6)P4 at Ins(l,4,5)P3 receptors.
Of course, it is possible that Ins(l,3,4,6)P4 may bind to the receptor in both
109modes, it may bind to different conformational states or isoforms of the receptor in 
different modes, and it is more than likely that this static view of binding is over­
simplified. However, it might be possible to use Ins(l,3,4,6)P4 as starting point for 
rational modification, with the aim of identifying the structural basis of its partial 
agonism and elucidating its mode of binding to the receptor. It might then be possible to 
design molecules with decreased Ca2+-releasing activity, while maintaining or 
enhancing binding affinity.
Evidence exists that naturally occurring Ins(l,3,4,6)P4 may be 
dephosphorylated103 by enzymes that are still not well-characterised, to give D- 
Ins(l,3,4)P3, D-Ins(l,4,6)P3, D-Ins(l,3,6)P3 [ = L-Ins(l,3,4)P3] and D-Ins(3,4,6)P3 [ = L- 
Ins(l,4,6)P3] (Figure 1.29).
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Figure 1.29 Relationship of the symmetrical Ins(l,3,4,6)P4 to four chiral trisphosphates.
As discussed above, D-Ins(l,3,4)P3 is already well-known and there were no 
reports of it showing partial agonist activity. The activity of the other trisphosphates was 
unknown, although D-Ins(l,4,6)P3 had been identified in WRK rat mammary tumour 
cells,104 and L-Ins(l,3,4)P3, (alternative name D-Ins(l,3,6)P3) had been identified as a 
minor inositol trisphosphate in avian erythrocytes and a product of Ins(l,3,4,6)P4
i mdephosphorylation by brain cytosol.
Now Figure 1.29 also illustrates the structural relationships of these five 
molecules. The four chiral trisphosphates can be regarded as simplified analogues of 
Ins(l,3,4,6)P4, each formed by the removal of a different phosphate group. It might 
therefore be possible to determine what feature of Ins(l,3,4,6)P4 leads to partial agonist 
activity by comparing the biological activities of the four trisphosphates.
The study would also enable us to find out the effect of changing the orientations 
of the hydroxyl groups of Ins(l,4,5)P3. It can be seen from Figure 1.30 that, by analogy 
with Ins(l,3,4,6)P4, each of these molecules can bind to the receptor in one of two 
possible orientations. However, in each case, only one of these orientations mimics the 
positioning of the three phosphate groups in Ins(l,4,5)P3. In the case of D-Ins(l,4,6)P3 
(Figure 1.30), this mode is (b) while for L-Ins(l,3,4)P3 it is (e).
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Figure 1.30 Possible binding modes (orientations) of D-Ins(l,4,6)P3 and L-Ins(l,3,4)P3 
at the Ins(l,4,5)P3 receptor.
Now in the D-Ins(l,4,6)P3 binding mode (b), the axial hydroxyl group replaces 
the usual equatorial 3-hydroxyl group of Ins(l,4,5)P3. In the L-Ins(l,3,4)P3 binding 
mode (e), the positioning of the phosphates forces the axial hydroxyl group of L- 
Ins(l,3,4)P3 into the equivalent position of the 6-hydroxyl group in Ins(l,4,5)P3. The 
fact that these modes of binding have an equatorial rather than axial hydroxyl at the 
equivalent of Ins(l,4,5)P3 position 2 is acceptable, because the 2-OH of Ins(l,4,5)P3 has 
been shown to have a relatively insignificant role in receptor binding and Ca2+ release105 
with DL-scy/Zc>-Ins(l,2,4)P3 (which can be regarded as DL-rayo-Ins(l,4,5)P3 with an 
equatorial 2-OH) being only slightly less potent than Ins(l,4,5)P3. 106
Current opinion holds that the 3-OH group plays a minor role in receptor 
recognition while the 6-OH is critical (Figure 1.11). This has been deduced from the fact 
that D-3-deoxy-Ins(l,4,5)P3107’108 has a high affinity for the Ins(l,4,5)P3 receptor while 
D-6-deoxy-Ins(l,4,5)P3 is 70-fold less potent than D-Ins(l,4,5)P3.109 Thus we 
hypothesised that, if altering the orientation of an hydroxyl group has a similar effect to 
deleting it then, while both D-Ins(l,4,6)P3 and L-Ins(l,3,4)P3 should bind to the
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Ins(l,4,5)P3 receptor and release calcium, D-Ins(l,4,6)P3 should bind with higher 
• ^affinity. Whether either of these molecules would also show partial agonist properties 
remained to be seen. This investigation is described in Chapter 2.
1.10.4 Inositol 1,3,4,5-tetrakisphosphate
The product of the action of 3-kinase on Ins(l,4,5)P3 is D-myo-inositol 1,3,4,5- 
tetrakisphosphate. The level of controversy surrounding this molecule is currently very 
high, and often focuses on the detailed methodology of various biological assays, some 
of which seem to be giving conflicting results. However, the situation with respect to D- 
Ins(l,3,4,5)P4 is far more complex than that already discussed for D-Ins(l,3,4)P3, and 
only the briefest account will be given here.
Debate exists as to whether D-Ins(l,3,4,5)P4 itself can mobilise intracellular Ca2+ 
stores by acting at Ins(l,4,5)P3 receptors. Wilcox et al.69,110,111 found that in SH-SY5Y 
cells, D-Ins(l,3,4,5)P4 appears to cause Ca release by direct interaction with the 
Ins(l,4,5)P3 receptor, being a 40 fold weaker ligand and 20-fold weaker agonist than 
Ins(l,4,5)P3. In contrast, using L I210 cells, Cullen et al.u l  found that D-Ins(l,3,4,5)P4 
caused no Ca2+ mobilisation in the absence of Ins(l,4,5)P3. Gawler et al.m  found that, 
using racemic Ins(l,3,4,5)P4, there appeared to be a synergistic effect of Ins(l,3,4,5)P4 
in enhancing Ca2+ release by Ins(l,4,5)P3, but also that Ins(l,3,4,5)P4 was capable of 
releasing Ca2+ from intracellular stores by itself. Other workers have reported that D- 
Ins(l,3,4,5)P4 acts synergistically with Ins(l,4,5)P3 but is not itself able to induce Ca2+ 
release.114
Another issue is the possible existence of specific receptors for D- 
Ins(l,3,4,5)P4.115 The identification of an D-Ins(l,3,4,5)P4-activated Ca2+ channel in the 
plasma membrane of endothelial cells116 has lent weight to suggestions that D- 
Ins(l,3,4,5)P4 may somehow modulate Ca2+ influx across the plasma membrane.117 
Specific binding sites for D-Ins(l,3,4,5)P4 have been identified in several tissues, and a 
D-Ins(l,3,4,5)P4 binding protein, purified from porcine platelets, has been demonstrated
I 1 Q
to be a member of the GAP1 family. The affinity of this site, now designated 
GAP1IP4BP, for various myo-inositol phosphates has been the subject of two recent
* But what of the remaining possible binding modes? The D-Ins(l,4,6)P3 binding mode (c) seems very 
unlikely, because the axial hydroxyl group would be placed at position 6, but the situation is less clear in 
the case of the L-Ins(l,3,4)P3 binding mode (d). In this orientation, the L-Ins(l,3,4)P3 molecule can avoid 
placing its axial hydroxyl group in the equivalent of the 6-position, but only at the expense of placing its 
1-phosphate group at the equivalent of position 2 in Ins(l,4,5)P3. We know that an equatorial phosphate 
group is tolerated in this position, because scy//o-Ins(l,2,4,5)P4 is highly active, but this does not allow us 
to deduce whether binding mode (d) or (e) would be lower energy for L-Ins(l,3,4)P3.
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investigations. 119’120 Another high-affinity D-Ins(l,3,4,5)P4 binding site, recently 
purified from mouse cerebellum and designated IP4BP/synaptotagmin n , may be 
involved in synaptic function.121
1.10.5 Syntheses of Optically Active Ins(l,3,4,5)P4 :Two Examples
Several syntheses of racemic Ins(l,3,4,5)P4 122-125 and D-Ins(l,3,4,5)P4 97’98 126-128
I <^Q
have been reported in the literature. Baudin et al. developed a synthesis of both 
enantiomers of Ins(l,3,4 ,5)P4 from myo-inositol orthoformate by the routes shown in 
Figure 1.31. This is the only reported synthesis of L-Ins(l,3,4 ,5)P4. Regioselective 
protection of the sterically most accessible hydroxyl group of the three130 gave the 
symmetrical silylated orthoformate 1.1 which was then benzylated to give the racemate 
1.2ab. Treatment of the racemate with 1 -phenylethyl isocyanate in the presence
of BuLi at -78°C gave a mixture of the diastereoisomers 1.3a and 1.3b and some 
starting material. The starting material could not be separated from the carbamates, but 
desilylation followed by medium-pressure liquid chromatography gave the 
diastereoisomers 1.4a and 1.4b plus starting material which was recycled. Benzylation 
of each diastereoisomer with benzyl trichloroacetamidate in the presence of 
trifluoromethanesulphonic acid gave the diastereoisomers 1.5a and 1.5b. Removal of 
the orthoformate groups with aqueous CF3COOH, followed by aqueous ammonia gave 
1.7a and 1.7b which treated with NaOEt in ethanol giving the enantiomeric tetrols 1.8a 
and 1.8b. The absolute configurations of 1.8a and 1.8b were deduced by converting the 
monobenzyl orthoformate intermediate 1.3a into the known lL-4-(9-benzyl-myo-inositol 
1.6a. Phosphitylation/oxidation of the tetrols followed by hydrogenolysis and treatment 
with cyclohexylamine gave D-Ins(l,3,4 ,5)P4 and L-Ins(l,3,4 ,5)P4 as the 
cyclohexylammonium salts, each in around 10% yield from the orthoformate. The 
authors also reported an enzymatic route, based on selective monodeacylation of meso- 
derivatives of myo-inositol by pig liver diesterase, although this strategy involved more 
synthetic steps.
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Figure 1.31 Synthesis of D-Ins(l,3,4,5)P4 and L-Ins(l,3,4,5)P4 (Baudin et al.129).
More recently, a large-scale synthesis of D-Ins(l,3,4,5)P4 has been reported by
QQ
Gou and Chen ( Figure 1.32). Regioselective stannylene-mediated acylation of racemic 
l,2:5,6-di-0-cyclohexylidene-mye>-inositol (DL-1.10) gave the racemic butyrate ester 
DL-1,11. Enantiospecific hydrolysis of DL-1.11 using porcine pancreatic lipase (PPL) 
gave lD-l,2:5,6-di-0-cyclohexylidene-myo-inositol (1.12). Allylation followed by 
selective hydrolysis of the trans ketal gave 1.14, which was also used for the synthesis 
of D-Ins(l,3,4)P3 (see Chapter 2). Regioselective benzylation at the C-6 position via the 
O-stannylene acetal in the presence of CsF provided 1.15, and allylation followed by 
removal of the 1,2-0-cyclohexylidene group gave 1.17. 1-0-allylation followed by 2-0- 
benzylation furnished the fully-protected 1.19 and deallylation gave the known tetrol
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1.8a. Phosphitylation/oxidation and finally debenzylation by catalytic hydrogenolysis 
gave D-Ins(l,3,4,5)P4 in 38% overall yield from 1.12.
This route, which was used to produce D-Ins(l,3,4,5)P4 in multigram quantities, 
has been described in some detail because most commercially available material 
obtainable at present has been synthesised using this method by the University of Rhode 
Island Foundation Chemistry Group. Consequently, this has been the source of the 
samples used in many biological studies of Ins(l,3,4,5)P4. The significance of this will 
be discussed in Chapter 7, where a very rapid and potentially large-scale synthesis of 
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Figure 1.32 Chemoenzymatic route to D-Ins(l,3,4,5)P4 (Gou and Chen 98)
PPL = porcine pancreatic lipase.
The routes discussed above also serve to illustrate some common features of 
most published syntheses of chiral inositol phosphates from myoinositol. These can be 
summarised as:
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1) Selective protection of hydroxyl groups.
2) Resolution of a protected intermediate (usually followed by more protection- 
deprotection steps).
3) Phosphorylation of exposed hydroxyl groups, either by P(V) or, more recently, 
P(in) methodology. The latter involves phosphitylation followed by oxidation.
4) Deprotection of hydroxyl groups and phosphate groups (sometimes simultaneously, 
sometimes in two stages).
5) Purification (e.g. by crystallisation or ion-exchange chromatography)
Much attention has been devoted to the first four of these steps over recent years
10 1 Q1
(see References ’ for reviews) although little attention has been paid to step 5 
(purification). It is now apparent that many inositol phosphates are biologically active at 
a range of sites, often in very low concentrations. It seems very likely that many of these 
activities are currently unknown, and even unsuspected. It will therefore become 
increasingly important that the samples used for biological investigations are subjected 
to a final purification step, (preferably ion-exchange chromatography or HPLC) and are 
demonstrated to be free of contaminants by a sensitive physical method. Failure to carry 
out these procedures may result in misleading biological results, and lead to confusion 
and unjustified speculation over the biological functions of naturally occurring inositol 
phosphates.
1.11 Ins(l,4,5)P3 Conformation
No information is yet available on the three-dimensional structure of the active 
site of an Ins(l,4,5)P3 receptor (although see below for a discussion of the recently- 
published X-ray structures of PH domains) and so we are presently limited to a study of 
the compounds that are active at these sites. In this situation, we attempt to make 
inferences about the active sites and the nature of the receptor-ligand interactions by 
systematically altering the structure of the natural ligand and observing the effects on 
activity. However, it is not always clear whether a change in activity, brought about by 
the modification of part of a molecule, results from a purely local effect, or whether 
there are more widespread consequences for the conformation or ionisation state of the 
molecule as a whole. Modification at C-3 of Ins(l,4,5)P3, for example, can have various 
consequences for affinity and efficacy of analogues at Ins(l,4,5)P3 receptors. Do these 
effects arise simply from the altered interaction of the 3-substituent with the receptor, or 
through effects on the orientation and ionisation state of the adjacent 4-phosphate
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group? An additional phosphate group at this position, as in D-Ins(l,3,4,5)P4 for 
example, must surely have dramatic effects on the 4-phosphate, and the evolution of a 
highly specific Ins(l,4,5)P3 3-kinase may be associated with the functional 
consequences of these effects. We could even imagine cases in which modifications 
(e.g. an axial phosphate) could alter the overall conformation of the cyclohexane ring. 
This idea has been invoked to explain the unexpectedly high activity found for L- 
Ins(2,4,5)P3 in one study.132
NMR studies can sometimes provide information on the relative proportions of 
equilibrating conformations in solution, but these may not necessarily resemble the 
receptor-bound conformation. The stabilising interactions in the receptor-ligand 
complex may be quite large, allowing considerable distortion of the ligand away from an 
energy minimum. This may be particularly relevant in the binding of a highly charged 
molecule such as Ins(l,4,5)P3 with positively charged residues at the binding site, so 
that electrostatic interactions with the receptor may compensate the energetic penalty of 
large conformational changes. Molecular modelling studies can be used to predict 
energy minima in the conformational space available to a molecule, and information 
gained from NMR (e.g. NOE studies and coupling constants) can be used as constraints 
in theoretical calculations. By comparing a number of agonists with varying structures it 
may be possible to deduce a theoretical three-dimensional pharmacophore that is 
attainable at reasonable energetic cost by all active ligands. It is then possible to use this 
pharmacophore as a template for the design of receptor ligands.
In the case of Ins(l,4,5)P3 however, we do not yet have available a range of 
active molecules that differ sufficiently in structure to make such a study feasible. The 
active molecules that we have are too similar to one another, and too conformationally 
mobile. In particular, the inositol phosphates that show significant affinity for the 
Ins(l,4,5)P3 receptors all contain the 4,5-bisphosphate motif. This conformationally 
mobile system is regarded as essential for binding and Ca2+-release, and yet little work 
has focused upon modification of this region of Ins(l,4,5)P3.* Thus, little is known 
about the way in which these two phosphate groups interact with the receptor in the 
series of events that leads to the opening of the integral ion channel. Could it be, for
* After the synthesis of the conformationally restricted analogue described in Chapter 4, but before the 
publication of our results, a synthesis of 3-deoxy-D-muc0-Ins(l,4,5)P3, was published.142 In this molecule, 
the configuration at C-4 is the opposite to that in Ins(l,4,5)P3. The affinity of this analogue for the 
Ins(l,4,5)P3 receptor is 3 orders of magnitude lower than that of Ins(l,4,5)P3, further demonstrating the 
importance of the trans relationship of the 4- and 5-phosphates.
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example, that the 4,5-bisphosphate binds to the receptor in one conformation, and then a 
mutual conformational change of receptor and ligand occurs during the opening of the 
ion channel? In that case, it might be possible to make an antagonist by fixing the 
bisphosphate in a conformation that binds to the receptor but cannot activate it (i.e. to 
separate affinity from efficacy).
The design and synthesis of a conformationally restricted analogue of 
Ins(l,4,5)P3 are described in Chapter 4. Preliminary biological results are given, and an 
account of a detailed potentiometric and NMR investigation into its ionisation state and 
solution conformation.
1.12 PH Domains
PH domains are recently-discovered structural modules o f around 100 amino acids that 
are present in many signal transduction proteins (e.g. protein kinases, phospholipases, 
PtdIns(4,5)P2 3-kinase and G A Pl134315). They also occur as part of some cytoskeletal
133 •proteins such as spectrin, and in dynamins, which are involved in endocytotic vesicle 
formation. Many proteins implicated in human cancers and in developmental disorders 
contain PH domains, although the medical significance of this is currently not clear. 
Mutational changes in the PH domain of Bruton’s tyrosine kinase are the cause of X- 
linked agammaglobulinaemia (XLA), a genetic disorder in which B lymphocytes fail to 
develop and consequently no circulating antibodies are produced, although the 
physiological ligand for this PH domain is presently unknown. A detailed review, 
dealing with the occurrence, structure and possible functions of PH domains has been 
published recently.134
In 1994 it was reported that the PH domain of pleckstrin bound PtdIns(4,5)P2, 
and the ligand binding site was located to the N-terminus.135 In November 1995, a study 
of an isolated PH domain from PLC-<5i showed that besides binding PtdIns(4,5)P2, it
1 3Awas also able to bind inositol phosphates. D-Ins(l,4,5)P3 was bound stereospecifically 
and with highest affinity and various inositol tetrakisphosphates, including 
Ins(l,3,4,6)P4 [but not D-Ins(l,3,4,5)P4] also bound, as did D-Ins(2,4,5)P3. Inositol 
mono- and bisphosphates and also D-Ins(l,3,4)P3 were not recognised. Similar results 
have been reported for the /3-spectrin PH domain.137 All PH-domain-containing proteins 
are associated with membrane surfaces, and numerous lines of evidence now suggest 
that the PH domains are involved in reversible anchoring of these proteins to the 
membranes, often by binding to phosphoinositides. In the case of PLC-5i, for example,
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a mechanism has been suggested 138 involving a negative feedback loop in which PLC- 
<5j uses its PH domain to bind PtdIns(4 ,5 )P2, in the cell membrane. The PLC enzyme 
than hydrolyses PtdIns(4 ,5 )P2 to give free Ins( 1 ,4 ,5 )P3, which then inhibits the binding 
of further PtdIns(4 ,5 )P2 to the PH domain.
At the end of 1995, two groups independently published X-ray crystal structures 
of Ins(l,4,5)P3 bound to pleckstrin homology (PH) domains. 137,139 These X-ray studies 
have allowed us to see, for the first time, the conformation of Ins(l,4,5)P3 at one of its 
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Figure 1.33 Schematic drawing of the Ins(l,4,5)P3 binding site of the /Tspectrin PH 
domain, showing hydrogen bonds and salt bridges between amino acid residues and 
ligand. Negative charges on phosphate groups are not shown. Adapted from Hyvonen et 
a l  (1995)137.
The first thing to notice is the importance of the 4 and 5-phosphate groups, 
which are anchored by salt bridges to positively charged amino acid residues, and by 
hydrogen bonds to Trp23 and Tyr69. The 1-phosphate group, in contrast, is linked by 
only one hydrogen bond to a Ser residue, and is mostly exposed to solvent. The upper 
face of the molecule, including the area around the axial 2 -hydroxyl group is also open 
to solvent. Modelling of several inositol phosphates onto the bound Ins(l,4,5)P3 ligand 
confirmed the importance if the 4,5-bisphosphate, and D-Ins(l,3,4)P3 and L-Ins(l,4,5)P3 
did not fit the binding site. Although the 3-hydroxyl group was not close enough to 
Trp23 to interact with it directly, it did form an H-bond to one bound water molecule 
which was, in turn, H-bonded to the main-chain NH group of Trp23. It might be 
interesting to examine the binding affinity of the hydroxymethyl analogue 44 (Chapter
5) and the adenophostins at this site.
43






(L ys 30 HN
Trp 36\ Arg 56)
Figure 1.34 The Ins(l,4 ,5 )P3 binding site of the PLC-<5j PH domain. Adapted from 
Ferguson et al. (1995).139
The X-ray structure of Ins(l,4,5)P3 at the PLC-<5j PH domain139 shows that, by 
contrast with the /3-spectrin PH domain, Ins(l,4,5)P3 is significantly more buried within 
a binding pocket, and there are many more interactions with residues at the binding site, 
(Figure 1.34) particularly for the 5-phosphate (additional H-bonds via water molecules 
are not shown). This is reflected in the greater stability of the Ins(l,4,5)P3-PLC-<5i 
complex. Again we see that the 4,5-bisphosphate is of primary importance for binding, 
while the 1-phosphate group forms a single hydrogen bond, this time to a Trp residue. 
The authors of this study make the remarkable observation that Trp 36 and Arg 40, 
which interact with the 1- and 5-phosphate groups of Ins(l,4,5)P3 are analogous to two 
residues in the Bruton’s kinase PH domain which, when altered by site-directed 
mutagenesis, result in XLA. Finally, both studies suggest that one function of the /3- 
spectrin and PLC-<5i PH domains is to anchor the respective proteins to the cell 
membrane in a reversible way. This is illustrated schematically for the /3-spectrin PH 
domain in Figure 1.35.
These two studies have been dealt with here in some detail because they 
represent an exciting new departure in the inositol phosphate field. For the first time, the 
interaction of Ins(l,4,5)P3 with binding sites has been observed in detail, and the results 
are in excellent agreement with the conclusions reached about Ins(l,4,5)P3 receptor 
binding as a result of structure-activity investigations conducted over a period of years. 
This is not to say that the Ins(l,4,5)P3 binding site of these PH domains necessarily 
resembles that of Ins(l,4,5)P3 receptors. Note, for example, that neither study showed 
any interactions of the 6 -hydroxyl group of Ins(l,4,5)P3 with the binding site, and yet 
this feature is known to be important for binding to Ins(l,4,5)P3 receptors. However,
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many of the structure-activity principles deduced for Ins(l,4,5)P3 receptors can be 
accommodated by the binding site structures shown in Figures 1.33 and 1.34, and this 






F ig u re  1.35 Schematic drawing of the proposed interaction of PtdIns(4,5)P2 with the PH 
domain of /3-spectrin. Adapted from Hyvonen et al. (1995)137.
It will be interesting to investigate the interactions of a range of naturally- 
occurring and synthetic analogues with the binding sites of PH domains. Some of the 
compounds whose synthesis is described in this thesis are already being used in an 




D-rayo-inositol 1,3,4-trisphosphate [D-Ins(l,3,4)P3, Fig. 2.1] is produced in 
stimulated cells by the sequential action of the enzymes 3-kinase and 5-phosphatase. As 
discussed in Chapter 1, there had been controversy as to whether D-Ins(l,3,4)P3 was 
active at Ins(l,4,5)P3 receptors, and therefore confusion about its biological role. L-myo­
inositol 1,3,4-trisphosphate [L-Ins(l,3,4)P3] had not previously been investigated, and its 
biological activities were unknown. Structure-activity considerations predicted that, in 
contrast to the D-enantiomer, L-Ins(l,3,4)P3 should be recognised by Ins(l,4,5)P3 
receptors and furthermore, arguments based on the possible ways in which the partial 
agonist Ins(l,3,4,6)P4 might bind to Ins(l,4,5)P3 receptors suggested that L-Ins(l,3,4)P3 
might show partial agonist properties.






Figure 2.1 Origin of D-Ins(l,3,4)P3 from D-Ins(l,4,5)P3 via D-Ins(l,3,4,5)P4. The 
enantiomer, L-Ins(l,3,4)P3 [ = D-Ins(l,3,6)P3] is also shown.
We would begin by synthesising racemic Ins(l,3,4)P3 in order to optimise the synthetic 
methods and to verify that this material could induce Ca -release in our assay system 
(permeabilised rabbit platelets). Recall that racemic Ins(l,3,4)P3 had previously been 
reported to cause Ca2+-release from permeabilised aortic smooth muscle cells,92 and the 
authors had concluded that D-Ins(l,3,4)P3 was the active component (Chapter 1).
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Figure 2.2 Synthesis of DL-myo-inositol-1,3,4-trisphosphate (11).
(i) (a) 2,2-Dimethoxypropane, PTSA DMF, reflux, (b) BzCl, pyridine; (ii) NaOH, 
MeOH, reflux; (iii) allyl bromide, NaH, DMF; (iv) ACOH/H2O, 4:1, reflux; (v) (a) 
Bu2SnO, toluene, reflux, (b) PMBC1, CsF, KI, DMF; (vi) BnBr, NaH, DMF; (vii) 
KOBu', DMSO, 50°C; (viii) MHCl/EtOH, 1:2, reflux; (ix) (a) (BnO)2PNPr'2, 1H- 
tetrazole, CH2CI2 (b) Bu'OOH (x) Na/liquid NH3. Bn, benzyl; Bz, benzoyl; PMB, p- 
methoxybenzyl. All compounds are racemic.
Racemic Ins(l,3,4)P3 was synthesised (Figure 2.2) using a new route starting from myo­
inositol The key fully-protected intermediate DL-l,4-di-0-allyl-2,5,6-tri-0-benzyl-3-0- 
p-methoxybenzyl-myo-inositol (7) was chosen for the following reasons:
First, partial deprotection of this compound leads to the known triol, 2,4,5-tri-O-benzyl- 
myo-inositol (9) which is then used as the precursor for phosphorylation. The absolute 
configurations of the enantiomers of this material had recently been assigned.143 Second, 
the use of allyl protection at positions 1 and 4, together with p-methoxybenzyl at 3 
allowed for two possible strategies of resolution using diastereoisomeric esters formed 
with a chiral resolving agent. The diastereoisomers must be capable of separation, either
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by recrystallisation or by chromatography, and in many cases, neither is possible. The p- 
methoxybenzyl protecting group also gives versatility and the possibility of Ins(l,3,4)P3 
analogues modified at position 3.
2.2.1 Synthesis of a Key Intermediate
DL-1,4-di-0-allyl-2,5,6-tri-0-benzyl-3-0-p-methoxybenzyl-my<9-inositol (7) was 
synthesised as shown in Figure 2.2 via the known DL-1,2:4,5-di-d-isopropylidene-myo- 
inositol (2). Following the procedure developed by Gigg et a/.,144 myo-inositol was 
treated with 2,2-dimethoxypropane in DMF with a catalyst of PTS A to give a mixture of 
three bisisopropylidene ketals (Figure 2.3 ).
Figure 2.3 Reaction of myoinositol with 2,2-dimethoxypropane gives a mixture of 
three bis-ketals.144
The three regioi somers were then converted into their dibenzoates by reaction with 
benzoyl chloride in pyridine. The dibenzoate 1 of the l,2:4,5-bis-ketal is, in contrast to 
the other two dibenzoates, almost insoluble in pyridine, water, acetone and ether, and so 
it can be isolated by filtration and washing with these solvents. The benzoyl groups are 
then removed by refluxing in methanolic sodium hydroxide to give d l - 1,2:4,5-di-O- 
isopropylidene-myo-inositol 2 .144
Allylation using sodium hydride in DMF followed by allyl bromide now gave 
the known l,4-di-0-allyl-2,3:5,6-di-D-isopropylidene-myo-inositol (3).145 Finally, the 
isopropylidene groups were removed by heating in acetic acid-water (4:1) to give the 
tetrol 4.149 The NMR spectrum of 4 initially posed some difficulties of interpretation 
due to overlapping signals from some of the inositol ring protons. 4 was therefore 
converted into the (highly crystalline) tetra-acetate 5. In the !H NMR spectrum of this 
compound, the signals from protons at positions 2,3,5 and 6 were, as expected, shifted 
downfield, well away from those corresponding to H-l and H-4. A 400MHz
1,2:3,4 1,2:4,5 1,2:5,6
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COSY NMR spectrum of 5 allowed an unambiguous assignment of the ring protons, 
and interpretation of the original overlapping signals.
The next step was a selective p-methoxybenzylation of the tetrol at position 3. 
This involved the regioselective protection of one equatorial hydroxyl group in the 
presence of three other OH groups: one axial and two equatorial. The difference in the 
reactivity between the equatorial OH groups in inositol is slight, and the use of 
organotin derivatives has found a place in the selective activation of the equatorial OH 
of a vicinal equatorial-axial pair.146 It has been shown that maximum yields in tin- 
mediated monoalkylations can be obtained by the use of caesium fluoride.147 The 
authors of this study suggest that the polarisable caesium cation interacts with the 
halogen atom of the alkyl halide, causing its activation, and furthermore that Sn-0 
bonds are also activated by the formation of a pentacoordinate complex. The tetrol 4 
was reacted with dibutyltin oxide by refluxing in toluene with azeotropic removal of 
water to give a dibutylstannylene derivative, which was not isolated, but reacted with p- 
methoxybenzyl chloride in DMF in the presence of caesium fluoride, to give the 3-0-/?- 
methoxybenzyl ether 6 in 65% yield. Finally, 6 was benzylated using sodium hydride 
and benzyl bromide in DMF to give the fully-protected, crystalline intermediate d l - 1 ,4 -  
di-0-allyl-2,5,6-tri-0-benzyl-3-0-/7-methoxybenzyl-myo-inositol (7).
2.2.2 Synthesis of d l - 2 ,4,5-Tri-O-benzyl-wyo-inositol
The next step was to generate the triol 9 by removing both the allyl and p- 
methoxybenzyl protecting groups from 7. Allyl groups are similar to benzyl groups in 
their high stability to acidic and basic conditions, but in the presence of very strong 
base, isomerisation of allyl ethers to cts-prop-l-enyl ethers occurs. These enol ethers can 
then be cleaved by mild acid hydrolysis. The isomerisation was carried out using the 
standard conditions of potassium-terr-butoxide* in DMSO at 50°C.145 The reaction 
proceeded smoothly and the highly crystalline cw-prop-l-enyl ether 8 was obtained in 
83% yield.
In contrast to the unsubstituted benzyl ethers, p-methoxybenzyl ethers are acid 
labile, although less so than ds-prop-l-enyl ethers. Thus 8 can be converted into a diol 
by subjecting it to mild acid hydrolysis, or to the triol 9 by the use of harsher conditions. 
In the synthesis of racemic Ins(l,3,4)P3, the triol was the desired product and so 8 was
* The potassium r-butoxide should be purified by sublimation for best results. When this step was omitted, 
the reaction was slower and poor yields were obtained.
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deprotected using the relatively vigorous treatment of refluxing in 1M HCl-ethanol (2:1)
benzyl protecting groups as judged by TLC. Flash chromatography removed the p- 
methoxybenzyl alcohol produced in the hydrolysis giving pure 9 in 90% yield.
There has been some disagreement in the literature as to the melting point of 
racemic 9, with values of 126-128°C 148 and 135-137°C 145 being reported. It was found 
during the course of the current project that two different batches of 9, both pure, had 
different melting points. On closer examination it was found that, when the temperature 
was very gradually increased as the crystals were observed on the hot stage microscope, 
they underwent a phase transition from plates to needles at about 128°C, with the 
needles then melting sharply at 135-136.5°C. If the temperature was increased slightly 
more rapidly, the plates melted at 128°C and then the liquid recrystallised to give 
needles which melted at the higher temperature. Thus it seems that racemic 9 can exist 
in at least two different crystalline forms (polymorphs) and the reason for the 
discrepancy in reported melting points is clear. Interestingly, another benzyl ether of 
myo-inositol (racemic-3,4-di-0-acetyl-l,2,5,6-tetra-0-benzyl-myo-inositol149 has been 
shown to show unusual behaviour on heating (“jumping crystals”), and the effect is 
thought to be associated with solid-solid phase transitions.150 X-ray crystal structures of 
the three crystalline phases have been published.151
2.2.3 Phosphorylation of DL-2,4,5-Tri-0-benzyl-myo-inositol
Figure 2.4 Phosphitylation of the triol 9, gives a trisphosphite triester, which is oxidised 
to the trisphosphate triester 10.
Because the triol possesses a vicinal diol, a P(III) approach to phosphorylation is 
appropriate. Direct phosphorylation of a vicinal diol using P(V) reagents, in which the











trisphosphite triester  
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phosphorus atom is already in the +5 oxidation state, can cause difficulties, such as the 
formation of unwanted five-membered cyclic phosphates. Using P(III) methods, the 
hydroxyl groups are first phosphitylated and subsequently oxidised to give the protected 
phosphate ester. P(DT) methodology can also be adapted to give phosphorothioates by 
the substitution of elemental sulphur for the oxidising agent in the second stage. The 
phosphitylation was carried out using the P(III) reagent bis-(benzyloxy)-A,A- 
diisopropylaminophosphine (Figure 2.4) v/hich has to be catalytically activated by a 
weak acid, such as 1 -H  tetrazole, giving a reactive tetrazolide complex.
It is useful, and informative, to follow the course of the 
phosphitylation/oxidation sequence by 31P NMR, if appropriate facilities are available. 
All such reactions reported in this thesis were monitored in this way by obtaining 31P 
NMR spectra at various stages of the process, using a JEOL FX90 spectrometer. A low- 
field machine such as this is quite adequate for this purpose and may even have some 
advantages.* P(HT) agents tend to be rather unstable, and by obtaining a 31P NMR 
spectrum after adding the 1//-tetrazole, it is possible to check the purity of the 
phosphitylating agent-tetrazolide complex before committing (often precious) inositol 
derivative to the reaction (Figure 2.5 A). When the substrate is added, any vicinal 
phosphite triesters formed will show 5/ pp spin couplings (Figure 2.5 B) and these 
couplings can give useful information, confirming the substitution pattern of the 
product. Finally, after oxidation (or sulphoxidation, which may be slower) the 
disappearance of all phosphite signals confirms that the reaction has gone to completion 
(Figure 2.5 C).
After 1//-tetrazole was added to a solution of the phosphitylating agent in dry 
dichloromethane, a proton-decoupled 31P NMR spectrum showed a singlet at <5p 127, 
confirming the presence of the phosphitylating agent-tetrazolide, and no impurities. The 
triol 9 was therefore added and now the 31P NMR spectrum showed the appearance of 
signals at <5p 140.39 (2P) and <5p 142.21 (IP), corresponding to the trisphosphite triester. 
A signal at Sp 127 (excess phosphitylating agent-tetrazolide) was also present. A high 
resolution, low sweep-width 31P NMR spectrum of the signals close to <5p 140 was able 
to resolve three signals, and two of these were doublets with a coupling constant of
*Spin couplings of low magnitude may be obscured in spectra acquired at high field as a result of signal 
broadening due to chemical shift anisotropy. This anistropic effect is reduced at low field strength (and 
high temperature).
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3.7Hz. This arises from the Vpp spin coupling between the P atoms at C-3 and C-4, and 
was clear evidence that the compound contained a vicinal bisphosphite.
A
Phosphitylating agent-tetrazolide
14 0  13 0  5P 10 0  - 10
B
Trisphosphite triester:
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14 0  13 0  5P 10 0 - 10
c
Absence of phosphite 
signals indicates that 
oxidation is complete
I I I I r
14 0  13 0
Figure 2.5 Proton-decoupled 31P NMR is a useful technique for following the progress 
of phosphitylation oxidation. A: After addition of 1//-tetrazole to phosphitylating agent, 
B: After addition of triol, C: After oxidation with terr-butyl hydroperoxide.
A small amount of water was now added before oxidation. It was reasoned that 
this would react with excess phosphitylating agent-tetrazolide and therefore simplify the 
later purification stage. The oxidation was then carried out by adding excess tert-butyl 
hydroperoxide. 3IP NMR now showed that oxidation to the protected trisphosphate was 
complete, with the signals around <5p 140 disappearing, to be replaced with three clear 
singlets at <5p -1.42, -1.57, and -1.81. The only by-product detectable by 31P NMR was 
an //-phosphonate at <5p 7.5 and it was found that this could easily be removed by flash 
chromatography to give 10 in 73% yield. It was later found, in the course of 
phosphorylating a range of other compounds, that higher yields (80-90%) could usually 







2.2.4 Deprotection and Purification
The final deblocking of 10 involved the removal of the nine protecting benzyl 
groups using sodium in liquid ammonia. A number of attempts were necessary before 
this was carried out successfully and the procedure found to be effective is detailed in 
the experimental section. Subsequent experience with many deprotection reactions of 
this type have shown that the quality of the sodium used is a major factor influencing 
yield. The apparatus should be dried in an oven and assembled under nitrogen while hot. 
Only a small volume of liquid ammonia (20-30mL) should be used because the amount 
of sodium needed is then reduced accordingly. This, in turn, means that the ionic 
strength of the crude product is lower, and it can be loaded onto the ion-exchange 
column in a smaller volume of water, saving time during the purification stage.
An alternative deprotection strategy for this synthesis would have been to use 
hydrogenolysis, which is more reliable and usually gives near-quantitative yields. 
However the necessary apparatus was not available at this time. Note also that 
hydrogenolysis cannot be used to deprotect phosphorothioates (Chapter 6), compounds 
with ester protecting groups (Chapter 7) or unsaturated compounds (Chapter 3). Traces 
of paramagnetic ions from the catalyst (usually Pd) can cause extreme broadening of 
NMR signals, unless these are removed completely by ion exchange chromatography. 
The sodium in liquid ammonia method has wider applicability, but can give poor yields.
Trisphosphate 11 was purified using ion-exchange chromatography. After 
deprotection, the crude product contains large amounts of sodium salts and uncharged 
by-products, but these can easily be separated from the highly charged inositol 
phosphates by the ion-exchange column. Problems do occur, however, if other, 
similarly-charged inositol phosphates, which may arise from phosphate migrations 
during deprotection, are present (see Chapter 7). It is advisable to filter the solution of 
crude product before loading onto the column because any oily or particulate matter can 
cause blockage of filters and valves.
The ion-exchange column is eluted using a gradient of triethylammonium 
bicarbonate (TEAB) buffer from 0 to 1 M. It is not immediately apparent which 
fractions contain the target compound because, as there is usually no chromophore 
present, the usual post-column detection by UV absorption is not possible. The fractions 
containing phosphate were detected using a method that relies on the complexation of 
free phosphate with molybdate ions152 and then subjected to 31P NMR to determine 
which phosphate-containing fractions contained the desired product.
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Because the inositol phosphates obtained by ion-exchange purification are 
isolated as their triethyl ammonium salts, whose stoichiometries may be different in each 
case, the formula mass is not known accurately and they cannot therefore be quantified 
on the basis of mass. Instead, a quantitative assay for phosphate must be carried out. The 
result of this assay is a quantity of phosphate (in ^moles) which is then divided by three 
for a trisphosphate, by two for a bisphosphate etc. The conventional method is to use the 
Briggs Phosphate Assay.152
The triethylammonium salt of racemic 11 was obtained as a colourless glass. The
 ^i
proton-coupled P NMR spectrum of 11 confirmed the presence of the three phosphate 
groups with heteronuclear / h c o p  coupling. The identity of 11 was confirmed by one- 
and two-dimensional !H NMR spectroscopy. It was possible to assign all the signals, 
including the separate assignments of H-l and H-3 (see below) leaving no doubt 
remaining as to the identity of 11.
2.2.5 Biological Testing of DL-Ins(l,3,4)P3
Previous work has shown that intracellular injection of Ins(l,4,5)P3 into the 
ventral photoreceptors of the horseshoe crab Limulus polyphemus, results in a transient 
depolarisation of the cellular membrane potential.153,154 This depolarisation 
accompanies, and is caused by, a burst of Ca2+ release from intracellular stores.155 
Poorly-metabolisable active analogues of Ins(l,4,5)P3, such as D-myo-inositol-1,4,5- 
trisphosphorothioate, induce a train of bursts of depolarisation due to bursts of Ca2+ 
release that persist for many minutes after injection.156
Racemic 11 was injected into Limulus ventral photoreceptors at a concentration 
in the injection pipette of 100/iM. It was indeed, highly active, producing bursts of 
depolarisation that persisted for minutes after injection, suggesting that the active 
component of 11 was poorly metabolisable. (An alternative explanation of the 
prolonged effect would be that one enantiomer of 11 was capable of inhibiting the 
metabolism of the other).
11 Was also evaluated for its ability to mobilise 45Ca2+ from saponin- 
permeabilised rabbit platelets, relative to Ins(l,4,5)P3 and Ins(l,3,4,6)P4. The results 
showed that racemic 11 was considerably less potent than Ins(l,4,5)P3 but equal to, or 
slightly greater in potency than Ins(l,3,4,6)P4 in its ability to mobilise 45Ca2+. As 
discussed above, structure-activity considerations predict that this activity should reside 
in L-Ins(l,3,4)P3, and not the D-enantiomer.
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A preliminary assay showed that 11 was capable of inhibiting 5-phosphatase 
(Ki=8.8/iM). Polokoff et al?1 also found their racemic Ins(l,3,4)P3 to behave in a 
similar way. It has previously been shown that D-Ins(l,3,4)P3 is not a 5-phosphatase
1 57inhibitor, so it follows that the L-enantiomer must be responsible. As discussed above, 
L-Ins(l,3,4)P3 has been found to be present in avian erthyrocytes103 but there is as yet no
I 5Qevidence that L-Ins(l,3,4)P3 attains levels that would inhibit 5-phosphatase in vivo.
It was at this stage in the project that Hirata et al. published a detailed biological 
study of D-Ins(l,4,6)P3 and L-Ins(l,3,4)P3 with no synthetic details.159 Strangely, 
although their L-Ins(l,3,4)P3 seemed active in binding studies in rat cerebellum (90-fold 
less potent than Ins(l,4,5)P3), as would be expected, it was almost inactive in Ca - 
release (3000 times weaker than Ins(l,4,5)P3). The latter result is totally at odds with our 
finding that racemic 11 was moderately potent in Ca2+ release. These results 
strengthened our suspicions that this group had tested the wrong enantiomer of 
Ins(l,3,4)P3, especially in the light of earlier discrepancies over the optical rotation of 
the D-enantiomer, and yet this could not explain the high potency in binding. The only 
other possibility seemed to be that the differences in Ca2+ release reflected differences in 
the Ins(l,4,5)P3 receptors in different cell types. Our results, as explained above were, 
based on experiments using rabbit platelets (and Limulus photoreceptors) whereas 
Hirata et a l  had used rat basophilic leukaemic (RBL) cells. Thus, it was important to 
continue with the original plan, synthesise both enantiomers of Ins(l,3,4)P3, prove their 
absolute configurations, and evaluate their biological activities in our own assays.
2.3 Optical Resolution of 2,4,5-Tri-O-benzyl-l-O-p-methoxybenzyl-wyo-inositol
The successful optical resolution of inositol derivatives via the formation of camphanate 
esters has been reported in various studies.143,160'162 Both S-(-)- and R-(+)~ camphanic 
acid chlorides are stable crystalline reagents available in high optical purities. The 
diastereoisomeric camphanate esters can sometimes be separated by crystallisation, or 
their polarities may be sufficiently different to allow separation by column 
chromatography. In other cases, neither method may be successful. The camphanate 
ester may also be used as a protecting group, allowing selective modification subsequent 
to resolution (see Chapter 7).
The decision was made to attempt the resolution via the formation of 3,6-bis- 
camphanates on the basis of a report that 1,2,4,5-tetra-O-benzyl-myo-inositol had been 
successfully resolved by this method.143 Accordingly, racemic 2,4,5-tri-0-benzyl-3,6-di-
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0Kcw-prop-l-enyl)-l-<9-/?-methoxybenzyl-ray0-inositol 8 was subjected to mild acid 
hydrolysis using 1M HCl-acetone (1:10) at 50°C. TLC showed complete conversion to 
the 1,4-diol within 5 minutes, after which the acid was rapidly neutralised with aqueous 
sodium hydrogencarbonate. Experiments showed that if the reaction was continued 
beyond 30 min, then significant amounts of triol began to appear, arising from loss of 
the p-methoxybenzyl group at position 3. The racemic diol 12 was obtained in 84% 
yield after purification by flash chromatography. Racemic 12 was then converted into its 
bis-[(7S)-(-)-<»-camphanate] esters by reaction with (75)-(-)-fi)-camphanic acid chloride 
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Figure 2.6 Optical resolution of 12 and conversion to D- and L-Ins(l,3,4)P3.
(i) 1M HCl/acetone, 1:10, 50°C; (ii) (5)-to-camphanic acid chloride, DMAP, pyridine; 
(iii) NaOH, MeOH, reflux; (iv) BnBr, NaH, DMF; (v) 1M HCl/EtOH 1:2, reflux; (vi) 
(a) (BnO)2PNPr*2, 177-tetrazole, (b) Bu'OOH; (vii) Na/liquid NH3. Bn, benzyl; PMB, p- 
methoxybenzyl; (-)Camph, (lS)-(-)-<2>-camphanate.
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Attempts to resolve the diastereoisomers by recrystallisation from various 
solvent systems (methanol, ethanol, ether, ethyl acetate/hexane) were not successful. 
The only remaining possibility was the use of chromatography, although the two 
diastereoisomers showed a ARf of only 0.07. However, no better TLC system could be 
found and so the separation was attempted using chloroform/acetone (30:1). Perhaps 
surprisingly, this was successful, and excellent separation was achieved.
The individual diastereoisomers proved to be very different. One of these, the 
(+)-diastereoisomer, was highly crystalline, with a very low solubility in cold methanol 
allowing easy crystallisation from hot solvent. The (-)-diastereoisomer was much more 
soluble in methanol and ethanol, and could not be induced to form satisfactory crystals 
from any of a range of solvents, tending instead to precipitate as a gel, which then had to 
be dried under vacuum to remove solvent. Unfortunately, it was not possible to grow 
crystals of either diastereoisomer that were suitable for X-ray analysis.
The NMR spectra of the two diastereoisomers showed them to be pure, with no 
trace visible of the other diastereoisomer in each case (!H NMR at 400MHz and 13C 
NMR at 100MHz). The efficiency of the resolution could be judged by the *H NMR 
resonances of the camphanate methyl groups. Further evidence came from an 
examination of the H-2 signal, which occurred at very different chemical shifts (54.11 
and 4.23) in the two diastereoisomers. Saponification of the individual diastereoisomers 
by refluxing with sodium hydroxide in methanol then gave the enantiomeric diols 12a 
and 12b.
As it had not been possible establish the absolute configuration of either 
biscamphanate by X-ray crystallography, the remaining option was to convert one of the 
enantiomeric diols into a compound whose absolute configuration was already well- 
established. Fortunately, this had been anticipated in the design of the synthesis, and the 
(-)-diol 12b was therefore converted into one of the enantiomers of the known 
1,2,4,5,6-penta-O-benzyl-myo-inositol 14 by benzylation followed by removal of the p- 
methoxybenzyl group. The absolute configuration of the (+)-enantiomer as 1D-1,2,4,5,6- 
penta-O-benzyl-myo-inositol had been established by Shvets, in 1973, based on its 
conversion to (+)-bomesitol.163 The product was found to have an JH NMR spectrum 
identical to that of racemic 1,2,4,5,6-penta-O-benzyl-myo-inositol164, but an optical 
rotation o f -11.5°, identifying it as (-)-lL-l,2,4,5,6-penta-0-benzyl myo-inositol L-14b. 
Thus the (-)-diol could be assigned as lL-2,5,6-tri-0-benzyl-3-0-p-methoxybenzyl myo­
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inositol L-12b allowing the absolute configurations of the diastereoisomeric 
biscamphanates and of the resolved enantiomers generated from them to be deduced.
However, at this stage in the project we encountered a problem. It emerged that 
there were, in fact, unacknowledged contradictions in the literature regarding the 
absolute configurations of the enantiomers of 14. Two independent X-ray studies165,166 
carried out on the (lS)-(-)-6>-camphanic acid ester of the (+)-enantiomer had deduced 
the lL-l,2,4,5,6-penta-(9-benzyl-myo-inositol configuration for the (+)-enantiomer, the 
opposite of that found by Shvets. The authors did not remark on the discrepancy, and, 
partly because of their use of different nomenclature for 14, we were unaware that 
Shvets’ assignment was in question. The disagreement is reflected in the reported 
conversions of both enantiomers into the same lD-myo-inositol-l-phosphate by 
phosphorylation and debenzylation.163,165 Fortunately, a study published in 1994 by
i fnAneja et al. resolved this conflict unambiguously, showing beyond doubt that Shvets’ 
original assignment was correct. Our assignments of the absolute configurations of (+) 
and (-)-12, and related compounds were therefore on solid ground.
The enantiomeric diols D-12a and L-12b were converted into the known triols D- 
9a and L-9b by removal of their p-methoxybenzyl groups as described for 9. The optical 
rotations of these enantiomers were in agreement with, although larger than, those 
previously reported143,98, thus confirming the absolute configurations proposed by Desai 
et al.m and of the D-Ins(l,3,4)P3 synthesised by Gou and Chen.98 Examination of a *H- 
COSY NMR spectrum of D-9a allowed the signals corresponding to each of the three 
hydroxyl groups to be assigned, as well as the ring protons. The melting point behaviour 
of the optically pure triols paralleled that of the racemate. The phase change occurred at 
lower temperature (93°C) with the needles then melting at 104-106°C in each case. 
Thus the individual enantiomers exist in polymorphic forms.
The triols were phosphorylated as described for the racemic material, followed 
by deprotection and purification as before to give D- and L-myo-inositol-1,3,4- 
trisphosphates D -lla  and L -llb  respectively as the triethylammonium salts. The 162 
MHz proton-coupled 31P NMR spectra of D -lla  and L -llb  showed that they were free 
from contamination with other phosphates. Previously published NMR spectra of
1A8Ins(l,3,4)P3 obtained from biological sources showed the material to be 
contaminated, probably with Ins(l,4,5)P3. In this respect it is also worth noting that, as 
L-Ins(l,3,4)P3 is now known to occur naturally in at least some cell types (see above), it 
follows that any Ins(l,3,4)P3 obtained from biological sources may contain L-
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Ins(l,3,4)P3, and of course, the two enantiomers would be indistinguishable by standard 
chromatographic analyses, or by NMR. However, as the diastereoisomeric 
biscamphanate intermediates in our route appeared pure by NMR, we can expect that 
neither D -lla  nor L -llb  would contain more than 1% of its enantiomer.
The NMR spectra of the enantiomers were identical with one another, and with 
that of racemic 11. 400MHz !H spectra were obtained, and a 2D COSY spectrum 
of L -llb .T he assignment of the lH NMR spectrum of L - llb  (Figure 2.7) is explained 
below.
• H-2 appears as a narrow triplet (actually a dd) at <5h 4.28. This is the only 
equatorial proton and it is deshielded relative to the axial protons. It can be 
deduced that this position is not phosphorylated because any 7hp heteronuclear 
coupling to phosphorus would cause a doubling of the signal.
• H-4 is seen at <5h 4.17. Three couplings are present; two axial-axial interactions 
with H-3 and H-5 and a 3/ h p  coupling to the phosphorus at C-4. The heteronuclear 
coupling constant has a similar magnitude to 3/ax-ax , giving a quartet (or ddd). This 
proton cannot be H-5 because, given that C -l and C-3 are also phosphorylated (see 
below) the molecule would then have a plane of symmetry.
• H-3 and H-l each give a doublet of triplets (or ddd). If these positions were not
phosphorylated, each signal would appear as a doublet of doublets. Again the 
pattern is a result of the heteronuclear coupling constant being similar in
magnitude to the homonuclear 3/ax-ax coupling. It is not possible, from the ID
spectrum to say which of the two signals is H-l and which is H-3, but in the ^ ^ H  
COSY, the downfield signal has a cross-peak with H-4, establishing it as H-3.
• The quartet centred at (5h 3.49 showed no cross-peaks with ring protons in the !H-
*H COSY spectrum. It arises from ethanol of crystallisation (or possibly 
CH3C //2NR2 of an impurity in the trie thy lamine).
• Finally, H-6 and H-5 appear as triplets (dd) at high field, indicating that these
positions are not phosphorylated. In myo-inositol derivatives, H-4 and H-6 tend to 
resonate downfield of H-5, given similar substituents, presumably as a result of a 
deshielding 1,3-diaxial interaction with the oxygen at position 2.
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Figure 2.7 400 MHz *H NMR spectrum of l i b  in D20 , pH~4.2. The inset shows the 
162 MHz ‘H-coupled 31P NMR spectrum of Xla in D20 , pH~4.2.
The complete 'H NMR spectra showed the number of triethylammonium cations 
to be between 3 and 3.5. Solutions of the salts in water were acidic (pH 4.2), and their 
specific rotations, calculated for the free acid, were highly dependent on pH, being small 
(<10°) at acidic pH and large (>40°) at pH 10.6. A similar pH-dependency has been 
found for the optical rotations of D-Ins(l,4 ,5 )P3 .169 The rotations for D-Ins(l,3,4)P3 were 
positive over this range and those for L-Ins(l,3,4)P3 were negative. At pH 7.8 the values, 
calculated for the free acids, were +37° and -40° respectively (c = 0.42, TEAB buffer ). 
The signs of the rotations therefore agreed with the positive rotation reported for the 
potassium salt of D-Ins(l,3,4)P3 by Gou and Chen.98 The larger magnitudes of our 
rotations may be attributed to pH differences. It is not clear why Ozaki et a/.95obtained a 
negative rotation for their D-Ins(l,3,4)P3 (ammonium salt). Had this group actually 
obtained the wrong enantiomer of Ins(l,3,4)P3? In fact this now seems very unlikely, 
and the reasons will be discussed in detail below.
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2.4 Biological Testing of D-Ins(l,3,4)P3 and L-Ins(l,3,4)P3
The structural considerations discussed in Chapter 1 predict that D-Ins(l,3,4)P3 should 
show little ability to release Ca2+. Our working hypothesis is that the essential 
requirement for Ca2+ release in inositol polyphosphates is the presence of a D-4,5- 
bisphosphate as found in D-Ins(l,4,5)P3, or a pseudo-D-4,5-bisphosphate [e.g. in 
Ins(l,3,4,6)P4 ]. L-Ins(l,3,4)P3 possesses this motif and we therefore predicted that it 
should release Ca2+. D-Ins(l,3,4)P3 does not, and for this reason, despite the reports to 
the contrary cited in Chapter 1, we would expect it to show little, if any, activity as an 
agonist at the Ins( 1,4,5)P3 receptor.
2.4.1 Effects of D-Ins(l,3,4)P3 and L-Ins(l,3,4)P3 in Limulus Photoreceptors
The two enantiomers of Ins(l,3,4)P3 D - l la  and L - l lb  were injected into Limulus ventral 





|  40 
|  30
o









100 A<M D-myo 1.3.4 lnsP3 100  mM D-myo 1.4.5 lnsP3
<u 30
o






0 5 10 15 20 25 30
Time (sec)
10O D-myo 1.3.4 lnsP3
D
0 5 10 15 20 25 30
Time (sec)
100  L-myo 1.3.4 lnsP3
0 5 10 15 20 25 30
Time (sec)
0 5 10 15 20 25 30
Time (sec)
Figure 2.8 Injection of InsP3 isomers into the rhabdomeral lobe of Limulus 
photoreceptors. Figures A and B show recordings of membrane potential made from a 
cell impaled with a double-barrelled micropipette containing 100 fiM D-Ins(l,3,4)P3 (D- 
11a) in one barrel and 100 jiM Ins(l,4,5)P3 in the other barrel. The pressure applied to 
either barrel was 60 psi for 1 0 0 ms.Figures C and D show recordings of membrane 
potential made from another cell impaled with a double-barrelled electrode containing 
100 jiM D-Ins(l,3,4)P3, (D - l la )  in one barrel and 100 jiM L-Ins(l,3,4)P3 (L - l lb )  in the 
other. Pressure applied to the first barrel was 20 psi. for 200ms and to the second barrel 
was 38 psi applied for 200ms.
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Ventral photoreceptors were impaled in their light-sensitive region with a double- 
barrelled micropipette, one barrel containing 100 pM D-Ins(l,3,4)P3 (D - l la )  and the 
other barrel either 100 pM D-Ins( 1,4,5)P3 or 100 pM L-Ins(l,3,4)P3 (L - l lb ) .  These 
solutions were injected into the photoreceptor by brief pressure pulses delivering 
approximately equal volumes. Photoreceptors remained in darkness throughout the 
experiment. Injection of D-Ins(l,3,4)P3 was found to be much less effective in inducing 
a rapid burst of depolarisation than injection of either D-Ins(l,4,5)P3 or L-Ins(l,3,4)P3 
(Figure 2.8). In addition, unlike the single burst of depolarisation seen following 
injection of D-Ins(l,4,5)P3 (Figure 2.8 B), repetitive bursts of depolarisation were 
induced by L-Ins(l,3,4)P3 (Figure 2.8 D). These bursts continued for up to 5 minutes 
after injection of L-Ins(l,3,4)P3, suggesting that L-Ins(l,3,4)P3 is metabolised at a slower 
rate than D-Ins(l,4,5)P3.
2.4.2 Effects o f  D- and L-Ins(l,3,4)P3 in Permeabilised Rabbit Platelets
The enantiomers D - l l a  and L - l l b  were also examined for their ability to release 45Ca2+ 
from permeabilised rabbit platelets (Figure 2.15). L-Ins(l,3,4)P3 (L - l lb )  behaved as a 
full agonist and was found to be some 11-fold weaker at releasing 45Ca2+ than D- 
Ins(l,4,5)P3. However D-Ins(l,3,4)P3 (D - l la )  was almost inactive, releasing only 16% 
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Figure 2.9 Calcium release from permeabilised rabbit platelets induced by Ins(l,4,5)P3, 
L-Ins(l,3,4)P3 (L - l lb )  and D-Ins(l,3,4)P3 (D - l la ) .  Values are mean ± S.E.M. for three 
separate experiments, each performed in triplicate.
The above findings were extended by examining the kinetics of Ca2+ release by 
the two enantiomers. Ca2+ release was monitored in the presence of the fluorescent dye 
fura-2 by spectrofluorimetry. Addition of 1 /jM  Ins( 1,4,5)P3 caused release of Ca2+ from
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the intracellular stores of platelets, detected as a rapid increase in the fluorescence of 
fura-2 free acid. The increase on fluorescence was transient, presumably due to 
metabolism of Ins(l,4 ,5 )P3 to inactive products, resulting in resequestration of Ca2+ 
back into the intracellular stores by Ca2+-ATPase activity. Addition of L - l l b  [L- 
Ins(l,3 ,4 )P3] caused a dose-dependent release of Ca2+ from the intracellular stores. 
However, unlike the effect of Ins(l,4,5)P3, Ca2+-release by L - l l b  reached a maximum 
which was then maintained at a plateau phase over the time-course of the experiment 
(Figure 2.10). In agreement with the findings for 45Ca2+-release, D - l la  [D-Ins(l,3,4)P3] 
was inactive, with no increase in fluorescence measured at 3 0 / llM  of D -l la .
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Figure 2 .10  Ca2+ mobilisation induced by D-Ins(l,3,4)P3 (D - l la )  and L-Ins(l,3,4)P3 (L- 
11b) monitored by spectrofluorimetry. Each trace is taken from a single experiment but 
is representative of 4 individual experiments.
As discussed in Chapter 1, heparin has previously been demonstrated to be a 
competitive antagonist at the Ins(l,4 ,5 )P3 binding site of the Ins(l,4 ,5 )P3 receptor.33 
Heparin was found to inhibit L-Ins(l,3,4)P3-induced Ca2+ release, indicating that the 
effects of L-Ins(l,3,4)P3 result from an interaction with the same site.
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Figure 2.11 Effect of heparin on L-Ins(l,3,4)P3-induced Ca2+-release.
2.4.3 Binding Studies in Rat Cerebellar Membranes
[3H]Ins(l,4,5)P3 was readily displaced from specific binding sites on rat cerebellar 
membranes by cold Ins(l,4,5)P3 with an IC50 of 0.045 ± O.Ol^M. Ins(l,3,4,6)P4 also 
displaced specifically bound [3H]Ins(l,4,5)P3 but was 36-fold weaker than Ins(l,4,5)P3. 
L-Ins(l,3,4)P3 was around 100-fold weaker than Ins(l,4,5)P3 but D-Ins(l,3,4)P3 was able 
to displace [3H]Ins(l,4,5)P3 only very weakly, even at the highest concentration 
examined (30/tM) with an IC50 > 30/nM (Figure 2.12).
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Figure 2.12 Displacement of specific [3H]Ins(l,4,5)P3 binding to rat cerebellar 
membranes by Ins(l,4,5)P3, L-Ins(l,3,4)P3 (L-llb) and D-Ins(l,3,4)P3 (D-lla). Values 
are mean ± S.E.M. for three separate experiments, each performed in duplicate.
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2.4.4 Comparison with Ins(l,3,4,6)P4 and the Enantiomers of Ins(l,4,6)P3
Table 2.1 summarises the results of the Ca2+-release and binding assays for Ins(l,4 ,5)P3, 
Ins(l,3,4,6)P4 and the enantiomers of Ins(l,3,4)P3 and Ins(l,4 ,6)P3. In both assays, the 
activities of D-Ins(l,3,4)P3 and L-Ins(l,4,6)P3 were so low that EC40 and IC50 values 
could not be measured. Recall that both of these molecules would be expected to be 
essentially inactive because they lack any equivalent to a 4,5-bisphosphate.
The potency orders of the remaining compounds is as shown below:
Binding assay:
Ins(l,4,5)P3 > D-Ins( 1,4,6)P3 = Ins( 1,3,4,6)P4> L-Ins( 1,3,4)P3
9+Ca release:
Ins(l,4,5)P3 > D-Ins( 1,4,6)P3 > L-Ins( 1,3,4)P3 > Ins(l,3,4,6)P4




EC40/^M  ± s .e .m .
D-Ins(l,4,5)P3 0.045 ±0.01 0.69 ± 0.24
Ins(l,3,4,6)P4 1.62 ±0.39 28.50 ± 1.06
L-Ins(l,3,4)P3 (L -llb ) 4.42 ± 1.29 8.05 ± 0.98
D-Ins(l,3,4)P3 (D -lla) > 30 >100
L-Ins(l,4,6)P3 > 10 > 100
D-Ins(l,4,6)P3 1.42 ±0.34 1.56 ±0.34
Table 2.1 Comparison of inositol phosphates for displacement of [3H]Ins(l,4,5)P3 from 
rat cerebellar membranes and for release of 45Ca2+ from permeabilised platelets. EC4o = 
concentration causing 40% 45Ca2+-release. (n = 3-10).
In both assays, D-Ins(l,4,6)P3 was more potent than L-Ins(l,3,4)P3. These results 
agree with the predictions made on the basis of the binding-orientation arguments given 
in Chapter 1, and confirm that the 3-hydroxyl group of Ins(l,4,5)P3 is more important 
for binding than the 6-hydroxyl group. The same conclusion was reached by Hirata et al. 
in their study of D-Ins(l,4,6)P3 and L-Ins(l,3,4)P3.159
All the analogues behaved as full agonists in the platelet Ca -release assay, and 
yet, as discussed in Chapter 1, Ins(l,3,4,6)P4 has been previously been demonstrated to 
behave as a partial agonist in SH-SY5Y cells. Both SH-SY5Y cells and platelets possess 
the type 1 Ins(l,4,5)P3 receptor,170’171 but while 99% of the Ins(l,4,5)P3 receptors in SH- 
SY5Y cells are type 1, the abundance of this subtype in platelets is not known. It is
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possible, then, that the difference may be related to different receptors in the two cell- 
types. It should also be borne in mind that there may be methodological problems in the 
detection of partial agonists (see Section 1.8.2 and Chapter 5) related to the details of 
the assay. It will therefore be necessary to investigate the effects of L-Ins(l,3,4)P3 and D- 
Ins(l,4,6)P3 in SH-SY5Y cells before we can come to any conclusions about the 
structural basis of the partial agonist behaviour of Ins(l,3,4,6)P4. This study is now 
being carried out.
Finally, note that the orders of potency of the analogues are different for the 
binding and Ca -release assays. Again, it must be remembered that the two assays were 
carried out in different cell-types, and it is also known that, even in the same cell-type, 
binding and Ca2+ release assays may not give the same results, due to differences in 
experimental conditions.172 Ins(l,3,4,6)P4 was more potent than L-Ins(l,3,4)P3 in the 
binding assay, being equal to D-Ins(l,4,6)P3 in its ability to displace [3H]Ins(l,4,5)P3 
from cerebellar membranes. However, in Ca release it was the least potent of the 
analogues tested. Thus Ins(l,3,4,6)P4 seems to be weaker in Ca2+ release from platelets 
than would be expected from its binding affinity in cerebellum. The significance of this 
observation is not clear at the time of writing.
2.4.5 Interaction with Ins(l,3,4)P3 5/6-kinase and Ins(l,4,5)P3 3-kinase
Both enantiomers were tested for their ability to inhibit phosphorylation of 
[3H]Ins(l,3,4)P3 by a purified Ins(l,3,4)P3 5/6-kinase preparation. As expected, D- 
Ins(l,3,4)P3 was a potent inhibitor (ICso= 5.25(jM) and in this respect was identical to 
commercially available Ins(l,3,4)P3. L-Ins(l,3,4)P3 was almost inactive (IC so »  
100/xM), which is what would be predicted using the structural arguments described in 
Section 1.9.4
In contrast, when tested for interaction with Ins(l,4,5)P3 3-kinase, D-Ins(l,3,4)P3 
was not a substrate, but L-Ins(l,3,4)P3 was phosphorylated by the enzyme with 
approximately 0.4-fold the speed of the natural substrate, Ins(l,4,5)P3. This finding is in 
agreement with the arguments given in Section 1.10.3, where it is argued that L- 
Ins(l,3,4)P3 but not D-Ins(l,3,4)P3 has structural similarities to Ins(l,4,5)P3.
Finally, neither enantiomer was able to inhibit phosphatidylinositol 3-kinase. As 
for Ins(l,4,5)P3 3-kinase, we would not expect D-Ins(l,3,4)P3 to be recognised, because 
it does not resemble Ins(l,4,5)P3. However, the fact that L-Ins(l,3,4)P3 is unable to 
interact with Ptdlns 3-kinase is significant, and is evidence for the hypothesis that an
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axial 2-OH group is a structural requirement for inositol phosphates to be recognised by 
this enzyme (Section 1.9.5).90 There are no possible binding orientations for L- 
Ins(l,3,4)P3 in which it can mimic both the 4,5-bisphosphate and the axial 2-hydroxyl 
group of Ins(l,4,5)P3.
2.5 Activities of D-Ins(l,3,4)P3 and L-Ins(l,3,4)P3: Conclusions
These results have clearly established that the Ca2+-releasing ability of racemic 
Ins(l,3,4)P3 resides in the L-enantiomer. In the biological assays described above, D- 
Ins(l,3,4)P3 was essentially inactive. This is what we would expect from structure- 
activity considerations, and indeed, it is what seems to be most logical from a biological 
point of view. That is, the conversion of Ins(l,4,5)P3 to D-Ins(l,3,4)P3 by the sequential 
action of 5-phosphatase and 3-kinase abolishes its ability to release Ca2+ and therefore 
terminates this branch of the signalling pathway.
In Limulus photoreceptors, L-Ins(l,3,4)P3 caused repetitive bursts of 
depolarisation, while in the fluorescence experiments with rabbit platelets it was seen to 
cause prolonged Ca2+ release. These observations both suggest that L-Ins(l,3,4)P3 is 
only poorly metabolised, and therefore has a prolonged effect. In the study by Hirata et 
al.,159 L-Ins(l,3,4)P3 was found to be 90-fold weaker in displacement of [3H]Ins(l,4,5)P3 
from rat cerebellar membranes. In a similar assay, L -llb  was 98-fold weaker than 
Ins(l,4,5)P3. These results are in excellent agreement, and are very strong evidence that 
the absolute configuration of the L-Ins(l,3,4)P3 synthesised by Hirata et al. was correctly 
assigned. As discussed above, we found that the optical rotations of D -lla  and L -llb  
were highly dependent on pH, and this may account for the discrepancies noted earlier.
As mentioned above, some samples of D-Ins(l,3,4)P3 tested by Dr Richard 
Payne, including those purchased from commercial sources, were consistently active in 
Limulus photoreceptors, while others, including D -lla  were always inactive. We 
conclude that the active samples were contaminated with some unknown substance. In 
the case of the biologically-derived D-Ins(l,3,4)P3 this contamination is likely to have 
been Ins(l,4,5)P3. The activity was not due to L-Ins(l,3,4)P3, because the active samples 
did not produce repetitive bursts of Ca release. Similarly, we conclude that when D- 
Ins(l,3,4)P3 was reported to release Ca2+ from Swiss 3T3 cells,91 this too was 
contaminated, most likely with Ins(l,4,5)P3. It was this report that led other workers92 to 
infer that the activity of racemic Ins(l,3,4)P3 in bovine aortic smooth muscle cells was 
due to D-Ins(l,3,4)P3.
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So the confusion over the activity of D-Ins(l,3,4)P3, it seems, has been resolved. 
All absolute configurations were correctly assigned, but some samples of D-Ins(l,3,4)P3 
were not pure. Pure D-Ins(l,3,4)P3 is essentially inactive at the Ins(l,4,5)P3 receptors of 
rabbit platelets, rat cerebellar membranes, Limulus photoreceptors, GH3 cells and Swiss 
3T3 cells. One puzzle, however, remains. Hirata et al. reported that their L-Ins(l,3,4)P3 
was almost inactive in Ca2+ release, being 3000-fold weaker than Ins(l,4,5)P3.159 (In fact 
this group found L-Ins(l,3,4)P3 to be so weak that they were unable to measure an EC50 
value). In the rabbit platelet assay, L -llb  was only 12-fold weaker than Ins(l,4,5)P3. 
What could be the reason for this anomaly? It is unlikely to result from the different 
preparations of L-Ins(l,3,4)P4 used in the two studies, because the affinities for rat 
cerebellar membranes were the same. The Ca2+-mobilising effect of L-Ins(l,3,4)P3 
cannot be unique to platelets, because it was also found in Limulus photoreceptors. 
Furthermore, we can infer from the results of Polokoff et al.92 with racemic Ins(l,3,4)P3 
that L-Ins(l,3,4)P3 was also quite potent in bovine aortic smooth muscle cells. It may be 
that the discrepancy somehow results from differences in assay conditions, but there is 
also the possibility that it is due to differences between the Ins(l,4,5)P3 receptor 
subtypes in the different cell types.
Since this study was carried out, more information has emerged regarding the 
different distributions of Ins(l,4,5)P3 receptor subtypes in various tissues.170 Platelets 
possess the type 1 Ins(l,4,5)P3 receptor, and this has been shown to be similar to the rat 
cerebellum type 1 receptor in its ligand-binding characteristics.171 In contrast, RBL cells 
have now been shown to express receptors that are primarily of the type 2 family, with 
very low amounts of type l . 172 The significance of Ins(l,4,5)P3 receptor diversity has 
not been established, although some have been reported to have a different inositol 
phosphate specificity.* The apparent difference in potency of L-Ins(l,3,4)P3 in RBL cells 
and platelets suggests the possibility that the Ins(l,4,5)P3 receptor subtypes in these two 
cell types might respond differently to L-Ins(l,3,4)P3.
* An Ins(l,4,5)P3 receptor associated with the plasma membrane of lymphocytes has been reported to 
show an unusually high affinity for Ins(l,3,4,5)P4.20 jn another study, the Ins(l,4,5)P3 receptor of olfactory 
cilia, also thought to be located in the plasma membrane, was found to bind Ins(2,4,5)P3 with higher 
affinity than Ins(l,4,5)P3 itself.174
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3 Acyclic and Ring-Contracted Analogues
3.1 An Acyclic Analogue of Ins(l,4,5)P3
Various studies have demonstrated that the hydroxyl groups at positions 2 and 3 of 
Ins(l,4,5)P3 play a relatively minor role in the recognition of this molecule by the 
Ins(l,4,5)P3 receptor. The clearest illustration of this fact is the finding that Id-2,3- 
dideoxy-Ins(l,4,5)P3 (Figure 3.1) is only about six-fold weaker than Ins(l,4,5)P3 in 
binding to bovine adrenal cortices and four-fold weaker in Ca2+ release from 
permeabilised SH-SY5Y cells.107 It might therefore be interesting to delete this area of 
the cyclohexane ring in the Ins(l,4,5)P3 molecule and examine the consequences for 
activity. The most drastic way to accomplish this would be to synthesise the acyclic 
trisphosphate 15 (Figure 3.1).
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Figure 3.1 Deletion of C-2 and C-3 in Ins(l,4,5)P3 gives the acyclic analogue 15.
This molecule retains a vicinal bisphosphate together with an adjacent hydroxyl group 
and a third phosphate group in an arrangement which is topologically equivalent to the 
important binding motifs of Ins(l,4,5)P3. Of course, conformationally, 15 would be 
expected to be very different from Ins(l,4,5)P3, and a molecular modelling simulation 
showed that many low energy conformers were possible. However, there was a report in 
the literature that L-glycerol 1,2-bisphosphate (but not glycerol 1,3-bisphosphate) could
>y, 119
release Ca in rat basophilic leukaemia cells at high concentrations (EC50 = 1.9mM). 
Furthermore, 2,3-diphosphoglycerate has been reported to be a weak competitive 
antagonist of Ins(l,4,5)P3 binding in rat cerebellar microsomes (IC50 = 400jUM)175 and, 
more recently, in calf cerebellar Ins(l,4,5)P3 receptors.176 This last observation implies 
that 2,3-diphosphoglycerate was recognised (albeit with very low affinity) by the
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Ins(l,4,5)P3 binding site and yet, perhaps as a result of its flexibility, was unable to 
cause the conformational changes in the Ins(l,4,5)P3 receptor that result in opening of 
the ion channel. If it was possible to obtain a similar, or improved antagonist effect with 
15, then it might be possible to improve the binding affinity of the antagonist by further 
modifications. *
The acyclic analogue 15 can be related retrosynthetically to L-tartaric acid, but it 
was soon found that a more suitable starting material, (2S,3S)-(+)-2-benzyloxybutane- 
1,3,4-triol was commercially obtainable (Fluka), and could be used to synthesise 15 in 
only two steps. As this triol was readily available, the route would also provide an 
opportunity to evaluate a novel phosphitylating agent, bis-(4-chlorobenzyloxy)-iV,iV- 
diisopropylaminophosphine (Figure 3.2) which had been developed for the preparation 
of phosphorylated amino acids and peptides.177 The advantages claimed for this reagent 
were that it is a solid, which is easy to handle, and that the 4-chlorobenzyl groups 
increased the crystallinity of the phosphorylated products, which are often oils and 
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Figure 3.2 Synthesis of acyclic analogue 15. Bn-Cl = 4-chlorobenzyl.
* For example, the 2'-AMP structure of the adenophostins appears to confer a hundred-fold increase in 
affinity for the receptor relative to analogues lacking this structure (See Chapter 5). Might it therefore be 
possible to design an acyclic analogue incorporating features of adenophostin, which would bind with 
high affinity, but not release Ca2+?
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The triol was phosphitylated using bis-(4-chlorobenzyloxy)-A,A- 
diisopropylaminophosphine / l//-tetrazole in dichloromethane. The 31P NMR spectrum 
of the intermediate trisphosphite triester showed very small 5/pp spin coupling constants 
(1.5 Hz), and unexpectedly, a 6/ pp coupling of approximately the same magnitude was 
present. Thus, the 31P NMR spectrum appeared as two doublets and a triplet. Oxidation 
gave the trisphosphate triester 16 which, disappointingly, was found to be an oil. 
Deprotection using sodium in liquid ammonia was successful, although the yield was 
low (42%) after purification by ion-exchange chromatography to give 15 as its 
triethylammonium salt.
3.1.1 Biological Evaluation
The acyclic trisphosphate 15 was tested for ability to release 45Ca2+ from permeabilised 
rabbit platelets. Not surprisingly, it showed no effect over the usual concentration range 
(0 to \00fiM ) although slight 45Ca2+ release was observed (19 ± 3.8%) at the highest 
concentration used (300jUM). More significantly, 15 showed no ability to inhibit 
Ins(l,4,5)P3 -induced 45Ca2+-release ( I f jM Ins(l,4,5)P3 ), and the slight 45Ca2+-release 
effect at high concentrations was additive with the effect of Ins(l,4,5)P3. Thus, 15 
seemed to be acting as a very weak agonist, similar behaviour to that reported for L- 
glycerol 2,3-bisphosphate. It was decided not to pursue the investigation of acyclic 
analogues any further, and binding studies were not carried out.
These results suggest that a particular, relatively rigid, spatial arrangement of 
phosphate groups is required for recognition by the Ins(l,4,5)P3 receptor. It might be 
reasoned that, although the acyclic analogue is capable of attaining the required 
conformation the suitable conformers are of relatively high energy, and are therefore 
present in very small amounts. An alternative interpretation is to invoke a more 
dynamic, induced-fit model, in which a flexible arrangement of phosphate and hydroxyl 
groups (even if it does mimic the appropriate binding conformation) will always be 
incapable of participating in a sequence of co-ordinated protein-ligand interactions 
which together constitute the process of ligand binding.
An examination of the ability of 15 to inhibit phosphorylation of Ins(l,3,4)P3 by 
Ins(l,3,4)P3 5/6-kinase showed that it was not recognised by the enzyme. The 
interaction of 15 with 5-phosphatase is under evaluation.
71
3.2 Five-membered Ring Analogues of Ins(l,4,5)P3.
Returning now to the possibility of deleting part of the Ins(l,4,5)P3 molecule, an 
approach based on ring-contraction might be more successful. In particular, a five- 
membered ring Ins(l,4,5)P3 analogue that maintained the important recognition features 
and the conformational rigidity of Ins(l,4,5)P3, but lacked any equivalent to positions 2 
and 3 of Ins(l,4,5)P3 might still be active. Of course, this ring-contracted version of 
Ins( 1,4,5)P3 would have to include an equivalent of the critical 4,5-bisphosphate feature, 
together with a surrogate for the important 6-hydroxyl group. A third phosphate group in 
a position corresponding to the 1-phosphate of Ins(l,4,5)P3 should enhance binding. The 
simplest version of this is shown in Figure 3.3.
Figure 3.3 Deletion of the 2- and 3-hydroxyl groups of Ins(l,4,5)P3 to give a five-
The prospect of such a five-membered ring analogue was enticing because, despite the 
many modifications made to Ins(l,4,5)P3 in the past, the requirement for a six- 
membered ring had never been questioned. Even in the adenophostins (see Chapter 5), 
which differ in many respects from Ins(l,4,5)P3, the important 3,4-bisphosphate/2- 
hydroxyl triad, analogous to the 4,5-bisphosphate/6-hydroxyl arrangement of 
Ins(l,4,5)P3, is contained within a six-membered pyranoside ring.
3.2.1 A Route to Five-Membered Rings from Glucose
This minimal structure did not seem to be easily accessible synthetically, and it was 
questionable whether the time and effort likely to be involved in developing a route was 
justified. At around this time a simple route to highly functionalised optically pure
178vmy/cyclopentanes from various carbohydrates was disclosed by Ito et al. The method 
involved a zirconium-mediated diastereoselective ring contraction of vinyl carbohydrate 
derivatives. Two examples are shown in Figure 3.4.
* Note that the five-membered analogue shown in Figure 3.3 could be regarded as a conformationally- 





Figure 3.4 Diastereoselective ring contraction of vinyl carbohydrates using the 
zirconocene equivalent “Cp2Zr” 178 (see text).
This prompted us to consider the feasibility of synthesising analogue 17. Notice that 17 
includes an hydroxymethyl group, which also occurs in adenophostin A (Chapter 5). 
Retrosynthetic analysis (Figure 3.5) showed that the required protected carbohydrate 
was the a-methyl-D-glucopyranoside derivative 18, and it turned out that a colleague had 
already developed a route to this compound as part of a separate project. The 
appropriately protected pyranoside 18 was synthesised in 4 steps from a-methyl-D- 








Figure 3.5. Retrosynthetic analysis suggests that the five-membered ring Ins(l,4,5)P3 
analogue 17 might be synthesised from glucose via the protected a-methyl-D- 
glucopyranoside derivative 18.
3.2.2 Ring Contraction
The synthesis of the critical vinylcyclopentane derivative 21b is shown in Figure 
3.6. Swem oxidation of 18 with DMSO/oxalyl chloride gave the aldehyde 19. This 
aldehyde was anticipated to be unstable and aqueous work-up was avoided. Instead the 
crude product was simply loaded onto a short column of silica and then eluted with ethyl 
acetate/hexane. Evaporation of solvents gave a yellow oil which was then used without
further purification. Wittig methylenation proceeded smoothly to give the required vinyl 
carbohydrate 20 in 75% overall yield from 18. The ring contraction was carried out
with Cp2Zr(«-Bu)2 (prepared in situ from zirconocene dichloride and 2 equivalents of n- 
butyllithium), followed by BF3#OEt2 in THF.
“Cp2Zr”/THF then BF3*OEt2, -78°C to r.t. Bn = benzyl, PMB = p-methoxybenzyl.
The authors178 propose a reaction mechanism (Figure 3.7) based on an NMR 
study of the reactive allylic zirconium intermediate, suggesting that the BF3*OEt2 
functions to accelerate the elimination of a methoxyl group by co-ordination to the 
methoxy oxygen of this intermediate. This gives two possible oxacarbenium ion 
transition states, one of which is of higher energy due an unfavourable steric interaction 
involving the protecting group at position 4 of the starting vinylpyranoside and a 
cyclopentadiene ring. The diastereoselectivity of the ring contraction is thought to 
originate in this energy difference. The stereochemistry of the new chiral centres in the 
product is thus strongly influenced by the stereochemistry at position 4 and the nature of 
the substituent. In this respect it was expected that a p-methoxybenzyl protecting group 
at this position would exert a similar influence to a benzyl group.




















Figure 3.6 Synthesis of the vinylcyclopentane intermediate 21b.
i) DMSO, (COCl)2, CH2C12 then Et3N, -60°C, ii) CH3PPh3, K O B u, THF, iii)
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Figure 3.7 Proposed mechanism for the zirconium mediated ring-contraction 178 applied 
to the formation of the two vinylcyclopentanes 21a and 21b.
One complication encountered, however, was that gradual loss of p- 
methoxybenzyl protecting groups after the addition of BF3»OEt2 became a competing 
reaction. Nevertheless, the major product was obtained in fair (46%) yield as a waxy 
solid, together with a small amount of another product which had a very similar Rf, but 
could be isolated by careful chromatography, and then crystallised. The two products 
had almost identical infra-red spectra, but very different NMR spectra and optical 
rotations. It seemed likely that the two products were the diastereoisomers 21a and 21b, 
the minor isomer being the kinetically disfavoured product resulting from collapse of 
the higher energy pseudochair transition state.
3.2.3 Assignment of Structures
At this stage it was not known which of the two products was the required structure 21b 
although, on the basis of the mechanistic argument above, it seemed likely that 21b 
would be the major product.
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1 13The H and C NMR spectra of this material closely resembled those obtained by Ito et 
al. for the related product with three benzyl protecting groups (Figure 3.4) while those 
for the minor product did not. However, Ito et al. did not isolate any of the minor 
product in the contraction of their glucopyranoside derivative, and so no data were 
available for comparison. X-ray crystal structures were out of the question, as the major 
product was a wax, and the other could be crystallised only with difficulty. However, the 
fact that we did have both diastereoisomers, meant that an NOE study was particularly 
appropriate.
JH - !H COSY NMR spectra were first obtained for both isomers and used to 
assign the ring protons in each case. The ID *H NMR spectra, with the assignments are 
shown in Figure 3.8. A phase-sensitive 2D-NOESY was then obtained for the major 
product. Evidence from the 2D-NOESY was not conclusive. A definite strong NOE was 
seen between H-4 and H-5, for example, confirming that the substituents on the new C- 
C bond are cis, but this was compatible with either structure. All the expected strong 
NOEs, e.g. within the p-methoxybenzyl rings, within the vinyl group and between the 
ring protons at protected positions and the CH2 protons of their respective protecting 
groups were visible, but other interactions within the five-membered ring were not clear.
The relative stereochemistries of 21a and of 21b were finally confirmed by NOE 
difference NMR spectroscopy. In each case, the H-5 proton was selectively irradiated 
and the NOE enhancements of the other ring protons were measured. The results are 
shown in Figure 3.9. This time, the expected NOEs could be seen, although there were 
some problems due to obscuring of signals by the p-methoxybenzyl methyl groups. 
However, the major product did indeed appear to be 21b. The critical observations were 
the existence of an H-2/H-5 interaction in 21b but not 21a, and an H-l/H-5 interaction 
in 21a, but not 21b. This example illustrates the value of having both possible products 
when assigning structures on the basis of NOE experiments. The failure to observe an 
NOE, for example, is not in itself sufficient evidence for a particular structure. 
However, the observation of an NOE between two protons in one molecule, although 



















Figure 3.8 1H-1H NMR spectra of vinylcyclopentanes 21a and 21b (400 MHz, CDCI3)
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Figure 3.9 Results of NOE difference NMR spectroscopy of the diastereoisomeric 
vinylcyclopentanes 21a and 21b. Positive NOEs to H-3 and/or H-4 were observed for 
21a, but could not be quantified due to overlap of these signals with one another and 
with OCH3 of PMBs.
3.2.4 A Prototype Vinylcyclopentane-based Analogue of Ins(l,4,5)P3
At this stage, oxidative cleavage of the vinyl group and further 
protection/deprotection steps would be required to give the triol precursor for the target 
trisphosphate 17. It was decided, with a relatively small amount of the ring-contracted 
intermediate 21b in hand, to consider making the prototype compound 22, which retains 
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Figure 3.10 The intermediate 21b could be converted to 22 in only three steps.
Molecular modelling showed that the vinyl group of 22 would be expected to 
occupy a position in space close to that of the axial 2-OH of Ins(l,4 ,5)P3, and it is 
known that bulky substituents are tolerated in this region.180 It therefore seemed logical 
to produce the immediately attainable trisphosphate 22, and to find out whether this 
prototype molecule retained any biological activity, before attempting the more lengthy 
synthesis of 17. If trisphosphate 22 did prove to be active, then the vinyl group of 
intermediate 21b would provide a starting-point for modification to provide a variety of 
functional groups, including the original target trisphosphate 17. Should this prototype 
prove to be totally inactive however, then the value of making other five-membered ring 
analogues might be called into question.
Removal of the p-methoxybenzyl protecting groups from the major product 21b 
by acid hydrolysis gave the triol 23. Phosphitylation using bis-(benzyloxy)-N,Af- 
diisopropylaminophosphine and 1/7-tetrazole, followed by oxidation of phosphites with
constant of 6.7 Hz [cf. 2.9 Hz and 3.4 Hz for precursors of Ins(4 ,5)P2181 and 
Ins(l,4 ,5)P3182 respectively], presumably reflecting the altered geometry of the P(III)- 
P(III) interaction in a five-membered ring.
Figure 3.11 Conversion of 21b to the prototype five-membered ring analogue 22. 
i) M HCl/EtOH 1:2, A, 3h, 87%; ii) a) Pr'2NP(OBn)2, lH-tetrazole, CH2C12 b) m-CPBA, 
-78°C, 82%; iii) Na/ liquid NH3, -78°C, 58%.
The !H-coupled 31P NMR spectrum of the trisphosphate triester 24 (Figure 3.12) 
showed a surprising feature. In previous compounds of this type, which were all based 
on six-membered frameworks, the signals for the three phosphorus atoms appear as 
sextets. This pattern arises from heteronuclear Vhp couplings to the four protons in the 
benzyl CH2 groups and also to the single cyclitol ring proton at the position of 
phosphorylation. As these five protons are all chemically inequivalent, the splitting 
pattern is strictly a ddddd, but because the coupling constants are usually similar, each 
signal approximates to a sextet. In the spectrum of 24, one of the three phosphorus 
atoms appears as a doubled sextet. The extra splitting (approximately 2.7Hz) must arise 
from a long-range 31P -*H coupling, probably related to the novel geometry of the five- 
membered ring, although it was not possible to locate this coupling in the complex *H
o i
m-chloroperoxybenzoic acid gave the fully protected trisphosphate 24. P NMR 














NMR spectrum. A 2D phosphorus-proton COSY experiment, which has not yet been 
carried out, should be able to identify the pair of atoms involved.
(BnO)2P O - ^ - ^
(BnO)2jj>0 ^ ^ < ^ O f j ,(OBn)2
O Bn0 O
24
- 2.4- 2 .3- 2.2- 1.9 - 2.0 - 2.1
Figure 3.12 31P NMR spectrum of 24 (’H-coupled, 400 MHz, CDCI3).
Deprotection using sodium in liquid ammonia removed the seven benzyl 
protecting groups, leaving the vinyl group intact. Purification by ion-exchange 
chromatography of the crude product gave the trisphosphate 2 2 , which was isolated as 
the triethylammonium salt and quantified by phosphate assay. A 'H-coupled 31P NMR 
spectrum of 22 showed the expected three doublets. The long-range heteronuclear 
coupling seen in the spectrum of its protected precursor had now disappeared.
3.2.5 Biological Evaluation
Trisphosphate 22 was examined for Ca2+ mobilising activity at the platelet Ins(l,4 ,5 )P3 
receptor using fluorescence techniques, and also using saponin-permeabilised platelets 
loaded with 45Ca2+ It was found to be a full agonist, around 65-fold weaker than 









0.01 0.1 1 10 100
inositol phosphate [p IV!
Figure 3.13 45Ca2+-release by 22 from permeabilised rabbit platelets (n=2).
These results demonstrated for the first time that potent Ins( 1,4 ,5 )P3 receptor-mediated 
Ca2+ mobilisation does not necessarily require a six-membered ring. A smaller ring 
phosphate that retains crucial recognition elements of Ins(l,4 ,5 )P3, i.e. three 
appropriately orientated phosphates and a surrogate for the 6 -hydroxyl group, is still 
recognised by the Ins(l,4,5)P3 receptor.
The Ca2+-releasing properties of 22 in SHSY-5Y cells and its interaction with a 
cloned 3-kinase are currently under investigation. As an optically pure analogue whose 
frarcs-bisphosphate has the d-4,5-configuration, we would not expect it to interact with 
D-Ins(l,3 ,4 )P3 5/6-kinase (Section 1.9.4), and biological testing has now confirmed that 
this enzyme does not recognise 2 2 .
3.3 Attempted Synthesis of Hydroxymethyl Analogue 17
It was not clear at this stage whether the considerably reduced potency of 22 
relative to Ins( 1,4 ,5 )P3* was related to the presence of the vinyl group or was a necessary 
consequence of the reduced ring size. In the five-membered ring, for example, 
molecular modelling shows that the torsion angle corresponding to 0 4 -C 4 -C 5 -0 5  of 
Ins(l,4,5)P3 is expected to be larger,1 and the relative position of the 1-phosphate group 
is altered. Increasing steric bulk at the 3-position of Ins(l,4 ,5 )P3 (see Chapter 5) reduces
* Strictly, 22 should be compared to D -3-deoxy-Ins(l,4 ,5)P3, which is reported to be 4-fold  weaker in Ca2+ 
release and 6-fold  weaker in binding than In s(l,4 ,5 )P 3.107
f The effect o f  increasing this torsion angle on biological activity could be explored by the synthesis o f  
cyclohexene-based analogues (see section 4.5.2)
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affinity for the receptor, and D-3-MeO-Ins(l,4 ,5)P3 is 150-fold weaker in Ca2+-release 
and 50-fold weaker in binding than Ins(l,4 ,5)P3183 while steric bulk at the axial position 
2 is well-tolerated. As the molecular modelling of 22 showed its vinyl group to occupy 
an area of space somewhere between positions 2 and 3 it was difficult to predict the 
extent of its effect. However, having demonstrated reasonably potent activity for the 
prototype 22, the next step was to synthesise and evaluate the 
hydroxymethylcyclopentane trisphosphate 17.
The synthesis of 17 would require oxidative cleavage of the vinyl group in 21b 
together with a number of protection/deprotection steps before phosphorylation and 
final deprotection. However, the intermediate 21b was by now in short supply, and so it 
was decided to attempt a short-cut by cleaving the vinyl group of the phosphorylated 
intermediate 24 with osmium tetraoxide/ sodium metaperiodate followed by sodium 
borohydride.
A solution of 24 in ether was treated with an aqueous solution of osmium 
tetraoxide and sodium metaperiodate.184 A TLC obtained 3 hours after addition of the 
OsCVNalCU mixture showed only highly polar products together with one spot at longer 
Rf. What was worse, this product, which was assumed to be the aldehyde (although 
worryingly, it did not stain with DNP) appeared to be diminishing with time. When 
sodium borohydride was added the spot was unaffected. The reaction had obviously 
failed, and isolation of the only non-polar product by flash chromatography showed it to 
be a small amount of the Wc-diol 25 (the stereochemistry at the position marked * is not 
established).
It seems, therefore that the initial dihydroxylation of the double bond had 
occurred, with the OsC>4 approaching exclusively from one face to give the glycol 25. 
Presumably, 25 would then be cleaved over a period of hours, by the metaperiodate to 
give the aldehyde, hence the gradual diminution of the corresponding spot in the TLC. 
However, as no aldehyde was seen, it is tempting to conclude that it was unstable, and 
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Figure 3.14 Unsuccessful attempt at oxidative cleavage of the vinyl group in 24
3.3.1 Improved Route to the Hydroxymethyl Analogue
It would therefore be necessary to synthesise more ring-contracted intermediate 
21b and then carry out the cleavage of the vinyl group prior to phosphorylation. 
However, at about this time, a more direct route to 17 became available. A recently 
reported samarium (II) iodide-mediated ring contraction185 could be used directly on 
aldehyde 19 to give the diol (Figure 3.15) required for the synthesis of 17. The route 
would be far shorter than that via the vinylcyclopentane intermediate. The synthesis of 
17 by this new method has now been successfully carried out by a colleague.
The vinylcyclopentane trisphosphate 22 and the hydroxymethyl analogue 17 
were compared for release of 45Ca2+ from permeabilised Jurkat T-lymphocytes (the 
rabbit platelet assay was no longer available). As expected, 17 showed greatly increased 
activity compared to vinylcyclopentane analogue 22, being only two to four-fold weaker 
than Ins( 1,4 ,5)P3 in this assay.
Sm l2-THF, HMPAPMBO
PMBO
Bu OH OHBnO I 






.185Figure 3.15 Sml2-mediated ring-contraction of an aldehyde provides a rapid route to 
the diol required for the target trisphosphate 17.
83
It is not yet clear whether this enhancement of activity in the hydroxymethyl 
analogue 17 is due simply to the removal of the hydrophobic vinyl group, or whether the 
primary hydroxyl group engages in favourable interactions with the Ins(l,4 ,5 )P3 receptor 
binding site. Another possibility is that the hydroxymethyl group influences the 
orientation of the nearby phosphate group by intramolecular hydrogen bonding. A 
molecular modelling simulation showed that, in many low energy conformations of both 
Ins(l,4 ,5 )P3 and 17, the 4-phosphate group of Ins(l,4 ,5 )P3 and its equivalent in 17 did 
form H-bonds to the neighbouring hydroxyl (Figure 3.16), although it is difficult to say 
how significant such intramolecular interactions may be in solution and at the receptor 
binding site.
Figure 3.16 Low-energy conformations of Ins(l,4 ,5 )P3 and 17 show intramolecular H- 
bonding interactions. (See Experimental for details of modelling).
84
4 A Conformationally Restricted Analogue of Ins(l,4,5)P3
4.1 Design
It was argued in Section 1.11 that it might be possible to gain more information about 
the Ins(l,4 ,5)P3 receptor binding site by studies of conformationally restricted 
analogues. A problem inherent in the use of this strategy is that it is not possible to 
achieve the desired constraint without altering the molecule in some other way. It is 
likely that steric bulk will be added, for example, and that charge distribution and 
hydrogen bonding interactions will be disrupted. The ideal is to constrain some part of 
the molecule, which is thought to be significant in its binding to the receptor, in such a 
way as to minimise the disturbance to other regions that are known to be important for 
activity. This may be difficult to achieve, and, should the molecule prove to be inactive, 
it is not possible to infer with certainty that its inactivity is related to its conformational 
rigidity per se.
Considering now the Ins(l,4,5)P3 molecule, it would be interesting to constrain 
the orientation of one of the phosphate groups. Apart from a study of the naturally 
occurring inositol l:2-cyclic,4,5-trisphosphate,186 which mobilises Ca2+, and the 
synthetic inositol l-phosphate-4,5-pyrophosphate,187 which was inactive, this approach 
had not yet been explored for Ins(l,4 ,5)P3. In the light of the discussion above, it might 
be particularly interesting to constrain the 4- or 5-phosphate group. To do this, we 
would need somehow to attach it to an adjacent position (Figure 4.1). Note that in the 
two analogues shown, the equivalent of the hydroxyl group at position 2 is equatorial 
rather than axial. This considerably simplifies the synthesis, as will be seen later. It was 
thought unlikely that the inversion of position 2 would significantly reduce activity, as 
jcy//o-Ins(l,2,4)P3 106 is almost equipotent with Ins(l,4 ,5)P3. Studies have shown that 
the Ins(l,4 ,5)P3 receptor is intolerant of added steric bulk at position 6 92 and that 
deletion of the hydroxyl group at 6 also reduces activity by a factor of 70.109 On the 
other hand, the Ins(l,4 ,5)P3 receptor can accommodate slightly increased bulk around 
the 3-position188 and what is more, 3-deoxy-Ins(l,4 ,5)P3 is highly active.107,108
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A Constrained 4-phosphate B Constrained 5-phosphate
Figure 4.1 Two cyclic phosphate analogues of Ins( 1,4 ,5)P3
Finally, constraining a phosphate group in this way would necessarily result in a 
decrease of negative charge on the constrained phosphate. Now NMR studies have 
shown that the binding affinity of Ins(l,4,5)P3 to its receptor correlates most closely 
with the ionisation state of the 5-phosphate group.189 Taken together, then, these 
observations suggested that the initial target should be structure A, in which the 4- 
phosphate group is constrained.
There are two possible epimeric molecules corresponding to structure A, and 
these are shown in Figure 4.2. When molecular modelling studies of Ins( 1,4 ,5)P3 were 
carried out, the energy-minimised structures were consistently found to resemble the 
trans-fused structure 26, in which the equivalent of the P 4-04 -C 4-H 4  torsion angle* is 









Figure 4.2 Two epimeric cyclic analogues of Ins(l,4 ,5)P3. The phosphate group 
equivalent to the 4-phosphate of Ins(l,4 ,5)P3 is constrained in one of two different 
orientations.
* Energy-minimised conformations of Ins(l,4,5)P3 all had a P 4-04-C 4-H 4 torsion angle between 0° and 
+60°, but the size of the angle appeared to depend on the way in which the charges on the phosphate 
groups were simulated, on the treatment of the dielectric constant of the medium, and on whether the 
minimised structure showed intramolecular H-bonding. However, structures resembling the cw-fused 
epimer were never seen.
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This arises because, at least in these simulations, the dominant factor in determining the 
conformation of the 4- and 5-phosphates is electrostatic repulsion. In some energy- 
minimised structures (e.g. Figure 3.16) a hydrogen-bonding interaction between the 4- 
phosphate and the 3-OH group was also seen, further stabilising a splayed arrangement 
of phosphate groups.
The decision was therefore made initially to develop a route leading to 26, in 
which the two rings of the target bicyclic system are fused in a trans sense. Ideally the 
route should be capable of modification to give the cw-fused epimer, if required, so that 
the biological properties of the two epimers could be compared. Retrosynthetic analysis 










Figure 4.3 Retrosynthetic analysis of the cyclic analogue 26 suggests a synthesis from 
myoinositol orthoformate.
4.2 Synthesis
The successful synthesis of 26 is shown in Figure 4.4. It has the advantage that the 
symmetrical nature of the intermediates is maintained well into the synthesis. This 
simplifies the interpretation of the NMR spectra, particularly for the orthoformate 
derivatives, whose ^  NMR spectra can be complicated by high multiplicity of the 
signals due to long-range couplings, and the fact that all vicinal couplings are of similar 
magnitudes, making signals difficult to assign.
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Figure 4.4 Synthesis of conformationally restrained analogue 26 
i) NaH (2.1equiv.), PMBC1 (2.0 equiv.), DMF; ii) DMSO, (COCl)2, CH2C12, -60°C then Et3N; 
iii) CH3PPh3Br, f-BuOK, THF, reflux; iv) a) 9BBN-H, THF, 50°C b) H20 2, OH'; v) 1M 
HCl/MeOH 1:10, 50°C; vi) C6H5CH(OMe)2, DMF, p-TsOH, vii) NaH, BnBr, DMF; viii) 1M 
HCl/THF/MeOH 1:5:5, reflux; ix) a) BnOP(NPr'2)2, ltf-tetrazole, b) m-CPBA, -78°C; x) DDQ, 
CH2C12, H20 ; xi) a) (BnO)2PNPr'2, l//-tetrazole, b) m-CPBA, -78°C; xii) Na/liq NH3 PMB = p- 
methoxybenzyl; Bn = benzyl; All asymmetrical compounds are racemic.
It was intended that the methylenation step would be carried out using a Wittig 
reaction or by the use of Tebbe's reagent.190 Difficulties had been reported in the use of 
Wittig reactions on inososes but apparently these could be overcome by introducing 
conformational restraint,191 and the rigid structure of ketone 29 should be particularly
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suited to this. Furthermore, it might be possible to exploit the structure of alkene 30 so 
as to determine the stereochemistry at the branch-point with high selectivity.
4.3 Synthesis of a Versatile Ketone Intermediate
p-Methoxybenzyl groups were chosen to protect positions 4 and 6 of myo­
inositol orthoformate. The protecting groups at these positions were required to be of a 
semi-permanent nature and although, like the orthoformate ester, these groups are acid- 
labile, it was known that an orthoformate ester could selectively be cleaved in their 
presence.83 Allyl groups, for example, were not suitable, because a hydroboration 
reaction might be required at a later stage. One route to the 4,6-di-O-alkylated 
compound 28 would be selectively to protect myo-inositol orthoformate at position 2 
(e.g. with terf-butyldimethylsilyl chloride), carry out the p-methoxybenzylation, and 
then remove the protection at position 2. This strategy has been used for the synthesis of
1 7Q 1 ™4- and 6- substituted myo-inositol orthoformates. * However, the overall yield after 
these three steps is low and this arises mainly from inefficiency in the introduction of 
the silyl protecting group. There is a report in the literature that, benzylation of myo­
inositol orthoformate using two equivalents of sodium hydride and two equivalents of 
benzyl bromide gave a mixture of mono-, di- and tri-O-benzylated orthoformates, with 
the 4,6-dibenzylated product as the major product (27% yield).125 It was felt that, if this 
yield could be improved, then this strategy would be preferable to the three-step route, 
particularly for large-scale production of 28.
Figure 4.5 Regioselective alkylation of myo-inositol orthoformate followed by Swem 
oxidation gives the strained ketone 29.
Reaction of 27 with 2.1 equivalents of p-methoxybenzyl chloride and 2.3 
equivalents of sodium hydride gave the symmetrical 4,6-disubsituted alcohol 28 as the 
highly crystalline major product, easily recognisable from the NMR spectra by its plane 
of symmetry. With careful work-up and chromatography it was possible to increase the 
yield of 28 to around 40%. The monosubstituted by-product was found to be exclusively 
the axially substituted diol, and this could be recycled to give more 28. No products 
substituted at position 2 were detected, apart from a small amount of the tri-O-p-
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methoxybenzyl ether. Alcohol 28 has obvious application as a precursor for position 
2-modified analogues of Ins(l,3,4 ,5,6)P5, and for the synthesis of position 2-modified 
Ins(l,4 ,6)PS3 analogues, potential partial agonists at the Ins(l,4 ,5)P3 receptor (see 
Chapter 6).
Swem oxidation of 28 using DMSO/oxalyl chloride was expected to give the 
inosose 29, and the reaction appeared to be successful, as judged by TLC. However, 
after aqueous work-up, an infra-red spectrum of the product showed two bands at 3540 
and 3440cm'1 suggesting two alcohol groups, together with a band at 1760cm'1, 
corresponding to the expected ketone. The alcohol bands were not due to starting 
material, which showed a single band at 3500cm'1. The NMR spectrum was 
confusing, showing a mixture of two compounds. Eventually it was realised that the 
desired ketone was present, but had been partially converted into the corresponding 
gem-diol (ketone hydrate 29a, Figure 4.6) in the work-up. Part of the sample was 
refluxed in toluene, with azeotropic removal of water, and the IR spectrum then showed 
that the bands around 3500cm"1 had disappeared. *H NMR and 13C NMR spectra were 
then obtained, and clearly showed the product to be the symmetrical ketone 29.
The gem-diol 29a could also be isolated by allowing a solution of the ketone in 
dioxane with a few drops of water to stand for a few days, followed by evaporation and 
re-crystallisation. The !H NMR spectrum of 29a showed the two OH protons, 
exchangeable in D2O within a molecule that maintained the same symmetry as the 
corresponding ketone. The chemical shifts of these protons were very different (5 3.82 
and 8 4.97, CDCI3). It is likely that the signal at 8 4.97 corresponds to the proton of the 
axial hydroxyl group, as the higher-field signal is similar to that seen in the spectrum of 
28, and the corresponding hydroxyl proton of the scyllo-inositol orthoformate derivative 
63 (Chapter 7) is also deshielded. The 13C NMR spectrum showed the unusual feature of 
a quaternary carbon resonating at 8 88.67, corresponding to C(OH)2-
The ease of hydration of ketone 29 may be attributable to strain effects in its 
rigid cage-like structure, resulting in destabilisation of sp2-hybridized carbon relative to
3 * 1sp . The unusually high stretching frequency of the C = 0 bond in 29 (1760cm' ) is 
further evidence of ring strain. Ketone 29 also reacted with methanol at room 
temperature to give a single hemiketal. The configuration of this product at C-2 has not 
yet been rigorously established, but it seems likely that it is 29b, with the O-methyl 
group equatorial. Of the two alternatives, this epimer is sterically less congested, and
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therefore likely to be the more thermodynamically stable. In the *£1 NMR of 29b, the 
singlet corresponding to the hydroxyl proton is found at very low field (S  4.92, CDCI3), 
an observation which may be interpreted as evidence that hydroxyl group is axial, thus 
supporting the structure shown.
Figure 4.6 Conversion of the ketone 29 to gem-diol 29a and hemiketal 29b
Ketone 29 is highly crystalline, and stable if kept out of contact with moisture. 
Its carbonyl group shows high reactivity, and the fact that one face is sterically hindered 
by the p-methoxybenzyl groups, while the other is highly exposed to attack from a 
variety of reagents should make it a useful intermediate for stereoselective modification. 
An example of this is its use in the synthesis of scyllo-inositol 1,2,3,5-tetrakisphosphate 
(Chapter 7).
4.4 Wittig Methylenation: Observation of an Unusually Stable Intermediate.
The next step was the methylenation of ketone 29 to provide the symmetrical alkene 30. 
It was planned to attempt this transformation initially by Wittig methylenation using 
methylenetriphenylphosphine, and then if this was unsatisfactory, to try Peterson 
olefination or the (much more expensive) Tebbe reagent. In a reported synthesis of 
conduritols from L-quebrachitol, Wittig methylenation of an inosose bearing 
cyclohexylidene and methyl ether protecting groups gave very poor yields, which the 
authors attributed to steric hindrance, although Peterson olefination was successful.192 A 
comparative study of the Wittig and Tebbe reagents190 claimed higher yields for the 
latter, and greater success with substrates that were sterically hindered. The strongly 
basic conditions of the Wittig reaction were not expected to be a problem, as neither 
orthoformate nor p-methoxybenzyl protecting groups are base-sensitive. Another 
important property of ketone 29 is that the protons a  to the carbonyl group are not 
acidic, being located at bridgeheads, so there is no possibility of enolisation.
In the first attempts at Wittig methylenation using methyltriphenylphosphonium 
bromide, potassium terf-butoxide as base and heating to 50°C for two hours, the yields 
were consistently low (30 to 50%). During a final attempt to improve yields, it was
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noticed that TLC of the crude product showed another polar by-product, besides 
triphenylphosphine oxide. In previous attempts, large quantities of highly polar, pale 
yellow solid material had been filtered off during work-up and discarded, assuming it to 
contain mainly triphenylphosphine oxide. However, one of the polar products stained 
purple with PMA, evidence that it contained p-methoxybenzyl groups. Some of the 
solid, still left in a Buchner funnel from the previous day’s reaction was added to THF 
and heated to reflux. It rapidly decomposed to give large quantities of alkene 30, and the 
cause of the low yields was immediately apparent. The intermediate oxaphosphetane 
formed by the reaction of ketone 29 with methylenetriphenylphosphorane was highly 
stable, and heating to 50°C was insufficient to decompose it fully within two hours. 
When the reaction was repeated, but with heating to reflux for two hours after adding 
ketone to Wittig reagent, 30 was obtained in 91% yield. In a later, large-scale run of the 
reaction, samples were taken and subjected to 31P NMR. After addition of base to 
methyltriphenylphosphonium bromide, the canary yellow ylide appeared as a peak at 
19.9 in the NMR spectrum. On addition of ketone, this was replaced by a single 
resonance at <5p -68.9, corresponding to the oxaphosphetane. A sample of this material 
was kept for 2 days at 4°C, after which time 31P NMR spectrum showed evidence of 
only slight decomposition.* The oxaphosphetane is assumed to have the structure shown 
in Figure 4.7, arising from attack at the less hindered face of the carbonyl group.
Figure 4.7 Wittig methylene of ketone 29 proceeds via a stable oxaphosphetane 
intermediate.
The orthoformate ester of 30 could be removed selectively using mild acid 
treatment to give the symmetrical crystalline triol 39. This compound has not been 
further investigated to-date.
* A detailed low-temperature study of the intermediates in the Wittig reaction193 has found that, although 
most oxaphosphetanes obtained from the reaction of aldehydes and ketones with CH2=PPh3 are unstable, 
being decomposed within a few minutes at -8°C, those derived from cyclobutanone and norbornanone 
require >0°C for conversion to the strained alkene.
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Figure 4.8 Selective removal of the orthoformate ester gives alkene 39.
4.5 Diastereoselective Hydroboration/O xidation
The alkene 30 was converted into alcohol 31 by hydroboration/oxidation using 9-BBN- 
H followed by alkaline hydrogen peroxide solution. It was hoped that the high steric 
demands of 9-BBN-H would give good regio- and stereoselectivity in this case. The 
results were even better than anticipated, and a single product was obtained in 97% yield 
after chromatography. Although the expected structure of this product was 31, rather 
than the epimeric 31a, this could not be deduced from the NMR spectrum simply by 
inspection of vicinal coupling constants. Both structures would show only axial- 
equatorial or equatorial-equatorial couplings which are of similar low magnitude, 
together with long-range-couplings, leading to rather complex or broadened signals 
from the ring protons. It would probably be possible to use NOESY to establish the 
correct structure of the product, but there was a more immediate way.
Figure 4.9 Hydroboration-oxidation of alkene 30 with 9-BBN-H gives a single product.
many of its derivatives shows a long-range 5-bond coupling (typically around 1 Hz)
whereas in the spectrum of the scyllo-inositol orthoformate derivative 63 (Figure 4.10 
and Chapter 7), no coupling can be seen. Now the corresponding signal in the spectrum 
of the hydroboration/oxidation product was a sharp singlet. The fact that there was no 
coupling to H-2 was evidence that this proton was no longer axial, and that the product 
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It has been noted that the lH NMR spectrum of myo-inositol orthoformate and
between the methylidine proton and the axial proton at C-2.129 Thus, in the *H NMR 
spectrum of 28, the methylidine proton appears as a narrow doublet with 5J  = 0.9Hz,
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predicting stereochemistry at C-2 of inositol orthoformate derivatives requires a well- 
resolved ]H NMR spectrum. In the spectra of more polar derivatives, which were 
obtained using d6-DMSO as solvent, all signals were broadened and small couplings 
were often not resolved.
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Figure 4.10 Determination of the structures of 28 and 32 by !H NMR.
Mild acid treatment cleaved the orthoformate ester without significant loss of p- 
methoxybenzyl groups to give the tetrol 32. The structure of this molecule can be 
identified unequivocally by inspection of the lH NMR spectrum. The inositol ring, freed 
of the constraining orthoformate ester now flips into its alternative chair conformation 
with the two /7-methoxybenzyl groups equatorial (Figure 4.10). Long-range couplings 
disappear and the signal from Hb moves to very high field (8  1.25ppm), transforming 
itself into a clear triplet of triplets. The only couplings between the inositol ring protons 
are now large, and therefore axial-axial. No doubt remained as to the structure of 32 or 
its precursor 31.
4.5.1 Ruthenium-Catalysed Dihydroxylation
The two most common reagents used for the cw-hydroxylation of alkenes are potassium 
permanganate and osmium tetraoxide, with the latter affording better yields, despite 
being both costly and highly toxic. Recently, a new “flash-dihydroxylation” method has 
been reported by Shing et al., using ruthenium tetraoxide.194 The procedure was reported 
to give rapid cw-hydroxylation of a variety of alkenes although its diastereoselectivity 
was, at the time, still under investigation. A sample of 30 was treated according to the 
published protocol, which is extremely straightforward, involving little more than
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stirring a solution of the alkene in acetonitrile with RuCh/NalC^ in water. The reaction 
was successful at the first attempt, complete within 3 minutes, and was totally 
diastereoselective as judged by NMR of the crude product. Chromatography gave a 
crystalline diol in 77% yield. It seems highly likely that the structure is 40, resulting 
from attack at the less-hindered face of the C=C bond (personal communication, Dr. T. 
K. M. Shing), but final confirmation of this will probably require NOESY. Time has not 
allowed further investigation of 40, but it has obvious possibilities as a precursor for 
novel cyclitols and derivatives. The reaction illustrates the potential of alkene 30 for 
diastereofacioselective modification, as well as the value of the ruthenium method as a 
rapid and safe alternative to osmium tetraoxide.
RuCI3/N al04




Figure 4.11 Ruthenium-catalysed dihydroxylation of alkene 30.
The reactions described in Sections 4.5 and 4.5.1 both exploit the fact that one 
diastereotopic face* of alkene 30 is exposed while the other is very hindered. A space­
filling model of alkene 30 (Fig. 4.12) demonstrates the extreme steric hindrance of one 
face of the C=C bond by the two p-methoxybenzyl groups, while the other face is
open
OPMB ch ?  
OPMB '  2
hindered
Figure 4.12 Space-filling model of alkene 30 showing hindrance of the C=C bond.
Note that the faces o f  the C=C bond in alkene 30 are diastereotopic even though the products, 31 and 40 
are not chiral. C-2 in alkene 30 (and also in ketone 29) is therefore prostereogenic but not prochiral.
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4.5.2 Investigation of an  Alternative Route
Another route to the epimers of the alcohol 31 was also explored in parallel with the 
methylenation/hydroboration strategy described above. A Wittig reaction was used to 
convert ketone 29 into the asymmetrical enol ether 41 in 93% yield. It was thought that 
mild acid treatment could be used to hydrolyse 41 to an aldehyde (or mixture of 
aldehydes) which could then be epimerised using mildly basic conditions and reduced to 
give 31a, the precursor for the ds-fused conformationally restrained analogue.
However, a series of experiments using a range of mildly acidic conditions all 
failed to give the required aldehyde, with TLC showing complete conversion to an 
unexpectedly polar compound. Under some conditions, an intermediate could be seen as 
a spot on the TLC plate, but rapid conversion to the polar product competed with its 
formation from 41, and it could not be isolated. An IR spectrum of the product showed 
the expected strong C =0 stretching band of an aldehyde, but the frequency was low 
(1685cm 1), suggesting a,/?-unsaturation. Alcohol groups were also present. The !H 
NMR spectrum clearly showed the aldehyde resonance as a singlet at S  9.43 and the 
corresponding carbonyl signal in the 13C NMR spectrum was shielded (<5c 194.63) again 
indicating conjugation. !H and 13C NMR both suggested the structure 42, and this was 
confirmed by COSY. The proton at C-3 gave a highly distinctive doublet of
triplets in the *H spectrum, caused by a long-range 5J  coupling to H-6, and H-2 was 
strongly deshielded (8 6.54). The other vicinal couplings confirmed that the ring was 
now distorted well away from the chair conformation previously seen in saturated 
inositol derivatives.
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Conversion of the enol ether 41 to the saturated aldehyde proved to be 
impossible. Elimination to give the conjugated aldehyde 42 always occurred, even under 
very mildly acidic conditions. When the reaction was scaled up and carried out using 1 
M HC1 in THF (1:10), it was possible to isolate a small amount of the intermediate 
previously observed in the TLCs. The intermediate was shown to be the 4-formate ester 
42a, and showed a !H NMR spectrum very similar to that of 42, except that the signal 
corresponding to H-4 was now shifted well downfield (by 1.29 ppm) establishing that 
this was the position of esterification. The distinctive singlet corresponding to the 
formate proton was at 8 8.11.
The failure to detect the saturated aldehyde 41a as an intermediate suggests that 
the elimination proceeds by a one-step mechanism (Figure 4.14) rather than a two-step 
elimination via a saturated aldehyde. The orthoformate structure holds the C-O bond in 
an axial orientation, almost at right angles to the developing double bond, and therefore 
ideally placed for elimination to occur (Figure 4.14).*
Figure 4.14 Proposed mechanism for formation of conjugated aldehyde 42. Incomplete 
hydrolysis gave the formate ester 42a.
a,/TUnsaturated aldehydes can themselves be valuable synthetic precursors, and 
42 may therefore be a useful intermediate. It was found that crystalline 42 could be 
obtained in 82% yield by heating the enol ether 41 in 1M HC1 / THF for 1 hour, and a 
large-scale synthesis would be straightforward. Treatment with sodium borohydride in 
methanol reduced the aldehyde group within 5 minutes, giving the racemic allylic 
alcohol 43 in 91% yield after crystallisation. A successful optical resolution of this 
material would provide two useful chiral intermediates, and the absolute configurations 
could easily be determined by hydrogenation to give the corresponding carbasugars, 
which are known.195
*
Note that, if this one-step elimination mechanism is valid, then there is no need to assume that the 
required saturated aldehyde 41a is itself prone to elimination. In fact elimination might be disfavoured, 
because it would have to proceed via a strained enol. It might still be possible, therefore, to make 
aldehyde 41a by oxidation of the primary alcohol, followed by epimerisation and reduction to give the 
required alcohol. This route still awaits further investigation.
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Deprotection of one enantiomer of 43, for example, would give an epimer of the 
plant growth regulator streptol. 196 In the inositol phosphate field, 43 could prove to be a 
valuable precursor for a range of deoxygenated and unsaturated inositol phosphate 
analogues. Limitations of time did not allow further exploration of these possibilities, 
some of which are now being investigated by a colleague. Having developed a highly 
efficient route to the required symmetrical tetrol 31, the priority was to continue with the 
planned route to the conformationally restricted analogue.
Figure 4.15 Reduction of the enal 42 with sodium borohydride gave allylic alcohol 43, 
one enantiomer of which is related to the plant growth inhibitor streptol. An optical 
resolution of 43 would provide a precursor for novel analogues of Ins( 1,4 ,5 )P3 .
4.6 Conversion to a Fully-Protected, Versatile Intermediate
Two protection steps were now used to produce the fully-protected 34. The racemic 
benzylidene acetal 33 was initially prepared in 70% yield by the reaction of tetrol 32 
with benzaldehyde dimethyl acetal (a,a-dimethoxytoluene) in dry DMF with a catalytic 
amount of PTSA at 70°C. However, in subsequent preparations in was found that the 
yield could be increased by applying a method described by Horton and Weckerle for 
the preparation of 2,3:4,6-di-0-benzylidene-a-D-mannopyranoside. 197 The key 
modification is simply to carry out the reaction with continuous removal of the liberated 
methanol. This can easily be achieved by fitting the reaction vessel with an air 
condenser attached to a water pump, so that the reactants and DMF are retained while 
methanol escapes, driving the equilibrium towards formation of the benzylidene acetal. 
This method was found to be faster, required a smaller excess of benzaldehyde dimethyl 




















Figure 4.16 Protection of two hydroxyl groups in 32 as the benzylidene acetal gave 
racemic 33 which was converted to the fully-protected 34.
Benzylation under standard conditions then gave fully-protected 34. This is a versatile 
intermediate because either the benzylidene or p-methoxybenzyl groups can be removed 
chemoselectively, or the benzylidene ring can be reduced regioselectively in either 
direction (see Chapter 5). Intermediate 34 is currently being used by a colleague in the 
synthesis of a potential 3-kinase inhibitor.
4.7 Construction of the Cyclic Phosphate
The next step would be the introduction of the cyclic phosphate triester structure, strictly 
a 1,3,2-dioxaphosphorinane. There were reports in the literature of the construction of 
related structures based on carbohydrates198 and rrans-2-hydroxymethyl-l-cyclohexanol 
199,200 -n  ^  c o u r s e  0 f  stereochemical investigations, and P(V) methodologies had been 
employed. However, a more recent report201 described the synthesis of some 5- 
membered cyclic phosphate triesters of myo-inositol using the bifunctional P(IH) reagent 
benzyloxy-bis(Af,Af-diethylamino)phosphine and l//-tetrazole, followed by oxidation 
with m-CPBA. The strained 5-membered rings are generally unstable in the presence of 
nucleophiles, and this property was exploited by treating them in situ with various 
alcohols, resulting in regioselective ring-opening. It the present case, it was reasoned 
that this P(m) approach should easily be adaptable to the construction of the more stable 
six-membered cyclic phosphate. The procedures were similar to that already used in 
previous work (Chapters 2 and 3), and employed the benzyl protecting group, which 
was ideal for the planned synthetic strategy. In the event, we decided to carry out the 
cyclic phosphitylation using a slightly different bifunctional phosphitylating agent, 
benzyloxy-bis(Af,7V-diisopropylamino)phosphine,202 which was readily accessible by the 
reaction of bis(diisopropylamino)chlorophosphine with one equivalent of benzyl 
alcohol. This phosphitylating agent has been employed in the synthesis of an analogue 
of PtdIns(4 ,5)P2,202 and can be regarded as the bifunctional equivalent of the 
monofunctional bis(benzyloxy)-Af,Af-diisopropylamino-phosphine203 described in 
Chapter 2.
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The first step was to establish conditions for the selective removal of the 
benzylidene acetal from 34 with minimal loss of p-methoxybenzyl groups. It was found 
that 1M HCl/methanol at 50°C was effective, the reaction being complete within 30 
minutes, giving diol 35. Benzyloxy-bis(N,iV-diisopropylamino)phosphine was 
synthesised according to Dreef et al.202 and reaction of 35 with 1.2 equivalents of this 
reagent and 3 equivalents of l//-tetrazole gave two cyclic phosphite triesters, epimeric 
at phosphorus as expected. These intermediates were visible as two spots close together 
on the TLC plate, and also as two distinct signals at <5p 125.0 and Sp 130.4 in the 31P 
NMR spectrum. These signals disappeared and were replaced by peaks at <5p -4 .6  and <5p 
-7 .5  after addition of w-CPBA. It was possible to separate the two epimeric cyclic 
phosphate triesters by column chromatography, and isolate them as crystalline solids.
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Figure 4.17 Formation of epimeric cyclic phosphite triesters by reaction of diol 35 with 
a bifunctional phosphitylating agent. Oxidation gives epimeric triesters 36a and 36b.
The configuration at phosphorus of the two epimers was determined by 
examination of their 31P and !H NMR chemical shifts, V h c o p  coupling constants and 
P = 0  stretching frequencies. Epimers 36a and 36b can be regarded as esters of 2-oxo- 
1,3,2-dioxaphosphorinanes, and studies have been published on simple related 
compounds.198' 199, 204 In all previous studies on isomeric pairs of phosphorinanes (see 
Reference199 and references therein) the axially substituted epimer has an upfield 31P
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chemical shift. This identifies the less polar epimer (6p -7.5) as 36a and the more polar 
isomer as the equatorially substituted 36b. The P = 0  stretching frequency in the IR 
spectrum of 36b is 21cm' 1 lower than for 36a ( Vp=o 1287cm'1) confirming this 
assignment.
The /7-methoxbenzyl ethers of 36a and 36b were successfully cleaved with DDQ 
giving the corresponding diols 37a and 37b. The lH NMR spectra of all four 
compounds were assigned completely with the aid of COSY. A detailed study of 
these spectra revealed further evidence for the assigned structures. In the equatorially 
protected epimers 36b and 37b, for example, H-l and CH2-ax are deshielded, as 
expected for protons in a 2,4-diaxial relationship with a P = 0  group. These protons 
therefore resonate downfield of the corresponding protons in 36a and 37a, while the 
CH2-eq protons have similar chemical shifts in all four molecules (Table 4.1).
BnO
R = PMB 36a R = PMB 36b
R = OH 37a R = OH 37b
-j
Table 4.1 Chemical shifts and /hcop coupling constants for cyclic phosphate triesters 
36a, 36b, 37a, 37b.
Compound Chemical Shifts/p.p.m. Coupling Constants/Hz
Sp ^Hax t^ Heq <5hi 37p-Hax 37p-Heq
36a -7.49 3.76 4.41 4.04 ~0 24.2
37a -7.27 3.81 4.43 3.86 ~0 24.4
36b -4 .56 4.03 4.39 4.32 3.9 20.4
37b -4.43 4.08 4.42 4.17 4.4 20.0
7hcop coupling constants have been used to investigate the solution conformations of 
phosphorinanes,199 and a Karplus-type relationship has been established for the HCOP 
dihedral angle and the magnitude of the coupling constant.205 Thus the coupling 
constants for 36a and 37a are consistent with a normal chair conformation, because the 
large 3/p-Heq and small 3/p-Hax values indicate an anti- dihedral angle for HeqCOP and a 
gauche dihedral angle for HaxCOP. In the equatorially protected esters 36b and 37b, the 
decrease in Vp-Heq accompanied by increased Vp-Hax is evidence for a slightly flattened
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chair conformation, or a rapidly equilibrating mixture of undistorted chair and twist-boat 
conformations. Some relevant NMR data for the four compounds are summarised in 









| 1 i i '  | i i i i |---------- 1----------1----------1----------1----------1----------1----------1----------1----------1----------1----------r










~-|— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i i r 
- 4 .3  -4 .4  - 4 .5  - 4 .6  -4 .7
Figure 4.18 3*P NMR spectra of 36a and 36b (162 MHz, 'H-coupled, CDCb)-
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4.8 Phosphitylation/Oxidation: An Unexpected PIII-PV Spin-Spin Coupling
The diols 37a and 37b were then phosphitylated using the monofunctional 
phosphitylating agent bis(benzyloxy)-iV,A^-diisopropylaminophosphine with 1H- 
tetrazole. This step involves the formation of a phosphite triester at a position vicinal to 
an existing phosphate triester and in each case we were able to observe in the 31P NMR 
spectrum a Vpp spin-spin coupling of 1.2 Hz between the phosphorus atoms of 
neighbouring phosphate and phosphite groups. To the best of our knowledge, such a 
long-range P(IH)-P(V) coupling has not been previously reported, although it is known 
in vicinal P(IH)-P(ni) systems. It is tempting to speculate that conformational restraint 
of the phosphate is responsible for this unusual effect, as no such coupling was observed 
in a mixed P(III)/P(V) species (Figure 4.19) leading the authors to conclude that two 
P(m) centres were necessary for the interaction.206 Oxidation with m-CPBA and 
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Figure 4.19 Phosphitylation of 37a and 37b gives mixed P(]H)-P(V) intermediates, 
which both showed unusual P(m)-P(V) 5/pp spin couplings. A similar arrangement in aOC\f\conformationally mobile system showed no such coupling.
4.9 Deprotection
The planned deprotection using sodium in liquid ammonia was first tried out on the
31protected cyclic phosphate 36a. An examination of a proton-coupled P NMR spectrum 
of the crude product showed only one signal; a doublet with a large splitting ( /  > 20Hz). 
This splitting could only have resulted from the large heteronuclear coupling to the
103
equatorial proton in the 1,3,2-dioxaphosphorinane ring and therefore confirmed beyond
doubt that the cyclic phosphate structure had remained intact. The fact that no other
couplings were observed showed that the benzyl protecting group had been removed
successfully. Thus is was established that the cyclic phosphate triester could be
effectively deprotected using sodium in liquid ammonia.
The axially protected 38a was deprotected using the same procedure and
purification by ion-exchange chromatography at last gave the target compound 26 in
1  ^1 1 ^78% yield as the triethylammonium salt. The structure was confirmed by H, P and C 
NMR. A COSY NMR allowed all the proton resonances to be assigned
unequivocally. 26 Could also be crystallised as the cyclohexylammonium salt. A sample 
of the latter, left at room temperature for a year, showed no sign of decomposition. 
Some time later, when further supplies of 26 were required for a potentiometric study 




O P(O Bn)2(BnO)2PO (BnO)2P O
26
Figure 4.20 Deprotection of either epimer 38a or 38b gives the target compound 26.
The proton-coupled 31P NMR spectrum of 26 (Figure 4.21a) shows the expected 
heteronuclear spin couplings, with the phosphorus atoms in the unconstrained phosphate 
groups at positions 2 and 4 appearing as doublets with 7hp approximately 7 Hz. 
However, notice that the signal from the cyclic phosphate phosphorus atom (dp -2.76) is
■i ( i
also a doublet, with a large coupling constant ( /p-Heq = 22.5 Hz). The predicted 7hp
90Scoupling constant for a dihedral angle of 180° is approximately 23 Hz and so we can 
conclude that the angle HeqCOP is close to 180°. This suggests that the 
dioxaphosphorinane ring adopts a chair conformation as shown in Fig. 4.20 Further 








Figure 4.21 ^-coupled 31P NMR spectra of the racemic conformationally restricted 
analogue 26 in D20  (162, MHz, pH~4). The inset shows the ‘H-decoupled spectrum.
Figure 4.21 also demonstrates an unusual effect: In the proton-decoupled 
spectrum (inset) the cyclic phosphate resonance at 5p -2.76 is much more intense 
(approximately three times more by integration) than either signal from the phosphorus 
atoms at positions 2 and 4. A categorical explanation for this observation awaits further 
NMR studies, but the finding that the effect disappears when the decoupler is switched
207off may suggest the involvement of heteronuclear NOEs.
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4.10 Biological Properties
Racemic 26 was examined for Ca2+-mobilizing activity at the platelet Ins(l,4,5)P3 
receptor using saponin-permeabilised platelets loaded with 45Ca2+. The results are 
shown in Figure 4.22. It appears that 26 behaves as a full agonist, although with an EC50 
around 40-70 fold higher than Ins(l,4 ,5 )P3. Assuming that only one enantiomer is 
active, this would imply a thrty-fold reduction in potency relative to Ins(l,4,5)P3.
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Figure 4.22 45Ca2+-release by the conformationally restricted analogue 26 in 
permeabilised rabbit platelets.
Binding studies in rat cerebellar membranes (Fig. 4.23) show that the affinity of 
the analogue for the Ins(l,4,5)P3 receptor is much reduced (200 to 300-fold). The 
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Figure 4.23 Inhibition of [3H]Ins(l,4,5)P3 binding to rat cerebellar membranes by 26.
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4.11 Protonation Sequence
A larger sample of 26 was synthesised (this time by deprotection of the equatorially 
protected epimer 38b) and used for detailed NMR and potentiometric titrations, which 
were carried out by Professor B. Speiss and his group at the Universite Louis Pasteur, 
Strasbourg.
4.11.1 Potentiometric Titration
A sample of 26 (triethylammonium salt) was first converted into the free acid and then 
titrated with potassium hydroxide solution. The titrations were carried out at 37°C in the 
presence of 0.2 M KC1, in order to mimic the intracellular medium. The potentiometric 
titration allows the calculation of macroscopic protonation constants, and for 26 the
values obtained were logA7 = 6.70 and logK2 = 5.60. These values are much lower than
208those found for Ins(l,4 ,5 )P3 under similar conditions (logA7  = 7.85, \ogK2 = 6.40). 
The Ky values allow the calculation of the percentage of each ionic species as a function 
of pH, although it is not possible at this stage to say which phosphate groups are 
protonated. In Figure 4.24 then, L represents the fully ionised species, LH the total 
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Figure 4.24 Distribution curves of various species of 26 plotted against pH. For clarity 
the charges are omitted.
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When Figure 4.24 is compared to a similar diagram for Ins(l,4,5)P3, it is evident that 
under these conditions, at physiological pH, 26 is less protonated than Ins(l,4,5)P3. 
Thus at pH 7.4, over 80% of 26 is in the fully ionised form L, while for Ins(l,4,5)P3 the 
predominant species is the monoprotonated form LH.
4.11.2 31P NMR Titration
A 31P NMR titration was now carried out under similar conditions, and accurate 
measurements of 31P chemical shifts and coupling constants were obtained over a pH 
range from 1.65 to 11.67. The phosphorus resonances of P2 and P4 were later assigned 
by performing a phosphorus-proton 2D COSY experiment. Figure 4.25 shows the 31P 
chemical shifts of PI, P2 and P4 plotted against pH. We see that the chemical shift of 
the cyclic phosphate phosphorus atom PI does not change at all over the pH range, 
implying that the basicity of the cyclic phosphate is very weak, so that it is protonated 
only at very low pH.. The chemical shifts of the phosphate atoms P2 and P4 in the two 
phosphate monoesters become progressively shielded with decreasing pH. The curves 
are monophasic, showing that P2 and P4 do not significantly interact (a similar lack of 
interaction is seen between the 1 and 4 phosphates of Ins(l,4 )P2 189). In each case, the 
change in chemical shift is related to the gain of one proton by each phosphate group as 
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Figure 4.25 Chemical shifts S from 31P NMR titration of 26, plotted as a function of 
pH.
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Now the chemical shift observed for any signal S °bs is just the weighted average of the 
shifts for the protonated and deprotonated forms:
Sobs = (Ap x 5,■.„) +  (/;,„ X <5j.d) (1 )
where fit p and /• d respectively correspond to the protonated and deprotonated fractions 
at position i, and S ,-t p and <5,, d are the chemical shifts of the monoprotonated and fully 
deprotonated forms of the phosphate. But f  p + f  d = 1 , and so equation (1) becomes:
Ap = ( 5 0bs- 5 , , d ) / ( 5 , . p - 5 , . d )  (2)
Equation (2) now allows the calculation of the protonated fractions / ,  p from the 
chemical shift information. The result is shown in Figure 4.26. There is no curve for PI 
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Figure 4.26 Protonation fraction/, p plotted against pH for 26.
Now equations (1) and (2) are based on an assumption that the measured chemical shifts 
are largely dependent on the protonation state of the phosphate groups. It is now 
necessary to demonstrate that this assumption is valid for 26. The mean number of 
protons, p  , bound per mole of 26, according to the NMR calculations, is just the sum of 
the protonation fractions.
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P  -  Z ^ / i n  “  A  p + A ( 3 )
However, p  can also be obtained directly from the potentiometric measurements by 
applying equation (4):
_  CH- [ h ' ]  + [o h ]
P
(4)
where Ch and Cl are the analytical concentrations of acid and ligand respectively.
Figure 4.27 shows values of p  calculated according to both equations, plotted against 
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Figure 4.27 Plots of p  (the mean number of protons bound per mole of 26) versus pH. 
Values o f p  calculated from the potentiometric titration are in excellent agreement with 
those derived from the 31P NMR titration.
Now the macroscopic protonation constants, calculated from the potentiometric titration 
can be considered to be composites of microscopic constants reflecting the behaviour of 
the individual phosphate groups ( in this case the phosphates at positions 2 and 4). The 
macro- and micro-constants for 26, are related by equations (5)-(7) and the protonation 
scheme is shown in Figure 4.26.
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K] — kj + k$ (5)
1 !K2 = 1/^24 + 1/&42 (6)
K1K2 = ki x 2^4 — k$x k^i (7)
Given the macroscopic constants (from the potentiometric titration) and the values / 2>  ^
and f 4iP (from the NMR experiments) it is now possible to calculate the microscopic 
constants £2, £4, £24 and £42 (equations not shown). This is relatively straightforward for 
26 because, as it behaves as a diprotic acid over this pH range, there are only three 
different protonated forms to be considered. The situation is more complicated in the 
case of an inositol trisphosphate with three phosphate triesters (such as Ins(l,4 ,5)P3 ), 
which will have seven protonated forms under similar conditions. The macroscopic and 
microscopic protonation constants for 26 are given in Table 4.2.
lOgKy ± <7 i logki ± cr ii' logfcif ± 0
1 6.70 ±0.01 2 6.57 ±0.01 24 5.73 ± 0.02
2 5.60 ±0.01 4 6.10 ± 0.01 42 6.20 ± 0.02
Table 4.2 Macroscopic and microscopic protonation constants for 26
From these results, £2/^ 4 is calculated to have a value of io (6'57'6 10) = 2.95. This is an 
indication of the lower basicity (higher acidity) of the P4 phosphate, which may be due 
to a greater probability of hydrogen bonding with the two neighbouring equatorial 
hydroxyl groups. The P4 phosphate is also less basic than the PI phosphate of either 
Ins(l)Pi or Ins(l,4)P2, which are flanked by one equatorial and one axial hydroxyl 
group, and is more similar to the P4 phosphate of Ins(l,4)P2. Thus, the fact that 26 has 
the scyllo- rather than the myo- configuration may have resulted in P4 being less basic 
than the equivalent PI of Ins(l,4 ,5)P3. The fact that this difference does not greatly 
influence Ins(l,4 ,5)P3 receptor binding is reflected in the high potency of scyllo- 
Ins(l,2,4)P3 and 6-deoxy-6-hydroxymethyl scy//o-Ins(l,2,4)P3 (Chapter 5), and also in 
the observation that Ins(l,4 ,5)P3 receptor binding, when measured over a range of pH 
values,175 does not correlate with the 31P NMR chemical shift of PI in Ins(l,4 ,5)P3.209
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Figure 4.28 Protonation scheme for 26. For interpretation of symbols, see text.
The cyclic phosphate of 26, as we have seen, has very low basicity and is 
therefore ionised over the whole pH range, while the 2-phosphate of 26, which is 
intended to mimic the 5-phosphate of Ins(l,4,5)P3, has log&2 = 6.57. While, as explained 
above, microscopic protonation constants are not available for Ins(l,4 ,5)P3, which 
behaves as a more complex system, the equivalent logfcs for Ins(4,5)P2 is 8.15.189 The 2- 
phosphate group of 26 is therefore jo (8'15‘6 57) = 38 times less basic (more acidic) than its 
equivalent in a vicinal phosphate pair. Thus, although conformational restraint of one 
phosphate in the vicinal pair necessarily reduces its charge, the ionisation of the other 
phosphate is enhanced. The first effect would be expected to reduce binding affinity, 
and the second to enhance it. It would seem that the decision to constrain the equivalent 
of the 4-phosphate (rather than the 5-phosphate) was well made, as constraining this less 
important phosphate group increases the ionisation of its vicinal partner at physiological
The microscopic protonation constants can now be used to calculate the 
proportion a  of each species present at a given pH (Figure 4.29). For example, at pH 10, 
26 is fully deprotonated, and when the pH is reduced, the proportion of the fully-ionised 
species gradually decreases as protons are added to the P2 and P4 phosphates. At
pH.
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physiological pH, around 80% of 26 is still in the fully-ionised form, while the rest is 
monoprotonated. The predominant monoprotonated form has the proton on P2, and the 
proportion of this species rises to a maximum at around pH 6 , when it forms 50% of the 
total. Below this pH, the proportion of the 2,4-diprotonated form increases, approaching 
100% at pH 3. The basicity of the cyclic phosphate PI, and the second basicities of the 








Figure 4.29 Distribution curves of the various species of 26 plotted against pH.
4.11.3 *H NMR Titration
Finally, a proton NMR titration was carried out under similar conditions. Figure 4.30 
shows the chemical shifts of protons at positions 3, 5 and 6  in 26, plotted against pH. 
These protons are at unphosphorylated positions, and perhaps not surprisingly, they are 
little affected by pH. Notice however that H3, which is vicinal to two phosphate 
monoesters, is most strongly influenced, and is deshielded by 0. lppm at high pH.
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Figure 4.30 ‘H NMR chemical shifts <5of H3, H5 and H6  in 26 plotted against pH.
Figure 4.31 shows a similar plot for the remaining five protons (note the larger scale). 
The chemical shifts of H2 and H4, which are at positions bearing phosphate monoesters, 
are pH-dependent, and follow a biphasic relationship. If we follow the plot for H2, from 
right to left, for example, we see that decreasing pH has no effect until around pH 7.6, 
after which it is progressively deshielded. This effect seems to be related to the first 
protonation of P2, and is also reflected in the 31P NMR plot (Figure 4.25). After a 
plateau, the deshielding begins again at pH 2.6, presumably as the second proton is 
added to P2. Hax and Heq are only slightly influenced by pH, behaving in a similar way 
to H5 and H6 , and this is in accordance with the finding from the 31P NMR titration that 
the cyclic phosphate PI is ionised over the whole pH range. HI shows a moderate pH 
dependency, and it seems likely that its chemical shift is influenced by the ionisation 
state of the adjacent P2. Thus it appears that the effect of pH on the chemical shifts of 
the protons in 26 is mediated by the ionisation state of the phosphate monoesters. The 
very weakly basic cyclic phosphate diester seems to have negligible effect.
Measurements of all 3J  vicinal coupling constants were also obtained. The effect 
of pH on these values seemed slight, which is what we would expect for a 
conformationally restrained bicyclic molecule such as 26. Some values did appear to 
steadily increase or decrease with pH, but the significance of these small changes, and 
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Figure 4.31 'H NMR chemical shifts 8of HI, H2, H4, H„ and Hcq in 26 plotted 
against pH
More definite conclusions can be drawn from the average values of the 
heteronuclear 3/ h c o p  coupling constants, which were measured in both the *H NMR and 
proton-coupled 31P NMR spectra. The mean values, together with standard deviations 
are given in Table 4.3.
Hax-Pl Heq-Pl HI-PI H2-P2 H4-P4
3«/hcop / Hz 2.00 22.66 1.33 7.85 8.48
a !  Hz 0.00 0.13 0.08 1.06 1.12
Table 4.3 Mean and standard deviation (a) values for phosphorus-proton coupling 
constants in 26.
4.11.4 Conformation
According to Lankhorst et. al.,205 Vhcop is dependent on the dihedral angle (p = H -C - 
O-P, and the relationship can be described by the Karplus-type equations given below:
V h c o p =  18.1 cos2<p-4.8 cos<p (for 0  < (p < 90°) (8 )
V h c o p =  15.3cos2<p-6.1 cos<p+ 1.6 ( for 90 < (p < 180°) (9)
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First consider the geometry of the cyclic phosphate in 26. Solving equations (8) 
and (9) for the mean V h c o p  values given in table yields (p = 61° for Hax-C-O-Pl, (p = 
64° for H l-C -O -P l and (p = 172° for Heq-C-O-Pl. These values are good evidence 
that the cyclic phosphate adopts a chair-like conformation. The very small variations in 
the magnitudes of the /h c o p  values for PI suggest that the conformation remains much 
the same over the entire pH range.
The conformation of the cyclic phosphate can be deduced from the coupling 
constants with a fair degree of confidence, even though solution of equations (8) and (9) 
actually yields four possible dihedral angles for each coupling constant. For example, 
the possible solutions for 3/h c o p  = 2 H z give values of +61°, +93°, -61° and -93° for the 
angle Hax-C-O-Pl. However, only one of these values (+61°) is both geometrically 
possible in the six-membered ring, and consistent with the other coupling constants. The 
situation with respect to the phosphate monoesters is far more complex. First notice that 
there seems to be greater variation in their /h c o p  values over the pH range, suggesting 
that their conformation is influenced by pH. This is what we would expect, because, as 
the protonation state of these phosphate changes with pH, their hydrogen-bonding 
interactions with neighbouring hydroxyl groups will be affected, as will the electrostatic 
repulsion between phosphates. Now application of equations (8) and (9) yields the (p 
values of around +35°, -35°, +120°, and -1209 for both H 2-C 2-02-P 2  and H 4 -C 4 -0 4 - 
P4. Similar results have been obtained for P4 and P5 of Ins(l,4 ,5)P3.210 If we take the 
coupling constants to arise from a single predominant rotamer then we can probably 
discard the last two solutions, which represent eclipsed conformations. We would 
expect the 2-phosphate group to be orientated away from the 1 phosphate (due to 
electrostatic repulsion) and towards the 3-hydroxyl (due to hydrogen bonding) and so 
we might tentatively suggest a value of close to +35° for the angle H 2-C 2-02-P 2  (and 
also for the 4-and 5-phosphate groups of Ins(l,4 ,5)P3). There may be some additional 
support for this value in the Jccop couplings measured from the C NMR of 26. 
However, many assumptions have now been made in arriving at this value, not least of 
which is the assumption that the coupling constant reflects the geometry of a particular 
predominant conformation, rather than a time-averaged value arising from a population 
of rapidly interconverting rotamers.
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4.12 Conclusions
The conformationally restricted analogue can be viewed physicochemically as a 
simplified version of Ins(l,4 ,5)P3. Because it is conformationally restricted, we can be 
reasonably sure of the orientation of one of its phosphate groups, and NMR studies 
confirm that this phosphate is held at a dihedral angle close to +60°, that is, a positive 
gauche orientation. An unexpected advantage of introducing the cyclic phosphate has 
been that the acid-base properties of 26 have been simplified. Thus, 26 behaves 
essentially as a diprotic acid and it has therefore been possible to carry out a detailed 
analysis of the protonation state of the individual phosphate groups, something that has 
not so far been possible with Ins(l,4 ,5)P3.
Turning now to the biological results, the finding that 26 appears to behave as a 
full agonist, but with considerably reduced potency, presents us with some problems, 
which would not have arisen had the analogue been highly active, completely inactive, 
or a partial agonist. Experience with D-Ins(l,3,4)P3 (Chapter 2) and D-Ins(l,3,4,5)P4 
(Chapter 7) shows that in the inositol phosphate field, when a biological assay 
demonstrates moderate full agonist activity for a compound, we must consider an 
important (and painful) question. The question is “Could the apparent activity of 
analogue X be due to the presence of a small amount of a second, highly potent, full 
agonist Y?” The problem is particularly acute if there is some obvious way in which the 
agonist Y can arise in the synthesis or metabolism of X. For example, phosphate 
migration during the synthesis of D-Ins(l,3,4,5)P4 can lead to D-Ins(l,2,4 ,5)P4, and 
metabolism in vivo can lead to Ins(l,4 ,5)P3 (Chapter 7). Opening of the cyclic phosphate 
ring of the (presumably) active enantiomer of the conformationally restrained analogue 
can, in principle, lead to two trisphosphates (Figure 4.32).
44
Figure 4.32 Ring-opening of the cyclic phosphate in 26 could give two possible 
products, one of which (44) is now known to be highly active.
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The symmetrical compound lacks a vicinal bisphosphate and is therefore expected to be 
inactive (this is currently under investigation), but we have now shown the alternative 
product, 44 to be highly potent in our assay systems (see Chapter 5).
We must therefore consider whether the apparent activity of 26 could 
conceivably be due to the presence of 44. It is difficult to see how the synthetic route 
could lead to the production of 44, unless some opening of the cyclic phosphate ring 
occurred on deprotection. Furthermore, the product was subsequently purified by ion 
exchange, and appeared to be pure by NMR. The FAB mass spectrum of 26 showed no 
evidence of contamination with 44. The six-membered cyclic phosphate structure fused 
to a six-membered ring would be expected to be highly stable to hydrolysis, and as 
already mentioned, a sample of the cyclohexylammonium salt showed no deterioration 
after a year at room temperature (samples for biological testing were kept at -20°C). It 
must be borne in mind, however, that neither NMR nor mass spectroscopy are ideal 
methods for the assay of inositol phosphates. The method of choice is currently HPLC 
with complexometric metal-dye detection,257 and it is hoped to apply this methodology 
to the analysis of 26 (and other analogues) in the near future.
There is also the possibility that enzymatic hydrolysis of the cyclic phosphate by 
non-specific phosphodiesterases during the biological assays could generate 44. A 
thorough evaluation of this possibility would involve consideration of the time-course of 
the assays, enzyme kinetics, and of the particular preparations used (whole cells, 
membranes, purified receptors etc.). An initial investigation, however, might involve 
comparison of an untreated sample of 26 to one pre-incubated with cell lysate or a 
purified phosphodiesterase.
With these reservations in mind, the finding that 26 retains full agonist activity 
might have significant implications for the understanding of Ins(l,4 ,5)P3 receptor 
function and the design of ligands. These involve considerations of affinity for the 
Ins(l,4 ,5)P3 receptor, efficacy in activation of Ca2+-release and the relation of these to 
the conformation of the ligand.
1) Conformational restraint together with charge reduction of the equivalent of the 4- 
phosphate of Ins(l,4,5)P3 decreases affinity for the Ins(l,4 ,5)P3 receptor. It is hardly 
surprising that charge-reduction causes this, but it does not necessarily follow from 
conformational restraint. Some rigid analogues of other natural ligands (e.g. of 
acetylcholine, to take a classical example) have higher affinity and greater selectivity
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than the natural ligand itself. However, in the present case, it is difficult to 
disentangle the biological impact of conformational restraint from the effect of 
reducing the charge on the constrained phosphate. The potentiometric and NMR 
investigations suggest that the reduction of charge compared to the equivalent 
phosphate of Ins(l,4 ,5)P3 may not be so great at physiological pH, and the ionisation 
of the other phosphate groups is increased.
2) The conformationally restrained analogue appears not to be an antagonist, nor a 
partial agonist. Therefore it does not seem that the path to an Ins(l,4 ,5)P3 antagonist 
lies in conformational restraint of the inositol ring nor of a phosphate group (at least 
not of the 4-phosphate in the positive gauche orientation). Assuming that the 
observed activity is due to 26, then conformational restraint and charge reduction of 
the 4-phosphate do not reduce efficacy. Therefore channel-opening cannot require the 
inositol ring to flip, and may not require a dramatic change in the orientation of the 4- 
phosphate.
3) Again assuming that 26 itself is recognised by the Ins(l,4 ,5)P3 receptor, the 4- 
phosphate group may be constrained in a way that is close to the conformation of 
Ins(l,4 ,5)P3 at the receptor binding site. This might be taken to suggest that in the 
active conformation of Ins(l,4,5)P3, the dihedral angle P4-04-C 4-H 4 is positive and 
synclinal (cp = +30° to +90°). Note that the 4,5-pyrophosphate analogue (Figure 4.29)
• • 187which mimics a high-energy conformation of Ins(l,4 ,5)P3, was totally inactive. It 
might still be interesting to synthesise the epimeric analogue, in which the phosphate 
is constrained in an anti orientation, but until the question of ring-opening is settled, 
the results could still be open to different interpretations.
Very recently, and since the work described in this Chapter was carried out, X-ray 
crystal structures, showing Ins(l,4,5)P3 bound to /2-spectrin137 and PLC-^i139 PH 
domains, have been published (See Chapter 1). In both these structures, the bound 
conformations of Ins(l,4 ,5)P3 appear to be similar, and are close to that predicted by our 
early molecular modelling, which was the basis for the design of 26. The dihedral angle 
P 4-04 -C 4-H 4  does indeed appear to be positive and synclinal, as in 26, and 
apparently* with (p < +60°.
* Co-ordinates had not yet been deposited with the appropriate databases at the time of writing and so 
measurements could not be made.
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Of course, the conformation of Ins(l,4 ,5 )P3 at the Ins(l,4 ,5 )P3 receptor itself 
need not necessarily resemble these structures. The Ins(l,4 ,5 )P3 receptor performs a very 
different function from these PH domains, which are now thought to act as membrane- 
anchoring modules. However, the similarity between these X-ray structures of bound 
Ins(l,4 ,5 )P3, and the picture of Ins(l,4,5)P3 derived from the theoretical and 
experimental investigations described above is quite striking. No doubt, X-ray structures 
of Ins(l,4 ,5 )P3 at other binding sites, and NMR studies, which will give more dynamic 
information about the process of binding, will be published in the near future.
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Figure 4.32 Orientation of the 4-phosphate group in the X-ray crystal structure of 
Ins(l,4 ,5 )P3 bound to PH-domains, and its equivalent in various conformationally 
restrained analogues.
Figure 4.33 Energy-minimised structure of Ins(l,4 ,5 )P3. For details of molecular 
modelling, see Experimental section.
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5 Adenophostins: Initial Structure-Activity Investigations
5.1 Adenophostins A and B
In 1994, two highly potent Ins(l,4,5)P3 receptor agonists were identified through 
screening of compounds for inhibition of [3H]Ins(l,4 ,5)P3 binding.211 Adenophostins A 
and B, found in the culture broth of Penicillium brevicompactum were reported to show 
very high potency in biological assays, being 100-fold more potent than Ins(l,4,5)P3 in 
Ca2+ release and producing detectable effects in cerebellar microsomes at concentrations 
as low as 1 nM. Their effect could be totally blocked by heparin. They appeared to be 
completely resistant to phosphorylation or dephosphorylation by the Ins(l,4 ,5)P3- 
metabolising enzymes 3-kinase and 5-phosphatase, and highly selective for Ins(l,4,5)P3 
receptors. The adenophostins, in contrast to Ins(l,4 ,5)P3 itself, showed no ability to 
inhibit [3H]Ins(l,3,4 ,5)P4-binding to a purified Ins(l,3,4 ,5)P4 -binding protein.32
5.1.1 Biological Effects of Adenophostin A
At this time there was no independent evidence for these surprising claims. Before 
embarking on a programme of research into synthetic adenophostin analogues it was 
important to establish whether the adenophostins had similar effects in our own 
biological assays. We were able to obtain a small amount (6mg) of adenophostin A 
from the discoverers and compare its activity to Ins(l,4 ,5)P3. A sample was first 
quantified accurately by UV assay and then accurately divided into 20nmole aliquots,
i ♦
while another (2mg) portion was used for H NMR studies.
An initial test for biological activity was carried out in permeabilised rabbit 
platelets, and calcium release was monitored in the presence of the fluorescent dye fura- 
2 by spectrofluorimetry. As can be seen from Figure 5.1a, adenophostin A was indeed 
astonishingly potent, causing measurable Ca2+ release at concentrations as low as 2nM. 
Figure 5.1b confirms that the effect was blocked by heparin. Note that the effect of 
adenophostin A, unlike that of Ins(l,4 ,5)P3 is prolonged, confirming its resistance to 
metabolism. Thus, what had seemed initially to be a small sample of adenophostin A 
was in fact sufficient for many biological studies, and the results of some of these, 
including dose-response and radioligand binding curves are given below.
* The high-resolution 400 MHz !H NMR spectrum of this sample in D2O confirmed the assigned structure, 
although in this spectrum, two signals showed greater than the expected multiplicity. Whether this showed 
an impurity in the sample, an experimental artefact or something more significant, is currently not clear. 
Further studies with synthetic adenophostin are planned.
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Figure 5.1b Inhibition of adenophostin-induced Ca2+-release by heparin.
5.2 Structures of the Adenophostins
The publication of the structures212 of the adenophostins (Figure 5.2) came as a shock. 
At first glance they appear to be strikingly different from Ins(l,4 ,5 )P3 and, like cyclic 
ADP-ribose, they are adenosine derivatives. However, the Ca2+-releasing potency of 
cyclic-ADP ribose, which is thought to act via ryanodine receptors (see Chapter 1), is 
much lower than that of the adenophostins, and is not inhibited by heparin. On closer 
examination, the resemblances to Ins(l,4 ,5 )P3 become more apparent. Most importantly,
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the 3",4"-bisphosphate of the adenophostins is analogous to the 4,5-bisphosphate of 
Ins(l,4 ,5)P3. As we have seen, this structural motif seems to be an essential feature of 
all agonists at Ins(l,4 ,5)P3 receptors. One cannot help thinking that the finding of this 
feature in a molecule discovered by mass screening, and so far removed from 
Ins(l,4 ,5)P3 or from any other Ins(l,4,5)P3 receptor ligands previously known, is a 
testament to its importance as a recognition feature for Ins(l,4,5)P3 receptors. The 
bisphosphate is in a six-membered ring, albeit a glucopyranose rather than an inositol 
ring, and is accompanied by an equatorial hydroxyl group at C-2", which can be seen as 
equivalent to the 6-hydroxyl of Ins(l,4,5)P3. Here the direct structural correspondence 
ends, but some other features of adenophostin A, and its 6"-acetylated homologue 
adenophostin B, can be shown to be compatible with existing structure-activity 
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Figure 5.2 Structures of adenophostins A and B compared to Ins( 1,4 ,5)P3
First, consider the axial 2-hydroxyl group of Ins(l,4 ,5)P3. Studies of 2-modified 
analogues have established that this group is of little or no importance in binding to the 
Ins(l,4,5)P3 receptor.213 Thus, 5cy//o-Ins(l,4,5)P3 106 [strictly 5cy//o-Ins(l,2,4)P3] and 2- 
deoxy-Ins(l,4 ,5)P3 214 is only slightly less potent than Ins(l,4 ,5)P3. In the adenophostins, 
the equivalent position is occupied by the pyranoside oxygen. Second, it is known that, 
although a third phosphate group is not essential for activity in inositol phosphates, it 
greatly enhances it. Thus Ins(4 ,5)P2 is a 460-fold weaker agonist than Ins(l,4 ,5)P3.215 
Now in Ins(l,4 ,5)P3, this extra phosphate group is at the equatorial position 1, but
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moving it to the axial position 2 [as in Ins(2,4 ,5)P3] causes little reduction in activity* 
and an axial phosphate at position 1 as in D-c/z/ro-Ins(l,3,4)P3 will greatly enhance 
activity relative to Ins(4 ,5)P2.132 We can conclude that the location of the third 
phosphate group is less critical than that of the first two (perhaps the interaction with the 
binding site is long-range, as suggested by some workers ) and a phosphate group 
located somewhere within a fairly large region of space will enhance binding to the 
receptor. Very significantly, in the adenophostins, removal of the phosphate group at 
position 2 ' of the ribose ring causes a 1000-fold reduction in activity. Now the 2'- 
phosphate group of the adenophostins does seem to be in a strange position, but it is 
known that many disaccharides and higher saccharides have rather rigid shapes, and it 
may be that the 2'-phosphate is held in a precise position with respect to the 
glucopyranose ring. Our own preliminary molecular modelling simulations seemed to 
show that, in most low-energy conformations, the 2'-phosphate occupies a position 
similar to that of the 1-phosphate of Ins(l,4 ,5)P3, but in a different orientation and 
slightly further away from the ring. An example of one of these conformations is shown 
in Figure 5.3a. In other words, it is possible that 2/-phosphate may be positioned to 
interact with a similar area of the Ins(l,4 ,5)P3 binding site to the 1-phosphate of 
Ins(l,4 ,5)P3, but more effectively than in Ins(l,4 ,5)P3 itself. Of course, it is also possible 
that the 2'-phosphate of the adenophostins interacts with a different area of the 
Ins(l,4 ,5)P3 binding site from the 1-phosphate of Ins(l,4,5)P3.
The adenosine component of the adenophostins is probably the most surprising, 
and currently the most mysterious feature of these molecules. Its steric bulk alone 
requires that we invoke the idea of some kind of binding pocket or vacant area of the 
receptor to accommodate it. It is known that very large substituents at position 2 of 
Ins(l,4 ,5)P3 can be tolerated with minimal effect on potency, and it may be that this area 
of the binding site is open to solvent. This might lead us to consider an alternative 
binding orientation for the glucopyranose ring of the adenophostins as illustrated in 
Figure 5.3b. In this case, the above arguments still apply, but the equivalent of the 6- 
hydroxyl in Ins(l,4 ,5)P3 is now occupied by an hydroxymethyl group, (at present there is 
no information on the effect of a 6-hydroxymethyl group in Ins(l,4 ,5)P3 derivatives) and
* It may be more useful to consider the axial 2-phosphate in Ins(2,4,5)P4 as equivalent to an axial 1- 
phosphate at the receptor binding site, by visualising Ins(2,4,5)P3 in an inverted binding orientation, so 
that the 1-phosphate is axial. It is interesting to note here that Ins(l,4,5)P3 receptors from rat olfactory 
membranes are reported to respond to a 100-fold lower concentration of Ins(2,4,5)P3 relative to 
Ins(l,4,5)P3. 247
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the third phosphate group is held in an area of space close to that occupied by the 2- 
phosphate of Ins(2,4 ,5)P3. Binding orientation 5.3a requires an adenosine binding 
pocket in the area “below” position 1 of Ins(l,4 ,5)P3, but there is currently no evidence 
against this, and indeed, the idea of a specific binding pocket, that may interact strongly 
with the adenosine moiety may be more appealing. Figures 5.3a, 5.3b and 5.3c are also 
intended to illustrate the possibility of extended and hairpin conformations, in which the 
adenine is either orientated well away from the glucopyranose ring (5.3a and 5.3b) or 
held close to it as in 5.3c.
Figure 5.3 Examples of binding conformations and orientations in which adenophostin 
A might mimic Ins(l,4,5)P3. See text for discussion.
Of the three conformations shown, only 5.3a conforms with the exo-anomeric effect, 
which is usually the dominant factor in determining conformation around a glycosidic 
bond. Furthermore, an NOE between H-3' of ribose and H -l"  of glucose has been 
reported,212 and these two protons can be seen to be close together in 5.3a, while at a 
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c
* This was actually reported for adenophostin B, which the authors used for the detailed NMR studies.
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is directly involved in the extraordinary potency of the adenophostins or whether it 
serves to orientate another part of the molecule (e.g. the 2'-phosphate?) in a particularly 
favourable way.
5.2.1 Is 2'-AMP Active at Ins(l,4,5)P3 Receptors?
If the Ins(l,4,5)P3 receptor has a binding pocket for 2'-AMP close to the Ins(l,4 ,5)P3 
binding site, can 2'-AMP itself bind to the Ins(l,4 ,5)P3 receptor? 2 '-AMP is readily 
available and quite surprisingly, it has been found to be a substrate for inositol 
monophosphatase216. Molecular modelling studies have been carried out on 2'-AMP in 
connection with research into the design of inositol monophosphatase inhibitors, and 
recently a study of the active conformation of 2'-AMP at the enzyme’s active site has 
been published.217
A sample of 2'-AMP free acid was converted to the triethylammonium salt in
 ^I
order to increase its aqueous solubility, and after the purity had been checked by P 
NMR and HPLC, it was tested for ability to release Ca2+ in permeabilised rabbit 
platelets. As might be expected, it showed no ability to release Ca2+, even at 
concentrations up to ImM. More importantly, however, 2'-AMP did not inhibit 
Ins(l,4 ,5)P3 -induced Ca2+ release at these concentrations. This finding, although not 
unexpected, demonstrates that 2'-AMP alone, separated from the phosphate-bearing 
glucopyranose ring does not have significant affinity for the Ins(l,4 ,5)P3 binding site of 
the Ins(l,4 ,5)P3 receptor. The activity of the isolated “other ha lf’ of adenophostin A, i.e. 
glucose 3,4-bisphosphate, is presently not known, although this molecule could easily 
be synthesised from a protected glucose intermediate.
5.2.2 The 5"-CH2OH Group
There is one structural feature of the adenophostins that is not easily accommodated by 
structure-activity relationships based on Ins(l,4,5)P3 analogues, namely the presence of 
an hydroxymethyl group at a position corresponding to the 3-hydroxyl (or conceivably 
the 6-hydroxyl) group of Ins(l,4 ,5)P3. In a study designed to explore the steric tolerance 
of the Ins(l,4 ,5)P3 receptor at the equatorial 3-position a series of racemic 3-O-alkylated 
analogues have been synthesised.188 When these compounds were evaluated as Ca2+- 
mobilising agonists in permeabilised SH-SY5Y cells, activity was found to decrease 
dramatically with increasing chain length (R = Me, Et, Pr"). When R=Me, for example, 
potency was 25 times reduced, while for R = Et potency was reduced by greater than
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500-fold. However, when R = CH2COO' the reduction in potency was less, despite the 
steric bulk of this substituent.
Another study of 3-position-substituted Ins(l,4 ,5 )P3 mimics, including
219halogenated analogues, used regression analysis to establish a negative, linear 
correlation between steric volume of an equatorial 3-substituent and activity at 
Ins(l,4 ,5 )P3 receptors. 183 However, further analysis of the data showed that 
Ins(l,3,4,5)P4, 3 PS-Ins(l,4 ,5 )P3 and Ins(l,4,5)P3 itself were more active than would be 
predicted by this correlation based on purely steric considerations, and therefore fell into 
a second group (see Figure 5.4).
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Figure 5.4 Potency of 3-position-substituted Ins(l,4 ,5 )P3 analogues plotted against 
molecular volume (A3) of the substituent. Adapted from Reference. 183
No analogue with a CH2OH group at the equivalent of position 3 had been 
synthesised, but based on the considerations above, its activity would be expected to fall 
somewhere between that of Ins(l,4 ,5 )P3 and Ins(l,3 ,4 ,5 )P4 (i.e. considerably weaker 
than Ins(l,4 ,5 )P3 ). And yet the equivalent of a 3-hydroxymethyl group is present in 
adenophostin A in the form of the 5"-hydroxymethyl, and adenophostin B has the even 
more unwieldy acetate at this position. Does this mean that the adenophostins must bind 
to the Ins(l,4 ,5 )P3 receptor in a different way to Ins(l,4 ,5 )P3?
After the publication of the structures of the adenophostins, it was quickly 
realised that intermediate 34, discussed in Chapter 4, could be used to synthesise the 
hydroxymethyl analogue 44 (Figure 5.5) in a few steps. Analogue 44, which can be 
considered as the 3-deoxy-3-hydroxymethyl scyllo-inositol analogue of Ins(l,4 ,5 )P3, 
would represent the first step away from Ins(l,4 ,5 )P3 towards an adenophostin-related
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structure. True, 44 would (at this stage) be racemic, but it would enable us to investigate 
the effect of introducing an hydroxymethyl group at a position adjacent to the 4,5- 
bisphosphate in a molecule closely related to Ins(l,4 ,5)P3.
P h / ^ 0 - 7
P M B O ^-* ^^ /-O P M B  
BnO
34
Figure 5.5 The intermediate 34, from the synthesis of the conformationally restrained 
analogue (Chapter 4) can be used to synthesise an Ins(l,4 ,5)P3 analogue 44, which bears 
an equatorial hydroxymethyl group, as in adenophostin A.
5.3 Synthesis of a 3-Hydroxymethyl Analogue of Ins(l,4,5)P3
The 3-hydroxymethyl analogue 44 (strictly 6-deoxy-6-hydroxymethyl-scy//o-inositol 







Figure 5.6 Synthesis of 6-deoxy-6-hydroxymethyl scy//o-inositol 1,2,4-trisphosphate 
(44).
5.3.1 Regioselective Cleavage of a Benzylidene Acetal
Benzylidene acetal s are versatile protecting groups in that they can be removed 
completely by acid hydrolysis to give a diol (see Chapter 4), or reductively cleaved in 
either direction to give primary or secondary benzyl ethers. In the synthesis of 44, the 
required product was 45, in which the acetal has been reduced regioselectively to a 
primary benzyl ether, exposing a secondary alcohol group. Reductions of this type have
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been reported for benzylidene acetals of carbohydrates, and have employed aluminium 
chloride/trimethylamine-borane complex,220 or sodium cyanoborohydride/hydrogen 
chloride,221,222(see below) and more recently, trifluoroacetic acid / triethylsilane.223
It was decided to try the first method, using aluminium chloride/trimethylamine- 
borane complex to reduce intermediate 34. The results were disappointing at first, and 
the reaction seemed sluggish, eventually yielding a mixture of products, some of which 
resulted from loss of p-methoxybenzylidene groups. Rather than separating and 
individually characterising the products, the crude mixture was treated with refluxing 
1M HCl/ethanol 2:1, giving only two products, which were shown to be the triol 46 
(41% from 34) and the (unwanted) symmetrical triol 48 (27% from 34). It seems likely 
that the unwanted hydrolysis of the /?-methoxybenzyl ethers, had interfered with the 
regioselectivity of the ring-opening.
A literature search located another more recent application of the same method 
in carbohydrate chemistry, with the modification that the reaction was carried out in the 
presence of 4A molecular sieves.224 When the reaction on 34 was attempted again, but 
this time with the addition of 4A sieves, the results were much improved and the 
required alcohol 45 was obtained in 65% yield. A small amount of the symmetrical 
alcohol 47 (5%) was also isolated, and the TLC still showed quantities of more polar 
products resulting from p-methoxybenzyl ether cleavage. However, with sufficient 
quantities of 45 now in hand, no further attempts were made to optimise the procedure. 
It was later shown that the regioselectivity of the benzylidene cleavage could be 
reversed by reduction using diisobutylaluminium hydride (DIBAL-H) in toluene,225 this 
time giving the symmetrical alcohol 47 as the major product (72%) together with a 










Conditions 45 (% yield) 47 (% yield)
BH3NMe3/AlCl3, THF, 0°C 65 5
DIBAL-H, toluene, 0°C 5 72
Table 5.1 Regioselective reduction of 34.
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5.3.2 Phosphitylation/Oxidation and Deprotection
The p-methoxybenzyl protecting groups of the asymmetrical alcohol 45 were removed 
by acid hydrolysis giving triol 46, which was phosphitylated using bis(benzyloxy)-A,7V- 
diisopropylaminophosphine/l//-tetrazole. The 3IP NMR spectrum of the intermediate 
trisphosphite triester showed a large Vpp coupling of 6.1Hz between the phosphorus 
atoms of the vicinal phosphite groups (values of 3 or 4 Hz are typical for vicinal 
phosphites in an inositol ring). Oxidation as usual with m-CPBA gave the fully 
protected trisphosphate triester 49 which was a low-melting point crystalline solid. 
Deprotection using sodium in liquid ammonia, and purification by ion exchange 
chromatography went smoothly and the trisphosphate 44 was obtained as the pure 
triethylammonium salt.
5.4 Biological Activity of 6-deoxy-6-hydroxymethyl-scy//o-inositol 1,2,4- 
trisphosphate
The ability of racemic 44 to release Ca2+ from permeabilised rabbit platelets was 
examined. It appeared that 44 was equal in potency to Ins(l,4 ,5 )P.3, despite being 
racemic. In an assay of this type, it is possible for a non-metabolisable compound to 
show artefactually high potency relative to Ins( 1,4 ,5 )P3 due to prolonged 45Ca2+ release. 
However, when 44 was tested for its ability to displace [3H]Ins(l,4 ,5 )P3 from rat 
cerebellar membranes, the results, shown in Figure 5.7 confirmed the 45Ca2+-release 
data, with racemic 44 being equipotent to Ins(l,4 ,5 )P3. Assuming that only the L- 
enantiomer* of 44 is active, these binding results suggest that it should be one of the 
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Figure 5 .7  Displacement of [3H]Ins(l,4,5)P3 from rat cerebellar membranes by d l -44.
* The enantiomer o f 44 whose structure is analogous to Ins(l,4 ,5 )P 3 is the L-enantiomer. See Appendix 1 
for an explanation o f this nomenclature.
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The observation that racemic 44 is equipotent with Ins(l,4 ,5)P3 implies that the 
CH2OH component, which is not present in Ins(l,4 ,5)P3 itself, is tolerated by the 
Ins( 1,4 ,5)P3 receptor despite the additional steric bulk. This finding seems to be at odds 
with the results of studies on 3-position modified Ins(l,4 ,5)P3 analogues (Figure 5.4), 
which found that any increase in steric volume in this area reduced affinity for the 
Ins(l,4 ,5)P3 receptor, and yet it is keeping with the high potency of the adenophostins. It 
would be interesting to establish whether analogues of 44 esterified at the primary 
hydroxyl group retained activity (as does adenophostin B) and if so, what limitations 
exist on the size and nature of the ester. Clearly, the potency of the adenophostins does 
not result from the CH2OH group. It must somehow be related to the 2'-AMP 
component, as discussed earlier, but equally well, there is no need to imagine an unusual 
binding conformation for the glucopyranose ring of adenophostin A to allow the 
receptor to accommodate the CH2OH group.
5.4.1 Comparison with scy/fo-Inositol 1,2,4-trisphosphate
Is a CH2OH at this position simply tolerated by the Ins(l,4 ,5)P3 receptor, or can it 
actually enhance binding? Unfortunately, 44 differs from Ins(l,4 ,5)P3 in two ways: it is 
modified at the equivalent of position 3, but also, it is strictly an analogue of scyllo- 
rather than myo-Ins(l,4,5)P3 (Figure 5.8).
Figure 5.8 Comparison of the structure of 44 with Ins(l,4 ,5)P3 and scy//o-Ins(l,2,4)P3.
We therefore need to exercise some care in drawing conclusions from direct 
comparisons between 44 and Ins(l,4 ,5)P3. However, it would be valid to draw 
conclusions from a comparison of 44 with racemic 5cy//o-Ins(l,2,4)P3. The two
and the results are shown in Figure 5.9. It appears that 44 is significantly more potent 
than 5cy//o-Ins(l,2,4)P3. Finally, racemic 44 was compared to racemic scyllo- 
Ins(l,2,4)P3 and Ins(l,4 ,5)P3 for ability to displace [3H]Ins(l,4,5)P3 from rat cerebellar 
membranes. Again, it was significantly more potent than racemic 5cy//o-Ins(l,2,4)P3, 
and equipotent to Ins(l,4 ,5)P3. The results of these experiments are summarised in 
Table 5.2. We can conclude that, in the scy/Zo-series at least, replacement of the
m y o - ln s ( 1 ,4 ,5 ) P 3 scyllo- l n s ( 1 ,2 ,4 ) P 3 4 4
analogues were therefore compared for ability to release 45Ca2+ from rabbit platelets,
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secondary hydroxyl group at position 3 (strictly now position 6 ) with a primary hydroxyl 
group enhances affinity for the Ins( 1 ,4 ,5 )P3 receptor.
100-1
—- — lns(1,4,5)P3 
—o— DL- 44
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Figure 5.9 45Ca2+-release by racemic 44, racemic 5cy//o-Ins(l,2 ,4 )P3 and Ins(l,4,5)P3.
Compound Ins(l,4,5)P3 receptor 
binding at 4°C 
ICso/^M ± S.E.M. (n=3)
45Ca2+ release at 4°C 
EC50/juM ± S.E.M. (n=6 )
D-Ins(l,4,5)P3 0.04 ±0.01 0.404 ±0.11
DL-^cy//o-Ins( 1,2,4)P3 0.15 ±0.018 1.67 ±0.35
d l -44 0.027 ±0.01 0.44 ± 0.26
Table 5.2 Comparison of inositol phosphates for displacement of [3H]Ins(l,4,5)P3 from 
rat cerebellar membranes and for release of 45Ca2+ from permeabilised platelets.
5.4.2 Interaction with Ins(l,4,5)P3 3-Kinase
DL-5cy//o-Ins( 1,2,4)P3 is known to be a substrate for 3-kinase, although the position 
of phosphorylation, and indeed, which enantiomer is metabolised, is not yet established. 
It might therefore be interesting to investigate the interaction of 3-kinase with 44. A 
sample of racemic 44 was incubated with a purified 3-kinase preparation and the 
product analysed by HPLC with metal dye detection.257 The results showed, perhaps 
surprisingly, that half of the sample had been phosphorylated, to give two unidentified 
tetrakisphosphates. This suggests that one enantiomer of 44 is being phosphorylated by 
the enzyme, but at two different positions. Although the specificity of 3-kinase for its 
natural substrate Ins(l,4,5)P3 is known to be very high, we cannot assume that it is 
necessarily the Ca2+ -releasing enantiomer that is phosphorylated. Benzene 1,2,4- 
trisphosphate226 and a mannose-based L-Ins(l,4,5)P3 analogue (Chapter 1) are
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recognised by 3-kinase, for example, but are inhibitors. Other possibilities exist; one 
enantiomer could be a 3-kinase inhibitor while the other is phosphorylated, for example, 
as was the case with racemic 2,2-difluoro-^cy//o-Ins(l,4 ,5)P3.64 Thus, the 
tetrakisphosphate products could have any one of five possible structures. How can they 
be identified?
The ideal solution is to resolve an intermediate in the synthesis of 44 (see 
below), synthesise optically pure D- and L-44, incubate the two enantiomers separately 
with the 3-kinase, and identify the product by NMR. However there is another strategy 
which might be able to establish which enantiomer is phosphorylated and at what 
positions (Figure 5.10).
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Figure 5.10 Proposed strategy to identify the products of phosphorylation of 44 by 
Ins(l,4,5)P3 3-kinase.
If a larger quantity of racemic 44 is incubated with the enzyme, then it should be 
possible to separate the tetrakisphosphate products from the unphosphorylated 
trisphosphate enantiomer using ion exchange chromatography. There is little doubt that 
the potent Ca -releasing enantiomer of 44 must have the D-4,5-bisphosphate 
configuration. If the Ca2+-releasing activity of the unphosphorylated trisphosphate is 
then compared to racemic 44, the assay must show that either its apparent activity has 
increased or decreased. The configuration of the phosphorylated enantiomer can then be 
deduced. A ^-coupled  31P NMR of the tetrakisphosphate product should then be able
133
to identify the relative configuration of the tetrakisphosphates, even if they cannot be 
completely separated. A triplet in the spectrum implies phosphorylation of the primary 
alcohol, four doublets means phosphorylation at position 3, while two doublets 
identifies the product as the symmetrical tetrakisphosphate resulting from 
phosphorylation at position 5. Putting this information together gives the absolute 
configuration of the products. Accordingly, a larger sample of racemic 44 was 
synthesised, and this study is now in progress.
5.4.3 Lack of Interaction with Ins(l,3,4)P3 5/6-kinase and Ptdlns 3-kinase
8 7When the interaction of racemic 44 with a purified D-Ins(l,3,4)P3 5/6-kinase was 
examined, racemic 44 was found to be completely inactive in inhibiting phosphorylation 
of [3H]Ins(l,3,4)P3. This result is quite remarkable, considering that all other racemic 
inositol phosphate analogues tested and all optically active analogues having the l-4,5 
bisphosphate [or equivalent, e.g. as in D-Ins(l,3,4)P3, see Section 1.9.4] were recognised 
by the enzyme, and yet in the case of 44, neither enantiomer was recognised. This 
finding might be rationalised by a consideration of the binding orientation of D-44 that 
might mimic the structure of D-Ins(l,3,4)P3, the natural substrate of 5/6-kinase (see 
Figure 5.11).
Figure 5.11 d-44 appears not to be recognised by Ins(l,3,4)P3 5/6-kinase, despite its 
similarities to D-Ins(l,3,4)P3.
Neither racemic 44 nor racemic 5cy//o-Ins(l,2,4)P3 were able to inhibit Ptdlns 3- 
kinase. This observation can be explained by the fact that the D-enantiomers of these 
molecules bear no resemblance to Ins(l,4,5)P3, while the L-enantiomers, although they 
may mimic the arrangement of phosphate groups in Ins(l,4,5)P3 , have no equivalent to 
the axial 2-hydroxyl group (see Section 1.9.5).
5.4.4 Optical Resolution
An attempt to resolve an intermediate in the synthesis of 26 and 44 by formation of bis- 
(-)-co-camphanate esters of diol 33 (Figure 4.4) was unsuccessful. The two 
diastereoisomeric biscamphanates, were inseparable by either chromatography or 
recrystallisation. Another attempt at resolution via monocamphanate esters of alcohol 45
Site of action 
of 5/6-kinase
primary hydroxyl?
0 P 0 32' Site blocked by
D -ln s(1 ,3 ,4 )P 3 d-4 4
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(Figure 5.6) also failed. However, when 45 was reacted with (5')-(+)-acetylmandelic acid 
(activated by DCC), the two products were well separated on the TLC plate. No more of 
the alcohol 45 remained at this stage, and so the reaction could not be scaled-up, but it is 
clear that the required optical resolution can be carried out at this stage, enabling the 
synthesis of the enantiomers of 44. This is now being carried out by another worker.
Should it not prove possible to obtain crystals suitable for an X-ray study, then 
reduction of the free alcohol group of (+)- or (-)-45 followed by hydrogenation will give 
the corresponding pseudosugar (either carba-/?-D-glucopyranose, or its enantiomer). The 
absolute configuration can then be deduced from the direction of the optical rotation ( 
[a ]D20 = +13.0° for the D-enantiomer in water227). Note that the enantiomers of 45 are 
precursors for optically active position-4 modified analogues of 44.
5.5 Phosphorylation of Carbohydrates
The L-enantiomer of 44 resembles both a scyllo-inositol derivative and a derivative of /?- 
D-glucopyranose. The fact that this structure showed highly potent activity at 
Ins( 1,4 ,5)P3 receptors suggested that a phosphorylated glucose derivative would also be 
active, even without the additional 2'-AMP feature found in the adenophostins. This 
may seem obvious in retrospect, but it must be remembered that the prevailing opinion 
at this time was that bulky substituents placed adjacent to the vicinal bisphosphate of 
Ins(l,4,5)P3 analogues would inevitably cause a reduction in potency.
The idea of producing inositol phosphate mimics based on carbohydrates is not 
new. A synthesis of a phosphonate-containing D-Ins(l,4 ,5)P3 analogue (Figure 5.12) 
from D-galactose has been described, for example.228 No biological results have been 
reported for this analogue, but in the light of our present knowledge it seems unlikely 
that it would be very active at Ins(l,4 ,5)P3 receptors. The galactose-based analogue 
retains an axial hydroxyl group, intended to mimic the 2-hydroxyl of myo-inositol, but 
the important 6-hydroxyl is replaced with pyranoside oxygen. It is now apparent, from 
studies of position 2-modified Ins(l,4 ,5)P3 analogues, from the discovery of the 
adenophostins, and from the potent activity of the hydroxymethyl analogue 44 described 
above, that the 2-hydroxyl group is of low importance with respect to Ins(l,4 ,5)P3 
receptor binding of trisphosphate Ins(l,4 ,5)P3 analogues. It can be changed to an 
equatorial hydroxyl, replaced with a pyranoside oxygen or removed completely. What is 
more, there is no need to retain a secondary hydroxyl group at position 3, and an 
hydroxymethyl group at this position is tolerated with no loss in activity. Thus, we
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would expect that analogues derived from D-glucose, D-xylose (or even D-mannose) 
would be better mimics of Ins(l,4,5)P3 at Ins(l,4 ,5)P3 receptors.
G alactose-based G lucose-based X ylose-based
Figure 5.12 Ins(l,4 ,5)P3 analogue based on D-galactose.228 Structure-activity 
considerations (see text) now suggest that analogues based on D-glucose or D-xylose 
may be better Ins(l,4 ,5)P3 receptor ligands. Y could have various structures (see below).
A synthesis of D-mannose 1,4,6-trisphosphate, intended as an L-Ins(l,4 ,5)P3 
mimic, has also been reported (quoted in Reference65) but it was found that the 
anomeric phosphate was chemically and stereochemically unstable. The fact that 
phosphates formed at the anomeric position (Y = OPO32' in Figure 5.12) are intrinsically 
unstable poses severe limitations on the use of phosphorylated simple monosaccharides 
as inositol polyphosphate mimics. (A phosphonate formed at the anomeric position is 
stable, but in general, phosphonates have not been found to be good phosphate mimics 
at the Ins(l,4 ,5)P3 receptor). If we were to phosphorylate some of the hydroxyl groups in 
a glycoside, or even a disaccharide, then the anomeric position would not be a problem. 
Disaccharides could give plenty of scope for novel polyphosphates, but the difficulties 
of protecting the hydroxyl groups selectively would be much greater. One solution is to 
protect selected hydroxyl groups in two monosaccharides and then couple the two 
together (ideally in a stereospecific way). Another solution might be to choose a 
disaccharide that is easy to manipulate because of its symmetry. This reasoning led us to 
consider the use of a,a-trehalose.
5.5.1 An Ins(l,4,5)P3 Analogue Based on Trehalose
Trehalose is the general name for D-glucosyl D-glucosides. Since the glucose residues 
are joined at their anomeric carbon atoms, there are three possibilities; a,a-, ft,ft- and 
a ,/3-trehaloses. The first of these, a,a-trehalose (a-D-glucopyranosyl 1,1/-o /-d- 
glucopyranoside) is the only isomer known to occur in Nature, although a,/3- and /?,/?- 
forms have been synthesised. The glucose residues in all three known trehaloses are in 
the pyranose form. a,a-Trehalose is found in "Trehalamanna", the cocoons of a 
parasitic beetle, and it also occurs in some fungi, and a variety of plants and bacteria. In 
insects, Cf,a-trehalose is the main sugar found in the blood, and in adult flies it is the
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sole source of energy for flight. It may also help to protect enzymes and membranes in 









Figure 5.13 The trehaloses. Only the a,a-form  is known to occur naturally.
A series of trehalose-based mycobacterial cell surface antigens have been 
isolated from Mycobacterium tuberculosis, the causative agent of tuberculosis. These 
glycolipids have been identified as a series of 2,3-di-0-acyl-a,ct-trehaloses230 and the 
related M. fortuitum, which is an opportunistic pathogen*, has also been found to 
contain 2,3,4- and 2,3,6-tri-O-acylated forms. These findings have stimulated renewed 
chemical interest in trehalose, and strategies have been developed for the regioselective
9^1protection of its hydroxyl groups. A major component of the M. fortuitum  lipid 
antigens has recently been synthesised from a,a-trehalose using these methods.232
It is interesting to note that sulphated /Tmaltosyl trehalose has recently been 
shown to have heparin-like antiproliferative effects and yet unlike heparin itself, has no 
(antithrombin Hi-mediated) anticoagulant properties.233 The authors hypothesise, on the 
basis of molecular modelling experiments, that the trehalose moiety is responsible for 
the biological activity of the molecule, although its site of action is not yet known. 
Although little information is available on trehalose phosphates, it is now thought that 
a ,a-trehalose-6-phosphate plays an important part in the regulation of yeast glycolysis, 
by feedback inhibition of hexokinase II, a role similar to that of glucose 6-phosphate in 
higher organisms.234 Syntheses of o^a-trehalose-b^'-phosphate and the four
235 236
monophosphates of a,a-trehalose have been published recently. ’
An important property of a,a-trehalose is that it possesses a C2 axis of 
symmetry, and no other symmetry elements. It therefore belongs to the C2 point group. 
Corresponding atoms e.g. C-l and C -l', C-2 and C-2' etc., are homotopic and are
* M. fortuitum  is becoming increasingly important because of its effects on AIDS patients.
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therefore identical chemically and indistinguishable by NMR. This gives some 
important advantages:
• The synthesis of symmetrical trehalose derivatives is greatly simplified.
• Interpretation of NMRs is straightforward.
• Molecular modelling studies require fewer computations and therefore less time.
The C2 symmetry of a,a-trehalose does lead to one disadvantage; that of 
determining its conformation and that of its derivatives by NMR. Because 
corresponding atoms in the two glucose residues are homotopic, the NMR equivalence 
of the two residues precludes determination of the solution conformation of symmetrical 
trehaloses by the measurement of chemical shifts, relaxation times, coupling constants 
or NOEs.237 However, X-ray structures are available for various trehalose derivatives 
(summarised in Reference ) and a detailed molecular modelling study has been earned 
out.238 The preferred conformations of the C-disaccharide equivalents of the trehaloses, 
in which the two methylene bridge protons are magnetically inequivalent, have recently 
been determined directly by NMR.239 These studies suggest that a,a-trehalose is less 
flexible than the other trehaloses, and probably more conformationally rigid than most
238other disaccharides, a factor which may be important in its various biological roles.
The observation that the adenophostins interact potently with the Ins(l,4,5)P3 
receptor binding site implies that the receptor can accommodate considerable steric bulk 
in an area of the binding site close to that normally occupied by Ins(l,4,5)P3. Exactly 
which area of space, relative to the inositol ring, is involved is currently unknown but, if 
the adenophostins bind in an extended conformation, then this suggests that the receptor 
should also be able to accommodate a disaccharide having an a,a-linkage (Figure 5.14).
Figure 5.14 The fact that the Ins(l,4,5)P3 receptor can accommodate the steric bulk of 
adenophostin A suggests that it might also be able to bind trehalose derivatives.
The C2 symmetry of a,a-trehalose makes it an ideal starting point for a molecule 




group strategies can be applied that have been developed for a-methyl-D- 
glucopyranoside. Furthermore, the glycosidic linkage in a,G'-trehalose is known to be 
resistant to a-glycosidase, a fact that should confer some metabolic resistance upon 
trehalose-based analogues. The initial target disaccharide chosen was the C2-symmetric 
3,4,3',4'-cx-D-glucopyranosyl-a'-D-glucopyranoside tetrakisphosphate 50. Note that, if 
we define the Ins(l,4 ,5 )P3 binding pharmacophore as described in Chapter 1, this 
molecule possesses two copies of it. Contrast this with Ins(l,3 ,4 ,6 )P4 which has a 
symmetry plane rather than axis, and belongs to the Cs (Cih) point group. In 
Ins(l,3 ,4 ,6 )P4 , positions 1 and 3 are enantiotopic, as are 4 and 6 . They are therefore not 
equivalent in a chiral environment such as the binding site of a receptor or enzyme, 
although they are chemically equivalent as far as NMR is concerned (in the absence of 
any chiral environment). Ins(l,3 ,4 ,6 )P4 therefore has only one vicinal bisphosphate that 
is equivalent to the 4,5-bisphosphate of Ins(l,4,5)P3.
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Figure 5.15 Proposed C2-symmetrical tetrakisphosphate analogue based on a,a- 
trehalose.
X-ray crystal structures of a,a-trehalose itself, and many derivatives generally 
show the torsion angles 0 and y/ to be negative and synclinal, with values between -40 
and -60°. This observation is a direct manifestation of the ^o-anomeric effect, which in 
trehalose will be an important factor in determining both 0 and y/. Applying this to the 
tetrakisphosphate 50 gives a conformation (Figure 5.16) in which the 3' and 4' 
phosphates are positioned such that neither corresponds to the crucial 2 ' phosphate of 
the adenophostins in the conformations shown in Figure 5.3.
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2'03P0
Figure 5.16 Theoretical conformation for 50 based on a consideration of the exo- 
anomeric effect, so that the torsion angles 0 and iff are both negative and synclinal.
There is no available information on the conformations of trehalose phosphates. 
(Note that it would not be possible to detect the expected NOE between H -l and H -l', 
because these protons are homotopic). Although it is certainly true that the ejco-anomeric 
effect does govern the conformations of most (but not all240) a,a-trehalose derivatives 
studied to-date, it seems possible that the influence of the charged phosphate groups 
may exert a major influence, and this is likely to vary with pH, ionic strength and 
counter-ion in solution. The symmetrical 50 seemed to be an immediately accessible, 
and aesthetically appealing starting point for an investigation into phosphorylated 
disaccharides.
Synthesis of the symmetrical tetrakisphosphate 50 required a protected precursor 
such as 56. A literature search showed that the diol 53 was known, and could be made in 
good yield from trehalose in two steps. The key synthetic strategy would be the 
regioselective reduction of both benzylidene acetals together to give 56. It was thought 
that the symmetry of 53 and its expected rigidity would mean that the two acetals could 
be regarded as being equivalent, and essentially independent from one another. The 
outcome of the reduction would be easy to determine by NMR because, of the three 
possible products, the required 56 is symmetrical and has no primary hydroxyl group.
50 OH 56 OBn
Figure 5.17 Retrosynthetic analysis of the symmetrical tetrakisphosphate 50 suggests a 
synthesis from 53.
The synthesis of 50 would also be expected to produce some of the asymmetrical
analogue, a,a-trehalose 2,4,3/,4/-tetrakisphosphate (Figure 5.18) This molecule 
preserves the pharmacophoric bisphosphate on one glucose residue, while the other 
bears a phosphate at the 2'-position, which was expected to be a better mimic of the 
adenophostin 2'-phosphate. Should 50 show biological activity, then, it would be 
interesting to compare it to the asymmetrical regioisomer.
Figure 5.18 The asymmetrical product of the benzylation reaction (52) could be used to 
make another, potentially active, asymmetrical tetrakisphosphate.
5.5.2 Other carbohydrate-based Ins(l,4,5)P3 /adenophostin mimics.
It was suggested that the planned synthesis was over-long, and that a direct route to 
tetrol 56, or a similarly protected precursor would be preferable. Accordingly, a series of 
attempts were made to prepare a precursor for phosphorylation by direct dibutyltin- 
mediated alkylation and acylation of trehalose. These experiments, which were carried 
out by a colleague, were unsuccessful, and attempts to synthesise 50 were abandoned.
Later, a report was published of the synthesis of a phosphorylated glucose 
derivative intended as an Ins(l,4,5)P3 /adenophostin A mimic241. This analogue showed 
potent activity at Ins(l,4,5)P3 receptors, as would be predicted from the results for the 
hydroxymethyl analogue 44, and by the reasoning given in Section 5.6. 2-Hydroxyethyl 
a-D-glucopyranoside 2',3,4-trisphosphate [Gluc(2',3,4)P3, Figure 5.19] was found to be 
a full agonist at the Ins(l,4,5)P3 receptors of rabbit platelets, but ten-fold weaker than
Figure 5.19 Structure of 2-hydroxyethyl-a-D-glucopyranoside-2',3,4-trisphosphate, 
[Gluc(2',3,4)P3], showing relationship to adenophostin A.
2,3'-di-G-benzylated 52 as a by-product, and this could be used to make another
toBnO ^  2 0 3p 






It seemed likely that the reduced potency of Gluc(2',3,4)P3 relative to 
adenophostin A, Ins(l,4,5)P3 and to the hydroxymethyl analogue 44 could be due to the 
flexibility of the ethylphosphate structure. A molecular dynamics simulation of 
G1uc(2',3,4)P3 supported this idea and as expected, low-energy conformations tended to 
be of the extended type, so that the primary phosphate group was positioned further 
away from the glucose ring than the equivalent 2'-phosphate of adenophostin A.
A comprehensive biological study of Gluc(2',3,4)P3 was published by another 
group,242 confirming its activity in SH-SY5Y neuroblastoma cells and MDCK cells. 
Binding studies were also carried out in pig cerebellum, and enzyme assays showed that 
G1uc(2',3,4)P3, like adenophostin A, was resistant to metabolism by 3-kinase and 5- 
phosphatase. These authors also carried out a molecular dynamics simulation, 
confirming our unpublished results and again showing that the ethylphosphate was too 
conformationally mobile and too distant from the glucose ring to be a good mimic of the 
2'-phosphate in adenophostin A. The authors also hypothesised that adenophostin A 
must interact with the Ins(l,4,5)P3 receptor in a different orientation than does 
Ins(l,4,5)P3 in order to minimise the negative effect of the hydroxymethyl group at 
position 5". However, our results for the hydroxymethyl analogue 44 (see above) imply 
that no such assumption is necessary, unless of course, 44 also interacts with the 
Ins(l,4,5)P3 receptor in a different orientation to Ins(l,4,5)P3.
Shortly afterwards, a third group published the syntheses of more analogues 
similar to Gluc(2',3,4)P3 but based on xylopyranosides.243 Their reported potencies were 
similar to that of Gluc(2',3,4)P3 (i.e. roughly ten times weaker than Ins(l,4,5)P3 ) 
although the j3-D-xylopyranoside with n = 3 appeared to be significantly weaker than the 
others. It would be interesting to compare the a-D-xylopyranosides with the 
glucopyranoside Gluc(2',3,4)P3 in the same biological assay so as to determine the 
contribution of the hydroxymethyl group to activity.
' 3
( n  =  2  o r  3 ) ( n  =  2  o r  3 )
Figure 5.20 a- and /3-xylopyranoside-based Ins(l,4,5)P3 mimics.243
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5.6 Synthesis of a,tf-trehalose-3,4,3',4'-tetrakisphosphate
The biological results reported for these phosphorylated carbohydrates did not bode well 
for the planned trehalose-based analogue, whose synthesis was now resumed. It seemed 
that the positioning of the third phosphate group was indeed a critical determinant of 
activity. (This did not imply, of course, that precise positioning of the phosphate group 
alone would necessarily give highly potent activity). As explained above, if we make 
that assumption that the exoanomeric effect would be dominant in determining the 
conformation of 50, and that the molecule would be quite rigid, then neither phosphate 
of the additional glucose ring would be in the right place. On the other hand, the 
published minimised energy conformation of adenophostin A, which was similar to that 
shown in Figure 5.3b, did not show any exo-anomeric effect either, and the idea of a 
disaccharide analogue with two copies of the essential pharmacophore was still 
attractive. At least the trehalose phosphate would be more rigid than the phosphorylated 
carbohydrate analogues discussed above, and if it showed any activity at all, it should be 
possible to produce various analogues in which the diequatorial bisphosphate motif was 
maintained on one ring while one or more phosphate groups were placed at various 
positions in the second. Finally, 50 and other trehalose polyphosphates might have 
interesting biological properties outside the phosphoinositide field. The synthesis of 50 
was finally carried out, and is shown in Figure 5.21.
5.6.1 Regioselective Benzylation of 4,6:4',6'-di-0-benzylidene-a,a-trehalose
The di-O-benzylidene acetal 51 was prepared according to the improved procedure of 
Baer and Radatus.244 The positive ion FAB mass spectrum of this compound, and of all 
subsequent derivatives in this synthesis showed a characteristic peak at [(M/2)-8]/z 
corresponding to the positive fragment ion produced by cleavage of the glycosidic bond. 
Regioselective benzylation according to Vicent et al.,245 using two equivalents of 
dibutyltin oxide, excess benzyl bromide and a catalyst of jV-methylimidazole gave the 
symmetrical 2,2'-di-O-benzyl-4,6:4/,6'-di-0-benzylidene-a,a-trehalose (53) in 54% 
yield and the asymmetrical 2,3'-di-0-benzylated derivative 52 in 32% yield after column 
chromatography. The authors of the original study reported that unchanged starting 
material (11%) was recovered, although in our hands, the conversion was complete as 
judged by TLC, and more of the asymmetrical 52 was obtained. Both 52 and 53 could 
be crystallised easily from ethyl acetate/hexane (52 had previously been reported to be a 
syrup). The isolation of substantial amounts of the unsymmetrically substituted 52 was
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useful, because it was a precursor for an asymmetrical trehalose tetrakisphosphate 
(Figure 5.18). The respective identities of 52 and 53 were immediately apparent from
1 13the H and C NMR spectra, in that 53 possesses a symmetry element, which is lacking 
in 52. The very simple NMR spectrum of 53 could be assigned completely, 
confirming the positions of the benzyl ethers.
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Figure 5.21 Synthesis of a,a-trehalose-3,4,3',4'-tetrakisphosphate 50. 
i) C6H5CH(OMe)2, DMF, p-TsOH, 75°C; ii) a) Bu2SnO, 3A sieves, CH3CN, 120°C b) BnBr, N- 
methylimidazole; iii) BzCl, DMAP, pyridine; iv) NaCNBH3, THF, 3A sieves, dry HC1; v) a) 
(BnO)2PNPr'2, l//-tetrazole, b) m-CPBA, -78°C; vi) Na/liq NH3. Bn=benzyl, Bz=benzoyl.
5.6.2 Regioselective Reduction of Benzylidene Acetals
The next step would be a regioselective reduction of both benzylidene acetals in the 
symmetrical derivative 53. As discussed above, the borane-trimethylamine/aluminium 
chloride method had been successful when used in the case of the protected inositol 34, 
but the yield had been modest, and regioselectivity was sometimes poor. It was therefore
• 991decided to attempt the reaction using the method of Garegg et al. , which employs 
sodium cyanoborohydride-hydrogen chloride, and if this was not successful, to try the 
newly reported method of DeNinno et al. using triethylsilane-trifluoroacetic acid.223 In 
both of these methods, the carbohydrate model compounds used by the authors to 
investigate the regioselectivity of their method had protecting groups at position 3 (or its 
equivalent), although it was not clear what might be the effect of a free hydroxyl group 
at this position. It was particularly important in this case that the regioselectivity of the 
reaction was maximised so as to avoid obtaining a mixture of three products, which may 
be difficult to separate. (In fact a small-scale trial of the reaction directly on 53 did give
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at least three products, which still await positive identification). It was therefore decided 
to protect this position temporarily as a benzoate ester. It was expected that this would 
also aid identification of the product, as the benzoylated 3-position should be easily 
recognisable in *H NMR spectra.
Accordingly 53 was benzoylated under standard conditions to give the highly
crystalline symmetrical derivative 54. Reduction using sodium cyanoborohydride and
0 0  1hydrogen chloride in dry ether according to the published procedure was successful at 
the first attempt, with total conversion to a single product within 5 minutes. When the 
reaction was scaled up, the pure diol 55 was obtained in 80% yield after flash 
chromatography. The simple lH NMR spectrum confirmed the symmetry of the product, 
and as expected, the distinctive H-3 resonance, a pseudo-triplet, was shifted well 
downfield away from other signals, resulting in a first-order spectrum that could be 
completely assigned. Saponification using methanolic sodium hydroxide gave the 
required tetrol 56 in 85% yield.
5.6.3 Phosphorylation and Deprotection
The tetrol was phosphitylated with bis(benzyloxy)-Af,Af-diisopropylaminophosphine / 
l//-tetrazole, following the usual procedure. The 31P NMR of the intermediate 
trisphosphite was a single AB system with Vpp = 4.9 Hz. This confirmed beyond any 
doubt the structure of the tetrol precursor, in that such a spectrum could only arise if the 
precursor contained vicinal alcohol groups and was symmetrical. It is worth mentioning 
here that phosphitylation of polyols could be a useful technique for assigning their 
structure in situations when the !H NMR spectrum is complex, or where the hydroxyl 
groups cannot be seen. It enables immediate identification of vicinal diols, and the 
phosphites derived from isolated alcohol groups appear as singlets. In six-membered 
rings, the coupling constant can often be used to judge whether the relative 
stereochemistry of two hydroxyl groups is trans or cis.
Oxidation with m-CPBA gave the tetrakisphosphate triester 57. The proton- 
coupled 31P NMR spectrum of this compound simply consists of two pseudo-sextets 
(Figure 5.22a). Deprotection using sodium in liquid ammonia removed all benzyl 
protecting groups, leaving the glycosidic linkage intact and the target tetrakisphosphate 
was obtained as the pure triethylammonium salt after ion exchange chromatography. 











Figure 5.22 31P NMR spectra (^ -coup led , 162 MHz) of a) protected tetrakisphosphate 
triester 57 in CDC13 b) a,a-trehalose-3,4,3',4'-tetrakisphosphate 50 in D20 ,  pH~7.
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5.6.4 Ca2+-mobilising Ability of Trehal(3,4,3',4')P4
a,a-Trehalose-3,4,3',4'-tetrakisphosphate (50) was tested for ability to release 45Ca2+ in 
permeabilised rabbit platelets. The results (Figure 5.23) showed that 50 was able to 
release Ca2+ although with a potency around 100-fold lower than Ins(l,4,5)P3. Thus 50, 
although relatively weak, is the first known example of a disaccharide-based analogue 
active at Ins(l,4,5)P3 receptors. The results do not allow us to judge whether 50 is 










0.10.00001 0.0001 0.001 0.01 1 10
Concentration / p M
Figure 5.23 45Ca2+-release from permeabilised rabbit platelets induced by adenophostin 
A, Ins(l,4,5)P3 , G1uc(2',3,4)P3 and Trehal(3,4,3',4')P4 (50).
The time-course of Ca2+-release induced by 50 can be seen in Figure 5.24. The effect is 
prolonged, indicating that 50 is poorly metabolised and is probably resistant to 3-kinase 
and 5-phosphatase. The effect of 50 is inhibited by heparin (Figure 5.25), which is good 
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Figure 5.24 Time-course of Ca2+-mobilisation by Trehal(3,4,3',4')P3 (50) monitored by 
spectrofluorimetry.
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Judging by these results, the affinity of 50 for the Ins(l,4 ,5 )P3 receptor appeared 
to be quite low, and this might be expected on the basis of the molecular modelling 
results discussed above. The results do show however, that the receptor is capable of 
accommodating the steric bulk of a second glucose residue, as predicted.
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Figure 5.25 Spectrofluorimetry shows that the action of Trehal(3 ,4 ,3 ',4 ')P4 (50) is 
inhibited by heparin.
5.6.5 Preliminary Binding Assay
Preliminary binding assays have recently been carried out for 50 (Figure 5.26). These 
results are puzzling, in that 50 appears to displace [3H]Ins(l,4 ,5 )P3 with a potency 
similar to that of Gluc(2',3,4)P3. Thus the affinity of 50 for the rat cerebellar 
Ins(l,4,5)P3 receptor appears to be surprisingly high, only 10-fold weaker than 
Ins(l,4 ,5 )P3 itself. On the basis of these results, 50 would be classified as a potent 
Ins(l,4 ,5 )P3 receptor ligand, and yet its ability to release Ca2+ release from rabbit 
platelets is low. Speculation as to the significance of this anomaly will be avoided until 
the findings can be confirmed.
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Figure 5.26 Displacement of [3H]Ins(l,4,5)P3 from rat cerebellar membranes by 
adenophostin A, Ins(l,4,5)P3, Gluc(2',3,4)P3 and Trehal(3,4,3',4/)P4 (50).
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Table 5.3 Binding and 45Ca2+ release data* for adenophostin A, Ins(l,4 ,5)P3, 
Gluc(2',3,4)P3 , Trehal(3,4,3',4')P4 (50) and 2'-AMP.
Compound Binding (ICso/juM) 45Ca2+ release (EC30//iM )
adenophostin A 0.00074 ± 0.00042 0.0073± 0.0036
2'-AMP — no release (ImM)
Ins(l,4 ,5)P3 0.038 ± .005 0.4 ±0.08
G1uc(2',3,4)P3 0.21 ±0.07 2.05 ± 0.3
Trehal(3,4,3',4')P4 0.37 ±0.17 100 ±65
*Displacement of specific [3H]Ins(l,4,5)P3 binding from rat cerebellar membranes, and 
45Ca2+ release from permeabilised rabbit platelets were used to determine the EC50 and 
IC50 values respectively. Values are mean ± S.E.M. ( n = 3 - 10).
5.7 Sum m ary
The discovery of the adenophostins has provided an important new stimulus to research 
in an area of medicinal chemistry where lead compounds were scarce and ideas were 
beginning to run out. The adenophostins possess the essential structural motifs that have 
been deduced for Ins(l,4 ,5)P3 mimics by application of the classical active analogue 
approach over a period of years, and they also confirm our existing ideas as to which 
features of Ins(l,4 ,5)P3 are not essential for activity. It was not previously appreciated 
that an hydroxymethyl group, and perhaps even larger structures, can be tolerated by the 
Ins(l,4 ,5)P3 receptor in the region that normally binds the 3-hydroxyl group of 
Ins(l,4 ,5)P3, but the high potency of 6-hydroxymethyl 5cy//o-Ins(l,2,4)P3 has shown 
that this is indeed the case, and the presence of a similar structure in adenophostin A is 
not mysterious.
Attempts to mimic the 2'-phosphate of the adenophostins with conformationally 
mobile primary phosphate groups have so far met with limited success, producing 
analogues weaker than Ins(l,4 ,5)P3 , but have established that simple carbohydrate- 
based analogues can show high potency. By comparing Gluc(2',3,4)P3 to 6-deoxy-6- 
hydroxymethyl-5cy//o-Ins(l,2,4)P3 we can deduce that the ethylphosphate of 
G1uc(2',3,4)P3 is not acting as a good surrogate for the 2/-phosphate, nor of the 1- 
phosphate of Ins(l,4 ,5)P3. However, it is almost certainly better than no phosphate at all. 
The fact that Gluc(2',3,4)P3 is far more potent than Ins(4 ,5)P2 , and the observation that 
the activity of the xylopyranoside-based Ins(l,4,5)P3 mimics (Figure 5.20) is dependent 
on the orientation and chain-length of the alkylphosphates, suggest that the
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conformationally mobile phosphate groups of these analogues enhance affinity for the 
Ins(l,4,5)P3 receptor binding site but that their interactions with it are sub-optimal. An 
attempted short-cut to a conformationally more rigid analogue 50 based on trehalose 
seems to have been less successful in terms of agonistic effect, but the preliminary 
binding assay apparently shows high-affinity binding for 50; an exciting result if it can 
be confirmed. Trehal(3,4,3',4')P4 is the first synthetic disaccharide active at Ins(l,4,5)P3 
receptors, and its other biological properties await investigation.
We still do not know whether high potency can be achieved with a minimal 
structure lacking adenine, but the next logical step is obviously to include a degree of 
conformational restraint in the structure of Gluc(2',3,4)P3 , and Desai et al.246 have very 
recently reported a synthesis of methyl 2-0-allyl-5-0-benzyl-j3-D-ribofuranoside 
intended for the synthesis of such an analogue (Figure 5.27A). Our molecular modelling 
suggests that, if the 4'-hydroxymethyl group is not important, then a similar effect might 
be achieved by an even simpler structure (Figure 5.27B), based on a conjugate of 
glucose with 1,4-anhydroerythritol. Comparison of the activities of these analogues 
would establish the importance of the 4'-hydroxymethyl group, which up to now, has 
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Figure 5.27 Attempt to establish the structural basis for the extreme potency of 
adenophostin A. Testing of A should establish whether the adenine is necessary. If not, 
the next step would be to synthesise and evaluate the even more simple B (or its 
cyclopentane-based equivalent). It is already established that Gluc(2',3,4)P3, with its 
conformationally mobile ethylphosphate does not retain high potency.
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6 Phosphorothioates as Partial Agonists
6.1 Overview
As discussed in Chapter 1, Ins(l,3,4,6)P4 has been shown to behave as a partial agonist 
at the Ins(l,4,5)P3 receptor of SH-SY5Y neuroblastoma cells.44 An attempt to determine 
the structural basis of this property by the synthesis and testing of L-Ins(l,3,4)P3 and D- 
Ins(l,4,6)P3 has not yet given conclusive results, because it now seems that 
Ins(l,3,4,6)P4 itself does not behave as a partial agonist in our biological assay system 
(permeabilised rabbit platelets). Although these analogues are now being evaluated in 
SH-SY5Y cells, the results are not yet available. So far, therefore, no inositol phosphate 
has demonstrated partial agonist properties in the rabbit platelet assay.
However, one inositol phosphorothioate, namely L-c/u’ro-inositol-2,3,5- 
trisphosphorothioate,45 had been found to be a partial agonist in rabbit platelets. During 
the course of our work on L-Ins(l,3,4)P3, described in Chapter 2, a colleague synthesised 
racemic Ins(l,4,6)PS3, and this analogue too was found to be a partial agonist with very 
low intrinsic efficacy in platelets. Ins(l,4,6)PS3 was also demonstrated to inhibit 
Ins( 1,4,5)P3-induced Ca2+-release in a concentration-dependent fashion.48 It was 
assumed that the D-enantiomer was responsible for this effect, and this can be 
rationalised by considering possible binding orientations at the Ins(l,4,5)P3 receptor as 
described for D-Ins(l,4,6)P3 in Chapter 1. Another low-intrinsic activity 
phosphorothioate partial agonist in SH-SY5Y cells, D-6-deoxy-myo-inositol-1,4,5- 
trisphosphorothioate,47 has not been tested in platelets.
It was possible to discern a pattern to these results (Figure 6.1), in which 
replacement of phosphate groups with phosphorothioates, coupled with the reorientation 
or deletion of the hydroxyl group at position 3 or 6 gives a partial agonist. Notice that 
two analogues are missing from this pattern and to the best of our knowledge, they have 
not so far been synthesised. Now in the suggested binding mode for L-Ins(l,3,4)P3 
(Chapter 1), the hydroxyl group corresponding to position 6 of Ins(l,4,5)P3 is also 
reorientated, so that it is now axial rather than equatorial, and in addition, the hydroxyl 
group corresponding to position 2 of Ins(l,4,5)P3 has now been changed from axial to 
equatorial, as in the suggested orientation for D-Ins(l,4,6)PS3. It was therefore thought 
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Figure 6.1 The finding that L-c/»>0-Ins(2,3,5)PS3, 6-deoxy-Ins(l,4,5)PS3 and D - 
Ins(l,4,6)PS3 are partial agonists suggested that L-Ins(l,3,4)PS3 might also share this 
property. Two other compounds are also predicted to be partial agonists from this 
pattern, but have not been synthesised. [PS = phosphorothioate, OP(S)C>22’].
6.2 Synthesis of DL-myo-Inositol 1,3,4-trisphosphorothioate
It was therefore decided to convert a small sample of the racemic triol 9 into DL-myo- 
inositol-1,3,4-trisphosphorothioate (59). If the racemic phosphorothioate showed 
interesting activity, then pure L-Ins(l,3,4)PS3 [and if necessary, D-Ins(l,3,4)PS3] could 
easily be made from the corresponding optically pure triols.
Figure 6.2 Syntheses of racemic Ins(l,3,4)PS3 (59) and L-Ins(l,3,4)PS3 (L-59)











9 Was phosphitylated as before and then stirred overnight with elemental 
sulphur in dry pyridine. After the solvents were removed, purification by column 
chromatography gave the protected trisphosphorothioate 58 as an oil in modest (50%) 
yield. Deprotection using sodium in liquid ammonia, and purification by ion exchange 
chromatography gave racemic Ins(l,3,4)PS3 (59) in 61% yield.
6.2.1 Biological Evaluation
The racemic trisphosphorothioate was found to have very low efficacy at the 
Ins(l,4,5)P3 receptor of rabbit platelets, releasing only 20% of the Ins(l,4,5)P3 -sensitive 
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Figure 6.3 45Ca2+ release by DL-Ins(l,3,4)PS3 (59) from permeabilised rabbit platelets.
Now this result, taken in isolation, does not show that DL-Ins(l,3,4)PS3 is a partial 
agonist; an extremely weak full agonist could give similar results. However, when 
platelets were treated with Ins(l,4,5)P3 at a concentration of 1/iM, together with 
increasing concentrations of DL-Ins(l,3,4)PS3 a definite inhibition of Ins(l,4,5)P3- 
stimulated Ca2+ release was observed (Figure 6.4). These results demonstrate that DL- 
Ins(l,3,4)PS3 was acting as a true partial agonist. The effect of Ins(l,4,5)P3 is reduced as 
the concentration of DL-Ins(l,3,4)PS3 is increased, until it eventually falls to a level 
approaching the intrinsic efficacy of DL-Ins(l,3,4)PS3 itself (the DL-Ins(l,3,4)PS3 - 
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Figure 6.4 Inhibition of Ins(l,4,5)P3 -induced 45Ca2+-release by DL-Ins(l,3,4)PS3
6.3 Synthesis and Evaluation of L-myo-Inositol 1,3,4-trisphosphorothioate
It was assumed that the partial agonist activity of racemic DL-Ins(l,3,4)PS3 resided in 
the L-enantiomer, but it was important to demonstrate that this was true. Accordingly a 
sample of optically active triol L-9b was phosphitylated as previously described. This 
time the sulphoxidation was carried out using an improved method, developed by a 
colleague.49 After the presence of the trisphosphite triester had been confirmed by 31P 
NMR, the dichloromethane was removed by evaporation under reduced pressure and 
DMF-pyridine (2:1) was added, followed by 3 equivalents of sulphur per phosphite 
group. Sulphoxidation was complete within 10 min as judged by 31P NMR. Note that 
this method is much faster than the use of sulphur in pyridine, which requires a few 
hours for complete conversion and can give poor yields. The small excess of sulphur 
was filtered off and the solvents evaporated in vacuo to give a syrup, which was purified 
by flash chromatography giving the fully protected trisphosphorothioate triester l-58 in 
71% yield, l-58 was deprotected as for the racemic compound and purification gave L- 
Ins(l,3,4)PS3 (l-59).
The ability of L-Ins(l,3,4)PS3 to displace [3H]Ins(l,4,5)P3 from rat cerebellar 
membranes was examined, and the results are shown in Figure 6.5. The observation that 
L-Ins(l,3,4)PS3 shows roughly twice the affinity of the racemic mixture in this assay 
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Figure 6.5 Displacement of [3H]Ins(l,4,5)P3 from rat cerebellar membranes by DL- 
Ins(l,3,4)PS3 (59) and L-Ins(l,3,4)PS3 (L-59).
D-Ins(l,4,6)PS3, which was synthesised in a parallel project by a colleague, 
showed even higher affinity for the Ins(l,4,5)P3 receptor in binding studies, an 
observation which can be rationalised by similar structure-activity arguments to those 
given in Chapter 1 for D-Ins(l,4,6)P3 and L-Ins(l,3,4)P3. Like L-Ins(l,3,4)PS3 this 
analogue also shows very low efficacy, releasing less than 20% of the Ins(l,4,5)P3 - 
sensitive Ca2+ pool (Figure 6 .6 ). D-Ins(l,4,6)PS3 therefore constitutes an important lead 
compound in the search for Ins(l,4,5)P3 receptor antagonists, and it should be possible 
to produce a series of analogues of this compound, selectively modified at the axial 2 - 





Figure 6.6 45Ca2+-release from permeabilised rabbit platelets induced by D- 
Ins(l,4,6)PS3 and L-Ins(l,3,4)PS3 (L-59).
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A further study was carried out in which Ca2+-release curves for Ins(l,4 ,5 )P3 in rabbit 
platelets were obtained in the presence of increasing concentrations of L-59. The results, 
shown in Figure 6.7 demonstrate that l-59 shows the classical antagonist behaviour, 
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Figure 6.7 Progressive shifting of the dose-response curve for Ins(l,4 ,5 )P3 -induced 
45Ca2+ release by increasing concentrations of L-Ins(l,3 ,4 )PS3 (L-59).
6.4 6-Deoxy-6-hydroxymethyl-scy//o-inositol-l,2,4-trisphosphorothioate
As discussed in Section 6.3, D-Ins(l,4,6)PS3 is currently the most promising lead 
compound in the search for partial agonists at Ins(l,4 ,5 )P3 receptors. Its intrinsic 
efficacy is very low, and yet it also binds with high affinity to Ins(l,4 ,5 )P3 receptors, a 
property inherited from its parent compound, D-Ins(l,4 ,6 )P3 . This suggested that a 
simple strategy for the design of a high affinity, low efficacy partial agonist might be to;
1) Identify a 3-position modified Ins(l,4 ,5 )P3 analogue that shows high affinity 
for the Ins(l,4 ,5 )P3 receptor, and then
2) Reduce its efficacy by replacing phosphates with phosphorothioates.*
Now the only difference between D-Ins(l,4 ,6 )PS3 and L-chiro-Ins(2 ,3 ,5 )PS3 is the 
orientation of one hydroxyl group, and yet this appears to lower the efficacy of D- 
Ins(l,4 ,6 )PS3 without reducing its affinity for the receptor. Ideally then, a candidate for a
* This strategy has since been shown to be valid. The 4,5-bisphosphorothioate o f  the highly potent D-3- 
deoxy-3-fluoro-myc>-Ins(l,4,5)P3 has recently been found to be a partial agonist in SH -SY 5Y  cells.50. If 3- 
deoxy-In s(l,4 ,5 )P S 3 itself is a partial agonist, then a xylose-based bisphosphorothioate conjugated with 2'- 
AM P (by analogy with the adenophostins) might be worthy o f investigation.
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partial agonist should also have this feature. Taken together these arguments, 
summarised in Figure 6.8, suggest that the phosphorothioate analogue 60 of the highly 
potent hydroxymethyl analogue 44 (Chapter 5) should be a promising candidate.
ot p o s itio n
Figure 6.8 Structural considerations suggest that, by analogy with D-Ins(l,4 ,6)PS3, the 
trisphosphorothioate 60 might also be a partial agonist.
Accordingly, racemic 60 was synthesised from the triol 46 (Figure 6.9). The structure of 
60 was confirmed beyond doubt by COSY NMR, 31P NMR and high resolution 
FAB mass spectrometry. The ^-coupled  31P NMR is shown in Figure 6.10. Note that 
the heteronuclear 3/ h c o p  coupling constants are quite large (11.9 Hz, 12.6 Hz and 9.9 
Hz). This seems to be a general feature in the 31P NMR spectra of phosphorothioates. 
The signals occur at lower field than those of the corresponding trisphosphate as a result 
of the greater electronegativity of sulphur compared to oxygen.
Figure 6.9 Synthesis of racemic 6-deoxy-6-hydroxymethyl-scy//oinositol 1,2,4- 
trisphosphorothioate (60)
i) a) (BnO)2PNPr'2, l//-tetrazole, CH2CI2 b) Sg; DMF/pyridine; ii) Na / liquid NH3.
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Figure 6.10 31P NMR spectrum of 60 ^H-coupled, 162 MHz, D20).
6.4.1 Biological Evaluation
The ability of racemic trisphosphorothioate 60 to release 45Ca2+ from permeabilised 
rabbit platelets was evaluated (Figure 6.11).
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Figure 6.11 45Ca2+ release by racemic 60 from permeabilised rabbit platelets.
It appears that phosphorothioate substitution in 60 results in a dramatic reduction 
in ability to release Ca2+ (more than 500-fold), relative to the trisphosphate 44. The
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situation is very different from that found for Ins(l,4,5)P3, whose trisphosphorothioate 
appears to be a full agonist and is only three to four times weaker than the parent 
compund.93 It is not possible to say whether 60 behaves as a full agonist or not from 
these results, but it does appear to have higher efficacy than L-Ins(l,3,4)PS3, in that it
94-can be seen to be releasing more than half of the Ins(l,4,5)P3 -sensitive Ca pool at a 
concentration of lOO^M. Whether the drastic reduction in the potency of 60 is reflected 
in a similar reduction in its affinity for the Ins(l,4,5)P3 receptor awaits the results of
'j
[ H]Ins( 1,4,5)P3 binding assays, but disappointingly, a preliminary assay appears to 
show that it does not inhibit Ins(l,4,5)P3 -induced Ca2+-release from rabbit platelets. 
Studies of the interaction of 60 with 3-kinase and 5/6-kinases are in progress.
6.5 Conclusions
The only low efficacy partial agonists at Ins(l,4,5)P3 receptors discovered to date have 
been phosphorothioates. L-Ins(l,3,4)PS3 can now be added to this small group of 
analogues, but D-Ins(l,4,6)PS3, which has higher affinity for the Ins(l,4,5)P3 receptor 
and yet maintains very low efficacy, is the most important lead compound. The 
behaviour of 6-deoxy-6-hydroxymethyl-5cy//o-inositol-l,2,4-trisphosphorothioate (60) 
is perplexing. The parent compound 44 (Chapter 5) showed one of the highest binding 
affinities to the Ins(l,4,5)P3 receptor of any Ins(l,4,5)P3 analogue yet synthesised and 
yet replacement of the phosphate groups with phosphorothioates seems, at present, to 
have given only a very weak, high-efficacy agonist. It is not known why the presence of 
the hydroxymethyl group should affect the activity of a trisphosphorothioate in this way, 
but this finding may have implications for the design of adenophostin-based partial 
agonists.
Finally, it should be noted that L-Ins(l,3,4)PS3 and D-Ins(l,4,6)PS3 only 
appeared to behave as partial agonists at 4°C. The effect disappeared when the 
experiments were repeated at 20°C, and this finding underscores the reservations that 
were expressed in Chapter 1 about our criteria for partial agonism. One of the hallmarks 
of quantal Ca release is that it disappears at low temperature, and it has been argued 
that the phenomenon of quantal Ca2+ release may obscure partial agonist behaviour.47
* This effect is in accordance with the kinetics predicted from a model based on stochastic recombination 
of high- and low-affinity Ins(l,4,5)P3 receptor subunits to give heterotetramers.23
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7 m yo -Inositol 1,3,4,5-tetrakisphosphate
7.1 Overview
Chapter 2 dealt with the synthesis and properties of the enantiomers of a naturally 
occurring inositol trisphosphate, Ins(l,3,4)P3. Recall that there had been disagreements 
in the literature as to whether D-Ins(l,3,4)P3 was active at Ins(l,4,5)P3 receptors, and 
therefore controversy as to its biological role. It was shown that pure D-Ins(l,3,4)P3 is 
essentially inactive, and it was suggested that studies finding otherwise had used 
contaminated Ins(l,3,4)P3. Today there are few workers in this field who would claim 
that D-Ins(l,3,4)P3 has any direct role in releasing intracellular Ca2+.
In contrast, the debate surrounding another, structurally-related and naturally- 
occurring inositol phosphate, D-myo-inositol 1,3,4,5-tetrakisphosphate [Ins(l,3,4,5)P4] 
is currently growing more complex by the week, and this molecule will be the subject of 
this final chapter. There are now many suggested biological roles for Ins(l,3,4,5)P4 and 
many putative Ins(l,3,4,5)P4 binding proteins. There is also the question of whether 
Ins(l,3,4,5)P4 is recognised by Ins(l,4,5)P3 receptors, by only certain subtypes of 
Ins(l,4,5)P3 receptors, or not recognised by Ins(l,4,5)P3 receptors at all. As this thesis 
was nearing completion (April 1996) a new study was published claiming that, not only 
does Ins(l,3,4,5)P4 not release Ca2+ at physiologically relevant levels, but that at least in 
mouse lachrymal acinar cells, Ins(l,3,4,5)P4 or perhaps one of its metabolites, actually
94- < 1inhibits Ca release, and therefore functions to turn o ff the Ins(l,4,5)P3 signal.
In this chapter we describe a new and rapid synthesis of both enantiomers of 
Ins(l,3,4,5)P4, and some problems encountered relating to the purity and biological 
activity of the D-enantiomer. In contrast to the study of D-Ins(l,3,4)P3, no firm 
conclusions can be given, because the compounds are still under biological evaluation, 
and the significance of the results is still being discussed. Clearer answers may be 
available in a few months time. We begin however with a synthesis of the previously 
unknown scy//o-inositol analogue of Ins( 1,3,4,5)P4.
7.2 Stereochemical Relationships of D-Ins(l,3,4,5)P4 and L-Ins(l,3,4,5)P4
Various Ins(l,3,4,5)P4 binding proteins have been identified in recent years, and some of 
these have been discussed briefly in Chapter 1. The beginnings of a structure-activity
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relationship are being established for an Ins(l,3,4,5)P4 binding protein purified from 
porcine platelets, and now designated G A Pl18488. It has been reported120 that at this site, 
phosphate groups at positions 3 and 5 of myo-inositol are essential for binding, but 
position 4 is not needed. A third phosphate in the 1-position enhances binding, but 
phosphorylation of the axial 2-position abolishes activity. Notice how different these 
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It is interesting to note that L-Ins(l,3,4,5)P4 129 appears to have only a 13-fold 
lower affinity for G A Pl184815 than D-Ins(l,3,4,5)P4.119 This is very different from the 
interaction of Ins(l,4,5)P3 with Ins(l,4,5)P3 receptors, where L-Ins(l,4,5)P3 has at least 
1000 times lower affinity than its enantiomer.111 The explanation for this finding may 
simply be that L-Ins(l,3,4,5)P4 is more similar to D-Ins(l,3,4,5)P4 than L-Ins(l,4,5)P3 is 
similar to D-Ins(l,4,5)P3. D-Ins(l,3,4,5)P4 and L-Ins(l,3,4,5)P4, although enantiomers, 
have identical arrangements of phosphate groups. L-Ins(l,3,4,5)P4 could therefore be 
regarded as an analogue of D-Ins(l,3,4,5)P4, in which the orientations of the hydroxyl 
groups at positions 2 and 6 have been interchanged (Figure 7.2). This is analogous to the 
relationship between D-Ins(l,4,5)P3 and L-Ins(l,3,4)P3, and from the point of view of a 
binding protein, must surely be more significant than the fact that D- and L- 
Ins(l,3,4,5)P4 are related to one another as an object is to its mirror image. Thus the 
concept of some “stereospecificity” as a property of the binding protein, and the notion 
that the Ins(l,3,4,5)P4 receptor may be “less stereospecific” than the Ins(l,4,5)P3
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receptor, without a consideration of the symmetry properties of the phosphate 
configurations in their respective ligands, may be misleading.*
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Figure 7.2 Stereochemical interrelationships of D-Ins(l,3,4,5)P4, L-Ins(l,3,4,5)P4 and 
scy//o-Ins(l,2,3,5)P4 (62).
To-date, all the inositol phosphates evaluated at Ins(l,3,4,5)P4 binding sites have 
been of the rayo-configuration, possessing an axial group at the 2-position. The scyllo- 
inositol analogue of Ins( 1,3,4,5)P4 (strictly scy/Zo-inositol 1,2,3,5-tetrakisphosphate, 62, 
Figure 7.2), in which this group is equatorial, will allow the importance of this feature to 
be explored at the various putative Ins(l,3,4,5)P4 binding sites. The mesc-compound 
^cy//o-Ins(l,2,3,5)P4 can be seen as an analogue of both D- and L-Ins(l,3,4,5)P4. It is 
epimeric with both, but because it possesses a plane of symmetry it is identical with its 
enantiomer. Thus D-Ins(l,3,4,5)P4 , L-Ins(l,3,4,5)P4 and scy//o-Ins(l,2,3,5)P4 all possess 
the structural elements identified as important for GAP 11154813 binding as shown in Figure 
7.1, but the different affinities of the D- and L-enantiomers show that hydroxyl group 
orientations must also be important, as they are at the Ins(l,4,5)P3 receptor (Chapter 2). 
In scy//o-Ins(l,2,3,5)P4, only the orientation of the 2-hydroxyl group is changed, and it
In opposition to this argument, it might be pointed out that L -Ins(l,3,4,5)P4 has been reported to be 
almost inactive in releasing 45Ca2+ from permeabilised SH -SY 5Y  cells, while D -Ins(l,3 ,4 ,5)P 4 appeared to 
be only 20-fold weaker than Ins(l,4 ,5)P3.m  Thus D -Ins(l,3 ,4 ,5)P4 seem s to be a more potent agonist at 
the In s(l,4 ,5 )P 3 receptors o f SH -SY 5Y  cells than would be predicted from the arguments given above.
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will be interesting to examine the effect of this single modification on GAP1IP4BP 
binding.
D-Ins(l,3,4,5)P4 is also recognised with high affinity by the enzyme multiple 
inositol polyphosphate phosphatase (MIPP) which removes its 3-phosphate group, 
generating Ins(l,4,5)P3, and this has sometimes caused problems in establishing the true 
effects of Ins(l,3,4,5)P4 (Chapter 1). Whether the adjacent 2-hydroxyl group of 
Ins(l,3,4,5)P4 is involved in the mechanism of hydrolysis is not known, but it may be 
enlightening to establish whether scy//o-Ins(l,2,3,5)P4 is recognised by MIPP, and if so, 
whether it can be dephosphorylated by this enzyme. Similarly, the effect of 5- 
phosphatase on scy//o-Ins(l,2,3,5)P4 should be studied, as inactivation of Ins(l,3,4,5)P4 
by 5-phosphatase, which dephosphorylates it to Ins(l,3,4)P3 is also a problem in studies 
of Ins(l,3,4,5)P4.
7.3 Synthesis of scy//o-Inositol 1,2,3,5-tetrakisphosphate
The symmetry of 5cy//o-Ins(l,2,3,5)P4 makes it a particularly accessible analogue of 
Ins(l,3,4,5)P4 synthetically, in that neither a stereospecific synthesis nor an optical 
resolution is required. The synthesis (Figure 7.3) began with the versatile ketone 29 
(Chapter 4), which was reduced rapidly and stereoselectively with sodium borohydride 
to the scyllo-inositol orthoformate derivative 63 in 89% yield.
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Figure7.3: i) NaBH4/M eO H / THF; ii) a) IM H C l/M eO H  1:10, A; b) aqueous NH3; 
iii) a) Pr'2NP(OR)2, l//-tetrazole, CH2C12 b) m-CPB A, -78°C iii) Na/liquid NH3, -78°C. 
PMB = /?-methoxybenzyl, R=CH2CH2CN.
The fact that the product had the scy/Zo-configuration was immediately apparent from 
the [H NMR spectrum of 63, because the signal corresponding to the methylidene 
proton was a singlet, while in the epimeric myo-analogue 28 (Chapter 4) it is doubled, 
due to a long-range spin coupling. The axial OH proton resonated at low field (S  4.12, 
CDCI3) and showed a very large / h c o h  value of 12.45 Hz. Selective cleavage of the 
orthoformate ester by mild acid hydrolysis gave the tetrol 64 in 68% yield.* 
Phosphitylation with bis(2-cyanoethoxy)-Af,/V-diisopropylaminophosphine / lf f-  
tetrazole, followed by oxidation of the intermediate tetrakisphosphite triester with m- 
CPBA gave the fully-protected 65 (85%). Deprotection using sodium in liquid ammonia 
caused some problems in that the /?-methoxybenzyl protecting groups proved more 
resistant to cleavage by this method than the more usual benzyl groups. This was 
apparent during the purification process by ion exchange chromatography as the target 
compound, which contains no chromophore, appeared to show some UV absorbance as 
it eluted from the ion-exchange column. A 31P NMR spectrum showed small impurity 
peaks, and the lH NMR spectrum showed small but characteristic signals due to the p- 
disubstituted aromatic ring protons. The deprotection reaction was therefore repeated, 
but left for 5 minutes rather than the usual 2 minutes before quenching. This time, 
deprotection was complete and pure 62 was obtained as the triethyl ammonium salt 
(71%) giving a 37% overall yield from 29.
5cy//o-Ins(l,2,3,5)P4 is intended as a probe for Ins(l,3,4 ,5)P4 binding sites, 
rather than Ins(l,4 ,5)P3 receptors, but its ability to mobilise intracellular Ca2+ in SH- 
SY5Y neuroblastoma cells has now been examined. 62 Appears to be some four-fold 
weaker than commercially available D-Ins(l,3,4,5)P4. The significance of these results is 
not yet clear, because the true activity of D-Ins(l,3,4 ,5)P4 is still in question, as will be 
seen later in this Chapter. A study of the interaction of 62 with GAP1IP4BP is now 
underway. 62 Showed potent ability to inhibit phosphorylation of Ins(l,3,4)P3 by the 
5/6-kinase enzyme as might be expected, because three of its phosphate groups can be 
superimposed upon those of D-Ins(l,3,4)P3 (Figure 7.4).
* These two steps were carried out by a final-year undergraduate project student, who also converted 
compound 63 into its tri-O-p-methoxybenzyl ether. The fact that the NMR spectra of this compound 
showed three-fo\d symmetry was irrefutable evidence that 63 had the scyllo configuration.
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Figure 7.4 scy//o-Ins(l,2,3,5)P4 may be recognised by Ins(l,3,4)P3 5/6-kinase because it 
is capable of mimicking certain aspects of the natural substrate Ins(l,3,4)P3
7.4. A Short Route to D-Ins(l,3,4,5)P4 and L-Ins(l,3,4,5)P4
As part of an investigation into long-range 31P-31P spin-spin coupling in the NMR 
spectra of phosphite triesters,248 an orthoformate ester of myo-inositol was required in 
which the two axial hydroxyl groups were chemically inequivalent. Thus it was 
necessary to break the symmetry of the molecule. It was thought that this might be 
achieved by reacting myo-inositol orthoformate with 1.1 equivalents of (lS)-(-)-co- 
camphanic acid chloride in pyridine with a catalyst of DMAP. The expectation was that 
the 2-camphanate ester 66 would be the major product, and that this would be 
sufficiently dissymmetric to make possible the direct observation of any spin-spin 






Figure 7.4a Reaction of the symmetrical myoinositol orthoformate with 1 equivalent of 
(15)-(-)-fi>camphanic acid chloride gives an unsymmetrical ester.
The reaction was carried out and when the major product was isolated, it was 
indeed found to be the 2-camphanate ester. The position of substitution was established 
beyond doubt by removing the orthoformate ester and obtaining a !H NMR of the 
product 66a (Figure 7.5). In this molecule, the proton at position 2 is easily identified by 
its distinctive splitting pattern (a narrow triplet or strictly, a narrow doublet of doublets), 
and in 66a this signal was shifted well downfield. Compound 66 was therefore used for 









H-2 is now the only ring proton 
with two small 3 J ax-eq couplings,
Figure 7.5 Confirmation of the structure of the 2-camphanate 66 by !H NMR.
The TLC also showed two minor products, close together at longer Rf. These 
were isolated and shown to be the 2,6-biscamphanate and the 2,4-biscamphanate. It was 










Figure 7.6 Reaction of myoinositol orthoformate with 2 equivalents of (1 £)-(-)-<*>- 
camphanic acid chloride gives mainly the 2,6- and 2,4-biscamphanate esters, which are 
precursors for D- and L-Ins(l,3,4,5)P4 respectively.
Note that this situation is quite different to the alkylation of myo-inositol orthoformate 
(Chapter 4) in which the disubstituted product was exclusively the 4,6-di-O-/?- 
methoxybenzyl ether, with no 2,4- or 2,6- disubstituted ethers detectable. It was quickly 
realised that the biscamphanates could provide a short and large-scale route to the 
enantiomers of Ins(l,3,4 ,5)P4 (Figure 7.6).
7.5 Synthesis of D-Ins(l,3,4,5)P4 and L-Ins(l,3,4,5)P4
Several syntheses of D-Ins(l,3,4,5)P4 have been published, although many are long or
employ special techniques, such as the use of enzymes. Two examples were described in
Chapter 1. The inconsistencies in the reports of the activity of D-Ins(l,3,4,5)P4 in 
2+releasing Ca might lead us to suspect that some samples were not pure and indeed, a 
study published by Gawler et al. in 1990 113 showed that when commercially available 
samples of D-Ins(l,3,4,5)P4, from more than one source, were treated with 3-kinase, 
their activity in SH-SY5Y neuroblastoma cells was markedly decreased. This is strong 
evidence that these samples contained Ins(l,4 ,5)P3.
The unnatural enantiomer, L-Ins(l,3,4,5)P4 is increasingly being used as a 
biological tool in studies of D-Ins(l,3,4,5)P4. m ’ 114, 119 There is only one reported 
synthesis of L-Ins(l,3,4,5)P4 ,129 and to the best of our knowledge, all the material used 
has come from this source. It is agreed that L-Ins(l,3,4,5)P4 has only low activity at 
Ins(l,4 ,5)P3 receptors (which would be expected from the structure-activity 
relationships outlined in Figure 1.11) and yet has moderate affinity for Ins(l,3,4,5)P4 
receptors. Therefore, it is argued, effects induced by L-Ins(l,3,4,5)P4 must be mediated 
by the Ins(l,3,4,5)P4 receptor. This strategy has been used to distinguish putative 
Ins(l,3,4,5)P4 binding sites from Ins(l,4,5)P3 receptors but has led workers to rather 
different conclusions. Wilcox et a i lu  have argued that, because D-Ins(l,3,4,5)P4 caused 
Ca2+ release, but L-Ins(l,3,4,5)P4 did not then D-Ins(l,3,4,5)P4 must cause Ca2+ release 
via Ins(l,4 ,5)P3 receptors. In contrast, Loomis-Husselbee et al.114 claim that both D- 
Ins(l,3,4,5)P4 and L-Ins(l,3,4,5)P4 can induce Ca2+ release by acting synergistically with 
Ins(l,4 ,5)P3, * but that, because both enantiomers have this synergistic effect with 
Ins(l,4 ,5)P3, this effect must be mediated by Ins(l,3,4,5)P4 receptors.
* D-Ins(2,4,5)P3, which is active at Ins(l,4,5)P3 receptors but 10-fold less so than Ins(l,4,5)P3 , was used 
instead of Ins(l,4,5)P3 in this study so as to obviate the possibility of conversion to Ins(l,3,4,5)P4.
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Whatever the validity of these biological arguments, it is clear that such studies 
require a reliable source of both D- and L-Ins(l,3,4 ,5)P4, which must be optically pure 
and free from contamination with other, potentially active, inositol phosphates. A 
synthesis of both enantiomers using the strategy outlined in Figure 7.6 might achieve 
this in the minimum number of synthetic steps.
7.5.1 Absolute Configurations of Biscamphanates: X-Ray Study
The esterification reaction was repeated, using 2.2 equivalents of S-(-)-G>camphanic 
acid chloride. Now, as expected, the major products were the two biscamphanates. 
These two diastereoisomers were quite distinct in their physical properties. The less 
polar diastereoisomer (minor product) was easily recrystallised from ethyl 
acetate/hexane, whereas the more polar major product showed low solubility in all but 
the most polar solvents (DMF, acetonitrile, pyridine, but not water). It was eventually 
found that this isomer could be recrystallised easily from DMF/water. In order to find 
out which biscamphanate was which an X-ray crystal structure would be required or 
failing this, it would be necessary to convert one of them to a known reference 
compound.
The crystals of the less polar diastereoisomer appeared to be the better 
candidates for X-ray analysis, and so larger crystals were grown slowly from a solution 
in propan-2-ol. The crystals proved to be of a suitable type and an X-ray study was 
carried out. The X-ray crystal structure (Figure 7.7a) showed this compound to be the 
Id-2,6-biscamphanate ester of myoinositol orthoformate 67a. Within the rigid 
adamantane-like cage structure all C-C bond lengths were in the range 1.502-1.538 A 
and all C-O bond lengths between 1.394 and 1.448 A, with bond angles ranging from 
105.8° to 114.3°. An examination of the supramolecular structure of 67a (Figure 7.7b) 
revealed that the lattice was dominated by one-dimensional linear polymers as a result 
of intermolecular hydrogen-bonding between the free hydroxyl groups and the lactone 
carbonyl oxygens. This interaction probably accounts for the high crystallinity of this 
material compared to diastereoisomer 67b. For full details, see Appendix 2.
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Figure 7.7a X-ray crystal structure of the lD-2,6-biscamphanate ester 67a. Note: the 
numbering of atoms used in this representation is not the same as that used in the rest of 
this thesis.
7.5.2 Optimising the Yield of the 2,6-Biscamphanate
Diastereoisomer 67a was therefore a synthetic precursor to D-Ins(l,3 ,4 ,5 )P4 , and the 
more polar, major product 67b would provide L-Ins(l,3 ,4 ,5 )P4 . It seemed likely that 
demand for the natural D-enantiomer of Ins(l,3 ,4 ,5 )P4 would exceed that for the L- 
enantiomer, and so attempts were made to alter the selectivity of the esterification 
reaction by using different conditions.
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7.7 b) The supramolecular structure of 67a shows intermolecular hydrogen 
bonding between the 4-hydroxyl groups and lactone carbonyl oxygens, giving a one­
dimensional, linear polymeric structure.
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The reaction was repeated, replacing the pyridine with dichloromethane, together 
with a small amount of triethylamine to act as base. Again, DMAP was used as the 
catalyst. This worked well, and although myo-inositol orthoformate is only very slightly 
soluble in dichloromethane the reaction went smoothly, with the suspended 
orthoformate rapidly disappearing as esterification progressed. The reaction was 
complete within half an hour, and this time, TLC showed that the major product was the 
desired 2,6-biscamphanate, with a reduced amount of 2,4-ester and almost no 
monocamphanate. However significant amounts of the unwanted 2,4,6-triscamphanate 
were now produced.
The reaction was repeated a number of times, using various amounts of 
camphanic acid chloride and adjusting the volume of solvent and the temperature. 
Optimised conditions provided a respectable 60% yield of the 2,6-biscamphanate after 
flash chromatography. Note that the yield of this regioselective esterification exceeds 
the maximum possible theoretical yield (50%) that could be obtained by a conventional 
optical resolution of a racemate (e.g. in the synthesis of D- and L- Ins(l,3,4)P3 , Chapter 
2). The 2,4-disubstituted product was obtained in 23% yield. It was found that no work­
up was needed, and these yields could be achieved with minimal effort by simply 
removing the solvents in a rotary evaporator and purifying the crude residue using flash 
chromatography. Careful recrystallisation of the two products at this stage was carried 
out to increase their optical purity further.
A 400 MHz COSY spectrum of the 2,6-biscamphanate 67a is shown in Figure 
7.8. Having established the absolute configuration, it was now possible to assign the 
spectrum completely. Note the narrow signals corresponding to the ring protons, which 
have only small vicinal couplings, and the long-range 5J  coupling between H -l and H-3. 
This interaction is not seen directly in the spectra of any of the symmetrical inositol 
orthoformate derivatives (Chapter 4) because in these compounds H -l and H-3 are 
enantiotopic, and therefore isochronous. The small (0.98 Hz) long-range coupling 
between the methylidine proton (8  5.54) and H-2 (5 5.30) is not seen as a cross-peak in 
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Figure 7.8 a) Part of the COSY NMR spectrum of the I d - 2 , 6 -biscamphanate 67a 
(CDC13, 400 MHz).
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Figure 7.8b An expansion of the part of the 270 MHz ‘H NMR spectrum of 67a, shows 
complex, narrow signals with splittings caused by long-range couplings. Note that the 
methylidine proton signal ( 8  5.54) is a narrow doublet, and couples to H-2.
7.5.3 Removal of Orthoformate Esters and Phosphitylation/Oxidation
It was now necessary to remove the orthoformate esters, while leaving the camphanate 
esters, with their lactone rings, intact. This was found to be straightforward for the 2,6- 
biscamphanate, and was carried out using a 1 to 10 refluxing mixture of 1M HC1 and 
methanol, without significant loss or migration of camphanate groups. The use of higher 
concentrations of acid was not successful, causing extensive loss of camphanates.
The 2,4-biscamphanate (which would lead to L-Ins(l,3,4,5)P4) posed much more 
of a problem. Although it was only slightly soluble in methanol or ethanol, it was 
thought that this would not preclude the use of the usual HCl/methanol or HCl/ethanol 
conditions. This was not the case, and almost no reaction was detectable after 5 to 6  
hours of reflux. Increasing the concentration of acid only caused loss of camphanate
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esters. The reaction was next attempted in refluxing 80% acetic acid, and this strategy 
was more successful. After 7 hours, most of the starting material was consumed and a 
clear solution was formed. However, the conversion was still not complete, with 
significant quantities of at least one intermediate formate ester being visible on the TLC. 
The reaction seemed to progress no further after this stage and the yield of tetrol was 
low.
Figure 7.9 Synthesis of D-Ins(l,3,4,5)P4 and L-Ins(l,3,4 ,5)P4 from myo-inositol 
orthoformate biscamphanates 67a and 67b. i) 1M HCl/MeOH 1:10, reflux (88%); ii) 
TFA/H20  4:1, 40h (85%); iii) a) Pr'zNPtOCHzCHjCN^, ltf-tetrazole, b) m- 
CPBA,78°C (80-84%) iv) Cone. NH3 solution, 60°C, 6 h (90-93%).
Another method of removing the orthoformate ester is to use 80% TFA at room 
temperature. This method had been avoided because it had previously been found to 
give significant amounts of formate esters, although these can be removed in a second 
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failed, the reaction was attempted. The 2,4-biscamphanate was, encouragingly, very 
soluble in 80% TFA, and the reaction was left at room temperature for 22 hours. TLC 
after this time showed that the reaction was not complete, and although the starting 
material had mostly been consumed, two intermediates, presumably formate esters were 
still present. This partial cleavage of an orthoester in compounds such as 67a and 67b 
could provide a rapid route to Ins(l,4,5)P3 or other chiral trisphosphates, and this 
prospect is now under investigation by a colleague. As expected, treatment with 
ammonia solution, even for a short time resulted in loss of the camphanate groups.
Finally it was found that 67b could be deprotected most successfully by simply 
stirring in 80% TFA at room temperature for a longer time. After 40 hours, the reaction 
was almost complete, with little formate remaining. This could easily be removed by 
flash chromatography and the pure tetrol 68b was at last obtained, in 85% yield.
Both of the diastereoisomeric tetrols 68a and 68b could easily be recrystallised 
(from propan-2-ol and DMF/water respectively). Note that, with a conventional optical 
resolution, the chiral resolving agent is normally removed immediately after the 
resolution step. The intermediates subsequent to this stage are therefore enantiomeric, 
and contamination with the unwanted enantiomer will not be apparent by NMR or TLC. 
Nor will chromatography give any increase in optical purity. At each step in this 
synthesis, the precursors to D-Ins(l,3,4 ,5)P4 and L-Ins(l,3,4 ,5)P4 were 
diastereoisomeric, having very different NMR spectra and different RjS. Any 
contamination would therefore be obvious, especially in the camphanate methyl 
resonances of the !H NMR spectra. No such contamination was visible in any of the 
NMR spectra.
The next stage was phosphitylation/oxidation, which was carried out without 
problems using bis(2-cyanoethoxy)-Af,A-diisopropylaminophosphine / 1/f-tetrazole 
followed by m-CPBA. This phosphitylating agent was chosen because the cyanoethyl 
protecting groups can be removed by alkaline hydrolysis and so could be removed 
together with the camphanate esters in a single deprotection step. It would eventually 
become clear that this choice was a serious mistake (see below).
'i 1
The two intermediate tetrakisphosphite triesters, gave quite different P NMR 
spectra but both showed the expected five-bond couplings between the P(III) atoms of
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the vicinal phosphites and the values of 5/ pp differed in magnitude for the two
intermediates. This characteristic pattern of a triplet (P4), two doublets (P3 and P5) and
a singlet (PI) in each confirmed the 1,3,4,5 arrangement of phosphites.
Oxidation gave the fully-protected tetrakisphosphate triesters 69a and 69b.
Again it is important to remember that these molecules are diastereoisomeric, as was
apparent from their very different 3lP , 13C, and *H NMR spectra. The ]H NMR
spectrum reconfirmed the substitution pattern, with the characteristic signals for H-2 and
H-6 in compound 69a, and for H-2 and H-4 in compound 69b, being shifted well
1 ^downfield away from all other resonances. The C NMR spectra of both compounds 
were complicated by extensive 31P - 13C couplings. Both compounds took the form of 
brittle white foams, so no further recrystallisations were possible, but their NMR spectra 
testified to their chemical and optical purity.
7.5.4 Deprotection: Problems with Phosphate Migration
A small-scale trial established that total deprotection of 69a could easily be achieved by
heating at 60°C in concentrated aqueous ammonia solution in a sealed container for 3 
1  ^1hours. A H-coupled P NMR of the product showed four clear doublets, confirming 
that the deprotection was complete. When the reaction was scaled up, the main problem 
was one of how to carry out this reaction safely, and the solution adopted was to carry 
out the reaction in a thick-walled, lOOmL glass autoclave bottle with a screw-cap. The 
foam (2g of 69a) was compressed into a fine powder, which was transferred to the 
bottle, followed by the ammonia solution and a magnetic stirring bead. The bottle was 
sealed and lowered into a water bath with a thermostatically-controlled heater-stirrer 
behind a safety screen. The thermostat was set to 60°C, and with the screen safely in 
place and the fume-cupboard closed, the heater stirrer was switched on. After the 
temperature had reached 60°C, heating was continued for 6 hours, and at the end of the 
reaction, the bottle was allowed to cool fully, before opening.
The product would now be in the form of the ammonium salt together with the 
hydrolysis products from the camphanate groups. A previous trial of the deprotection 
method using only ethyl camphanate and ammonia solution had established that the 
hydrolysis product, which was water-soluble, could be removed by acidification 
followed by extraction into dichloromethane or ether. This strategy was successfully
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employed, with Dowex-50 H+ resin being used to reduce the pH to ~2, prior to 
extraction. The aqueous layer was then titrated to pH 10 with 1M KOH. A final 
purification stage, designed to remove any excess KOH, was to re-dissolve the product 
in a small volume of de-ionised water and then add methanol, thus precipitating the 
potassium salt of D-Ins(l,3,4 ,5)P4 , and leaving residual KOH in solution. This stage 
also served to remove a slight brownish colour which had originated from the Dowex 
resin. The precipitate was dissolved once more in de-ionised water and lyophilised to 
give the potassium salt of D-Ins(l,3,4 ,5)P4 in 94% yield.
A smaller quantity of 69b was deprotected in exactly the same way to give L- 
Ins(l,3,4 ,5)P4 (potassium salt) in 90% yield. The !H and I3C NMRs of the two 
enantiomers D-70a and L-70b were identical and fully agreed with the previously 
published NMR data168. The 400 MHz *H NMR spectrum of L-70b and the 
corresponding 100 MHz 13C NMR spectrum are shown in Figure 7.10.
However, the 162 MHz 31P NMR spectra did show some slight impurity in each 
case although this was not seen at lower field. It was not clear at this stage how the 
impurities arose, as the precursors 69a and 69b appeared pure by high field 31P NMR. 
The potassium salts are not highly crystalline, tending instead to precipitate as fine or 
fibrous amorphous material from a number of solvent systems, and no improvement 
could be obtained by recrystallisation. A portion of the D- enantiomer was converted to 
both the ammonium and the cyclohexylammonium salts, and although the latter could 
be crystallised (with some difficulty), the impurity seen in the 31P NMR persisted. These 
attempts at purification, involving conversion to free acid, titrations and various 
attempts at crystallisations, occupied many weeks. High field NMR spectra had to be 
obtained after each attempt, each time adjusting pH to separate the signals, and often the 
sample had to be treated to remove paramagnetic ions (with Chelex-100 resin or 
EDTA), meaning that it could not be re-used. Time was running out, the originally large 
supply of D-Ins(l,3,4,5)P4 was dwindling, and the impurity would not go.
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Figure 7.10 a) 400M Hz !H NMR spectrum and b) 100 MHz 13C NMR spectrum of L- 
Ins(l,3,4,5)P4 (potassium salt, D20 ,  pH 8-9).
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7.5.5 Preliminary Biological Testing
The slightly impure potassium salts of D- and L-Ins(l,3,4,5)P4 were evaluated for Ca2+ 
release from permeabilised SH-SY5Y cells. As expected, the L-Ins(l,3,4,5)P4 proved to 
be weak (results not shown), and was able to release only about 37% of the Ca2+-pool at 
a concentration of KXtyiM. The D-Ins(l,3,4,5)P4 proved to be almost identical in its 
effect to the commercially available material, that is, around forty times weaker than 
Ins(l,4 ,5 )P3. Interestingly, scy//e>-Ins(l,2,3,5)P4 was considerably less active. Now as 
discussed above, there has been much controversy as to whether D-Ins(l,3,4,5)P4 can 
mobilise Ca2+ via Ins(l,4 ,5 )P3 receptors, and this has caused concern as to the purity of 
the D-Ins(l,3,4,5)P4 used. In this case, it was known that the D-Ins(l,3,4,5)P4 contained 
an unidentified impurity, and yet it behaved in an almost identical way to commercially 
available Ins(l,3,4,5)P4.
— lns( 1,4,5) P3 
— irrpure D-hs(1,3,4,5)P4 
v— scy/fe>lns(1l2,3,5)P4
Q001 Q01 Q1 1
Concentration (n M)
10 100
Figure 7.11 45Ca2+-release from SH-SY5Y neuroblastoma cells induced by Ins(l,4 ,5 )P3 
(potassium salt), 5cy//o-Ins(l,2 ,3 ,5 )P4 (62, triethylammonium salt) and impure D- 
Ins(l,3,4,5)P4 (D-70a, potassium salt). 45Ca2+-release is given relative to the maximal 
release induced by Ins(l,4 ,5 )P3.
It was intended to repeat the large-scale route and optimise it as a method of 
producing pure D- and L-Ins(l,3,4,5)P4 at a later stage, but time was pressing, and it 
seemed that the best course of action would be to purify the D-Ins(l,3,4,5)P4 by ion- 
exchange chromatography, and then test it again. A small sample (lOOmg) of the impure 
D-Ins(l,3,4,5)P4 was subjected to careful ion-exchange chromatography, taking only the 
fractions eluting above 700mM buffer strength, so as to exclude the possibility of
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overlap with any trisphosphate. However, the ion-exchange purified D-Ins(l,3,4 ,5)P4 
still contained around 2-3% of an impurity as judged by high-field phosphorus NMR. At 
low pH the D-Ins(l,3,4,5)P4 peaks were broad and no impurities could be seen (Figure 
7.12a), but after adding EDTA to chelate paramagnetic ions, impurities were visible in
31the P NMR spectrum (Figure 7 .12b). In order to spread the peaks as far as possible and 
therefore minimise overlap, the pH was raised to -10  by addition of KOH solution 
(Figure 7.12c). Four small impurity peaks could now be seen, suggesting a 
tetrakisphosphate, and of course, this finding was what might be expected for a 
compound that co-eluted with Ins(l,3,4 ,5)P4. Significantly, the fact that there were four 
peaks and not two, ruled out the possibility that the contaminant was a symmetrical 
tetrakisphosphate such as Ins(l,3,4 ,6)P4. It seemed very likely, therefore, that the 
contaminant was an asymmetrical tetrakisphosphate arising from phosphate migration at 
some stage during or after the deprotection. Figures 7.12a to 7.12c illustrate the 
importance of careful adjustment of conditions if 31P NMR is to be used as a criterion 
for the purity of inositol phosphates. The 400MHz !H NMR spectrum also showed 
irregularities in the baseline (as in Figure 7.10a) that suggested the presence of a second 
inositol phosphate, although overlap with other peaks made it impossible to identify the 
contaminant.
Now a consideration of the possible asymmetrical migration products obtainable 
from D-Ins(l,3,4,5)P4 shows that the production of D-Ins(l,2,4 ,5)P4 is a distinct 
possibility. A literature search revealed that another group had previously encountered 
problems with phosphate migration (under acidic conditions) and they reported that 
migration to an unprotected 2-position was particularly favoured.249 Thus, the expected 
migration products from D-Ins(l,3,4 ,5)P4 are D-Ins(2,3,4 ,5)P4 and D-Ins(l,2,4 ,5)P4. Now 
D-Ins(l,2,4,5)P4 is highly active at Ins(l,4 ,5)P3 receptors, being almost equipotent with 
Ins(l,4 ,5)P3.250'252 It was therefore possible that the apparent activity of our D- 
Ins(l,3,4,5)P4 (Figure 7.11) could result from around 2-3% contamination with D- 
Ins(l,2,4,5)P4. However, this would mean that commercially available D-Ins(l,3,4 ,5)P4 
was also contaminated with a Ca2+-mobilising material.
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Figure 7.12 162 MHz 31P NMR spectra of ion-exchange purified D-70a 
(triethylammonium salt in D20). a) pH 4-5; b) pH 4-5, EDTA added; c) pH -10, EDTA 
added.
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It seemed possible that the migration had occurred as a result of acidification 
with Dowex-H+ resin, and so the deprotection was repeated, and the crude product 
purified immediately by ion exchange with no work-up procedure. However, the 
impurity was still present, suggesting that migration was taking place at the deprotection 
stage, which employed alkaline conditions. It is known that, in the cleavage of 
cyanoethyl groups under alkaline conditions by /^-elimination, the first cyanoethyl group 
is removed very rapidly, while the second is then cleaved slowly. Perhaps migration was 
occurring at this prolonged intermediate stage, and the presence of cyanoethyl groups or 
the use of a slow deprotection method was the source of the problem.
More tetrol 68a was synthesised and this time phosphorylated using 
bis(benzyloxy)-Af,Af-diisopropylaminophosphine, giving 71a which was deprotected 
using sodium in liquid ammonia. It was not known how rapidly camphanate groups 
would be cleaved by this method, and so the reaction was quenched after five minutes, 
rather than the usual one or two minutes. This method gave better results, and all 
protecting groups were cleaved within this time, but a small amount of migration 
product was still visible in the NMR spectra after ion-exchange chromatography. Now 
migration had not been detected in previous deprotections of this type, notably in the 
synthesis of Ins(l,3,4)P3, which also has a vacant 2-position, so it seemed likely that it 
was the presence of camphanate esters at positions 2 and 6 that were causing the 
problem. Perhaps the esters were being cleaved more rapidly than the phosphate 
protecting groups, so that unprotected 2- and 6-hydroxyl groups were available as 
targets for phosphate migration during the deprotection. Presumably, the mechanism of 
migration would then be as shown in Figure 7.13. If this were so then it would seem that 
the camphanate groups were the cause of the difficulties. However, the selective 
protection of positions 2 and 6- with camphanate esters was the basis of the synthetic 
strategy, and if the problems they entailed were insurmountable, then that strategy 
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Figure 7.13 Possible mechanism for base-catalysed migration of a phosphate group to 
the axial 2-position via a five-membered cyclic phosphate intermediate. R = benzyl or 2- 
cyanoethyl.
7.5.6 Another Strategy: Two-Step Deprotection
There was one method remaining that should make migration impossible. It was to 
deprotect the phosphate groups first, and then remove the camphanate esters (Figure 
7.14). The fully protected compound 71a was therefore hydrogenolysed using a catalyst 
of palladium on carbon, and hydrogen at 50 p.s.i. overnight.
D - ln s ( 1 ,3 ,4 ,5 ) P 4
Figure 7.14 Two-step deprotection of D-71a avoids migration of phosphate groups.
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It was impossible to tell whether the intermediate tetrakisphosphate was pure 
because residual palladium ions caused severe broadening of the NMR spectra, and 
could not be removed with EDTA. The camphanate esters were removed from this 
intermediate by heating at 60°C in concentrated ammonia solution as before and the 
crude product purified by ion exchange giving the triethylammonium salt of D- 
Ins(l,3,4,5)P4. The impurities that had been seen in all the previous samples of D-70a 
were no longer visible in the 31P NMR (Figure 7.15) and the baseline in the 400 MHz 
NMR was now smooth.
Figure 7.15 162 MHz 31P NMR spectrum of D-Ins(l,3,4,5)P4 produced by the two-step 
deprotection method (triethylammonium salt in D2O, pH 4-5; EDTA added).
Compare with Figure 7.12b.
Now that the problems with this synthesis appear to have been solved, it should 
provide a rapid and simple access to D- and L-Ins(l,3,4,5)P4. The strategy should enable 
either enantiomer of Ins(l,3,4,5)P5 to be synthesised from myo-inositol orthoformate, 
using procedures that require only a few days work. It now only remains to repeat the 
route using the optimised methods and produce larger amounts of both enantiomers. The 
methodology could also be adapted to give a rapid route to [3H]Ins(l,3,4,5)P4. Oxidation 
of the unprotected 4-position in 67a followed by stereoselective reduction of the 
resulting ketone with [3H]NaBH4 should yield 67a tritiated at position 4, which can then 
be converted to optically pure D-[3H]Ins(l,3,4,5)P4 in only three steps, using the 
methods already developed for 67a.
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The remaining impure D-Ins(l,3,4,5)P4 is currently being put to good use in a 
potentiometric/NMR investigation of Ins(l,3,4 ,5)P4 in the hope of gaining information 
on the ionisation state and solution conformation of Ins(l,3,4 ,5)P4.* It should be 
particularly interesting to establish how the addition of a phosphate group to position 3 
of Ins(l,4 ,5)P3 may affect the conformation and ionisation state of the adjacent 4,5- 
bisphosphate. Samples of the purified D-Ins(l,3,4 ,5)P4 are being used in an NMR study 
of their interaction with the isolated PH domain of human dynamin.
The purified D-Ins(l,3,4,5)P4 is now being evaluated in SH-SY5Y cells under 
the same conditions as before, and compared to the impure sample. Commercially 
available D-Ins(l,3,4 ,5)P4, HPLC-purified commercial D-Ins(l,3,4 ,5)P4, and HPLC- 
purified biologically-derived D-Ins(l,3,4 ,5)P4 are also being compared in the same 
assay. Further tests are in progress, and full binding assays are still to be carried out 
before firm conclusions can be drawn. It is hoped that the complete results, which 
should be available soon, will allow a clearer understanding of the effects of D- 
Ins(l,3,4,5)P4 and its role in cell signalling.




Chemicals were purchased from Aldrich and Fluka. Dichloromethane was dried over 
phosphorus pentoxide, distilled and kept over 4 A molecular sieves. Pyridine was dried 
by refluxing with sodium hydroxide pellets, followed by distillation, and stored over 5 A 
sieves. Dimethylformamide was stored over 4 A sieves. Tetrahydrofuran (THF) was 
dried by passing through activated alumina to expel peroxide radicals, followed by 
distillation from sodium in the presence of benzophenone ketyl.
TLC was performed on pre-coated plates ( Merck TLC aluminium sheets silica 
F254, Art. no. 5554 ) with detection by UV light or with methanolic phosphomolybdic 
acid followed by heating. Flash-column chromatography was performed on silica gel 
(Sorbsil C60).
!H and 13C NMR spectra (internal Me4Si as reference) were recorded with a Jeol 
GX270 or EX400 NMR spectrometer, and 31P NMR spectra (external aq. 85% 
phosphoric acid as reference) were recorded with a Jeol EX400 or Jeol FX90Q 
spectrometer. Mass spectra were recorded at the SERC Mass Spectrometry Service 
Centre, Swansea, and at the University of Bath. Microanalysis was carried out by the 
Microanalysis Service, University of Bath. FAB-mass spectra were carried out using m- 
nitrobenzyl alcohol as the matrix. Melting points (uncorrected) were determined using a 
Reichert-Jung Thermo Galen Kofler Block. Optical rotations were measured using an 
Optical Activity Ltd. AA-10 polarimeter. Ion-exchange chromatography was performed 
on an LKB-Pharmacia Medium Pressure Ion Exchange Chromatograph using DEAE 
Sepharose or Sepharose Q Fast Flow by elution with a gradient of triethylammonium 
hydrogencarbonate (TEAB) buffer as eluent. Quantitative analysis of phosphate was 
performed using a modification of the Briggs phosphate assay.152,83
Dichloro-A,A-diisopropylaminophosphine was prepared by the method of 
Tanaka et al.253 by adding 2 equiv. of Af,iV-diisopropylamine to a solution of PCI3 in dry 
ether at -78°C. The crude product (<5p 166.4) was purified by distillation under reduced 
pressure, and reaction with 2 equiv. of benzyl alcohol in the presence of 2 equiv. of 
triethylamine afforded bis(benzyloxy)-A7V-diisopropylaminophosphine254 (<5p 145.24) 
which was purified by flash chromatography.
Benzyloxy-bis(A,7/-diisopropylamino)phosphine was prepared by the method of Dreef 
et al.202 Chloro-bis(A,iV-diisopropylamino)phosphine (2.67g, lO.Ommol) was dissolved
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in dry ether (20mL) and cooled to 0°C under N2. Dry triethylamine (1.4mL, lO.Ommol) 
was added followed by anhydrous benzyl alcohol (1.39mL, lO.Ommol). The mixture 
was allowed to reach room temperature and stirred for a further 30 min. The mixture 
was then poured into pentane at 0°C (30mL) and rapidly filtered to remove the 
precipitated triethylammonium chloride. The filtrate was evaporated in vacuo giving 
benzyloxy-bis(N,iV-diisopropylamino)phosphine as a colourless oil (3.17g, 9.37mmol, 
94%).
'H NMR (CDC13) 270MHz): S 1.17 (12 H, d, J  = 6.8 Hz, 4 x CH3), 1.19 (12 H, d, J  =
6.8 Hz, 4 x CH3), 3.55 (2 H, septet, J  = 6.8 Hz, 2 x CH), 3.59 (2 H, septet, J  = 6.8 Hz, 2 
x CH), 4.65 (2 H, d, 3/ Hp = 7.1 Hz, CH2C6H5), 7.30 - 7.40 (5 H, m, C<7/5).
31P NMR (CDC13, 36 MHz, ‘H-decoupled): 5 123.6.
Bis(4-chlorobenzyloxy)-A^,A^-diisopropylaminophosphine was prepared according to de 
Bont et al.111
8.1.2 Com puter assisted M olecular Modelling
Energy minimisations of structures and molecular dynamics simulations were carried 
out using the AMBER or MM+ forcefields within the software packages Discover 2.95 
(Biosym Technologies, San Diego, USA) running on a Silicon Graphics workstation or 
Hyperchem release 4 for Windows (Hypercube Inc.) on a 486DX266 personal computer. 
Partial charges for the fully ionised molecules were calculated using a semi-empirical 
method (CNDO or AMI). Molecular dynamics simulations were conducted at 900K for 
50psec after an initial equilibration period of O.lpsec.
8.1.3 Biological Assays
The investigations involving 45Ca2+ release from rabbit platelets, the spectrofluorimetric 
studies of Ca2+ release from platelets and the binding assays in rat cerebellar membranes 
were carried out by or under the supervision of Dr C. Murphy, in the Group of Prof. J. 
Westwick, School of Pharmacy and Pharmacology, University of Bath. Experimental 
details are given in Reference.255
Assays for inhibition of phosphatidylinositol 3-kinase were carried out by Dr S. 
Ward in the School of Pharmacy and Pharmacology, University of Bath. Full details of 
procedures are given in Reference.90
Testing of D- and L-Ins(l,3,4)P3 in Limulus ventral photoreceptors was carried 
out by Dr R. Payne of the Dept of Zoology, University of Maryland, USA. Experimental 
details are given in Reference.
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Investigations into the effects of Ins(l,3,4,5)P4 analogues in SH-SY5Y 
neuroblastoma cells were undertaken by Dr R. A. Wilcox, Dept, of Cell Physiology and 
Pharmacology, University of Leicester. Full details of procedures are given in 
Reference.110
Preliminary assays of the interaction of analogues with Ins(l,3,4)P3 5/6-kinase 
were performed by Dr P. J. Hughes at the Centre for Clinical Research in Immunology 
and Signalling, The Medical School, University of Birmingham. For details of 
procedures see Reference.87
The compounds described in this thesis are being examined for their interaction 
with a purified Ins(l,4 ,5)P3 3-kinase preparation, with analysis of the phosphorylation 
products by HPLC with metal-dye detection.257 These studies are being conducted by Dr 
G. W. Mayr and Dr U. Bertsch at the Institute for Physiological Chemistry, University 
of Hamburg, Germany.
8.1.4 Potentiometric and 31P NMR Investigations
These studies were carried out by Professor Bernard Speiss and his group at the
1 RQUmversite Louis Pasteur, Strasbourg. Details of procedures are given in Reference.
8.1.5 X-ray Crystallography
The X-ray crystallographic study of compound 67a was carried out by Dr M. Mahon in 
the Dept of Chemistry, University of Bath. Full details are given in Appendix 2.
8.2 D- and L-m yo-Inositol 1,3,4-trisphosphate
DL-l,4-Di-O-benzoyl-2,3 :5,6-di-0 -isopropyIidene-/7iy0-inositol (1)
A mixture of myo-inositol (lOOg, 0.55mol), A/iV-dimethylformamide (500mL), 2,2- 
dimethoxypropane (400mL), and toluene-p-sulphonic acid monohydrate (2g) was stirred 
at 100-120°C for 2 h. Triethylamine (20mL) was added to the cooled solution and the 
low-boiling solvents were evaporated at 50°C under reduced pressure. Pyridine (400mL) 
was added, followed by benzoyl chloride (400mL) dropwise with stirring and cooling 
over 25 min. The mixture was left to stand for a further 2 h, and then the solid was 
removed by filtration and washed successively with water, triethylamine, acetone and 
ether to give 1 (41.3g, 94mmol, 17%).
Mp: 328 - 330°C ( from D M F) (lit.144 328 - 330° C)
'H  NMR (CDCU, 270MHz): 5 1.30, 1.44, 1.51, 1.64 (12 H, 4 s, 4CH3); 3.72 (1 H, dd, J  
= 11.0 Hz, 9.3 Hz, C-5-H), 4.40 (1 H, dd, /  = 10.6 Hz, 9.3 Hz, C-6-H); 4.40 (1 H, dd, J
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= 6.6 Hz, 4.6 Hz, C-3-H); 4.79 (1 H, dd, J  = 4.6 Hz, 4.6 Hz, C-2-H), 5.43 (1 H, dd, J  =
10.6 Hz, 4.4 Hz, C-l-H); 5.61 (1 H, dd, 7 = 11.0 Hz, 6.6 Hz, C-4-H), 7.41-7.51 (4 H, m, 
C ^sC O O ), 7.53-7.63 (2 H, m, C ^sC O O , 8.08-8.18 (4 H, m, C ^sC O O ).
DL-l,2:4,5-Di-0-isopropylidene-m;y0-inositol (2)
A mixture of 1 (20g, 45mmol), sodium hydroxide (6g), and methanol (250ml) was 
heated under reflux for 30 min producing a clear solution which was allowed to cool. 
The solution was neutralised with solid carbon dioxide and the resulting white paste was 
then diluted with water (lOOmL) and evaporated to dryness under reduced pressure. The 
residue was extracted with dichloromethane (6 x 150mL), dried (MgSCU) and 
evaporated under reduced pressure to give a solid, which was recrystallised from ethyl 
acetate giving 2 as colourless crystals (9.7g, 37mmol, 82%).
Mp: 166 - 170°C ( from ethyl acetate) (lit.144 171-173°C).
‘H NMR (CDC13, 270MHz): S 1.38, 1.46, 1.49, 1.54 (12 H, 4 s, 4 CH3), 2.48 (1 H, d, J  
= 8.6 Hz, D20  ex, C-3-OH), 2.67 (1 H, d, / =  3.1 Hz, D20  ex, C-6-OH), 3.33 (1 H, dd, J  
= 10.6 Hz, 9.4 Hz, C-5-H), 3.84 (1 H, dd, 7 =  10.1 Hz, 10.1 Hz, C-4-H), 3.90 (1 H, ddd, 
J  = 10.6 Hz, 6.0 Hz, 3.0 Hz, C-6-H), 4.03 (1 H, ddd, J  = 10.0 Hz, 8.6 Hz, 4.4 Hz, C-3- 
H), 4.08 (1 H, dd, J  = 6.5 Hz, 5.0 Hz, C-l-H), 4.49 (1 H, dd, J  = 5.0 Hz, 5.0 Hz, C-2-H). 
I3C NMR (CDC13, 68 MHz): 8  25.85, 26.89, 28.06 (3 q, 4 CH3), 69.74, 74.76, 77.56, 
77.97, 81.28, 81.83 (6d, inositol ring C), 110.28, 112.71 (2 s, 2 C(CH3)2 ).
DL-l,4-Di-0-alIyI-2,3:5,6-di-0-isopropylidene-/wyo-inositol (3)
To a solution of diol 2 (18.2g, 70mmol) and sodium hydride (4.8g, 200mmol) in N,N- 
dimethylformamide (250mL) at 0°C was added dropwise allyl bromide (13mL, 
150mmol), with stirring. The reaction mixture was stirred for 2 h at 20°C. Excess 
sodium hydride was destroyed with ethanol and the mixture evaporated to dryness under 
reduced pressure. Water (200mL) was added and the product extracted with ether (3 x 
200mL). The combined organic layers were dried (MgSCU) and evaporated under 
reduced pressure to give 3 (22g, 65mmol, 93% yield).
Mp: 83 - 85°C ( from hexane ); (lit.145 85 - 87°C).
!H NMR (CDC13, 270 MHz): 8  1.38, 1.43, 1.46, 1.54 (12 H, 4 s, 4 CH3), 3.34 (1H, dd 7 
= 10.5 Hz, 9.8 Hz, C-5-H), 3.66 (1 H, dd, 7 = 10.6 Hz, 6.4 Hz, C-4-H), 3.80 (1 H, dd, 7 
= 10.3 Hz, 4.2 Hz, C-l-H), 3.98 (1 H, dd, 7 =  10.1 Hz, 10.1 Hz, C-6-H), 4.10 (1 H, d d 7
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= 6.1 Hz, 4.6 Hz C-3-H), 4.21-4.37 (4 H. m, OCH2), 4.46 (1 H, dd, 7 = 4.4 Hz, 4.4 Hz, 
C-2-H), 5.17-5.35 (4 H, m, =CH2), 5.90-5.60 (2 H, m, -CH=)
l3C NMR (CDC13, 68 MHz): 525.91, 26.95, 28.06 (3q, 4CH3), 71.16, 71.26 (2t, OCH2), 
74.76, 76.42, 76.84, 78.56, 80.11, 81.38 (6d, inositol ring), 109.99, 112.10 (2 s, 
C(CH3)2), 117.38, 118.16 ( 2 1, =CH2), 134.67, 134.74 (2d, -CH=).
DL-l,4-Di-0-allyl-/wjo-inositol (4)
Compound 3 (21.0g, 61.7mmol) was dissolved in acetic acid-water (4:1 , 200mL) and 
the solution was refluxed for 30 min. The solvents were then evaporated under reduced 
pressure. The white residue was recrystallised from ethanol to give 4 (15.0g, 57.6mmol, 
93%).
Mp: 133-136°C ( from ethanol); Lit149 137-139°C.
‘H NMR (d6-DMSO, 270 MHz): 52.96 (1 H, dd, J  = 9.7 Hz, 2.6 Hz, C-l-H), 3.03 (1 H, 
ddd, J  = 9.0 Hz, 9.0 Hz, 4.8 Hz, D20  ex gives dd, J  = 9.0,9.0, C-5-H), 3 .16- 3.28 (2 H, 
m, C-3-H and C-4-H), 3.46 (1 H, ddd, J  = 9.6 Hz, 9.3 Hz, 4.6 Hz, D20  ex gives dd, J  =
9.6 Hz, 9.3 Hz, C-6-H), 3.86 (1 H, ddd, J  = 3.2 Hz, 2.6 Hz, 2.6 Hz, D20  ex gives dd J  =
2.6 Hz, 2.6 Hz, C-2-H), 3.97 - 4.12, (2 H, m, C tf2CH=CH2), 4.16 - 4.26 (2 H, m, 
CH2CH=CH2), 4.54 (1 H, d, J  = 6.0 Hz, D20  ex, OH), 4.61 (1 H, d, J  = 3.7 Hz, D20  ex, 
C-2-OH), 4.64 (1 H, d, /  = 4.8 Hz, D20  ex, OH), 4.69 (1 H, d, J  = 4.8 Hz, D20  ex, OH),
5.01 - 5.29 (4 H, m, CH2CH=CH2), 5.80 - 5.98 (2 H, m , CH2Cfl=CH2)
13C NMR (d6-DMSO, 68 MHz): <569.83, 71.42, 72.20, 75.02, 79.53, 81.41 (6d, inositol 
ring C), 70.09, 72.94 (2 t, CH2CH=CH2), 115.30, 115.99 (2 t, CH2CH=CH2), 136.23,
137.06 (2 d, CH2CH=CH2)
DL-2,3,5,6-Tetra-0-acetyl-l,4-di-O-allyl-my0-inositol (5)
To a solution of 4 (1.3g, 5 mmol) in pyridine (lOmL) were added acetic anhydride 
(2.8mL, 30mmol) and DMAP (lOOmg). The mixture was stirred at room temperature for 
1 h, after which TLC (ether) showed conversion to a major product at Rf 0.60. The 
liquid was evaporated under reduced pressure and the product dissolved in 
dichloromethane (lOOmL), washed with sat. sodium hydrogencarbonate solution 
(lOOmL) then water (lOOmL), dried (MgS04) and evaporated to give an off-white solid 
which was recrystallised from hexane / ethyl acetate yielding 5 (1.70g, 3.97mmol, 79%). 
Mp: 118.5 - 119.5°C ( from hexane / ethyl acetate ).
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'H  NMR (CDCI3, 400 MHz): 52.04, 2.05, 2.06, 2.16 (12H, 4s, 4 CH3), 3.55 (1 H, dd, 7 
= 10.3 Hz, 2.9 Hz, C-l-H), 3.84 (1 H, dd, 7 = 10.3 Hz, 9.8 Hz, C-4-H), 3.89 - 4.17 (4 H, 
m, C tf2CH=CH2). 4.87 (1 H, dd, 7 =  10.3 Hz, 2.9 Hz, C-3-H), 5.07 (1 H, dd, 7 = 9.8 Hz,
9.8 Hz, C-5-H), 5.11 - 5.26 (4 H, m, CH2CH=Ctf2), 5.31 (1 H, dd, 7 =  10.3 Hz, 10.3 Hz, 
C-6-H), 5.64 (1 H, dd, 7 = 2.9 Hz, 2.9 Hz, C-2-H), 5.71 - 5.84 (2 H, m, CH2Ci7=CH2). 
13C NMR (CDCI3, 68 MHz): 5  20.69 (q, 4 CH3), 67.37, 71.06, 71.26, 72.52, 74.41, 
76.61 (6 d, inositol ring Q , 70.97, 73.92 (2 t, CH2CH=CH2), 116.70, 117.67 (2 t, 
CH2CH=CH2), 133.63, 134.28 (2 d, CH2CH=CH2), 169.73, 169.90, 170.06 (3 s, 4 C=0) 
MS: m/z (+ve ion FAB, rel intensity) 429 [(M + H)+, 80%] 371 [ ( M -C H 2CHCH20 ‘ )+ , 
80%], 369 [(M -CH3C O O ')+, 100%]
Anal. Calcd for C20H28Oi0 (428.44): C, 56.07; H, 6.59. Found: C, 56.0; H, 6.64.
DL-1,4-Di-O-alIy 1-3-0-/? -methoxy benzyl-my o -inositol (6)
A mixture of 1,4-di-O-allyl-myo-inositol 4 (13.0g, 50mmol), dibutyltin oxide (14.9g, 
60mmol) and toluene (200mL) were heated under reflux for 3h in a Dean and Stark 
apparatus. The mixture was allowed to cool and the toluene removed by evaporation in 
vacuo giving an off-white solid. Caesium fluoride (19.0g, 125mmol), potassium iodide 
(12.5g, 75mmol) and DMF (200mL) were added, followed by p-methoxybenzyl chloride 
(10.2mL, 75mmol). After stirring for 3h at rt TLC (ethyl acetate) showed a major 
product at Rf 0.30. The mixture was left overnight at room temperature and then 
evaporated in vacuo. The residue was taken up in dichloromethane, washed with water, 
stirred with sodium hydrogencarbonate solution (10% w/v) for 30 min, and washed with 
water again. The insoluble tin derivatives were removed by filtration through Celite and 
the solution was dried (MgS04), and evaporated to give an oil which was 
chromatographed on silica gel (ethyl acetate) giving 6 (12.4g, 32.6mmol, 65%).
Mp: 94-96°C ( from ethyl acetate / hexane ).
'H  NMR (CDC13, 270MHz): 52.62 (1 H, br s, D20  ex., OH), 3.11-3.16 (3 H, m, D20  
ex. gives 1H, dd, 7 = 9.5 Hz, 2.6 Hz, 2 OH and C-l-H  or C-3-H), 3.32 (1 H, dd, 7 = 9.5 
Hz, 2.8 Hz, C -l-H  or C-3-H), 3.36 (1 H, ddd, 7 =  9.5 Hz, 9.5 Hz, 1.5 Hz, D2O ex gives 
dd, 7 = 9.5 Hz, 9.5 Hz, C-5-H), 3.66 (1 H, dd, 7 = 9.5 Hz, 9.5 Hz, C-4-H), 3.88 (1 H, br 
dd, 7 = 9.5 Hz, 9.5 Hz, D20  ex gives dd, C-6-H), 4.07 - 4.45 (5 H, m, 2 C7/2CH=CH2 
and C-2-H), 4.63, (2 H, br s, Cff2Ph), 5.15 - 5.32 (4 H, m, 2 CH2CH=CH2), 5.86 - 6.05 
(2 H, m, 2 CH2CH=CH2), 6.86 - 6.90 (2 H, m, /ViOMe), 7.27 - 7.31 (2 H, m, PhO U t)
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13C NMR (CDCI3, 68 MHz): 8 55.27 (q, OCH3), 67.01, 71.55, 74.05, 78.85, 79.34,
80.08 (6d, inositol ring C), 71.29, 72.27 (2 t, CH2CH=CH2), 74.24 (t, CH2Ph), 113.89, 
129.51 (2 d, PhOMe) 116.83, 117.87 (2 t, CH2CH=CH2), 129.94 (s, PhOMe) 134.51, 
135.26 (2 d, CH2CH=CH2), 159.35 (s, P/iOMe)
MS: m/z (+ve ion FAB, rel intensity) 379 [(M -H)+, 5% ], 259 [ (M -CH2C6H4OCH3)+, 
2% ], 137(12) 121 [ (CH2C6H4OCH3)+ , 100% ] ;
MS: m/z (-ve ion FAB, rel intensity) 759 [ (2 M -H )', 20%) ], 533 [ (M +NBA)', 92% ], 
379 [ (M -H)', 100% ], 339(25), 322(20), 249(21).
Anal. Calcd for C20O7H28 (380.44): C, 63.14; H, 7.42. Found: C, 62.9; H, 7.42.
DL-l,4-Di-0 -allyl-2,5,6-tri-O-benzyl-3-0 -p-methoxybenzyl-f7fy0-inositol (7)
To a solution of triol 6 (6.85g, 18mmol) in dry Af-N-dimethylformamide (lOOmL) was 
added sodium hydride (2.0g, 83mmol). The mixture was cooled to 0°C and benzyl 
bromide (7.0mL, 59mmol) was added dropwise with stirring. The mixture was stirred at 
room temperature for 2 h, after which TLC (hexane/ether 1:1) showed the reaction to be 
complete, with a major product at Rf 0.43. The excess sodium hydride was carefully 
destroyed with water and the mixture concentrated in vacuo. The residue was dissolved 
in dichloromethane (lOOmL), the solution was washed successively with water, 
0.1MHC1, sat. NaHC03 solution and water (lOOmL of each), dried (M gS04) and 
evaporated in vacuo to give 11.8g of a solid which was recrystallised from hexane 
giving 7 (10.2g, 15.7mmol, 87%).
Mp: 72 - 74°C ( from hexane ).
‘H NMR (CDCI3, 270MHz): 53.23 (1H, dd J  = 9.9 Hz, 2.2 Hz, C -l-H  or C-3-H), 3.28 
(1H, dd J  = 9.9 Hz, 2.2 Hz, C -l-H  or C-3-H), 3.39 (1H, dd, J  = 9.3 Hz, 9.3 Hz, C -5-H ), 
3.81 (3H, s, OCH3), 3.91 (1 H, dd, J  = 9.3 Hz, 9.3 Hz, C-4-H or C-6-H), 3.97 ( 1 H, dd, 
J  = 2.2 Hz, 2.2 Hz, C -2-H ), 3.98 (1 H, dd, J  = 9.7 Hz, 9.7 Hz, C-4-H or C-6-H), 4.07 - 
4.14 (2 H, m OC/72CH=CH2) , 4.27 - 4.44 (2 H, m O C//2CH=CH2), 4.54, 4.59 (2 H, 
AB, 7ab 11.4 Hz, CH2C6H40Me), 4.76 - 4.90 (6 H, m 3 OCH2C6H5 ), 5.13 - 5.35 (4 H, 
m =CHi), 5.83 - 6.06 (2 H, m, -C7/=), 6.86 - 6.90 (2 H, m, CH2C6ff4OMe), 7.24 - 7.42 
(17 H, m, 3 CH2C67/5 and OfeCrffcOMe)
13C NMR (CDCI3, 68 MHz): 55.27 (q, OCH3), 571.62, 72.54, 73.95, 74.54, 75.80 (6t, 
OCH2 ), 74.44, 80.50, 80.63, 81.41, 81.57, 83.65 (6 d, inositol ring Q , 113.72 (d, 
CH2C6H40Me), 116.54 and 116.60 ( 2 1, =CH2), 127.28, 127.50, 127.79, 127.92, 128.09,
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128.31 (6 d, CH2C6H5 and CH2C6H4OMe), 130.62 (s, CH2C6H4OMe), 134.93 and 
135.48 (2 d, 2-CH=), 138.92 and 138.98 (2 s, CH2C6H5), 159.13 (s, CH2C6H4OMe)
MS: m/z (+ve ion FAB, rel intensity) 649 [ (M -H)+, 1.5% ], 121 [ (CH2C6H40CH3)+ , 
100% ] 91 [ (M -C7H7)+, 70% ].
MS: m/z (-ve ion FAB, rel intensity) 803 [ (M+NBA)', 100% ], 529 [ (M - 
CH2C6H40CH3)', 10% ].
Anal. Calcd for C4iH460 7 (650.81): C, 75.67; H, 7.12. Found: C, 75.6; H, 7.09.
DL-2,4,5-tri-0-Benzyl-l-0-p-methoxybenzyl-3,6-di-O-(as-prop-l-enyl)-my0-inositol
(8)
A solution of 7 (l.Og, 1.54mmol) and freshly sublimed potassium terf-butoxide (2.0g, 
17.8mmol) in dry DMSO (50mL) was stirred for 3 h at 50°C, after which TLC 
(hexane/ether 1:1) showed complete conversion from starting material (Rf 0.44) to a 
product at Rf 0.56. Water (50mL) was added to the cooled brown solution, which was 
then extracted with ether (3 x lOOmL). The combined organic layers were dried 
(M gS04) and evaporated under reduced pressure to give an off-white solid which was 
recrystallised from ethanol giving 8 (0.83g, 1.28mmol, 83%).
Mp: 110-112°C ( from ethanol).
*H NMR (CDCI3,400MHz): 5 1.64 (3 H, dd, J=  6.8 Hz, 1.5 Hz, CH=CH-Cff3), 166 (3 
H, dd, J  = 6.8 Hz, 1.5 Hz, CH=CH-C7/3), 3.33 (1 H, dd, J  = 9.8 Hz, 2.4, C -l-H  or C-3- 
H), 3.44 (1 H, dd, 9.3 Hz, 9.3 Hz, C-5-H), 3.53 (1 H, dd, 9.8 Hz, 2.4 Hz, C -l-H  or C-3- 
H), 3.81 (3 H, s, OCH3), 3.99 (1 H, dd, 7 =  2.4 Hz, 2.4 Hz, C-2-H), 4.03 (1H, dd, J  = 9.8 
Hz, 9.8 Hz, C-4-H or C-6-H), 4.15 (1 H, dd, J = 9.3 Hz, 9.3 Hz, C-4-H or C-6-H), 4.35 
(1 H, dq, J  = 6.8 Hz, 6.8 Hz, CH=C//-CH3), 4.44 (1 H, dq, J=  6.8 Hz, 6.8 Hz, CH=CH- 
CH3), 4.51, 4.56 (2 H, AB, Jab 11.7 Hz, C tf2Ph), 4.72, 4.80 ( 2 H, AB, Jab 10.3 Hz, 
C # 2Ph), 4.73,4.80, (2 H, AB, Jab 10.7 Hz, C //2Ph), 4.82 (2 H, br s, CH2Ph), 6.08 (1 H, 
dq, J  = 6.8 Hz, 1.5Hz, CH=CH-CH3), 6.27 (1 H, dq, J  = 6.8 Hz, 1.5 Hz, C//=CH-CH3), 
6.85 - 6.88 (2 H, m, C ^ C ^ O M e ) ,  7.24 - 7.35 (15 H, m, OfcCftfs), 7.37 - 7.42 (2 H, 
m, CK^C^-tOMe)
13C NMR (CDC13, 100 MHz): S 9.36, 9.42 (2 q, CH=CH-CH3), 55.29 (q, 
CH2C6H40CH3), 72.29, 74.47, 75.69, 75.78, (4 t, CH2Ph), 75.88, 78.35, 80.71, 82.55, 
84.40, 82.94 (6d, inositol ring ), 98.19. 100.62, (2 d, CH=CH-CH3), 113.72 (d, 
CH2CsH40Me), 127.38, 127.61, 127.83, 128,13, 129.26 (6 d, CH2C6H5 and
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CH2C6H40Me), 130.34 (s, CH2C6H4OMe), 138.50, 138.61, 138.71 (s, CH2C6H5), 
145.66, 147.77 (2 d, OCH=CH), 159.18 (s, CH2C6H40Me)
MS: m/z (+ve ion FAB, rel intensity) 649 [ (M -H)+ , 0.4%)], 559 [ (M -C 7H7)+ , 0.5%) ], 
121 [ (CH2C6H4OCH3)+ , 100% ], 91 [ (C7H7)+, 80% ];
MS: m/z (-ve  ion FAB, rel intensity) 803 [ (M+NBA)' , 100% ], 696 (32%) 559 [ (M - 
C7H7)' 10% ] 529 [ (M -CH2C6H4OCH3) ' , 10% ]
A nal Calcd for C4iH460 7 (650.81): C, 75.67; H, 7.12; Found; C, 75.7; H, 7.17. 
dl-2,4,5-T  ri-O-benzyl-myo-inositol (9)
The cw-propenyl ether 8 (500mg, 0.77mmol) was refluxed in 1M HC1 - ethanol (1:2) for 
2h, after which TLC (ethyl acetate/hexane 4:1) showed conversion to a major product at 
Rf 0.34. After cooling, the mixture was evaporated to dryness under reduced pressure. 
The residue was taken up in dichloromethane (50mL), washed with sat. N aHC03 and 
water (50mL of each), dried (M gS04) and evaporated to give a white solid, which was 
purified by column chromatography (ethyl acetate/ hexane 4:1) giving 9 (310mg, 
0.69mmol, 90%).
Mp: 135 - 136.5°C with a phase change at 127 - 128°C (from ethyl acetate/ hexane); Lit. 
145 135-137°C; Lit.124 126-128°C.
!H NMR (CDC13, 270MHz): <52.38 (1 H, d, J =  5.4 Hz, D2O ex, C-3-OH), 2.48 (1H, 
dd, J  = 5.9 Hz, D20  ex, C-l-OH), 2.63 (1 H, br s, D20  ex, C-6-OH), 3.32 (1 H, dd, /  =
9.3 Hz, 9.3 Hz C-5-H), 3.44 (1 H, ddd, J  = 9.7 Hz, 5.9 Hz, 2.8 Hz, DzO ex gives dd, J  =
9.7 Hz, 2.8 Hz, C-l-H  ), 3.57 (1 H, ddd, J  = 9.7 Hz, 5.4 Hz, 2.6, D20  ex gives dd, J  =
9.7 Hz, 2.6 Hz, C-3-H), 3.78 (1 H, dd, J  = 9.3 Hz, 9.3 Hz, C-4-H), 3.83 (1 H, br dd, D20  
ex gives dd, J  = 9.5 Hz, 9.5 Hz, C-6-H), 3.98 (1 H, dd, J  = 2.7 Hz, 2.7 Hz, C-2-H), 4.75- 
4.94 (6H, m, OCi72C6H5), 7.26 - 7.38 (15H, m, O CHzC^s)
13C NMR (CDC13, 68 MHz): 5 72.33, 72.70, 74.02, 78.89, 81.78, 82.95 (6 d, inositol 
ring C), 75.17, 75.23, 75.41 (3 t, OCH2C6H5), 127.76, 127.79, 127.89, 128.04, 128.46, 
128.54 (6 d, 3 CH2C6H5) 138.35, 138.48 (2 s, 3 CH2C6H5)
MS: m/z (+ve ion FAB, rel intensity) 451 [ (M+ H)+ , 3% ], 181(20%), 91 [ (C7H7)+ , 
100% ]
MS: m/z (-ve ion FAB, rel intensity) 616 (70%), 603 [ (M + NBA)‘> 92% ], 496 (30%), 
449 [ (M -  H )- , 100% ], 359 [ (M -  C7H7)', 23%].
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DL-2,5,6-Tri-0-benzyl-77ry0-inositoI l,3,4-tris(dibenzyIphosphate) (10)
To a solution of bis(benzyloxy)-iV,Af-diisopropylaminophosphine (920mg, 2.66mmol) in 
dry dichloromethane (3mL) was added lif-tetrazole (280mg, 4.00mmol). The mixture 
was stirred at room temperature for lOmins. 9 (200mg, 0.44mol) was added, and stirring 
continued for a further lh. TLC (ethyl acetate) showed complete conversion of the triol ( 
Rf 0.44 ) to a product ( R/0.10  ) and 31P NMR spectroscopy showed phosphite triester 
peaks at 140.39 (2P) and 142.2 (IP) . Water (5mL) was added and after stirring for a 
further 5min, terr-butyl hydroperoxide (lm L of a 70% solution in water). Stirring was 
continued overnight after which TLC showed conversion of the trisphosphite to a new 
product ( R f  0.64 ). The solvents were removed by evaporation in v a c u o  and then 
ethanol (20mL), water (20mL) and sodium metabisulphite (1.5g) were added. After 
stirring at rt. for 15min the mixture was evaporated to give a paste which was taken up 
in ether (lOOmL), washed with water (2 x 50mL), dried (MgSCU), and evaporated to 
give an oil (680mg). This was purified by column chromatography (ethyl acetate) giving 
10 (398mg, 0.323mmol, 73%) as a colourless oil.124
*H NMR (CDC13, 270 MHz): 5 3.45 (1 H, dd, J = 9.4 Hz, 9.4 Hz C-5-H), 4.06 (1 H, dd. 
J  = 9.4 Hz, 9.4 Hz, C-6-H), 4.22-4.36 (2 H, m, C-l-H  and C-3-H), 4.62 (1 H, dd, J  = 2.3 
Hz, 2.3 Hz, C-2-H), 4.74 - 5.05 (19 H, m, 9 0 7 2C6H5 and C-4-H), 7.12 - 7.38 (45 H, m, 
9 CH2C6/ / 5).
13C NMR (CDCI3, 68 MHz): S 69.20, 69.28, 69.36, 69.49, 69.74, 69.82 (6 t, 6 PO- 
CH2C6H5), 75.27, 75.51, 75.74 (3 t, 3 OCH2C6H5), 77.63, 77.92, 78.04, 79.37, 79.47, 
80.53, (6 d, inositol ring C), 127.21, 127.29, 127.36, 127.42, 127.53, 127.65, 127.73, 
127.79, 127.96, 128.07, 128.12, 128.25, 128.46, 128.72, 130.80 (15 d, 9 CH2C6H5), 
135.47, 137.93, 138.19 (3 s, 9 CH2C6H5)
31P NMR ( CDCI3, 162MHz ) <51.41, -1.56 and -2.01.
MS: m/z (+ve ion FAB, rel intensity) 1231 [ (M + H)+, 5% ], 1230(6%), 181 (10%), 91 [ 
(C7H7)+, 100% ].
MS: m/z (-ve ion FAB, rel intensity) 1383 [ (M + NBA)', 5% ], 1139 [ (M -  C7H7)\ 
30% ], 1138(35%), 1138 (35%), 277 [ (C6H5CH20 )2P 0 2)', 100% ].
DL-myo-Inositol-l,3,4-trisphosphate (11)
Ammonia was condensed into a three neck flask at -78°C. An excess of sodium was 
added to dry the liquid ammonia, which was then distilled into a second three neck flask 
and kept at -78°C. Sodium was added until the solution remained blue. Compound 10
195
(lOOm g, 81 .2 m m o l) w as d isso lv ed  in  anhydrous d io x an e  (2m L ) and  added  to  the 
so d iu m  - liq u id  am m o n ia  m ix tu re. A fte r stirring  fo r 3 m in  the  reac tio n  w as q u en ch ed  
w ith  e thano l. A m m o n ia  and  e thano l w ere evaporated . T h e  re s id u e  w as d isso lv ed  in  d e ­
io n ised  w a te r (500m L ) and  p u rified  by  io n -ex ch an g e  ch ro m ato g rap h y  on Q  S ep h aro se  
F as t F low , e lu tin g  w ith  a  g rad ien t o f  trie th y lam m o n iu m  b ica rb o n a te  b u ffe r (0  to  1M ), 
p H  8.0. T h e  trie th y lam m o n iu m  salt o f  11 e lu ted  b e tw een  4 0 0  m M  and  4 7 0  m M . Y ie ld  
2 6 m m o l, 3 2 % ).I24' 258
‘H  N M R  (D 20 ,  4 0 0  M H z, p H  -4 .2 ): S 3 .40  (1 H , dd , 7  =  9 .3  H z, 9 .3 H z, C -5 -H ), 3 .68 
(1 H , dd, 7  =  9.3 H z, 9 .3  H z, C -6-H ), 3 .85 (1 H , ddd , 7  =  9 .3  H z, 8.8 H z, 2 .4  H z, C - l -  
H ), 3.95 (1 H , ddd , 7  =  9 .8  H z, 9 .8 H z, 2 .5 H z, C -3 -H ), 4 .1 6  (1 H , ddd , 7  =  9 .3  H z, 9.3 
H z, 9 .3  H z, C -4 -H ), 4 .4 0  (1 H , dd , 7  = 2 .4  H z, 2 .4  H z, C -2 -H )
31P N M R ( D 20 ,  162 M H z, p H -7 )  5 0 .1 3  ( 1 P , d , 7  =  8.6 H z ), 0 .2 4  ( 1 P , d, 7 = 9 . 5  H z 
), 0 .97  ( 1 P , d , 7  =  8.5 H z ).
M S: m/z (+ v e  ion F A B , re l in tensity ) 102 [ (Q H s ^ N H 4, 100%  ]
M S: m/z ( - v e  ion  F A B , rel in tensity ) 838 [ 2M ', 12% ], 41 9  [ M \  100% ], 97  [ H 2P 0 4‘, 
10%]
M S: m/z 4 1 8 .9 5 4  (M -H )‘ (calcd  fo r Q H m O u P j,  4 18 .955).
D L -2 ,4 ,5 -T ri-0 -b e n zy I- l-O -p -m e th o x y b e n zy I- /7 iy 0 -in o s ito l (12)
A  so lu tion  o f  8 (0 .83g , 1.28m m ol) in  acetone (45m L ) w as w arm ed  to  50°C  w ith  stirring . 
1M HC1 (5m L ) w as added , and  stirring  co n tin u ed  fo r lO m ins, a fte r w h ich  T L C  (ether) 
sh o w ed  co m p le te  co n v ers io n  o f  starting  m ateria l (R /0 .7 6 ) to  a  m ajo r p ro d u c t at Rf 0 .56 . 
S o d iu m  h ydrogen  ca rb o n ate  ( lg )  w as added , and  s tirring  co n tin u ed  fo r a  fu rth e r lO m in, 
as the so lu tio n  w as a llo w ed  to  cool to  rt. T he  so lven ts  w ere  rem o v ed  u n d er red u ced  
p ressu re  an d  the re s id u e  w as taken  up  in  d ich lo ro m eth an e  (100m L ). T h e  su sp en sio n  w as 
w ash ed  w ith  w a te r (2 x 100m L), d ried  (MgSCU), an d  ev ap o ra ted  to  g ive  an  oil w h ich  
w as p u rified  by  co lu m n  ch ro m ato g rap h y  (e ther) to  g ive  12 (0 .69g , 1.21 m m ol, 94% ).
M p: 100 - 102°C  (from  h ex an e  /  ethy l acetate).
!H  N M R  (CDC13, 270M H z): 5 2 .2 7  (1 H , d, J =  6 .4  H z, D 20  ex . C -3 -O H ), 2 .5 0  (1 H , d, 
J = 1.5 H z, D 20  ex , C -6 -O H ), 3 .26  (1 H , dd , J = 9 .5  H z, 2 .2  H z, C - l-H ) , 3 .38 (1 H , dd, 
7  =  9.3 H z, 9 .3  H z, C -5-H ), 3.51 (1 H , ddd , J =  9.3 H z, 6 .4  H z, 2 .2  H z, D 20  ex  g ives dd, 
J =  9.3 H z , 2 .2  H z, C -3 -H ), 3 .78  (1 H , dd, J =  9.3 H z, 9 .3  H z, C -4 -H ), 3.81 (3 H , s, 
C 6H 4O C //3), 4 .0 4  (1 H , dd , J =  2 .2  H z, 2 .2  H z, C -2-H ), 4 .13  (1 H , ddd , J =  9 .3  H z, 
9 .3H z, 1.5, D 20  ex  g ives dd, J  = 9.3 H z, 9 .3 H z, C -6-H ), 4 .53 , 4.61 (2H , A B , 7a b , 11.4,
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O C /f2Ph), 4 .6 7  - 4 .93  (6  H , m , O C //2Ph), 6 .8 8  (2 H , b r d, J =  8 .2H z, C H z Q /^ O M e ) ,
7 .2 4  - 7 .74  (17  H , m , C l f e C ^ O M e  and  3 C H 2C 6H5).
13C  N M R  (CDC13, 6 8  M H z): S 55 .27  (q, O C H 3), 72 .15 , 74 .6 2 , 75 .20 , 75 .46 , (4  t, 
O C H 2P h), 72 .5 1 , 73 .04 , 76 .14 , 80 .03 , 81 .87 , 83.23 (6  d, in o sito l ring  C ), 113.98 (d, 
0 C H 2C6H 4 0 C H 3), 127.65, 127.78, 127.91, 128.04, 128.35, 128.41, 128.48, 129.45 (8  d, 
3 C H 2C 6H 5 an d  C H 2C6H 4O C H 3), 129.32 (s, C H 2C6H 4O M e), 138.04, 138.17 (2 s, 3 
C H 2C6H 5), 158.90 (s, C H 2C6H 4 0 M e).
M S: m/z (+ v e  ion F A B , rel in tensity ) 569 [ (M -H )+, 7%  ], 4 7 9  [ (M -C 7H 7)+, 2% ], 4 4 9  [ 
(M -C H 2C 6H 40C H 3)+, 10% ], 181(60% ), 121 [ (C H 2C 6H 4 0 C H 3)+, 90%  ], 91 [ (C 7H 7)+, 
100% ];
M S: m/z ( - v e  ion  F A B , re l in tensity ) 723 [ (M + N B A )', 100%  ], 569 [ ( M - H ) \  50%  ], 
322  (42% ), 140 (52% ).
Anal C alcd  fo r C 35H 3 8 0 7 (570 .68) C , 73 .66 ; H  6 .71 , F o u n d  C , 73 .8 ; H , 6.65.
Resolution of DL-2,4,5-tri-0-benzyl-1 -O-p-me thoxybenzyl-myo-inositol
A  m ix tu re  o f  12 (1 .35g, 2 .37m m ol) and  (l£ ,4 /? )-(-)-< o-cam phan ic  ac id  ch lo rid e  (1 .54g , 
7.11 m m o l) an d  D M A P  (50m g, 0.41 m m ol) in dry  p y rid ine  (lO m L ) w as s tirred  fo r lh  at 
rt, a fte r w h ich  T L C  (ch lo ro fo rm /ace tone  30:1) show ed  co m p le te  co n v ersio n  from  
startin g  m ateria l (R /0 .1 3 ) to  tw o  p roducts  (R /0 .1 7  and  R /0 .2 4 ) . T h e  m ix tu re  w as co o led  
in an ice b a th , and  w ate r ( lm L )  w as added. S tirrin g  w as co n tin u ed  fo r a  fu rth e r lh . 
E th e r (lOOm L) and  d ich lo ro m eth an e  (50m L ) w ere added , an d  the  o rg an ic  p h ase  w as 
w ash ed  su ccessiv e ly  w ith  sat. KC1, ice-co ld  1M  HC1, sat. KC1, an d  sat. N aH C C >3 
(lOOm L o f  each), d ried  (M g S 0 4), and  ev ap o ra ted  to  g ive  the  m ix tu re  o f 
d ias te reo iso m ers  (2 .16g , 2 .32m m ol, 98% ).
T h e  m ix tu re  o f  d iaste reo isom ers w as separa ted  by  co lu m n  ch ro m ato g rap h y  
(ch lo ro fo rm /ace to n e  30 :1 ) in to  tw o fractions, w h ich  w ere  recry sta llised  fro m  m eth an o l 
to  g ive  the  tw o  d iaste reo isom ers; 13a , Rf 0 .17  (683m g, 0 .7 3 4 m m o l, 63 .3%  o f  th is 
d iaste reo iso m er) and  13b, Rf 0 .2 4  (796m g, 0 .8 5 5 m m o l, 7 3 .7%  o f  th is d iaste reo iso m er).
lD-2,5,6-Tri-O-benzyl-l,4-di-O-[(-)-ft>camphanoyl]-3-O-p-methoxybenzyl-my0-
inositol (13a)
M p: 186-188°C  ( from  m e th a n o l)
'H  N M R  (C D C I3,2 7 0 M H z ): 5 0 .7 4 ,0 .8 4  (6  H , 2 s, cam p h -C H 3), 0 .9 6  (6  H , b r  s, cam p h - 
C H 3), 1.04, 1.07 (6  H , 2s, cam p h -C H 3), 1 .60-1 .74  (2  H , m , c a m p h -C H 2), 1.78 - 1.96 (4
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H , m , cam p h -C H 2), 2.21 - 2 .37 (2 H , m , cam p h -C H 2), 3 .63 (1 H , dd, J =  10.8 H z, 1.5 
H z, C -3 -H ), 3 .70  (1 H , dd, J =  9.5 H z, 9 .5  H z, C -5-H ), 3 .79  (3 H , s, C H 2C 6H 4O C //3),
4 .23  (1 H , b r s, C -2-H ), 4 .28  (1 H , dd, / =  9 .7  H z, 9 .7  H z, C -6 -H ), 4 .47  - 5 .05  (9 H , m , 4  
C t f 2P h  an d  C - l-H ) , 5 .85  (1 H , dd, J =  9 .9  H z, 9 .9  H z C -4 -H ), 6 .8 6  (2 H , b r d, J =  8 .4  
H z, C f ^ O M e ) ,  7 .20  - 7 .44  (17 H , m , C ^ O M e  an d  3 C ^ s ) .
13C  N M R  (CDC13, 6 8  M H z): 8  15.72, 15.97, 16.06, (3 q, cam p h -C H 3), 28 .35 , 30 .33 ,
30 .47  (3 t, cam p h -C H 2), 53.42, 53 .57 , 54.18 (3 s, cam p h ), 5 4 .70  (q, O C H 3), 71 .62 ,
74 .0 3 , 74 .18 , 74 .63  (4 t, C H 2Ph), 73 .24 , 73 .47 , 74 .41 , 77 .85 , 78 .22 , 8 0 .10  (6  d, inosito l 
rin g  C ), 90 .1 7 , 90 .43  (2 s, cam ph), 113.31 (d, C6H 4O M e), 126.37, 126.61, 126.82, 
126.92, 127.10, 127.16, 127.70, 127.76, 128.23 (9 d, 3 C H 2C6H 5 and  C 6H 4O M e), 
137.30, 137.40 (2  s, 3 C H 2C 6H 5), 158.78 (s, CaKUOMe), 166.17, 166.83, 177.21, 
177.70, (4  s, cam p h  C = 0 ) .
MS: m/z (+ve ion FAB, rel intensity) 929 [ (M -H )+, 0.7% ], 839 [ (M -C 7H7)+, 0.7% ], 
809 [ (M -C H 2C6H40CH3)+, 1.2%], 121 [ (CH2C6H 40CH 3)+, 100% ], 91 [(C7H7)\6 8 %  ] 
MS: m/z (-ve ion FAB, rel intensity) 1083 [ (M +  NBA)', 7% ], 197 [ (camphO)\100% ] 
[ a ] D27 = -1 1  (c = 1 in CHC13)
Anal. C a lcd  fo r C s s lfe O is  (931 .09); C , 70 .95; H  6 .71 , F o u n d  C , 70 .8 ; H , 6 .76.
lL-2,5,6-Tri-0-benzyI-l,4-di-0-[(-)-C0-camphanoyI]-3-0-/j-methoxybenzyl-/?ry0- 
inositol (13b)
M p: 194-195°C  ( fro m  m e th a n o l).
‘H  N M R  (C D C I3, 400M H z): 8  0 .82 , 0 .88 , 0 .96 , 1.00, 1.05, 1.08 (18 H , 6  s, cam p h - 
C H 3), 1.54 - 1.71 (2  H , m , cam p h -C H 2), 1.72 - 1.88 (4  H , m , cam p h -C H 2), 2 .3 4  - 2.31 (2 
H , m , cam p h -C H 2), 3 .62  (1H , dd , J  =  10.4 H z, 2.1 H z C -3 -H ), 3 .68 (1 H , dd , J  =  9 .5  H z,
9 .5  H z, C -5 -H ), 3 .79  (3 H , s, C 6H 4O C //3), 4 .12  (1 H , d d , J  =  2 .1H z, 2.1 H z, C -2 -H ),
4 .2 4  (1 H , dd , J  =  9 .5  H z, 9 .5 H z, C -6 -H ), 4 .4 7 , 4 .5 8  (2  H , AB, J AB 11.3 H z, 
C ff2C 6H 4 0 C H 3), 4 .59  - 4 .88  ( 6  H , m , 3 C H 2C 6H 5), 5 .0 0  (1 H , dd , 7 =  10.4 H z, 2 .4  H z, 
C - l-H ) , 5 .82  (1 H , dd , J  =  9 .8  H z, 9 .8  H z, C -4 -H ), 6 .8 6  (2  H , b r  d, J  =  8 .9 H z, 
C M O M c), 7 .1 9  - 7 .38  (17 H , m , C ^ O M e  an d  3 C M )
13C  N M R  (C D C I3, 6 8  M H z): S 16.45, 16.59, 16.72, (3 q, cam p h -C H 3), 28 .8 5 , 30 .73 , 
3 0 .85  (3 t, cam p h -C H 2), 54 .18 , 54 .77 , 54 .83  (3  s, cam p h ), 55 .27  (q, O C H 3), 71 .88 , 
75 .0 1 , 7 5 .2 0  7 5 .2 7  (4  t, C H 2P h ), 74 .0 7 , 74 .77 , 74 .8 1 , 77 .8 8 , 78 .7 7 , 81 .23  ( 6  d, in o sito l 
rin g  C ), 90 .7 5 , 91 .13  (2  s, cam ph), 113.88 (d, C 6H 4O M e), 127.21, 127.26, 127.49, 
127.55, 127 .67, 128.25, 128.36, 128.82 129.38 (9d , 3 C H 2C 6H 5 an d  C 6H 4O M e), 137.96
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138.14  (2  s, 3 C H 2C 6H 5), 159.32 (s, C6H 4O M e), 166 .73 , 167.29, 177.84, 178.46, (4  s, 
c am p h  C = 0 ) .
M S : m/z (+ ve ion F A B , rel in tensity) 929  [ ( M - H ) +, 0 .8%  ], 839  [ ( M - C 7H 7)+, 1.1%  ], 
809  [ ( M - C H 2C 6H 4 0 C H 3)+, 1 .2 % ], 121  [ ( C 7H 6O C H 3)+, 100%  ], 91 [ (C 7H 7)+, 58%  ]
M S: m/z ( - v e  ion  F A B , rel in tensity) 1083 [ (M  +  NBA)'* 11%  ], 197 [ (cam p h -O )', 
100% ]
[cc]D21 = +5 (c =1 in CHC13)
Anal. C a lcd  fo r C 55H 62O 13 (931 .09); C , 70 .95 ; H  6 .71 , F o u n d  C , 70 .6 ; H , 6 .70
(+)-lD-2,5,6-Tri-O-benzyl-3-0-/?-methoxybenzyl-fwy0-inositol (12a)
T h e  (- )-b iscam p h a n a te  es te r 13a (570m g, 0 .6 1 2 m m o l) w as d isso lv ed  in m eth an o l 
(lOOm L) co n ta in in g  so d iu m  h ydrox ide  pelle ts  (4g) and  re flu x ed  fo r 30m in . T h e  m ix tu re  
w as co o led  an d  then  n eu tra lised  w ith  so lid  ca rbon  d iox ide. A fte r the  so lv en ts  w ere  
rem o v ed  by  ev ap o ra tio n  u n d er red u ced  p ressu re , the  re s id u e  w as tak en  up  in  w a te r 
(lOOm L), ex trac ted  w ith  ch lo ro fo rm  (2 x lOOmL), d ried  (M g S 0 4 ) an d  ev ap o ra ted  to  
g ive  a  w h ite  so lid . T h is  w as recrysta llised  fro m  ethyl ac e ta te / h ex an e  g iv in g  12a 
(334m g, 0 .5 8 5 m m o l, 96% )
M p: 95- 96 .5 °C  ( fro m  ethy l aceta te  /  h e x a n e ).
[ a ] D24 =  + 4  (c  =  1, C H C I3)
Anal. C a lcd  fo r C 35H 380 7  (570 .68); C , 73 .66 ; H  6 .71 , F o u n d  C , 73 .6 ; H , 6 .6 4  
N M R  and  m ass sp ec tro m etry  d a ta  w ere  iden tical to th o se  fo r the  racem ic  d io l 12.
(-)-lL-2,5,6-Tri-O-benzyl-3-0-p-methoxybenzyl-/fiy0-inositol (12b)
T h e  (+ )-b iscam p h an a te  es te r 13b (77 0 m g ,0 .8 2 7 m m o l) w as co n v e rted  to  the  d io l 12b as 
d esc rib ed  fo r co m p o u n d  13a. Y ield  46 1 m g , 0 .8 0 8 m m o l, 98% .
M p: 95- 9 7 °C  ( fro m  e th y l aceta te  /  h ex an e  ).
[ a ] D 22 = - 4  (c  =  1, CHC13)
Anal. C a lcd  fo r C 35H 38O 7 (570 .68); C , 73 .66 ; H  6 .71 , F o u n d  C , 73 .6 ; H , 6 .6 6  
N M R  an d  m ass sp ec tro m etry  d a ta  w ere  iden tical to  those  fo r  th e  racem ic  d io l 12.
(-)-lL -l,2,4,5,6-Penta-O-benzyl-my0-inositol (14b)
T h e  ab so lu te  co n fig u ra tio n  o f  12b w as d e te rm in ed  by  co n v e rtin g  it to  the  k now n  
p en tab en zy l e th e r 14b. A  sam ple  o f  the ( - ) -d io l 12b (60m g, 0 .1 0 5 m m o l) w as d isso lv ed  
in d ry  D M F  (5m L ), and  so d iu m  hydride  (20m g o f  a 60%  d isp ers io n  in  o il, 0 .5 0 m m o l)
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w as added. A fte r s tirrin g  at room  tem p era tu re  fo r lO m in, benzy l b ro m id e  (0 .05m L , 
0 .4 2 m m o l) w as ad d ed  and  stirring  co n tin u ed  fo r 2 h. T h e  ex cess so d iu m  h ydride  w as 
destro y ed  by  ad d itio n  o f  w ater (5m L ) and  the  m ix tu re  co n cen tra ted  u n d er reduced  
pressu re . T h e  re s id u e  w as taken  u p  in  d ich lo ro m eth an e  (20m L ), w ash ed  w ith  0 .1 M  HC1 
(20m L ) and  ev ap o ra ted . T he residue w as then  re flu x ed  in  m eth an o l /  1M  HC1 2:1 fo r 5 h 
a fte r w h ich  tim e  T L C  show ed  com ple te  co nversion  to the  p en ta-O -b en zy l ether. T h e  
so lven ts  w ere rem o v ed  by evaporation  in vacuo and  the re s id u e  w as taken  up  in 
d ich lo ro m eth an e  (30m L ), w ashed  w ith  sat. N aH CC >3 and  w a te r (2 0 m L  o f  each ), d ried  
(MgSC>4) and  ev ap o ra ted . C olum n ch rom atography  (pen tane  /  e th e r 1 :1 )  gave th e  p u re  
p en ta-O -b en zy l e ther, w hich  had  an N M R  sp ec tru m  iden tical to  an racem ic  1 ,2 ,4 ,5 ,6- 
p en ta-O -b en zy l-m y o -in o sito l , 164 b u t a  spec ific  ro ta tio n  o f  -1 1 .5 ° ,  a llo w in g  its ab so lu te  
co n fig u ra tio n  to  be  assig n ed  as L -14b. (52m g, 0 .0 8 2 4 m m o l, 78%  from  12b).
[ a ]d 22 =  - 1 1 .5  (c  =  2  in CHC13) [lit. 163 [ a fo  =  -1 3 .5  (c =  0 .5 , C H C I3); lit. 259 [ a ] D =  
+ 1 0 .0  (c  =1, C H C I3) fo r  th e  enan tiom er; L it . 167 [ a ]o  =  + 9 .7  (c  =  1.5, C H C I3) fo r  the 
enan tiom er].
!H  N M R  (C D C I3 , 2 70M H z): 82.22  ( 1 H , d, / =  6 .0H z, D zO  ex ., C -3 -O H  ); 3 .43 - 3.53 
( 3H , m , C - l-H , C -3 -H , C -5-H ); 3.81 ( 1 H , dd , J =  9 .5  H z, 9 .5 H z, C -6 -H  o r C -4 -H );
4 .03  ( 1 H , dd, J  =  2 .2  H z, 2 .2  H z, C - 2 - H ); 4 .0 6  ( 1 H , dd, J =  9 .5  H z, 9 .5  H z, C -6 -H  o r 
C -4 -H  ); 4 .7 0  - 5 .02  ( 10 H , m , C tf2C 6H 5 ); 7 .25 - 7 .38  ( 25 H , m , CeH5 ).
( - ) - 1 d -2 ,5 ,6 -T r i-O -b e n z y l-w y o -in o s ito l (9a)
T h e  (+ )-d io l 1 2 a  (300m g, 0 .5 2 6 m m o l) w as d isso lv ed  in e th an o l (80m L ) an d  1M  HC1 
(40m L ) w as added . T h e  m ix tu re  w as re flu x ed  fo r 4h  an d  the  so lv en ts  ev ap o ra ted  u n d er 
red u ced  p ressure . T h e  resid u e  w as taken  up  in d ich lo ro m eth an e  (50m L ), w ash ed  w ith  
w ater, sa tu ra ted  N aH C C >3 and  b rine  (30 m L  o f  each) and  d ried  (M gSCU). T he  so lven ts  
w ere  rem o v ed  an d  th e  re sid u e  p u rified  by  flash  ch ro m ato g rap h y  (e thy l ace ta te / h ex an e  
4 :1 ) to  g ive  a w h ite  so lid  w h ich  w as recrysta llised  fro m  ethy l ace ta te / h ex an e  g iv in g  the 
trio l 9 a  (213m g, 0 .4 7 3 m m o l, 90% ).
M p: 104 - 106°C  w ith  a  ph ase  change at 92  - 93°C  ( fro m  ethy l aceta te  /  h ex an e  ); L it . 143 
103 - 105°C
[ a ] D23 =  - 3 2  (c  =  1, C H C I3) [ L i t .23 [ah 25 =  - 2 7  (c =  1, CHC13). L it. 24 [ a ] D =  - 2 5  ( c  =  
0 .5 , C H C I3)].
N M R  an d  m ass sp ec tro m etry  d a ta  w ere  iden tical to  those  fo r the  racem ic  trio l 9.
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(+)-lL-2,5,6-Tri-0 -benzyl-f7ryo-inositoI (9b)
T h e  ( - ) -d io l  12b (350m g, 0 .613m m ol) w as trea ted  as d esc rib ed  fo r the  en an tio m er 
above  to  g ive  the  (+ )-trio l 9b (250m g, O .555m m ol, 91% ).
M p: 104- 106°C  w ith  a  ph ase  change a t 93 - 9 4°C  ( fro m  ethy l ace ta te  /  h ex an e  ); L it . 143 
104 - 106°C
[ a ] D21 =  + 32  (c  =  1, C H C U ). [L it. 143 [ a ] D25 =  +  25 (c  =  1, CHC13)].
N M R  an d  m ass sp ec tro m etry  d a ta  w ere  iden tica l to  those  fo r the  racem ic  trio l 9.
(+)-lD-2,5,6-Tri-0-benzyl-myo-inositol l,3,4-tris(dibenzylphosphate) (10a)
T h e  ( - ) - t r io l  9a (60m g, O .133m m ol) w as p h o sp h ity la ted  as d esc rib ed  fo r the racem ic  
m ate ria l. O x id a tio n  and  p u rifica tio n  as befo re  gave 10a as a  co lo u rle ss  o il (126m g, 
0 .1 0 2 m m o l, 77% ).
[ a ] D20 =  +6 ( c =  1 ,C H C 13)
Anal. C a lcd  fo r C 69H 69O 15P 3; C , 67 .31 ; H  5 .65, F o u n d  C , 67 .3 ; H , 5 .70  
N M R  an d  m ass spec trom etry  d a ta  w ere iden tical to those fo r racem ic  10.
(-)-lL-2,5,6-Tri-0-benzyI-myo-inositol l,3,4-tris(dibenzylphosphate) (10b)
T h e  (-h)-triol 9b (60m g, 0 .13 3 m m o l) w as p h o sp h ity la ted  as d esc rib ed  fo r the  racem ate  
g iv in g  9b as a  co lo u rle ss  oil. Y ield  123m g, O.lOOmmol, 75% .
[ a ] D20 =  - 6  (c =  1, C H C I3) L it . 143 [ a ] D25 =  - 5 .8  (c  = 1, C H C I3)
N M R  an d  m ass sp ec tro m etry  d a ta  w ere iden tical to  those  fo r racem ic  10.
(+)-lD-myo-inositol-l,3,4-trisphosphate (11a)
T h e  fu lly -p ro tec ted  trisp h o sp h ate  tries te r 10a (80m g, 6 5 p n o l )  w as d ep ro tec ted  and  
p u rified  as d esc rib ed  fo r the  racem ic m ateria l to  g ive  11a as the  g lassy  
trie th y lam m o n iu m  salt. Y ie ld  34 /tm o l, 52%
[cx]d26 =  + 37 ( c = 0 .42 , T E A B  buffer, pH  7.8 ) C alcu la ted  fo r the  free  acid . L it .95 [a]v 
= - 6 ( c  = 0 .5 , H 20  ), L it .98 [ a ] D = + 13 .6  ( c = 2, H 20 ,  p H  8.2, p o tass iu m  salt).
M S: m/z 4 1 8 .9 5 6  (M -H )“ (ca lcd  fo r C 6H i40 i5P 3, 418 .955).
N M R  d a ta  w ere  iden tica l to  those  fo r the racem ate  11.
(-)-lL-/wy0-inositol-l,3,4-trisphosphate (lib )
C o m p o u n d  104b (lOOmg, 8 1 .2 ^ m o l) w as d ep ro tec ted  an d  p u rified  as d esc rib ed  fo r the 
racem ic  m ateria l g iv ing  the  trie th y lam m o n iu m  salt l ib . Y ield  31/zm ol, 38% ).
[a]d 26 =  - 4 0  ( c =  0 .42 , T E A B  buffer, pH  7 .8  ) C alcu la ted  fo r th e  free  acid .
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M S: m/z 4 1 8 .9 5 7  (M -H )“ (calcd  fo r Q H 14O 15P 3, 418 .955).
N M R  d a ta  w ere  iden tica l to  those  fo r 11.
8.3 Acyclic Analogue
(2S,3S)-butane-l,2,3,4-tetrol-l,2,4-tris[bis(4-chlorobenzyl)phosphate)] (16)
T o  a  so lu tio n  o f  b is(4 -ch lo robenzy loxy)-A f,A -d iisop ropy lam inophosph ine177 (1 .24g , 
2 .9 9 m m o l) in d ry  d ich lo ro m eth an e  (5m L ) w as added  l / /- te tra z o le  (420m g, 5 .9 9 m m o l). 
T h e  m ix tu re  w as stirred  at ro o m  tem pera tu re  fo r 10 m in  an d  th en  (2S,3S)-(+)-2- 
b en z y lo x y b u ta n e -l,3 ,4 -tr io l (106m g, 0 .49 9 m m o l) w as added . T h e  m ix tu re  w as s tirred  
fo r a  fu rth e r 0 .5  h, a fte r w hich  a  9 0  M H z 31P  N M R  sp ec tru m  sh o w ed  signals a ro u n d  
139ppm  (tw o  d o ub le ts  and  a  trip le t, 7pp =  1.5 H z) co rresp o n d in g  to  th e  trisp h o sp h ite  
tries te r. T h e  m ix tu re  w as co o led  to  -78°C  and  m -C P B A  (570m g, 3 .30  m m ol) w as added . 
T h e  m ix tu re  w as w arm ed  to  room  tem peratu re , w ith  stirring , and  then  d ilu ted  w ith  e th e r 
(50m L ). T h e  so lu tion  w as w ashed  w ith  10% so d ium  su lp h ite  so lu tio n , sat. N aH C O s and  
b rin e  (5 0 m L  o f  each), d ried  (M gS 0 4 ) and  ev ap o ra ted  in vacuo to  g ive an  oil. 
P u rifica tio n  by  co lu m n  ch rom atography  (e ther, then  ethyl aceta te) gave the 
trisp h o sp h a te  tries te r 16 as a  co lo u rless oil (437m g, 0 .3 6 4 m m o l, 73% ).
Rf 0.54 (E thy l aceta te); [ a ] D20 - 0  ( c  = 1, CHC13).
‘H  N M R  (C D C I3, 4 0 0  M H z): 5  3 .76  (1 H , d t, ]=  4 .6  H z, 4 .6  H z, C -3 -H ), 4 .0 3 -4 .0 9  (1 H , 
m , C f tO P ) ,  4 .1 3 -4 .1 9  (1 H , m , CH2 O P), 4 .2 1 -4 .2 6  (2 H , m , CH2 OP), 4 .47 , 4 .5 9  (2  H , 
A B q, JAK =  11.6 H z, O C //2Q H 5), 4 .68  (1 H , m , C -2-H ), 4 .8 5 -4 .9 8  (12  H , m , 6  x 
O O T 2C 6H 4CI), 7 .1 1 -7 .2 9  (29 H , m , 6  x C ^ C l  an d  C y / 5).
13C  N M R  (C D C I3 , 100 M H z): 5  6 5 .1 4  (t, b road , C H 2O P ), 69 .93  (t, b road , C H 2O P),
68 .6 4 , 68 .73 , 6 8 .76  (overlapp ing  trip le ts w ith  J Cop co up ling , 6  x  P O C T ^A r), 7 3 .1 2  (t, 
O C H 2C6H 5), 7 5 .8 6  (d, Jcop = 5 .5H z, 7.3 H z, C -2  o r  C -3), 7 6 .1 2  (d, Jcop =  5 .5 H z, 5 .6  
H z, C -2  o r C -3), 127.83, 128.11, 128.22, 128.49, 128.77, 128.82, 129.04, 129.21, 
129.24, 129.30, 129.55 (d, C6H 5 and  C6IUC\), 133.80, 133.87, 133.94, 134.55, 134.60, 
134 .66  (6  s, 6  x  C - l  and  C -4  o f  C6H 5C1), 137.01 (s, C - l  o f  C 6H 5).
31P  N M R  ( CDC13,1 6 2 M H z , 'H -d eco u p led ) 5 -0 .9 6 , -1 .13  an d  -1 .52 .
M S: m/z (+ v e  ion  F A B , re l in tensity ) 1202(30% ), 1201(76% ), 1200(42% ) 1199(82% ), 
1198(16% ), 1197(34% ) [iso topom ers o f  (M + H )+], 127 [ (C 7H 637C 1)+, 100% ], 125 [ 
(C 7H 635C l)+,33%  ].
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M S: m/z ( - v e  ion F A B , rel in tensity ) 1073 [ (M -C 7H 635C 1) \  85%  and  various 
iso to p o m er p eaks ], 345 [ (35C 1C 7H 6 0 )2P 0 2 ) \  100%  ].
Anal C a lcd  fo r C 53H 49O 13P 3CI6 (1199 .60); C , 53 .07 ; H  4 .12 , F o u n d  C , 52 .8 ; H , 4 .14 .
(2S,3S)-butane-l,2,3,4-tetroI-l,2,4-trisphosphate (15)
A m m o n ia  (-lO O m L ) w as co n d en sed  in to  a th ree -n eck  flask  a t -7 8 ° C . A n ex cess  o f  
so d iu m  w as ad d ed  to  dry  the  liq u id  am m o n ia  an d  the deep  b lu e  so lu tio n  w as s tirred  at -  
7 8 °C  fo r 30m in . A  sm all v o lum e o f  the d ry  am m o n ia  (~ 30m L ) w as th en  d is tilled  in to  a 
seco n d  th ree -n eck  flask  and  k ep t at -7 8 ° C . S o d iu m  w as added  un til the so lu tion  
rem a in ed  b lu e-b lack  fo r 10 m in. A  so lu tion  o f  16 (95m g, 7 9 ^ m o l)  in d ry  d io x an e  (2m L ) 
w as ad d ed  to  the  v igo ro u sly -stirrin g  sod ium  - liq u id  am m o n ia  m ix tu re . A fte r 60  - 9 0  sec 
th e  reac tion  w as ca refu lly  q u en ch ed  w ith  m ethano l, fo llo w ed  by  d e-io n ised  w ater. 
A m m o n ia  and  so lven ts  w ere  then  rem oved  by ev ap o ra tio n  in vacuo. T h e  re sid u e  w as 
d isso lv ed  in  d e-io n ised  w ate r (500m L ) and  p u rified  by  io n -ex ch an g e  ch ro m ato g rap h y  on 
Q  S ep h aro se  F ast F low  R esin , e lu tin g  w ith  a g rad ien t o f  trie th y lam m o n iu m  b ica rb o n a te  
b u ffe r (0 to  1M ), pH  8.0. T h e  g lassy  trie th y lam m o n iu m  salt o f  15 e lu ted  b e tw een  300 
m M  and  360  m M . Y ie ld  3 3 ^ m o l, 42% ).
[T he N M R  sp ec tra  o f  15 w ere d ifficu lt to  in terp re t, due to  b ro ad  signals  in the  31P  N M R  
sp ec tru m  at ac id ic  pH , and  ob scu rin g  o f  signals in the lH N M R  sp ec tru m  by  p eak s from  
the  trie th y lam m o n iu m  ions. 15 w as therefo re  co n v erted  to  its N a+ salt by  trea tm en t w ith  
H + D o w ex  resin , fo llo w ed  by  C h elex -100  (N a+ form )].
[ a h 20  ~ 0  ( c  =  0 .2 , H 2O ).
'H  N M R  (D 20 ,  4 0 0  M H z, N a+ salt, p H  6-7): 8 3 .6 8 -3 .7 6  (1 H , m , C tf 2O P ), 3 .7 7 -3 .8 6  (3 
H , m , C t f 2O P ), 3 .86-3 .91  (1 H , m , C -3 -H ), 4 .1 1 -4 .1 8  (1 H , m , C -2 -H ).
31P  N M R  (D 20 ,  161.7 M H z, ‘H -coup led , N a+ salt, p H  6-7) 5 0 .9 6  (1 P , d, 7Hp =  9 .4  H z, 
P -2 ), 1.92 (1 P , t, 7Hp =  5.8 H z), 2 .07  (1 P, t, 7Hp =  6.5 H z)
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8.4 Five-membered ring Analogue
M e th y l 2 -0 -b e n z y l-6 ,7 -d id e o x y -3 ,4 -d i-0 -p -m e th o x y b e n z y l-a -D -g /a c o -h e p t-6 -  
e n o p y ra n o s id e  (1 ,5) (20)
In to  a  d ry  th ree -n eck  flask  u n d er N 2 w as p laced  oxaly l ch lo rid e  (3 .2 m L  o f  a  2M  so lu tion  
in  d ich lo ro m eth an e , 6 .4m m ol) fo llo w ed  by  dry  d ich lo ro m eth an e  (lO m L ). T h e  appara tus 
w as co o led  to  -6 0 ° C  and  a  so lu tion  o f  anhydrous d im eth y lsu lp h o x id e  (0 .90m L , 
12 .7m m ol) in  dry  d ich lo ro m eth an e  (15m L ) w as carefu lly  in jec ted  o v er a  p e rio d  o f  5 
m in . T he  m ix tu re  w as stirred  fo r 5 m in  and  then  a  so lu tion  o f  m ethy l 2 -O b e n z y l-3 ,4 -d i-  
O -p -m eth o x y b en zy l-a -D -g lu co p y ran o sid e  (18) (3 .00g , 5 .7 2 m m o l) in dry
d ich lo ro m eth an e  (lO m L ) w as added  d ropw ise  o v er 5 m in . S tirrin g  w as co n tin u ed  a t - 6 0  
°C  fo r a  fu r th e r 20  m in  and  then  d ry  trie thy lam ine (5m L ) w as added . A fte r s tirrin g  fo r 5 
m in , the  reac tio n  w as a llow ed  to  reach  ro o m  tem peratu re . T h e  so lv en ts  w ere  rem o v ed  
by  ev ap o ra tio n  in vacuo and  the  residue w as tak en  up  in  d ich lo ro m eth an e  (15m L ) to  
g ive  a  slurry , w h ich  w as loaded  onto  a  short co lu m n  o f  s ilica  and  e lu ted  w ith  ethyl 
ace ta te /h ex an e  3 :2 , g iv ing  the crude  a ldehyde as a pale  yellow  oil (2 .6g). T h is  w as u sed  
fo r the n ex t s tep  w ith o u t fu rth e r purifica tion .
A  dry  lOOmL flask  w as charged  w ith  m eth y ltrip h en y lp h o sp h o n iu m  b ro m id e  (3 .70g , 
10 .36m m ol), p rev io u sly  d ried  in vacuo at 60°C . D ry  T H F  (lO m L ) w as ad d ed  an d  the 
su sp en sio n  w as co o led  to  -1 0 ° C , w ith  stirring , u n d er N 2. P o ta ss iu m  terr-b u to x id e  
(9 .8 m L  o f  a  1.0M  so lu tio n  in  dry  T H F , 9 .8m m ol) w as added , an d  the  yellow  su sp en sio n  
w as a llo w ed  to  reach  room  tem peratu re . A fte r s tirring  fo r a  fu rth e r 10 m in  the 
su sp en sio n  w as co o led  to  -1 0 ° C  once m ore, and  a  so lu tion  o f  the  c rude  aldehyde (2 .6g) 
in d ry  T H F  (5m L ) w as added . T he  co lo u r d arkened  to  deep  o ran g e  a lm o st im m ed ia te ly , 
and  the  m ix tu re  w as a llo w ed  to  w arm  to  room  tem peratu re . S tirrin g  w as co n tin u ed  fo r a 
fu rth e r 1 h  an d  then  th e  so lv en t w as rem oved  by  ev ap o ra tio n  in vacuo g iv in g  a  b ro w n  
oil. P u rifica tio n  by co lu m n  ch ro m ato g rap h y  (ethyl ace ta te /p en tan e  1:3) gave p u re  2 0  as 
a w axy  so lid  (2 .23g , 4 .2 8 m m o l, 75%  from  18.
‘H  N M R  (C D C I3, 270M H z): S 3.21 (1 H , dd, 7  =  9 .3  H z, 9 .2  H z, C -4 -H ), 3 .37  (3 H , s, 
O C H 3), 3 .5 0  (1 H , d d  7  =  9 .7  H z, 3 .2  H z, C -2-H ), 3 .79 , 3 .80  ( 6  H , 2  s, 2 x A rO C H 3),
3 .9 6  (1 H , dd , 7  =  9 .5  H z, 9 .2  H z, C -3-H ), 4 .0 2  (1 H , dd , 7  =  9 .3  H z, 6 .8  H z , C -5 -H ), 
4 .5 1 -4 .9 0  (6  H , m , 3 x A1 CH2O A B  system s), 4 .58  (1 H , d, 7  =  3 .2  H z, C - l-H ) , 5 .26  (1 
H , b r  d , 7  =  10.1 H z, C -7-H , c is ,, 5 .4 0 (1  H , b r d , 7  =  17.2 H z, C -7 -H , trans), 5 .88  (1H , 
d d d , 7 =  17.2 H z, 10.1 H z, 6 .8  H z, C -6 -H ), 6 .8 3 -7 .3 6  (13 H , m , a ro m atic  C H ).
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I3C  N M R  (CDC13, 67 .8  M H z): <555.11, 55 .25  (2  q, O C H 3), 71.41 (d , C H ), 73 .3 8 , 74 .75 , 
75 .51  (3 t, A rC H jO ), 79 .87 , 81 .44 , 81 .95  (3 d, C H ), 98 .08  (d , C - l ) ,  113.75, 113.80 (2 d, 
2 x C -3  an d  C -5  o f  P M B  rings), 118.01 (t, C -7 ), 127.84, 128.05, 128 .41 , 129.56, 129.59 
(5 d , a ro m atic  C H ), 130.42, 131.07 (2  s, 2 x C - l  o f  P M B  rin g s), 135.32 (d, C -6 ), 138.24 
(s, C - l  o f  benzy l ring), 159.18, 159.26 (2 s, 2 x C -4  o f  PM B  rings).
M S: m/z (+ ve ion  F A B , rel in tensity) 519 [ (M -H )+ , 2 .0% )], 121 [(C H 2C 6H 4 0 C H 3)+, 
1 0 0 %  ], 91 [ (C 7H 7)+ 2 0 % ];
M S: m/z ( - v e  ion F A B , rel in tensity ) 673 [ (M  +  N B A )- , 25%  ], 399  [ (M -
C H 2C 6H 4O C H 3) - , 100% ].
[cc ]d 23 = - 2 3  (c = 1 ,C H C 1 3)
A nal, ca lcd . fo r C 3iH 360 7 (520 .62) C , 71 .52 ; H , 6 .97  F ound : C , 71 .5 ; H , 7 .07. 
Zirconium-Mediated Ring Contraction178
Z irco n o cen e  d ich lo rid e  (672m g, 2 .30m m ol) w as p laced  in to  a  d ry  lOOmL fla sk  u n d er 
N 2, fo llo w ed  by  dry  T H F  (lO m L ). T he  su spension  w as co o led  to  -7 8 ° C  an d  n- 
b u ty llith iu m  (1 .8 4 m L  o f  a  2 .5M  so lu tion  in  hexane, 4 .6 0 m m o l) w as added . T h e  m ix tu re  
w as s tirred  at -7 8 ° C  fo r 1 h and  then  a  so lu tion  o f  the  vinyl p y ran o sid e  20 (l.OOg, 
1 .92m m ol) in  d ry  T H F  (8 m L ) w as added. T h e  c lea r yellow  so lu tion  w as a llo w ed  to  
reach  ro o m  tem p era tu re  and  stirring  w as co n tin u ed  fo r 3 h , d u rin g  w h ich  tim e  it 
g rad u ally  d ark en ed  to  red d ish  orange. T he  so lu tio n  w as co o led  to  0°C  and  a  so lu tio n  o f  
b o ro n  triflu o rid e  e th era te  (0 .45m L , 3 .7m m ol) in  dry  T H F  (5m L ) w as added . S tirrin g  w as 
co n tin u ed  a t ro o m  tem p era tu re , and  T L C  (d ich lo ro m eth an e/e th y l aceta te  10:1) show ed  
co n v e rs io n  o f  s ta rtin g  m ateria l (Rf 0.72) to  a  m a jo r p ro d u c t (Rf 0.56 ) w ith in  30m in . 
A fte r 4 5 m in , T L C  sh o w ed  th a t PM B  groups w ere  b e in g  lost. 1M HC1 (50m L ) w as 
ad d ed  an d  th e  m ix tu re  ex trac ted  w ith  d ich lo ro m eth an e  (2 x  50m L ). T h e  o rgan ic  ex trac ts  
w ere  co m b in ed , w ash ed  w ith  b rin e  (lOOmL), d ried  (MgSC>4) and  ev ap o ra ted  in  vacuo 
g iv in g  a  yellow  o il, w h ich  w as p u rified  by  co lu m n  ch ro m ato g rap h y  
(d ich lo ro m eth an e /ace to n e  30 :1) to  g ive the m ajo r d ias te reo iso m er 21b (433m g, 
0 .8 8 3 m m o l, 4 6 % ) as a  w axy  so lid . A  sm all am o u n t o f  the  m in o r d ia s te reo iso m er 21a 
w as a lso  iso la ted  (~ 30m g, 0 .06m m ol, 3% ).
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(1/?, 2 5 ,3 5 ,4R, 55)-3-Benzyloxy-4-hydroxy-l,2-di-/?-methoxybenzyIoxy-5- 
vinylcyclopentane (Major Diastereoisomer) (21b)
Rf= 0 .3 2  (d ich lo ro m eth an e/ace to n e  30:1)
!H  N M R (C D C 13, 400M H z): S 1.99 (1 H , d, /  =  4 .2 2  H z, D 20  ex , C -4 -O H ), 2 .86  (1 H , 
ddd , J =  7 .8  H z, 7 .8  H z, 6 .2  H z, C -5-H ), 3 .77 , 3 .78  (6 H , 2s, 2 x O C H 3), 3 .77  (1 H , 
o b scu red  by  O C H 3, C -3-H ), 3.93 - 4.01 (2 H , m , C - l -H  an d  C -2 -H ), 4.11 (1 H , m , D 20  
ex  g ives dd , J  =  6 .0  H z, 3.1 H z, C -4-H ), 4 .45  - 4 .65  (6  H , m , 3 x A rC / /20  A B  system s),
5 .23 (1 H , b r d, J =  17.2 H z, = C H 2, trans), 5 .25 ((1 H , b r  d , J =  10.6 H z, = C H 2, cis),
5.91 (1 H , ddd , J =  17.2 H z, 10.8 H z, 8 .0  H z, C H = ), 6 .83 - 6 .87  (4 H , m , C ^ O M e ) ,
7 .2 0  - 7 .25  (4  H , m , C ^ O M e ) ,  7 .28 - 7 .35  (5 H , m , C JI5).
13C  N M R  (CDC13, 67.8  M H z): 5  50 .96  (d, C -5), 55 .20  (q, 2 x O C H 3), 7 1 .57  (t, 
O C H 2A r), 7 1 .6 0  (t, 2 x O C H 2A r), 75 .36 , 84 .49 , 87 .17 , 87.91 (4 d, C - l ,  C -2 , C -3 , C -4), 
113.67, 113.72 (2 d, C -3 and  C-5 o f  PM B  rings), 118.76 (t, = C H 2), 127.65, 127.73, 
128.33, 129.40, 129.51 (5 d, arom atic  C H ), 130.13, 130.36 (2 s, 2 x C - l  o f  PM B  rings), 
134.69 (d, C H =), 138.06 (s, C - l  o f  benzyl ring), 159 21, 159.13 (2  s, C -4  o f  PM B  
rings).
M S: m/z (+ ve ion F A B , rel in tensity ) 489  [ (M -H )+ , 1.2% )], 369 [ ( M -  
C H 2C 6H 4 0 C H 3)+, 6 .0% ), 121 [ (C H 2C 6H 4O C H 3)+, 100% ];
M S: m/z ( - v e  ion F A B , rel in tensity ) 643 [ (M  +  N B A )" , 100%  ]
[a h  = +9 (c=  1 ,C H C 13)
A nal. C alcd . fo r C 30H 34O 6: C , 73 .45; H , 6 .99  F ound: C , 73 .2 ; H , 7 .05.
(1R, 2 5 ,3 5 ,4 5 ,5R)-3-Benzyloxy-4-hydroxy-l,2-di-p-methoxybenzyIoxy-5- 
vinylcyclopentane (Minor Diastereoisomer) (21a)
Rf= 0 .36  (d ich lo ro m eth an e /ace to n e  30:1)
M p: 83 -8 5 °C  (from  ethano l)
‘H  N M R  (CDC13, 4 0 0 M H z): <52.53 (1 H , d , 7 =  8.3 H z, D 20  ex , C -4 -O H ), 2 .71 (1 H , 
d d d , J =  8 .3  H z, 7 .8  H z, 7 .8  H z, C -5-H ), 3 .66  (1 H , d d  J =  7 .8  H z, 4 .4  H z , C - l-H ) ,  3 .79 ,
3 .8 0  ( 6  H , 2 s, 2 x O C H 3), 3 .79  - 3 .87  (2  H , m , p artly  o b scu red  b y  O C H 3, C -3 -H  an d  C - 
4 -H ), 3 .9 4  (1 H , dd , J  =  4 .3  H z, 2 .44  H z, C -2-H ), 4 .43  - 4 .6 9  ( 6  H , m , 3 x A tCH20  A B  
system s), 5 .1 6  (1 H , b r  d, J  =  10.3 H z, = C H 2, cis), 5 .23  (1 H , b r  d, J = 17.1, = C H 2, 
trans), 5 .8 4  (1 H , ddd , J =  17.1 H z, 10.3 H z, 7 .8  H z, C H = ), 6 .85  - 6 .89  (4  H , m , 
C^HiOMe), 7.31 - 7 .37  (4  H , m , C ^ O M e ) ,  7.31 - 7 .37  (5 H , m , C ^ s ) .
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13C  N M R  (C D C I3, 67 .8  M H z): <5 5 3 .7 4  (d, C -5), 5 5 .1 9  (q, 2 x  O C H 3), 71 .4 5 , 71 .62 , 
7 1 .7 5  (3 t, O C H 2A r), 7 3 .7 9 , 81 .75 , 85 .21 , 86 .13  (4  d, C - l ,  C -2 , C -3 , C -4), 113.67,
113.78 (2  d, C -3 an d  C -5  o f  P M B  rings), 117.12 (t, = C H 2), 127.79, 127.89, 128.44,
129 .35 , 129.38 (5  d, a ro m atic  C H ), 129.93, 130.24 (2  s, 2 x C - l  o f  P M B  rings), 137.59 
(s, C - l  o f  benzy l ring), 137 .82  (d, C H =), 159 14, 159.29(2  s, C -4  o f  PM B  rings).
M S: m/z (+ve ion F A B , rel in tensity) 48 9  [ (M -H )+ , 1.0% )], 369  [ ( M -  
C H 2C 6H 4 0 C H 3)+, 5 .0% ), 121  [ (C H 2C 6H 4O C H 3)+ , 1 0 0 % ]; 91 [ ( C 7H 7)+, 1 0 %]
[a]D = -2 6  ( c =  1 ,C H C 13)
A nal. C alcd . fo r C 30H 34O 6: C , 73 .45 ; H , 6 .99  F ound: C , 73 .6 ; H , 7 .02 .
(1R, 2S, 3S, 4R, 5R)-3-Benzyloxy-l,2,4-trihydroxy-5-vinylcycIopentane (23)
T h e  alcoho l 21b (175m g, 0 .3 5 7 m m o l) w as d isso lv ed  in  e th an o l (40m L ) and  1M  HC1 
(20m L ) w as added . T h e  so lu tio n  w as re flu x ed  fo r 3 h and  then  the  so lven ts  w ere 
rem o v ed  by ev ap o ra tio n  in vacuo. T he residue w as taken  u p  in  ethyl ace ta te  (50m L ), 
and  w ashed  w ith  sat. N a H C 0 3 and  b rine  (25 m L  o f  each). T h e  co m b in ed  aqueous layers 
w ere  re -ex trac ted  w ith  e thy l ace ta te  (50m L ) and  the co m b in ed  o rgan ic  layers w ere  then  
d ried  (M g S 0 4) and  ev ap o ra ted  in vacuo to  g ive  a  yellow  o il. P u rifica tio n  by  co lu m n  
ch ro m ato g rap h y  (ch lo ro fo rm /m eth an o l 5 :1) gave the  trio l 23 as a  w axy  so lid  (78m g, 
0 .3 1 2 m m o l, 87% ).
M p: 6 4 -66°C  (from  e th er)
[H  N M R  (CDC13, 4 0 0 M H z): <52.55 (1 H , ddd, 7  =  9.3 H z, 7 .8  H z, 7.3 H z, C -5 -H ), 2 .79  
(1 H , b r s, D 20  ex , O H ), 2 .9 2  (1 H , b r s, D 20  ex , O H ), 3 .65 (1 H , d d  J  =  5 .4  H z, 2 .0  H z, 
C -3 -H ), 3 .88 (1 H , b r dd , D 20  ex  g ives dd, J =  7 .3  H z, 5 .4  H z, C -2 -H ), 3 .95 - 4 .0 0  (2 H , 
b r  m , sharpens on D 20  ex , C - l -H  and  C -4-H ), 4 .1 0  (1 H , b r  s, D 20  ex , O H ), 4 .54 , 4 .58  
(2 H , A B , 7ab = 11-7 H z , OCH2C6H5 ), 5 .20  (1H , dd, J = 17.1 H z, 1.6 H z, = C H 2, trans),
5.23 (1 H , dd, 7 =  10.3 H z, 1.6 H z, = C H 2, cis), 5 .82  (1 H , ddd , 7 =  17.1 H z, 10.3 H z, 7 .8 
H z, C H = ), 7 .22  - 7 .32  (5 H , m , CeHs).
13C  N M R  (C D C I3, 100.4 M H z): 5 5 1 .4 7  (d, C -5 ), 7 1 .8 4  (t, O C H 2C 6H 5), 74 .7 3 , 76 .67 ,
81 .4 6 , 89 .09  (4 d, C - l ,  C -2 , C -3 , C -4), 119.56 (t, = C H 2), 127.86, 127.91, 128.48 (3 d, 
a rom atic  C H ), 133.77 (d , C H = ), 137.79 (s, C - l  o f  ben zy l ring)
M S: m/z (+ ve ion F A B , re l in tensity ) 501 [ (2M  +  H )+, 2 .0%  ], 249  [ (M -H )+  , 5 .0% )], 
149 (30% ), 91 [ (C 7H 7)+, 100% ]
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M S : m/z ( - v e  ion F A B , rel in tensity) 403 [ (M  +  N B A )" , 100%  ], 249  [ (M -H )"  , 
50% )], 149 (50% ).
[« ] d =  +53 (c = 1 ,C H C 1 3)
A nal. C alcd . fo r C i4H i80 4: C , 67 .18; H , 7 .25 F ound: C , 66.9; H , 7 .44.
(LR, 2R, 3 S , 4R, 5 S )-3 -B e n zy Io x y -l,2 ,4 - tr is (d ib e n z y Io x y p h o sp h o ry Io x y )-5 -  
v in y lc y c lo p e n ta n e  (24)
T o  a  so lu tio n  o f  b is(benzyloxy)-A f,A f-diisopropylam inophosphine (670m g, 1 .94m m ol) in 
dry  d ich lo ro m eth an e  (2m L ) w as added  1 /f-te trazo le  (200m g, 2 .8 5 m m o l). T h e  m ix tu re  
w as s tirred  at ro o m  tem p era tu re  fo r 10 m in  and  then  the  trio l 23  (80m g, 0 .3 2 0 m m o l) 
w as added . T h e  m ix tu re  w as stirred  fo r a  fu rth e r 1 h, afte r w h ich  a  90  M H z 31P  N M R  
sp ec tru m  sh o w ed  signals aro u n d  139ppm  (a s ing le t and  an A B  q u arte t w ith  /  = 6 .7  H z) 
co rresp o n d in g  to  th e  trisp h o sp h ite  triester. T he  m ix tu re  w as co o led  to  -7 8 ° C  an d  m- 
C P B A  (517m g, 3 .00m m ol) w as added. T he  m ix tu re  w as w arm ed  to  ro o m  tem pera tu re , 
w ith  stirring , and  then  d ilu ted  w ith  ethyl acetate  (50m L ). T h e  so lu tio n  w as w ash ed  w ith  
10% so d iu m  su lp h ite  so lu tion , 1M HC1, sat. N a H C 0 3 and  b rin e  (5 0 m L  o f  each ), d ried  
(M g S 0 4) and  ev ap o ra ted  in vacuo to  g ive  an oil. P u rifica tio n  by  co lu m n
ch ro m ato g rap h y  (ch lo ro fo rm /ace to n e  10:1) gave the trisp h o sp h a te  trie s te r 2 4  as a
co lo u rle ss  o il (271m g, 0 .2 6 3 m m o l, 82% ).
lH N M R  (CDC13, 400M H z): 5 3 .0 2  (1 H , m , C -5-H ), 4 .2 0  (1 H , b r  s, C -3 -H ), 4 .5 0  (2  H , 
A B , Jab = 11.2 H z, O C /72C 6H 5), 4 .68  (1 H , b r dd, J = 7 .8  H z, 4 .9  H z, C -4 -H ), 4 .8 7  -
5 .08  (14  H , m , 6  x OCH2C6H5, C - l -H  and  C -2-H ), 5 .18 (1 H , d, J = 10.3 H z, 1.5 H z, 
=CH2, cis), 5 .26  (1 H , d, J =  17.1 H z, 1.5 H z, =CH2, trans), 5 .86  (1 H , ddd , /  =  17.1 
H z, 10.3 H z, 8.3 H z, C H = ), 7 .17  - 7 .33 (35 H , m , 7 x C 6H 5)
13C  N M R  (CDC13, 100.4 M H z): 5 5 0 .8 5  (d, C -5), 69 .24 , 69 .37 , 69 .48 , 69 .57 , 7 1 .9 6  (5 t, 
7 x O C H 2C 6H 5), 81 .18 , 84 .05 , 85.57, 86.23 (4 d, C - l ,  C -2 , C -3 , C -4 ), 120.72 (t, = C H 2), 
127.43, 127.52, 127.74, 127.89, 127.98, 128.13, 128.18, 128.29, 128.46 128.86 (10  d, 
a rom atic  C H ), 131.38 (d, C H =), 135.40, 135.48, 135.53, 135.59, 135.66, 135.75, 137.29 
(7 s, 7 x C - l  o f  ben zy l ring)
3IP  N M R  (CDC13, 161.7 M H z): 5 - 1 .9 7 ,  -2 .1 2 ,  - 2 .3 4
M S: m/z (+ v e  io n  F A B , re l in tensity ) 1031 [ (M  +  H )+ , 2 .5% )], 149 (20% ), 91 [
(C 7H 7)+, 100% ]
M S: m/z ( - v e  ion  F A B , re l in tensity ) 938(14), 277  [ (C 6H 5 0 )2P 0 2‘ , 100%  ]
[ « ] D26 =  + 3 .5  (c  =  1 ,C H C 13)
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A nal. C alcd . fo r C 56H 57O 13P 3 C , 65 .24; H , 5.57 Found: C , 65 .0 ; H , 5 .60.
(1/?, 2R, 3S, 4R, 5S)-3-Hydroxy-l,2,4-trisphospho-5-vinylcyclopentane (22)
T h e  trisp h o sp h a te  tries te r 24 (80m g, 77.6jUmol) w as d ep ro tec ted  as d esc rib ed  fo r 
co m p o u n d  15. P u rifica tio n  by  ion -exchange  ch ro m ato g rap h y  on  Q  S ep h aro se  F ast F low  
R esin , as b e fo re  gave  the  g lassy  trie th y lam m o n iu m  salt o f  22, w h ich  e lu ted  b e tw een  300  
m M  an d  4 0 0  m M  T E A B . Y ie ld  45jUmol, 58% )
‘H  N M R  (D 2O , 4 0 0  M H z, p H  3.2): S 2 .76  (1 H , ddd , J =  8 .9  H z. 7 .9  H z , 7 .9  H z, C -5 - 
H ), 3 .98  (1 H , dd , J  =  3 .7  H z, 3 .7 H z, C -3-H ), 4 .1 4  - 4.21 (2  H , m , C -2 -H , C -4 -H ), 4 .37  
(1 H , ddd , J  =  8 .9  H z, 8 .9  H z, 5 .2  H z, C - l-H ) , 5 .07  (1 H , b r  d, J = 10.4 H z, =CH2, cis), 
5 .1 2 (1  H , b r  d , 7  =  17.4 H z, = C H 2, trans), 5 .7 5 (1  H , d d d , / =  17.4 H z, 10.4 H z, 7 .9  H z, 
CH=)
31P  N M R  (D 20 ,  161.7 M H z, p H  3.2 , ’H -coup led ) S 1.62 (1 P , d , / Hp =  9 .0  H z), 1.86 (1 
P , d, JHp =  8 .8  H z ), 2 .20  (1 P , d , JHp =  9 .0  H z)
M S: m/z (+ ve ion F A B , rel in tensity ) 102 [ (C 2H 5)3N H +, 100%  ]
M S: m/z ( - v e  ion  F A B , re l in tensity ) 798 [ 2 M \ 10% ], 399  [ M ', 100%  ]
[cc]d =  - 8 , [a ]436 =  - 2 8  (c =  0 .36 , T E A B  bu ffer p H  7.8) ca lcd  fo r the  free  ac id  
M S: m/z 398 .963  (M ‘) ca lcd  fo r C7H 14O 13P3', 398.965.
Attempted oxidative cleavage of vinyl group
T h e  a ttem p ted  o x id a tiv e  c leavage  o f  v in y lcyclopen tane 24 acco rd in g  to  a  rep o rted  
p ro c e d u re 184 gave on ly  a  sm all am oun t o f  25 iso la ted  as an oil an d  id en tified  as (1/?, 2R, 
35, 4  R, 5 5 )-3 -B en zy lo x y -1,2 ,4 -tris(d ib en zy lp h o sp h o ry lo x y )-5 -( 1,2 -d ihydroxyethy l)-
cy c lo p en tan e . N M R  d a ta  fo r 25 are g iven  below .
*H N M R  (C D C I3, 270M H z): S 2 .57  (1 H , b r  t, C -5 -H ), 3 .58  (1 H , dd, J =  11.5 H z, 6 .6  
H z, C -7 -H ), 3 .7 4 -3 .8 6  (2 H , m , C -6 -H  and  C -7-H ), 4 .13  (1 H , b r  s, C -3 -H ), 4 .37 , 4 .43  (2 
H , A B , 7ab =  11.7 H z, O C //2C 6H 5), 4 .82  - 5 .05 (15 H , m , 6  x OCH2C6U5, C - l-H , C -2 -H  
an d  C -4 -H ), 7 .1 6  - 7 .32  (35 H , m , 7 x C 6H 5)
13C  N M R  (C D C I3, 100.4 M H z): 5 5 0 .1 0  (d, C -5), 6 4 .32  (t, C -l), 68 .85  (d, C -6 ), 69 .37 ,
69 .4 7 , 69 .77 , 69 .95 , 7 0 .2 4  (5 t, 6  x P O C H 2C 6H 5), 71 .65  (t, O C H 2C 6H 5), 79 .9 7 , 83 .16 , 
86 .83  (3 d, C - l ,  C -2 , C -4), 84 .30  (d, C -3), 127.67, 127.80, 127.85, 127.91, 128.00,
128.03, 128.07, 128.13, 128.31, 128.51, 128.69, 128.78, 128.98, 129.22, 129.31 (15 d, 
C 6H 5), 135.20, 135.28, 135.40, 135.46, 135.53, 135.61 137 .14  (7 s, 7 x C - l  o f  benzy l 
rings).
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31P  N M R  (C D C I3, 109.4 M H z): 5 - 1 .7 5 ,  - 0 .7 7 ,  0 .52
M S : m/z (+ ve ion FA B , re l in tensity ) 1065 [ (M  +  H )+ , 50% )], 281(8 0 % ), 91 [ (C 7H 7)+, 
100%]
M S: m/z ( - v e  ion  F A B , rel in tensity ) 973 [M -C 7H 7]‘, 85% ], 277  [ (C 6H 50 ) 2P 0 2' ,100%  ]
8.5 Conformationally-Restricted Analogue
l ,3,5-O-Methylidene-/fiy0-inositol [ = myo-inositol orthoformate] (27)130
1 9Q
T h is  co m p o u n d  w as syn thesised  accord ing  to  the im proved  p ro ced u re  o f  B au d in  et a l 
rayo-Inosito l (50 .0g , 0 .2 7 8 m o l) and  to lu en e-p -su lp h o n ic  ac id  (13 .8g , 0 .0 7 3 m o l) w ere 
su sp en d ed  in dry  D M F  (500m L ). T rie thy l o rth o fo rm ate  (83m L , 0 .5 0 m o l) w as added  
d ro p w ise  u n d er N 2 at 100°C. T he m ix tu re  w as stirred  at 100°C  fo r 4  h , a fte r w h ich  the 
reac tion  w as ju d g e d  to  be  com ple te  by T L C  (aceton itrile , p ro d u c t a t R /0 .4 4 ) . D M F  w as 
d is tilled  o ff  u n d e r reduced  p ressu re  at 50°C . T he  resid u e  w as trea ted  w ith  10% so d iu m  
hydro g en carb o n ate  so lu tion  (lOOmL), stirred  fo r 15m in at rt, d ilu ted  w ith  w a te r (1L), 
an d  ex trac ted  w ith  ch lo ro fo rm  (3 x 250m L ). T h e  aqueous p h ase  w as ev ap o ra ted  to  
d ryness u n d er red u ced  p ressu re  at 40°C , and  the resid u e  w as th en  s tirred  w ith  m eth an o l 
(2L ) at 50°C . T h e  su spension  w as filte red  and  ev ap o ra ted  to  g ive  a  s ticky  o ff-w h ite  
so lid .(~ 70g). T h is  w as d isso lv ed  in the m in im u m  am o u n t o f  w ater, and  p u rified  by  flash  
ch ro m ato g rap h y  (aceton itrile ) to  g ive 27 (40 .5g , 0 .213m ol, 77% )
M p: 297-3 0 0 °C  (from  m eth an o l/e th y l aceta te) (lit . 130 300 -302°C ).
*H N M R  (d6-D M S O , 270M H z): 8 3.95 (2 H , dd , J  = 3.0  H z, 1.7 H z, C - l-H , C -3-H ),
3 .99  (1 H , b r  s, C -2-H ), 4 .0 6  (1 H , m , C -5-H ), 4 .27  (2 H , b r s, D 20  ex  g ives dd, J  =  3.8 
H z, 3.8 H z, C -4-H , C -6 -H ), 5 .32  (1H , b r s, D 20  ex , C -2 -O H ), 5 .44  (1H , d, J  =1.1 H z, 
C O 3H ), 5 .47  (2H , b r  s, D 20  ex , C -4-O H , C -6 -O H ).
4,6-Di-0 -/7-methoxybenzyl-l,3,5-0 -methylidene-/wyo-inositol (28)
T o  a  so lu tion  o f  m yo-inosito l o rtho fo rm ate  27 (15 .0g , 7 8 m m o l) in  d ry  D M F  (300m L ) at 
0 °C  w as added  so d iu m  hydride  (7 .2g  o f  a  60%  d isp ers io n  in  o il, 180m m ol). T h e  m ix tu re  
w as s tirred  fo r 20  m in  at 0 °C  and  then  p -m eth o x y b en zy l ch lo rid e  (22 .5m L , 166m m ol) 
w as added . T h e  m ix tu re  w as stirred  fo r a  fu rth e r 2h  a t rt, a fte r w h ich  T L C  
(d ich lo ro m eth an e/e th y l aceta te  2:1) show ed  a m ajo r p ro d u c t a t Rf 0 .4 9  and  m in o r 
p ro d u c ts  (m ono- and  tri-O -p -m eth o x y b en zy la ted  m ateria l) at Rf 0 .2 2  an d  0 .64 . W a te r 
(lO m L ) w as added  ca refu lly  to  quench  the  reaction . S o lven ts  w ere  ev ap o ra ted  in vacuo 
an d  the  re sid u e  p artitio n ed  be tw een  w ate r (200m L ) and  d ich lo ro m eth an e  (400m L ). T h e
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o rg an ic  layer w as w ash ed  w ith  b rine  (200m L ), d ried  (M g S 0 4), and  ev ap o ra ted  to  g ive 
an  o il w h ich  w as p u rified  by flash  ch ro m ato g rap h y  (d ich lo ro m eth an e/e th y l ace ta te  5:1) 
g iv ing , in  o rd e r o f  e lu tion ; the tri-O -p -m eth o x y b en zy la ted  ether, d i-O-p- 
m eth o x y b en zy la ted  m ateria l, and  finally , m o n o -su b stitu ted  p roduc ts . R ecry sta llisa tio n  
o f  the seco n d  frac tio n  from  ethy l aceta te /hexane gave 28 (13 .5g , 3 1 .4m m ol, 40%  yield). 
M p: 120 - 121 °C  (from  ethy l aceta te /hexane).
‘H  N M R  (CDC13, 4 0 0  M H z) 8  3 .26  (1 H  d, /  =  11.3 H z , D 20  ex , C -2 -O H ), 3 .79  (6  H , 
s, 2 x C H 2C 6H 4 0 CH3), 4 .1 6  (1 H , b r d, J =  11.2 H z, D 20  ex g ives b r  s, C -2 -H ), 4 .1 8 -
4 .2 0  (2  H , m , C - l -H  and  C -3-H ) 4 .3 2  (2 H , dd, J =  3 .4  H z, 3 .4  H z, C -4 -H  and  C -6 -H ), 
4 .4 0  (1 H , m , C -5 -H ), 4 .48 , 4 .56  (4 H , A B , 7ab =  11-0 H z, 2 x C / / 2C 6H 4 0 C H 3) 5 .4 6  (1 
H , d, /  =  0 .9  H z, 0 3C H ), 6.81 (4 H , d, J =  8.9 H z, 2 x C H 2C 6^ 4O C H 3), 7 .17  (4  H , d, J 
=  8 .6  H z , 2  x C H 2C 6t f 4O C H 3)
13C  N M R  (CDC13, 67 .8  M H z) 5  55 .14  (q, 2 x Q ^ O O T s ) ,  61 .12  (d, inosito l ring  C ), 
67 .7 4  (d , inosito l rin g  C ), 71.21 (t, 2 x C H ^ t U O C H ^ ,  7 2 .9 0  (d, 2 in o sito l rin g  C ), 
73 .38  (d, 2 in o sito l ring  C ), 103.24 (d, 0 3C H ), 113.75 (d, 2 x C H 2C6H 4 0 C H 3), 129.27 
(d, 2 x C H 2C6H 4 0 C H 3), 129.53 (s, 2 x C H 2C6H 4 0 C H 3), 159.29 (s, 2 x C -O C H 3)
M S: m/z (+ ve ion  F A B , rel in tensity ) 431 [(M + H )+, 12% ], 309  [ (M -C 7H 6O C H 3)+, 
15% ], 121 [ (C 7H 6O C H 3)+, 100% ].
Anal C a lcd  fo r C 23H 260 8 (430 .45); C , 64 .18; H  6 .09 , F o u n d  C , 63 .9 ; H , 6 .05
2,4,6/3,5-Pentahydroxy-3,5-di-O-/j-methoxybenzyl-2,4,6-0-methyIidene- 
cyclohexanone (29)
D ry  d ich lo ro m eth an e  (40m L ) w as p laced  in to  a  2 5 0 m L  flask  u n d er an a tm o sp h ere  o f  N 2. 
A  so lu tio n  o f  oxaly l ch lo rid e  in dry  d ich lo ro m eth an e  (1 2 .8 m L  o f  a  2M  so lu tio n , 
2 5 .6 m m o l) w as in jec ted , and  the fla sk  w as co o led  to  -6 0 ° C  u sin g  a  ch lo ro fo rm /so lid  
C 0 2 bath . A n hydrous D M S O  (3 .6m L , 51m m ol) d isso lv ed  in  dry  d ich lo ro m eth an e  
(5m L ) w as ad d ed  d ro p w ise  o v er 5 m in  {care! rapid evolution of gas) an d  s tirring  
co n tin u ed  fo r 5m in . A  so lu tion  o f  28 (lO.Og, 2 3 .2m m ol) in d ry  d ich lo ro m eth an e  (30m L ) 
w as ad d ed  d ro p w ise  o v er 5m in  and  s tirring  co n tin u ed  fo r an  ad d itio n al 2 0m in , 
m ain ta in in g  a  tem p era tu re  o f  - 5 5  to  -6 0 ° C . D ry  trie th y lam in e  (15m L ) w as added  
d ro p w ise  o v er 2 m in  an d  th e  reaction  w as stirred  fo r a  fu rth e r 5m in  b efo re  a llo w in g  it to  
w arm  to  rt. T h e  m ix tu re  w as stirred  w ith  w a te r (lOOm L) fo r lO m in, an d  then  
d ich lo ro m eth an e  (200m L ) w as added. T h e  o rgan ic  layer w as separated , an d  the  aq ueous 
layer re -ex trac ted  w ith  a  fu rth e r 2 00m L  o f  d ich lo ro m eth an e . T h e  co m b in ed  o rgan ic
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layers w ere  then  w ash ed  successively  w ith , sat. N aC l, 1% HC1, w ater, 10%NaHCC>3, 
an d  w a te r (2 0 0 m L  o f  each), d ried  (M gS 0 4 ), and  ev ap o ra ted  to  g ive  a  w h ite  so lid  
co n sis tin g  o f  a  m ix tu re  o f  the  k e to n e  29 and  its hydra ted  gem-d io l 29a. T h e  m ix tu re  w as 
d isso lv ed  in  to lu en e  (300m L ) and  re flu x ed  w ith  azeo tro p ic  rem oval o f  w a te r in  a  D ean  
an d  S ta rk  apparatus fo r 3 h. T he  to luene w as rem o v ed  by  ev ap o ra tio n  in vacuo and  the 
re sid u e  rec ry sta llised  fro m  ethyl aceta te /hexane to  g ive  the  k e to n e  29 (9 .14g , 21 .3 m m o l, 
92% ).
M p: 125 - 126°C  (from  ethy l aceta te /hexane).
IR : Vc=o 1 7 6 0 cm '1
‘H  N M R  (CDCI3, 2 7 0  M H z) 5 3 .7 8  (6  H , s, 2 x C 6H 4O C tf3), 4 .3 9  (2  H , dd , J  =  2 .7  H z,
1.0 H z, 2 in o sito l ring  C -H ), 4 .47  - 4 .56  (7 H , m , 3 in o sito l rin g  C -H  an d  2 x 
C /72C 6H 4O C H 3), 5 .63 (1 H , s, O3CH), 6.81 (4 H , d, J = 8 .2 H z, 2 x CaH*O C H 3), 7 .1 6  (4 
H , d, J =  8 .4  H z, 2 x C e /^ O C H s)
13C  N M R  (C D C I3, 67 .8  M H z) 5 5 5 .2 2  (q, 2  x C 6H 4O C H 3), 6 8 .8 8  (d , C -4), 71 .18  (t, 2 x 
C H 2C 6H 4O C H 3), 7 6 .37  (d, 2 inosito l ring  C ), 77 .97  (d, 2 in o sito l rin g  C ), 102.64 (d, 
0 3C H ), 113.85 (d, 2  x C H 2C6H 4O C H 3), 128.90 (s, 2  x C H 2C 6H 4O C H 3), 129.50 (d, 2  x 
C H 2C6H 4O C H 3), 159.47 (s, 2  x C -O C H 3), 199.23 (s, C = 0 ).
M S: m/z (+ ve ion F A B , rel in tensity ) 447  [(M + H 20 + H )+, 0 .3 % ], 429  [(M + H )+, 1 .2% ], 
121  [ (C 7H 6O C H 3)+, 1 0 0 %].
M S: m/z ( - v e  ion F A B , re l in tensity ) 580  [(M + N B A -H ) ', 7 5 % ], 427  [ ( M - H ) \  30% ], 
322  (80), 303 (100), 287  (60% ).
Anal. C a lcd  fo r C 23H 24O 8 (428 .44); C , 64 .48; H  5 .65 , F o u n d  C , 64 .6 ; H , 5 .66
2-C-Hydroxy-4,6-di-(9-/?-methoxybenzyl-l,3,5-0-methylidene-myo-inositol (gem- 
diol, 29a)
T h e  k e to n e  29 (400m g, 0 .92 4 m m o l) w as d isso lv ed  in d ioxan  (4m L ) an d  w a te r (0 .4m L ) 
w as added . T he  so lu tio n  w as left a t ro o m  tem p era tu re  fo r 3 days an d  then  w a te r w as 
ad d ed  d ro p w ise  un til crysta ls began  to  appear. A fte r an o th er day  at ro o m  tem p era tu re  
th e  c rysta ls  w ere  filte red  off, and  w ere found  to  co n sis t o f  p u re  gem-d io l 29a (315m g, 
0 .7 0 6 m m o l, 76% ).
M p: 1 2 9 -1 3 1°C. (from  ethy l aceta te /hexane).
‘H  N M R  (C D C I3, 2 7 0  M H z) 5 3 .7 9  (6 H , s, C6 lUOCH3), 3 .82  (1H , s, D 20  ex , C -2 -O H ),
4 .13  (2H , b r  d, 7 =  1.5 H z, C - l-H  an d  C -3-H ), 4.41 - 4 .6 0  (7 H , m , 2 x CH2A r , C -4 -H , 
C -6 -H  an d  C -5-H ), 4 .97  (1 H , s, D 20  ex , C -2 -O H ), 5 .50  (1 H , s, 0 3C tf)  6 .8 0  (4  H , d , J =
8 .6  H z, C 6t f 4O C H 3), 7 .12  (4  H , d, J =  8 .6  H z, C ^ O C H s ) .
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13C  N M R  (C D C I3, 6 8  M H z) <5 55.25 (q, 2 x C 6H 5O C H 3), 67.51 (d , C -5 ), 7 1 .4 2  (t, 2 x 
C H 2C 6H 4O C H 3), 73 .32  (d, 2 x inosito l ring  C ), 7 3 .56  (d, 2 x in o sito l rin g  C ), 88 .67  (s, 
C (O H )2), 102 .30  (d, O 3C H ), 113.95 (d, C -3 and  C -5 o f  p -m eth o x y p h en y l rings), 128.74 
(s, C - l  o f  p -m eth o x y p h en y l rings), 129.76 (d, C -2  an d  C -6  o f  p -m eth o x y p h en y l rings), 
159.58 (s, C -4  o f  p -m eth o x y p h en y l rings).
M S : m/z (+ v e  ion F A B , rel in tensity ) 4 4 7  [(M + H )+, 2% ], 121 [(C 7H 6O C H 3)+, 100% ] 
Anal. C a lcd  fo r C 23H 26O 9 (446 .45); C , 61 .88; H  5 .87 , F o u n d  C , 61 .8 ; H , 5 .89
2-C-Hydroxy-4,6-di-0 -/7-methoxybenzyI-2-0 -methyl-l,3,5-0 -methylidene-7nyo- 
inositol (hemiketal 29b)
A  so lu tio n  o f  the ketone 29 in m eth an o l/T H F  u n d er N 2 w as k ep t a t ro o m  tem p era tu re  fo r 
on e  w eek . T h e  fo rm ed  crysta ls w ere rem o v ed  by  filtra tio n  an d  fo u n d  to  be  the  h em ik eta l 
29b. (M e th o d  n o t op tim ised ).
M p: 134-146°C . (from  ethy l aceta te /hexane).
lH N M R  (C D C L 3, 2 7 0  M H z) 5 3 .4 8  (3 H , s, O C H 3), 3 .79  (6  H , s, 2 x C 6H 4O C tf3), 4 .2 6 - 
4 .2 9  (2 H , m , C - l-H  and  C -3-H ), 4 .47  (2 H , dd , J =  3 .7  H z, 3 .7 H z, C -4 -H  an d  C -6 -H ), 
4 .4 8 -4 .5 8  (1 H , m , C -5-H ), 4 .54 , 4 .56  (4  H , A B q, JAB =  10.4 H z, 2 x O C H 2A r), 4 .9 2  (1
H , s, D 20  ex , C -2 -O H ), 5 .52  (1 H , s, 0 3CH) 6 .7 6 -6 .8 4  (4 H , m , C effcO C H s), 7 .10 -7 .18  
(4 H , m , C 6/ / 4O C H 3).
13C  N M R  (C D C I3, 100 M H z) 8  48 .28  (s, O C H 3), 55.23 (q, 2 x C 6H 5O C H 3), 67 .72 , 
70 .08 , 7 3 .5 7  (3 d, 5 inosito l ring  C H ), 71 .38  (t, 2 x C H 2C 6H 4O C H 3), 90.91 (s, C -2), 
102.30 (d, O 3C H ), 113.88 (d, C -3 and  C -5 o f  p -m eth o x y p h en y l rings), 128.71 (s, C - l  o f  
p -m e th o x y p h en y l rings), 129.83 (d, C -2  and  C -6  o f  p -m eth o x y p h en y l rings), 159.54 (s, 
C -4  o f  p -m eth o x y p h en y l rings).
M S: m/z (+ v e  ion F A B , re l in tensity ) 461 [(M + H )+, 2% ], 121 [(C 7H 6O C H 3)+, 100% ] 
Anal. C a lcd  fo r C 24H 2 8 0 9 (446 .45); C , 62.6; H  6 .13 , F o u n d  C , 62 .5 ; H , 6 .03
2,4-Di-0-/?-methoxybenzyl-6-methylidene-l,3,5-0-methylidene-cyclohexane- 
I,3,5/2,4-pentol (30)
M eth y ltrip h en y lp h o sp h o n iu m  b ro m id e  (6 .13g , 17 .2m m ol), p rev io u sly  d ried  in vacuo at 
70 °C , w as su sp en d ed  in  dry  T H F  (20m L ) u n d er N 2 at 0°C . P o ta ss iu m  tert-b u to x id e  
(1 6 .3 m L  o f  a  1M  so lu tion  in  T H F, 16 .3m m ol) w as added . T he  re su ltin g  yellow  
su sp en sio n  w as a llo w ed  to  reach  rt and  w as then  stirred  a t rt fo r lO m in. A  so lu tio n  o f  
k e to n e  29 (3 .50g . 8 .1 7 m m o l) in d ry  T H F  (30m L ) w as added . [A t th is stage, a  31P  N M R  
sp ec tru m  o f  a  sam p le  taken  fro m  the  yellow  su spension  sh o w ed  the  p resen ce  o f  an
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o x ap h o sp h e tan e  in te rm ed ia te  (<5p -6 8 .9 p p m ). T h is signal co u ld  still be  o b serv ed  in the 
N M R  sam p le  a fte r several days at 4°C ]. T h e  m ix tu re  w as re flu x ed  fo r 2 h , afte r w hich  
its co lo u r h ad  d ark en ed  to  o range and  T L C  (ethyl ace ta te /h ex an e  1:1) sh o w ed  the 
reac tio n  to  b e  co m p le te , w ith  the p ro d u c t at Rf 0 .52 . T h e  so lv en t w as rem o v ed  by 
ev ap o ra tio n  in vacuo and  the  residue w as taken  up  in  e th e r (lOOm L), the  so lu tion  
w ash ed  w ith  b rin e  (lOOm L), d ried  (MgSCU) and  ev ap o ra ted  to  g ive  a  c lea r b row n  oil. 
P u rifica tio n  b y  flash  ch ro m ato g rap h y  (ethyl ace ta te /h ex an e  1:2) gave the  a lkene 30  as a 
w h ite  c ry s ta llin e  so lid  (3 .17g, 7 .42m m ol, 91% ).
M p: 9 5 -9 7 °C  (fro m  ethano l).
’H  N M R  (CD C13, 2 7 0  M H z) 8  3 .80  (6  H , s, 2 x  O C H 3), 4 .23  (2  H , d d , J  =  3 .6  H z, 3 .6  
H z, C -2 -H , C -4 -H ), 4 .31 (1 H , tt, J =  3 .6  H z, 1.7 H z, C -3-H ), 4 .4 0  (2  H , dd , J = 3 .6  H z,
1.7 H z, C - l -H ,  C -5 -H  ), 4 .54 , 4 .58  (4  H , A B q, J  =  11.8 H z, 2 x O C f tC s R tO M e ) ,  5 .25 
(2  H , s, =CH2), 5 .57  (1 H , s, 0 3C H ), 6 .82 -6 .87  (4  H , m  2 x C ^ O M e ) ,  7 .2 2 -7 .2 6  (4  H , 
m , 2  x C fcf^O M e).
13C  N M R  (CD C13, 67 .8  M H z) 8  55 .19  (q, 2 x O C H 3), 68 .9 4 , 73 .5 5 , 7 4 .2 6  (3 d , 5 x 
inosito l rin g  C ), 71 .05  (t, 0 C H 2C 6H 4 0 M e), 103.73 (d, 0 3C H ), 113.75, 129.43 (2  d, 2  x 
C eH tO M e), 114.27 (t, C = C H 2), 129.82 (s, C =C H 2), 137.15 (s, 2  x C6H 4O M e), 159.32 
(s, 2  x CeFUOM e).
M S: m/z (+ ve  ion  F A B , rel in tensity ) 427  [(M + H )+, 1% ], 305[ (M -C 7H 6O C H 3)+, 6 % ], 
121  [ (C 7H 6O C H 3)+, 100% ].
Anal. C alcd  fo r C 24H 2 6 0 7 (426 .47); C , 67 .59; H  6 .15 , F o u n d  C , 67 .3 ; H , 6 .15.
( l ,3 ,5 /2 ,4 ,6 )-6 -H y d ro x y m e th y l- l ,3 ,5 -O -m e th y I id e n e -2 ,4 -d i-0 - /? -m e th o x y b e n z y l-  
c y c lo h e x a n e - l ,2 ,3 ,4 ,5 -p e n to l (31)
A  d ry  2 5 0 m L  th ree-n eck ed  flask  w as charged  w ith  the  a lk en e  3 0  (6 .0g , 14 .0m m ol), 
p rev io u sly  d ried  a t 60°C  in vacuo. 9 -B B N -H  (60 m L  o f  a  0 .5M  so lu tio n  in  T H F , 
3 0 m m o l) w as added  u n d er an a tm osphere  o f  N 2 at ro o m  tem pera tu re . T h e  tem p era tu re  
w as in creased  to  50°C  and  the  m ix tu re  w as stirred  u n d er N 2 fo r  2h. T h e  m ix tu re  w as 
a llo w ed  to  co o l to  ro o m  tem p era tu re  and  then  fu rth e r co o led  to  0°C  in  an  ice  bath . 
E th an o l (20m L ), 6 M  N aO H  (5m L ) and  30%  H 20 2 (lO m L ) w ere  ad d ed  d ro p w ise  (care! 
exothermic reaction with rapid evolution of gas), and  th en  the tem p era tu re  w as 
in creased  to  50°C . A fte r s tirring  a t 50°C  fo r 30m in , the  m ix tu re  w as co o led  to  ro o m  
tem p era tu re  an d  the  aqueous layer w as sa tu ra ted  w ith  K 2C Q 3. T h e  o rgan ic  layer w as
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rem o v ed , d ried  (M g S 0 4 ) and  ev ap o ra ted  in vacuo to  g ive  a  co lo u rle ss  o il w hich  w as 
p u rified  by  co lu m n  ch ro m ato g rap h y  g iv ing  31 as a  w h ite  so lid  (6 .0 4 g ,1 3 .6 m m o l, 97% ). 
M p: 8 1 -8 2 °C  (from  ethano l o r e thy l aceta te /hexane)
‘H  N M R  (C D C I3, 27 0  M H z) S 1.58 (1 H, t, J  =  5 .9  H z, D 20  ex ., O H ), 2 .97  (1 H , b r  t, J 
=  8.2 H z, C -6 -H ), 3 .80  (6  H , s, 2 x O C H 3), 4 .08  (2  H , dd , J  =  8 .2  H z, 5 .9  H z, D 20  ex 
g ives d , J = 8 .2  H z, C H 2O H ), 4 .27  (2  H , b r  s, C - l-H , C -5 -H ), 4 .3 6  (2  H , b r  s, C -2 -H , C - 
4 -H ), 4 .4 9 ,4 .5 9  (4  H , A B q, J  =  10.8 H z, 2 x C / / 2C 6H 4O M e), 4 .53  (1 H , m , C -3 -H ), 5 .58 
(1 H , s, O ,CH), 6 .7 9 -6 .8 2  (4  H , m , 2 x C ^ O M e ) ,  7 .1 5 -7 .2 6  (4  H , m , 2 x C ^ O M e ) .  
13C  N M R  (CDC13, 67 .8  M H z) <542.88 (d, C -6 ), 55 .17  (q, 2 x O C H 3), 59 .89  (t, C H 2O H ), 
6 8 .5 0  (d, C -3 ), 69 .0 2 , 7 3 .0 6  (2  d, C - l ,2 ,4 ,5), 71.41 (t, 2 x C H 2C 6H 4 0 M e), 103 .84  (d, 
O 3C H ), 113.78 (d , 2 x C sH tO M e), 129.29 (d , 2 x C6H 4O M e), 129.63 (s, 2 x C6H 4O M e), 
159.26 (s, 2  x C 6t l ,O M e ) .
M S: m/z (+ v e  ion  F A B , re l in tensity ) 445  [(M + H )+, 1.2% ], 323 [ (M -C 7H 6O C H 3)+, 
3 .1 % ], 121 [(C 7H 6O C H 3)+, 100% ].
M S: m/z ( - v e  ion F A B , rel in tensity) 597 [(M + N B A )', 100% ], 323 [ (M -C 7 H 6 O C H 3 ) ',  
90% ].
Anal C alcd  fo r C 24H 28O 8 (444 .48); C , 64 .85; H  6 .35 , F o u n d  C , 65 .1 ; H , 6 .47
(l,3,5/2,4,6)-6-Hydroxymethyl -2,4-di-0-/?-methoxybenzyl-cycIohexane-l,2,3,4,5- 
pentol (32)
A lco h o l 31 (2 .32g , 5. 22m m ol) w as d isso lv ed  in m eth an o l (lOOm L) and  hea ted  to  50°C . 
1M HC1 (lO m L ) w as added  and  the m ix tu re  s tirred  a t 5 0°C  fo r 30m in . E x cess 
co n cen tra ted  am m o n ia  so lu tio n  w as added  and  the  m ix tu re  w as a llo w ed  to  cool. S tirrin g  
w as co n tin u ed  at room  tem p era tu re  fo r a fu rth e r 30m in , an d  the  so lv en ts  w ere  rem o v ed  
by  ev ap o ra tio n  in vacuo. T he  resid u e  w as ex trac ted  w ith  ho t e thy l aceta te  ( 2 x lOOmL) 
and  the  co m b in ed  ex trac ts  ev ap o ra ted  in vacuo to  g ive a  w h ite  so lid  w h ich  w as p u rified  
by  flash  ch ro m ato g rap h y  (C H C U /M eO H  100:0 - 50 :50 ) g iv ing  te tro l 32 (1 .98g , 
4 .5 6 m m o l, 87% ).
M p: 136-137°C  (from  ethy l aceta te /hexane)
'H  N M R  (dfi-D M SO , 4 0 0  M H z) S 1.25 (1 H , tt, J  =  10.7 H z, 2.1 H z, C -6 -H ), 3 .09  (2  H , 
dd , J  =  9 .3  H z, 9 .3  H z, C -2 -H , C -4-H ), 3 .20  (1 H , dt, J  =  9 .2  H z, 5 .4  H z, D 20  ex  g ives 
t, J  =  9 .2  H z, C -3 -H ), 3 .29  (2  H , ddd , J = 10.7 H z, 9 .3  H z, 5 .9  H z, D 20  ex  g ives dd , J  =
10.7 H z, 9 .3  H z, C - l-H , C -5 -H ), 3 .69  (2  H , dd , J  =  5 .4  H z, 2.1 H z, D 20  ex  g ives d , J  =  
2.1 H z, C H 2O H ), 3 .73 (6  H , s, 2 x O C H 3), 4 .27  (1 H , t, J  =  5 .4  H z, D 2Q  ex , C H 2O fl) ,
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4.71 (4  H , s, 2 x C H 2C 6H 4O C H 3), 4 .74  (2 H , d, /  =  5 .9  H z, D 20  ex , C - l -0 7 / ,  C-5-O T/),
4 .9 2  (1 H , d, J  =  5 .4  H z, D 20  ex , C -3 -0 T /), 6 .83 -6 .87  (4  H , m , 2 x C ^ O C H , ) ,  7 .29-
7 .3 6  (4  H , m , 2  x C 6T/4O C H 3)
13C  N M R  (de-D M S O , 67.8 M H z) 5  48 .13  (d, C -6 ), 5 5 .4 9  (q, 2  x O C H 3), 5 7 .5 4  (t, 
C H 2O H ), 6 9 .0 0  (d, 2 inosito l rin g  C ), 73 .87  (d, C -3 ), 73 .88  (t, 2 x  C H 2C 6H 4 0 C H 3), 
8 5 .9 0  (d, 2  in o sito l ring  C ), 113.78 (d, 2 x C 6H 4O C H 3), 129.80 (d, 2  x  C 6H 4O C H 3),
132.07 (s, 2 x  C 6H 4 0 C H 3), 158.91 (s, 2 x C 6R 1O C H 3)
M S : m/z (+ v e  ion  F A B , rel in tensity ) 433  [ (M -H )+, 2 .0% ], 313  [ (M -C 7H 6O C H 3)+, 
7 .0 % ], 121 [(C 7H 6O C H 3)+, 100% ].
M S : m/z ( - v e  ion FA B , rel in tensity ) 587 [(M + N B A )', 100% ], 433  [ ( M - H ) \  100% ], 313 
[(M -C 7H 6O C H 3) \  20% ]
Anal. C a lcd  fo r C 23H 30O 8 (434 .49); C , 63 .58; H  6 .96 , F o u n d  C , 63 .4 ; H , 6 .94
DL-(l,3,5/2,4,6)-l,7-O-Benzylidene-6-hydroxymethyl-2,4-di-0-/?-methoxybenzyI- 
cyclohexane-l,2,3,4,5-pentol (33)
T h e  te tro l 32 (2 .00g , 4 .6 0 m m o l) w as d isso lv ed  in d ry  D M F  (lO m L ) in a  lOOmL round  
b o tto m ed  flask . A  ca ta ly tic  am o u n t o f  to lu en e-p -su lp h o n ic  ac id  (50m g) w as added , 
fo llo w ed  by benzald eh y d e  d im ethy l acetal (0 .80m L , 5 .33m m ol). T h e  flask  w as fitted  
w ith  a  2 5 0 m m  air co n d en ser co n n ected  to  a  filte r p u m p  an d  the  so lu tio n  w as s tirred  at 
65 - 7 5°C  u n d er red u ced  p ressu re  fo r lh ,  afte r w hich  T L C  (ethyl aceta te) sh o w ed  the 
reac tio n  to  be com ple te . T he  so lu tion  w as co o led  to  ro o m  tem p era tu re  an d  trie th y lam in e  
( lm L )  added . A fte r stirring  fo r 30m in  at ro o m  tem p era tu re  the  so lv en ts  w ere  rem o v ed  
by  ev ap o ra tio n  in vacuo. T h e  resid u e  w as taken  up  in  d ich lo ro m eth an e  (lOOm L), 
w ash ed  w ith  b rin e  (50m L ), d ried  (MgSCU) and  ev ap o ra ted  in vacuo to  g ive  a  so lid  
w h ich  w as p u rified  by  co lum n  ch rom atography  (ethyl ace ta te /ch lo ro fo rm  1:1) g iv in g  the 
d io l 33 as a  w h ite  so lid  (2 .24g , 4 .29m m ol, 93% ).
M p: 158 - 160°C  (from  ethy l aceta te /hexane).
lU N M R  (C D C I3, 2 7 0  M H z) S 1.92 (1 H , dddd , J  =  11.3 H z, 11.3 H z, 10.1 H z, 4 .4  H z, 
C -6 -H ), 2 .36  (1 H , b r  s, D 20  ex , O H ), 2 .69  (1 H , b r s, D 20  ex , O H ), 3 .22  (1 H , b r dd, 
D 20  ex  g ives dd, J = 11.0 H z, 8 .8  H z, C -3-H ), 3 .33 (1 H , dd , J =  8 .8  H z, 8 .6  H z , C -4- 
H ), 3 .5 0 -3 .6 6  (3 H , m , C - l-H , C -2-H , C -3-H ), 3 .68 (1 H , dd , 7 = 1 1 .1  H z, 11.1 H z, C -7- 
Hax ), 3 .78  (6  H , b r s, 2 x O C H 3), 4 .49  (1 H , dd , 7  =  11.2 H z, 4 .4  H z, C-7-Heq), 4 .61 ,
4 .9 7  (2 H , A B q, 7  =  11.2 H z, C / / 2C 6H 4 0 C H 3), 4 .63 , 4 .9 6  (2 H , A B q, 7  =  11.0 H z,
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C / / 2C 6H 4O C H 3), 5 .53 (1 H , s, CHPh), 6 .84 -6 .92  (4 H , m , C ^ O C H s ) ,  7 .2 4 -7 .3 2  (4  H , 
m , C 6H 4O C H 3), 7 .3 4 -7 .5 4  (5 H , m , Crfs).
13C  N M R  (C D C I3, 67 .8  M H z) S 39.51 (d, C -6 ), 55 .27  (q, 2 x O C H 3), 69 .39  (t, C-l), 
69 .41 , 74 .6 8 , 80 .03 , 82 .03 , 84.33 (5 d, inosito l ring  Q ,  7 4 .62  (t, C H 2C 6H 4O C H 3), 74 .75  
(t, C H 2C 6H 4O C H 3), 101.10 (d, C H Ph), 113.97, 114.09 (2  d, C6H 4O C H 3), 125.98, 
128.27, 128.87, 129.74, 129.87 (5 d, C6H 4O C H 3 and  C6H 5), 130.47, 130.62 (2  s, 
C 6H 4O C H 3), 138.06 (s, C6H 5), 159.42, 159.45 (2  s, C6H 4O C H 3).
M S : m/z (+ ve  ion F A B , rel in tensity ) 523 [(M + H )+, 1.0% ], 522 [ M +, 2 .0% ], 401 [ (M -  
C 7H 6O C H 3)+, 2 .0% ], 121  [(C 7H 6O C H 3)+, 1 0 0 % ].
M S: m/z ( - v e  ion  F A B , rel in tensity ) 1043 [(2 M -H )\ 30% ], 8 28(10% ), 688(10% ), 675 
[(M + N B A )', 100% ], 521 [ ( M - H ) \  100% ], 401 [ (M -C 7H 6O C H 3)-, 40% ]
Anal C a lcd  fo r C 3oH34 0 8 (522 .60); C , 68 .95; H  6 .56 , F o u n d  C , 6 8 .8 ; H , 6 .53.
DL-(l,3,5/2,4,6)-l,3-Di-0-benzyl-5,7-O-benzylidene-6-hydroxymethyl-2,4-di-0-/?- 
methoxybenzyl-cyclohexane-l,2,3,4,5-pentol (34)
T h e  d io l 33 (l.OOg, 1.91 m m ol) w as d isso lv ed  in  d ry  D M F  and  so d iu m  hydride  (250m g 
o f  a  60%  d isp ers io n  in oil, 6 .25m m ol) w as added . T h e  su sp en sio n  w as s tirred  fo r 20m in  
at ro o m  tem p era tu re  and  then  benzyl b ro m id e  (0 .50m L , 4 .6 0 m m o l) w as added , and  
s tirrin g  w as co n tin u ed  fo r 2h , afte r w h ich  T L C  (ethyl ace ta te /h ex an e  1:1) sh o w ed  the 
reac tio n  to  b e  com plete . E xcess N aH  w as carefu lly  d estroyed  by  d ro p w ise  ad d itio n  o f  
w a te r and  th e  so lven ts  w ere  rem o v ed  by ev ap o ra tio n  in vacuo. T h e  resid u e  (w h ich  h ad  a 
very  low  so lu b ility  in e ther) w as taken  u p  in d ich lo ro m eth an e  (50m L ), w ash ed  w ith  
b rin e  (2 x 50m L ), d ried  (MgSCU) and  ev ap o ra ted  in vacuo to  g ive  a  w h ite  so lid  w h ich  
w as w ash ed  w ith  p en tan e  and  then  recry sta llised  from  h o t e th an o l y ie ld ing  34 (1 .26g ,
I.7 9 m m o l, 94% ) as co lo u rle ss  crysta ls.
M p  135 - 137°C  (from  e thano l).
‘H  N M R  (C D C I3, 4 0 0  M H z) 8  1.98 (1 H , dddd , J  =  11.2 H z, 11.2 H z, 10.8 H z, 4 .4  H z, 
C -6 -H ), 3.21 (1 H , dd , J  =  10.8 H z, 9 .3 H z, C - l - H ) ,  3.45 - 3 .73  (5 H , m , C -2 -H , C -3 -H , 
C -4 -H , C -5 -H , C - 7 -H ax), 3 .76  (3 H , s, O C H 3), 3 .78  (3 H , s, O C H 3), 4 .4 2  (1 H , dd , J =
I I .2  H z , 4 .4  H z, C-7-Heq), 4 .51 -4 .9 7  (8 H , m , 4  x CH2Ar), 5 .48  (1 H , s, C H P h ), 6 .77  -
6.81 (4 H , m , C6ff4O C H 3), 7 .2 0  - 7 .5 0  (19 H , m , CJJ^OCH, an d  Cifls).
13C  N M R  (CDC13, 100 M H z) 8 39 .69  (d , C -6 ), 55.21 (q, 2 x O C H 3), 69.31 (t, 
C H C H 2O C H P h ), 74 .9 3 , 75 .2 0 , 75 .62 , 7 6 .0 6  (4  t, O C H 2A r), 7 7 .9 4 , 80 .03 , 82 .77 , 83 .19 , 
8 5 .7 0  (5 d , inosito l ring  C ), 100.95 (d , C H Ph), 113.73, 113 .84  (2 d, C sfttO C H -,),
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125.91, 127.60, 127.78, 127.96, 128.05, 128.18, 128.38, 128.51, 128.77, 129.59, 129.83 
(11 d, C 6H 4O C H 3 and  C6H 5), 130.58, 130.74 (2  s, C6H 4O C H 3), 138.00, 138.04, 138.64 
(3 s, C 6H 5), 159.20, 159.23 (2  s, C e ^ O C H ^ .
M S: m/z (+ ve ion  F A B , rel in tensity ) 703 [(M + H )+, 0 .5 % ], 70 2  [ M +, 0 .7 % ], 611 [ (M -  
C 7H 7)+, 0 .3% ], 581 [(M -C 7H 6O C H 3)+, 3 .5% ], 121 [(C 7H 6O C H 3)+, 100% ], 91 [(C 7H 7)+, 
22%].
M S: m/z ( - v e  ion  F A B , rel in tensity ) 855 [(M + N B A )', 100% ], 611 [ (M -C 7H 7)', 40% ], 
581 [ (M -C 7H 6O C H 3) \  20% ].
Anal. C a lcd  fo r C 44H 460 8 (702 .84); C , 75 .19 ; H  6 .60 , F o u n d  C , 75 .2 ; H , 6 .62
D L -( l ,3 ,5 /2 ,4 ,6 ) - l ,3 -D i-0 -b e n z y l-6 -h y d ro x y m e th y l-2 ,4 -d i-O -/? -m e th o x y b e n z y I-  
c y c lo h e x a n e - l ,2 ,3 ,4 ,5 -p e n to l (35)
C o m p o u n d  3 4  (l.OOg, 1 .42m m ol) w as d isso lv ed  in a  m ix tu re  o f  T H F  (25m L ) and  
m eth an o l (25m L ). 1M HC1 (5m L ) w as added  and  the so lu tio n  w as re flu x ed  fo r 30m in , 
a fte r w h ich  T L C  (ethyl acetate) show ed  th a t no s tarting  m ateria l rem ained . E x cess 
N a H C 0 3 ( lg )  w as added  and  the m ix tu re  w as a llow ed  to  coo l to  rt w ith  s tirring  befo re  
the  so lven ts  w ere rem o v ed  by  evapora tion  in vacuo. T h e  re sid u e  w as taken  up  in 
d ich lo ro m eth an e  (lOOm L), w ashed  w ith  w a te r (50m L ) and  b rine  (50m L ), d ried  
(M g S 0 4) and  ev ap o ra ted  in vacuo to  g ive  a  so lid  w h ich  w as p u rified  by  flash  
ch ro m ato g rap h y  y ie ld ing  the d io l 35  (720m g, 1 .17m m ol, 82% ).
M p  1 1 6 - 1 17.5°C  (from  ethano l).
]H  N M R  (CDC13, 2 7 0  M H z) 8 1.65 (1 H , dddd , J =  9.3 H z, 9 .3  H z, 4 .5  H z, 3 .0  H z, C -6 - 
H ), 2 .27  (1 H , b r  dd, J =  5.1 H z, 5.1 H z, D 20  ex , C -7 -O H ), 2 .77  ( 1 H , d, J = 1.5 H z, 
D 20  ex , C -5 -0 H), 3 .34  - 3.51 (4 H , m , 4  x inosito l ring  H ), 3 .63 (1 H , dd , J =  9 .3  H z,
9.3 H z, inosito l rin g  H ), 3.73 (1 H , b r m , D 20  ex  g ives dd, /  =  11.2 H z, 4 .5  H z, C -7-H ), 
3 .89  (1 H , b r m , D 20  ex  g ives dd, J =  11.2 H z, 3 .0  H z, C -7 -H ), 3 .77 (3 H , s, O C H 3 ),
3 .78  (3 H , s, O C H 3), 4 .59  - 4 .97  (8  H , m , 4  x C H 2A r), 6 .79  - 6 .87  (4 H , m , C 6/ / 4O C H 3), 
7 .18  - 7 .23  (4 H , m , C 6# 4O C H 3), 7 .29  - 7 .38  (10  H , m , 2 x C ^ s ) .
13C  N M R  (C D C I3, 67 .8  M H z) S 4 6 .0 7  (d , C -6 ), 5 5 .2 0  (q, 2  x O C H 3), 60 .22  (t, C-l), 
7 0 .3 7 , 77 .5 2 , 83 .20 , 84 .80 , 85 .95  (5 d, inosito l rin g  C ), 75 .1 0 , 7 5 .2 0 , 7 5 .4 3 , 7 5 .5 7  (4  t, 
C H 2A r), 113.80, 114.03 (2  d, C eftiO C H j), 127.63, 127.84, 127.99, 128.41, 129.37, 
129.53 (6  d , C 6H 5 an d  C6H 4 0 C H 3), 130.49, 130 .60  (2  s, C6H 4O C H 3), 138.14, 138.45 (2 
s, C 6H 5), 159.14, 159.37 (2  s, C eU tO C H j).
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M S : m/z (+ ve ion  F A B , rel in tensity ) 615 [(M + H )+, 0 .5% ], 614  [ M +, 0 .4% ], 523 [ (M -  
C 7H 7)+, 0 .2% ], 493  [ (M -C 7H 6O C H 3)+, 2 .8% ], 121  [(C 7H 6O C H 3)+, 1 0 0 % ], 91 [(C 7H 7)+, 
20%].
M S: m/z ( - v e  ion  F A B , rel in tensity ) 767  [(M + N B A )', 60% ], 613 [ ( M - H ) \  100% ), 493 
[ (M -C 7H 6O C H 3)', 35% ].
Anal C alcd  fo r C 37H 420 8 (614 .74); C , 72 .29 ; H  6 .89 , F o u n d  C , 72 .3 ; H , 6 .8 8 .
C y c lic  P h o s p h o ry la t io n
B enzy loxy-b is(A ,iV -d iisopropy lam ino)phosph ine202 (285m g, 0 .8 4 m m o l) w as p laced  in a 
d ry  ro u n d -b o tto m ed  flask  and  d ich lo ro m eth an e  (5m L ) w as added , fo llo w ed  by  1H- 
te tra zo le  (150m g, 2 .14m m ol). T h e  suspension  w as stirred  fo r lO m in an d  then  co o led  to 
0°C . T h e  d io l 35 (430m g, 0 .7 0 m m o l, p rev io u sly  d ried  in vacuo at 60°C ) w as ad d ed  and 
s tirrin g  w as co n tin u ed  at 0°C  fo r 2h. 31P  N M R  sp ec tro sco p y  now  sh o w ed  signals  a t <5p
125.0 and  130 .4ppm , co rresp o n d in g  to  the  tw o  cyclic  p h o sp h ite  trie s te r invertom ers. 
T h e  m ix tu re  w as co o led  to  -7 8 ° C  and  m -C P B A  (240m g, 1 .4m m ol) w as added . T he  
c lea r so lu tion  w as n o w  allow ed  to  w arm  to ro o m  tem p era tu re  and  then  d ilu ted  w ith  
e thy l aceta te  (50m L ), w ashed  w ith  10% N a2S 0 3, 1MHC1, sa tu ra ted  N a H C 0 3 an d  b rine  
(5 0 m L  o f  each), d ried  (M g S 0 4) and  ev ap o ra ted  in vacuo to  g ive  a  co lo u rle ss  oil. 
P u rifica tio n  by  flash  ch ro m ato g rap h y  (ethyl ace ta te /h ex an e  1:1) gav e  the  tw o  cyclic  
p h o sp h a te  trieste rs  36a, Rf 0 .30  (246m g, 0 .3 2 m m o l) and  36b, Rf 0 .18  (214m g, 
0 .2 8 m m o l) co rresp o n d in g  to  a  to tal y ie ld  o f  0 .6 0 m m o l (8 6 % fro m  35).
DL-(l,3,5/2,4,6)-3,5-Di-0-benzyI-6-hydroxymethyl-2,4-di-O-p-methoxybenzyl- 
cyclohexane-l,2,3,4,5-pentol l,7-(benzylphosphate) (Epimer 36a)
M p: 130 - 132°C  (fro m  ethyl aceta te /hexane).
IR : ( K B r d isk ) Vp=o 1 2 8 7 c m 1
‘H N M R  (CDC13, 270  M H z) 5 2 .1 9 ( 1  H , dddd , /  =  11.3 H z, 11.3 H z, 11.3 H z, 4 .5  H z, 
C -6 -H ), 3 .08 (1 H , dd, J =  11.2 H z, 9 .2  H z, C -5-H ), 3 .40  (1 H , dd , 9 .3 H z, 9 .3  H z, C -3- 
H ), 3 .63  (1 H , dd , J =  9 .4  H z, 9 .4  H z, C -2 -H  o r C -4-H ), 3 .66  (1 H , dd , J =  9 .4  H z, 9 .4  
H z, C -2 -H  o r C -4 -H ), 3 .76  (1 H , dd, J =  11.3 H z, 11.3 H z, C-7-Hax), 3 .768  (3 H , s, 
O C H 3), 3 .773  (3 H , s, O C H 3), 4 .0 4  (1 H , dd , y  =  11.2 H z, 9 .2  H z, C - l-H ) , 4.41 (1 H , 
d dd , J  =  24 .2  H z, 11.4 H z, 4 .5  H z, C-7-Heq), 4 .41 (1 H , d, J = 11.2 H z, p art o f  a  b ro ad  
A B  system , C / / 2A r), 4 .68  - 4 .93  (7 H , m , O C //2A r), 5 .06 , 5.11 (2 H , A B X , Jab  =11 .7
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H z, J Hp =  7 .7  H z, 7 .7  H z, P ( 0 ) 0 C / / 2C 6H 5), 6 .79  - 6 .83  (4 H , m , C 6# 4O C H 3), 7 .1 5  -
7 .3 6  (19  H , m , C ^ O C H ,  an d  C 6H 5).
13C  N M R  (C D C I3, 6 8  M H z) S 40 .28  (d, C -6 ), 5 5 .2 0  (q , 2 x O C H 3), 6 8 .9 3  (t, 
P ( 0 ) 0 C H 2A r), 7 0 .2 6  (t, C -7), 75 .02 , 75 .59 , 76.01 (3 t, 4  x C H 2A r), 76 .2 9 , 81 .2 2 , 82 .30 , 
82 .6 0 , 84 .93  (5  d, inosito l rin g  C ), 113.77, 113.83 (2  d , C 6H 4O C H 3), 127 .58 , 127.65, 
127.97, 128.13, 128.38, 128.56, 128.67, 128.72, 129.50, 129 .76  (10  d, C6H 4O C H 3 and  
C 6H 5), 130 .15 , 130 .24  (2  s, C6H 4O C H 3), 135.44 (s, P ( 0 ) 0 C H 2C 6H 5), 137 .30 , 138.25 (2  
s, C H O C H 2C 6H 5), 159.30 (s, C 6H 4O C H 3).
31P  N M R  (C D C I3, 162 M H z) -7 .4 9  (ddd , 7Hp =  24 .2  H z, 7 .7  H z, 7 .7  H z).
M S: m/z (+ v e  ion  F A B , re l in tensity ) 767  [(M + H )+, 1.2% ], 675  [ (M -C 7H 7)+, 1.2% ], 645 
[ (M -C 7H 6O C H 3)+, 1.4% ], 121 [(C 7H 6O C H 3)+, 100% ], 91 [(C 7H 7)+, 28% ].
M S : m/z ( - v e  ion  F A B , rel in tensity) 919  [(M + N B A )', 80% ], 765  [ ( M - H ) \  30% ), 675 
[ (M -C 7H 7) ',1 0 0 % ], 645 [ (M -C 7H 6O C H 3)', 30% ], 187 [C 7H 70 P 0 3H )', 80% ], 97 
[(H 2P 0 4) \  45% ].
Anal C a lcd  fo r G w H ^O io P  (766 .82); C , 68.92; H  6 .18 , F o u n d  C , 69 .1 ; H , 6 .11.
DL-(l,3,5/2,4,6)-3,5-Di-O-benzyI-6-hydroxymethyI-2,4-di-0-p-methoxybenzyI-
I,2,3,4,5-cycIohexanepentoI l,7-(benzylphosphate) (Epimer 36b)
M p  101 - 102 .5°C  (from  ethano l).
IR  ( K B r d isk ) Vp=o 1 2 6 6 cm '1
*H N M R  (CDC13, 27 0  M H z) 5 2 .1 7  (1 H , dddd , J =  11.2 H z, 11.2 H z, 11.2 H z, 4 .8  H z, 
C -6 -H ), 3 .18  (1 H , dd, J =  11.0 H z, 9 .0  H z, C -5-H ), 3 .44  (1 H , dd, 9 .0  H z, 9 .0  H z , C -3- 
H ), 3.51 (1 H , dd, J =  9.1 H z, 9.1 H z, C -2 -H  o r C -4-H ), 3 .60  (1 H , dd , J  =  9 .0  H z, 9 .0  
H z, C -2 -H  o r C -4 -H ), 3 .76  (3 H , s, O C H 3), 3 .78 (3 H , s, O C H 3), 4 .03  (1 H , d d d , J  =
I I .2  H z, 11.2 H z, 3 .9  H z, C-7-Hax), 4 .32  (1 H , b r dd, J =  11.2 H z, 9 .2  H z, C - l-H ) ,  4 .3 9  
(1 H , ddd , J =  20 .4  H z, 11.2 H z, 4 .7  H z, C-7-Heq), 4 .45  - 4 .9 0  (8  H , m , O C tf 2A r), 5 .08 ,
5 .13  (2 H , A B X , Jar =  11.9 H z, 7Hp =  9 .9  H z, 9 .9  H z, P ( 0 ) 0 C t f 2C 6H 5), 6 .78  - 6 .8 4  (4 
H , m , C 6/ / 4O C H 3), 7 .17  - 7 .38  (19 H , m , C 6^ 4O C H 3 and  C 6H 5).
13C  N M R  (CDC13, 6 8  M H z) 5 4 0 .4 1  (d, C -6 ), 55 .19 , 55 .22  (2 q , 2 x O C H 3), 6 9 .4 7  (t, 
P (0 )O C H 2A r), 7 0 .4 0  (t, C -7), 75 .12 , 75 .59 , 7 6 .06  (3 t, 4  x C H 2A r), 76 .47 , 81 .1 4 , 82 .29 ,
82 .65 , 8 5 .0 4  (5 d, in o sito l ring  C ), 113.65, 113.85 (2 d, C 6H 4 0 C H 3), 127.63, 127.71, 
127.86, 128.17, 128.26, 128.35, 128.62, 128.65, 129.50, 129.72 (10  d, C6H 4 0 C H 3 and  
C 6H 5), 130.18, 130.26 (2  s, C6H 4 0 C H 3), 135.45 (s, P (0 )O C H 2C 6H 5), 137.28, 138 .30  (2  
s, C H O C H 2C 6H 5), 159.22, 159.30 (2 s, C6H 4 0 C H 3).
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31P  N M R  (CDC13> 162 M H z) 6 - 4 .5 6  (dddd, JHp =  20 .3  H z, 9 .9  H z, 9 .9  H z, 3 .9  H z).
M S: m/z (+ v e  ion  F A B , re l in tensity ) 767  [ (M + H )\  2 .0 % ], 675  [ (M -C 7H 7)+, 1.0% ], 645  
[(M -C 7H 6O C H 3)+, 4 .0 % ], 121 [(C7H 6O C H 3)+, 100% ], 91 [(C 7H 7)+, 22% ].
M S: m/z ( - v e  ion  F A B , re l in tensity ) 919 [(M + N B A )', 20% ], 765  [ (M -H ) ',  10% ), 675 
[ (M -C 7H 7)',1 0 0 % ], 645  [ (M -C 7H 6O C H 3) \  12% ], 187 [C 7H 70 P 0 3H ) \  70% ], 97  
[(H 2P 0 4)', 45% ].
Anal C a lcd  fo r C w H ^ O io P  (766 .82); C , 68 .92; H  6 .18 , F o u n d  C , 69 .1 ; H , 6.13.
DL-(l,3,5/2,4,6)-3,5-Di-0-benzyI-6-hydroxymethyl-cyclohexane-l,2,3,4,5-pentol 1,7- 
(benzylphosphate) (Epimer, 37a)
T o  a  so lu tio n  o f  36a (3 00m g, 0 .39m m ol) in  d ich lo ro m eth an e  (lO m L ) w as added  w a te r 
( lm L )  and  2 ,3 -d ich lo ro -5 ,6 -d icy an o -l,4 -b en zo q u in o n e  (D D Q ) (355m g, 1 .56m m ol). T h e  
m ix tu re  w as s tirred  at rt fo r  2.5 h, afte r w hich  T L C  (ethyl ace ta te / h ex an e  2 :1 ) sh o w ed  
th e  reac tion  to  b e  co m p le te . D ich lo ro m eth an e  (60m L ) w as added  and  the  o rg an ic  lay er 
w as w ash ed  w ith  10%  N a 2S 0 3 so lu tion  (3 x 50m L ), sat N a H C 0 3 so lu tio n , an d  b rin e  
(5 0 m L  o f  each), d ried  (M g S 0 4) and ev ap o ra ted  in vacuo to  g ive  a  yellow  o il w h ich  w as 
p u rified  by  co lu m n  ch ro m ato g rap h y  (ethyl ace ta te /p en tan e  3 :2) g iv ing  the  d io l 37a 
(137m g, 0 .2 6 0 m m o l, 66% ).
M p  145-149°C  (fro m  e th y l ace ta te / hexane).
Rf 0 .45  (e thy l a ce ta te / d ich lo ro m eth an e  1:1), /? /0 .31  (e thy l ace ta te / h ex an e  2:1).
IR  ( K B r d isk) vP=0 1280cm ’1
[H  N M R  (CDC13, 4 0 0  M H z): 5 2 .0 7 ( 1  H , dddd , J =  11.2 H z, 10.7 H z, 10.7 H z , 4 .4  H z , 
C -6 -H ), 2 .83  (1 H , d , J  =  1.96 H z, D 20  ex ., C -4 -O H ), 3 .07  (1 H , dd , J  =  10.7 H z, 9 .3  
H z, C -5 -H ), 3 .20  (1 H , dd , J  =  9 .3  H z, 9.3 H z, C -3 -H ), 3 .55 (1 H , d , J  =  2 .9  H z, D 20  ex . 
C -2 -O H ), 3 .63  - 3 .7 0  (2 H , m , C -2-H , C -4-H ), 3.81 (1 H , dd , J = 11.2 H z, 11.2 H z, C -7 - 
Hax), 3 .86  (1 H , dd , J =  10.7 H z, 9 .3 H z, C - l-H ) , 4 .43  (1 H , ddd , J = 24 .4  H z, 11.2 H z ,
4 .4  H z, C-7-Heq), 4 .4 8  - 5 .13  (6  H , 3 x  A B  system s, 3 x C H 2C 6H 5), 7 .25  - 7 .38  (15 H , m , 
3 x CiHs).
13C  N M R  (CDC13, 100.4 M H z): 5 3 9 .6 0  (d, C -6), 69 .15 , 70 .45  ( 2 1, 2 x P O CH2), 7 4 .3 5 , 
7 5 .1 7  (2  t, 2 x  O C tf2C 6H 5), 74 .70 , 75 .8 5 , 76 .6 9 , 80 .90 , 81 .32  (5 d, inosito l rin g  Q ,  
127 .99, 128 .06 , 128 .13 , 128.28, 128.39, 128.52, 128.59, 128.72, 128.85 (9  d , C6H 5), 
135.28 (s, P O C H 2C6H 5), 137.59, 138.17 (2  s, 2  x  O C H 2C 6H 5).
3IP  N M R  (CDC13, 162 M H z) 5 - 7 .2 7  (1 P, ddd , J HP =  24 .2  H z, 8.1 H z, 8.1 H z)
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M S : m/z (+ ve ion  F A B , rel in tensity) 527 [(M + H )+, 22% ], 435  [ (M -C 7H 7)+, 3% ], 391 
(10), 181(6), 91 [(C 7H 7)+, 100% ].
M S : m/z ( - v e  ion  F A B , rel in tensity ) 679 [(M + N B A )', 90% ], 525 [ (M -H ) ',  100% ), 435 
[ (M -C 7H 7) \9 0 % ], 187 [C 7H 70 P 0 3H )', 40% ], 97 [(H 2P 0 4) \  20% ].
Anal C a lcd  fo r C 28H 3i 0 8P (526 .52); C , 63 .87; H  5 .93 , F o u n d  C , 63 .7 ; H , 6 .00
DL-(l,3,5/2,4,6)-3,5-Di-0-benzyl-6-hydroxymethyl-cycIohexane-l,2,3,4,5-pentol 1,7- 
(benzylphosphate) (Epimer 37b)
T h e  p -m eth o x y b en zy l g roups w ere rem oved  fro m  36b (260m g, 0 .3 4 m m o l) u s in g  the 
sam e p ro ced u re  as fo r 36a. P u rifica tio n  by  co lu m n  ch ro m ato g rap h y  (ethyl ace ta te / 
d ich lo ro m eth an e  1:1) gave 37b (125m g, 0 .237m m ol, 70% ).
M p  160 - 162°C  (from  ethy l ace ta te / hexane).
Rf 0 .25  (e thy l ace ta te /d ich lo ro m eth an e  1:1), R /0 .15 (e thyl ace ta te /h ex an e  2:1).
IR : ( K B r d isk) vP=o 1 2 6 3 cm '1
*H N M R  (CDC13, 4 0 0  M H z): 5 2 .1 3  (1 H , dddd , J =  11.2 H z, 10.8 H z, 10.7 H z, 4 .9  H z, 
C -6 -H ), 2 .93 (1 H , d, J =  2 .4  H z, D 20  ex., O H ), 3 .13 (1 H , dd , 7 =  10.7 H z, 9.3 H z, C -5- 
H ), 3 .25 (1 H , dd , 7 =  9.3 H z, 9 .3  H z, C -3-H ), 3 .50  (1 H , b r s, D 20  ex ., O H ), 3 .63 - 3 .69  
(2 H , b r m , C -2 -H  and  C -4-H ), 4 .08  (1 H , ddd, 7 =  11.2 H z, 11.2 H z, 7HP =  4 .4  H z, C -7- 
Hax), 4 .17  (1 H , dd, 7 =  10.8 H z, 10.7 H z, C - l-H ) , 4 .42  (1 H , ddd , 7 =  2 0 .0  H z, 10.7 H z,
4 .9  H z, C-7-Heq), 4.51 - 5 .12  (6  H , AB system s, 3 x CH2C6 H 5), 7 .25  - 7 .4 0  (15 H , m , 3 x 
C 6H 5).
13C  N M R  (C D C I3 , 100.4 M H z): 5 4 0 .1 3  (d, C -6 ), 70 .16 , 7 0 .8 6  (2 t, 2 x P O C H 2 ), 74 .81 , 
7 5 .5 4  (2  t, 2  x O C H 2C 6H 5), 75 .39 , 76 .56 , 77 .13 , 80 .08 , 81 .94  (5 d, in o sito l rin g  C),
128.32, 128.48, 128.55, 128.72, 128.87, 128.90, 129.05 (7 d, C 6H 5), 135.41 (s, 
P O C H 2C6H 5), 137.90, 138.56 (2  s, 2  x O C H 2C6H 5).
31P  N M R  (C D C I3, 162 M H z) 5 - 4 .4 3  ( IP , b r  dddd , 7HP =  20  H z, 8  H z , 8  H z, 4  H z)
M S: m/z (+ve ion  F A B , rel in tensity ) 527 [(M + H )+, 20% ], 435  [ (M -C 7H 7)+, 4 % ], 91 
[(C 7H 7)+, 100% ].
M S: m/z ( - v e  ion  F A B , rel in tensity ) 1051 [(2M -H )', 4 % ], 960 (5 ), 679  [(M + N B A )’, 
40 % ], 525 [ (M -H ) ',  80% ), 435  [ (M -C 7H 7) ',1 0 0 % ], 187 [C 7H 70 P 0 3H ) \  50% ], 97 
[(H 2P 0 4) \  2 2 % ].




T o  a  so lu tion  o f  bis(benzyloxy)-A f,A f-diisopropylam inophosphine (345m g, l.O Om mol) in 
d ry  d ich lo ro m eth an e  (3m L ) w as added  1 /7-tetrazole (140m g, 2 .0 0 m m o l). T h e  m ix tu re  
w as s tirred  at rt fo r 2 0m in  and  then  the diol 37a (130m g, 0 .2 4 7 m m o l) w as added . 
S tirrin g  w as co n tin u ed  fo r 30m in , afte r w h ich  31P  N M R  sh o w ed  signals  a t 5  143 (1 P , s, 
p h o sp h ite  a t C -4 ), 142 (1 P , d, Vpp = 1 .2  H z, p h o sp h ite  trie s te r a t C -2 ), - 7 .9  (1 P , d, 5/p P 
=  1.2 H z, cyc lic  p h o sp h a te  triester). T h e  m ix tu re  w as co o led  to  -7 8 ° C , m -C P B A  
(3 4 5 m g , 2 .0 0 m m o l) w as added , and  the  co o lin g  b a th  w as rem oved . T h e  m ix tu re  w as 
a llo w ed  to  reach  rt and  then  d ilu ted  w ith  ethyl aceta te  (50m L ). T h e  c lea r so lu tio n  w as 
w ash ed  w ith  10%  N a 2SC>3, 1MHC1, sat. N aH CC >3 and  b rin e  (5 0 m L  o f  each) d ried  
(MgSC>4) an d  ev ap o ra ted  in vacuo g iv ing  a  so lid  residue . P u rifica tio n  by  co lu m n  
ch ro m ato g rap h y  (e thy l ace ta te /d ich lo ro m eth an e  1:2) affo rd ed  38a (192m g, O .183m m ol, 
7 4 % ) as a  w h ite  solid .
M p  171 - 172.5°C  (from  ethano l).
'H  N M R  (C D C U , 2 7 0  M H z): 5 2 .2 0  (1 H , dddd , J  =  1 1.2 H z, 11.0 H z, 11.0 H z, 4 .4  H z, 
C -6 -H ), 3.21 (1 H , dd , J  =  11.0 H z, 9 .0  H z, C -5-H ), 3 .5 8 (1  H , dd , J  =  9 .2  H z, 9 .2  H z, 
C -3 -H ), 3 .68  (1 H , dd , J  =  11.2 H z, 11.0 H z, C -7 -H » ), 4 .1 0  (1 H , b r  dd , J  =  11.2 H z, 9 .4  
H z, C - l-H ) , 4 .3 2  (1 H , ddd , J =  24 .2  H z, 11.0 H z, 4 .4  H z, C -7-H *,), 4 .33  (1 H , d, J  =
11.4 H z, p a rt o f  a  b ro ad  A B  system , C / /2C 6H 5), 4 .5 0  - 4 .68  (2 H , m , C -2 -H  and  C -4-H ),
4 .7 2  - 5 .10  (13 H , m , CH2C 6H 5 AB system s), 6 .95 - 7 .42  (35 H , m , CeH5).
13C  N M R  (C D C I3 , 6 8  M H z): 5 3 9 .0  (d, C -6 ), 6 9 .04  (t, C -7), 69 .40 , 69 .49 , 69 .60 , 69 .68  
(4  t, 5 x P O C H 2C 6H 5) 7 4 .1 6  (t, 2 x O C H 2C 6H 5) 75 .04 , 78 .2 0 , 78 .7 5 , 79 .38 , 80.81 (5 d, 
in o sito l rin g  C), 127.36, 127.44, 127.84, 127.89, 128.09, 128.17, 128.23, 128.26,
128.36, 128.39, 128.51, 128.67, 128.77 (13 d, C 6H 5), 135.51, 135.63, 136.75, 137.54 (4 
s, 7 x C6H 5)
31P  N M R  (C D C I3 , 162 M H z) 5 - 8 .3 3  (1 P , ddd , J =  24.1 H z, 7 .6  H z, 7 .6  H z), - 1 .8 1 ,  -  
1.65 (2 P, o v erlap  to  g ive  m  in  1H - co u p led  spectrum ).
M S : m/z (+ v e  ion  F A B , rel in tensity ) 1047 [(M + H )+, 5% ], 181(10), 91 [(C 7H 7)+, 100% ]. 
M S : m/z ( - v e  ion  F A B , rel in tensity ) 1199 [(M + N B A )', 8 % ], 1045 [ (M -H ) ',  3% ] 955
[(M -C 7H 7)~,55% ], 277  [ (C 6H 50 ) 2 P 0 2 ', 100%  ], 187(38% ), 97 [ H 2P (V , 10% ].




C o m p o u n d  37b (1 lO m g, 0 .20 9 m m o l) w as ph o sp h o ry la ted  u sin g  th e  p ro ced u re  d escrib ed
fo r 37a. P u rifica tio n  by flash  ch rom atography  (e thyl ace ta te /d ich lo ro m eth an e  1:3)
a ffo rd ed  38b (190m g, 0 .182m m ol, 87% ) as a  w h ite  solid .
M p  136 - 138°C (from  ethy l aceta te /hexane).
'H  N M R  (C D C I3, 4 0 0  M H z): 5 2 .2 4  (1 H , dddd , J  =  11.0 H z, 11.0 H z, 11.0 H z, 4 .6  H z, 
C -6 -H ), 3 .33  (1 H , dd , J  =  9 .8  H z, 9 .8 H z, C -5-H ), 3 .62  (1 H , dd , J  =  9 .2  H z, 8 .9 H z, C -
3 -H ), 4 .0 0  (1 H , b r dd , J  =  11.0 H z, 11.0 H z, C -7 -H alt), 4.31 (1 H , ddd , J  =  2 1 .4  H z, 11.0 
H z, 4 .6  H z, C-7-Heq), 4 .39  (1 H , d, J  =  11.3 H z, p art o f  a  b ro ad  A B  system , C / / 2C 6H 5), 
4 .4 4  (1 H , b r dd, J =  10.7 H z, 10.1 H z, C - l-H ) , 4.61 (1 H , ddd , J  =  9 .2  H z, 9 .2  H z, 8.9 
H z, C -2 -H  o r C -4-H ), 4 .67  - 5 .27 (14 H , m , C H 2C 6H 5 A B  system s and  C -2 -H  o r C -4-H ),
6 .99  - 7 .4 0  (35 H , m , CaH5).
13C  N M R  (C D C I3, 100.4 M H z): 5  39.3 (d, C -6 ), 6 8 .8 8  (t, C -7), 69 .17 , 69 .5 4 , 69 .59 , 
7 0 .8 2  (4 t, P O C H 2C 6H j), 74 .18 , 7 4 .3 4  (2 t, 2 x C H 2C 6H 5), 75 .3 1 , 77 .1 4 , 7 8 .8 2 , 79 .44 ,
81 .03  (5 d, inosito l rin g  Q ,  127.27, 127.32, 127.72, 127.89, 128.00, 128 .13 , 128.22,
128.33, 128.42, 128.60, 128.71 (11 d, C 6H 5), 134.88, 135.54, 135.66, 135.73, 135.83, 
136.76, 137.65 (7 s, 7 x C 6H 5)
31P  N M R  (CDC13, 162 M H z) 5 - 5 .2 8  (1 P , dddd , J =  21 .4  H z, 7 .6  H z, 7 .6  H z, 2 H z), -  
1.58, -1 .5 1  (2  P, o v erlap  to  g ive  m  in H - co u p led  spec trum ).
M S : m/z (+ ve ion  F A B , rel in tensity ) 1047 [(M + H )+,70% ], 91 [(C 7H 7)+, 100% ].
M S: m/z ( - v e  ion  F A B , rel in tensity ) 1212(65), 1199 [(M + N B A )', 30% ], 1046(50), 955 
[ (M -C 7H 7) ',1 0 0 % ], 277  [(C6H 50 ) 2P 0 2- , 60% ]
Anal. C a lcd  fo r C asH nO w P s (1046 .98); C , 64 .24; H  5 .49 , F o u n d  C , 64 .4 ; H , 5 .55
DL-(l,3,5/2,4,6)-6-Hydroxymethyl-cyclohexane-l,2,3,4,5-pentoI l:7-cyclic,2,4- 
trisphosphate (=  DL-6-deoxy-6-hydroxymethyl-scy//o-inositol l:7-cyclic,2,4- 
trisphosphate) (26)
E ith e r co m p o u n d  38a o r 38b (95m g, 9 1 /u n o l) w as d ep ro tec ted  as d esc rib ed  fo r 
co m p o u n d  15. P u rifica tio n  by  ion -ex ch an g e  ch ro m ato g rap h y  on  Q S ep h aro se  F ast F low  
R esin , as b e fo re  gav e  the g lassy  trie th y lam m o n iu m  salt o f  26, w h ich  e lu ted  b e tw een  500  
m M  and  6 5 0  m M  T E A B . Y ie ld  78 - 82% )
*H N M R  (D 20 ,  4 0 0  M H z, N a+ salt, pH  8 ): 8 1.94 (1 H , d d d d  7 =  10.7 H z, 10.7 H z, 10.7 
H z, 4 .4  H z, C -6 -H ), 3 .32  (1 H , dd, J =  10.7 H z, 9 .3  H z, C -5 -H ), 3.41 (1 H , dd , J  =  9.3
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H z, 8 .8  H z, C -3 -H ), 3 .80  (1 H , ddd , J  =  8.8 H z, 8 .8 H z, 7 .8  H z, C -4 -H ), 3.85 - 3 .98  (3 
H ,m ,  C - l-H , C -2 -H , C-7-Hax), 4.21 (1 H , ddd , J  =  22 .9  H z, 11.3 H z, 4 .4  H z, C -7-H eq) 
13C  N M R  (D 20 ,  100.4 M H z, N a+ salt, p H  8) 4 1 .6 7  (d , C -6), 69 .15  (t, C -7), 70 .58 , 74 .37 , 
77 .5 7 , 78 .14 , 80.21 (5 d, inosito l rin g  C).
31P  N M R  (D 20 ,  162 M H z, ‘H -coup led , N a+ salt, pH  8) 8 -2 .1 6  (1 P , d, 7Hp = 22 .5  H z, 
P I ) ,  2 .99  (1 P , d, 7Hp =  7.1 H z, P 2), 3 .96 (1 P, d, 7Hp =  6.8 H z, P4).
M S: m/z ( - v e  ion  F A B , rel in tensity) 831 [ (2M -H )', 20% ], 415  [ (M -H ) ',  90% ], 
159(100), 97 [H 2P 0 4\  83% ].
M S: m/z 4 1 4 .9 6 2  (M -H ) ' (calcd  fo r C 7H 140 14P 3', 414 .960).
8.6 Various Compounds from the Route to 26
2,4-Di-0-/?-methoxybenzyl-6-methylidene-cyclohexane-l,3,5/2,4-pentol (39)
T he a lk en e  30 (4 .0g , 9 .38  m m ol) w as susp en d ed  in m eth an o l (lOOm L) and  h ea ted  to  
reflux . 1M  HC1 (lO m L ) w as added , and  hea ting  co n tin u ed  fo r 30  m in , afte r w h ich  T L C  
(ethyl ace ta te /h ex an e  2 :1) sh o w ed  th a t a lm ost all the  s tarting  m ateria l (R /0 .6 7 ) had  been  
co n su m ed . T h e  so lu tion  w as a llow ed  to  coo l, co n cen tra ted  am m o n ia  so lu tio n  (5m L ) w as 
added , and  the m ix tu re  w as stirred  at room  tem p era tu re  fo r a  fu rth e r 1 h. T he  so lven ts  
w ere  rem o v ed  by ev ap o ra tio n  in vacuo g iv ing  a  w h ite  so lid , w h ich  w as d ry -ex trac ted  
w ith  h o t ethyl aceta te  (2 x lOOmL). T he co m b in ed  ex trac ts  w ere  ev ap o ra ted  in v acu o  to 
g ive  a w h ite  so lid  w h ich  w as p u rified  by flash  ch ro m ato g rap h y , (ethyl ace ta te / 
d ich lo ro m eth an e  1:1) y ie ld ing  the  ally lic  a lcoho l 39 (2 .66g , 6 .3 9 m m o l, 68% ).
M p: 161 .5-163°C  (fro m  ethy l aceta te /hexane); IR: Vc=c 1 6 6 0 cm '1
‘H  N M R  (ds-D M S O , 4 0 0  M H z) S 2 .92  (2 H , d d , J = 9 .5 H z, 9 .2  H z, C -2 -H  an d  C -4 -H ),
3 .47  (1 H , d t, J  =  9 .2  H z, 5 .8  H z, D 20  ex  g ives t, J = 9 .2  H z, C -3 -H ), 3 .74  (6  H , s, 2 x 
O C H 3), 3 .87  (2  H , dd , J  =  9 .5 H z, 5.5 H z, D 20  ex  g iv es d, J  =  9 .5  H z, C - l -H  an d  C -5 - 
H ), 4 .7 2 , 4 .75  (4 H , A B q, Jab =  11.0 H z, 2 x O C ff2A r), 5 .0 4  (1 H , d, J = 5 .8  H z, D 20  
ex , C -3 -O H ), 5 .18  (2  H , d, 7 =  5 .50  H z, D zO  ex , C - l-O H , C -5 -O H ), 5 .22  (2 H , s, =CH2), 
6 .88  (4  H , d , J  =  8 .6  H z, C ^ O M e ) ,  7 .37  (4  H , d, J  =  8 .6  H z, C ^ O M e ) .
13C  N M R  (ds-D M S O , 100 M H z) <555.03 (q, 2 x O C H 3), 71 .23  (d , C -2  an d  C -4 ), 7 3 .5 2  
(t, O C H 2A r), 73 .83  (d , C -3), 85.68 (d, C - l  an d  C -5), 105.59 (t, = C H 2), 113.27 (d, C -3  
an d  C -5  o f  p -m eth o x y p h en y l rings), 129.26 (d, C -2  an d  C -6  o f  p -m eth o x y p h en y l 
rin g s),), 131 .64  (s, C - l  o f  p -m eth o x y p h en y l rings), 149.14 (s, C -6 ), 158.45 (s, C -4  o f  p- 
m eth o x y p h en y l rings).
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MS: m/z (+ve ion FAB, rel intensity) 415(35), 295[(M-C7H6OCH3)+, 100%], 173(100) 
MS: m/z (-ve ion FAB, rel intensity) 582(100), 569[(M+NBA)\ 50%], 415[(M -H)', 
60%],
A nal Calcd for (416.47); C, 66.3; H 6.78, Found C, 66.2; H, 6.66
2-C-Hydroxymethyl-l,3,5-0-methylidene-4,6-di-0-/j-methoxybenzyl-#wy0-inositol
(40)
To a vigorously stirred solution of the alkene 30 (426mg, l.Ommol) in ethyl 
acetate/acetonitrile (6mL of each) at 0°C was added a solution of RUCI3.3H2O (15mg, 
0.072mmol) and NaIC>4 (320mg, 1.5mmol) in distilled water (2mL). The two-phase 
mixture was stirred vigorously for 3 min and then quenched with sat. Na2S0 3 solution 
(lOmL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20mL). 
The combined organic layers were dried (MgSCU) and evaporated in vacuo to give a 
brown oil. Purification by flash chromatography (ethyl acetate/hexane 1:1) gave pure 40 
as a white crystalline solid (356mg, 0.733mmol, 77%).
Mp: 120-121.5°C (from ethyl acetate/hexane).
'H NMR (CDC13, 270 MHz) <52.13 (1 H, t, 7 = 6.9 Hz, D20  ex., CH2OH), 3.77 (1 H, s, 
D20  ex, OH), 3.80 (6 H, s, 2 x OCH3), 4.09 (2 H, d, 7 = 6.8 Hz, D20  ex gives s, 
C //2OH ), 4.17 (2 H, m, 2 x inositol ring C-H), 4.42 (3 H, m, 2 x inositol ring C-H and 
C-5-H), 4.54 (4 H, br s, 2 x C /^C e^O M e), 5.52 (1 H, s, 0 3CH), 6.81 (4 H, d, J  = 8.6 
Hz, 2 x C6/ / 4OMe), 7.16 (4 H, d, J=  8.6 Hz, 2 x C ^ O M e ) .
13C NMR (CDC13, 68 MHz) <555.21 (q, 2 x OCH3), 63.49 (t, CH2OH), 67.89 (d, C-5), 
70.16 (s, C-2), 71.52 (t, 2 x CH2Ar), 72.69, 74.13 (2d, C -l, C-3, C-4, C-6), 103.19 (d, 
0 3CH), 113.82 (d, C-3 and C-5 of p-methoxyphenyl rings), 129.53 (d, C-2 and C-6 of p- 
methoxyphenyl rings), 132.68 (s, C-l of p-methoxyphenyl rings), 158.35 (s, C-4 of p- 
methoxyphenyl rings).
MS: m/z (+ve ion FAB, rel intensity) 461 [(M+H)+, 54%], 339 [ (M -C 7H6OCH3)+, 
14%], 121 [(C7H6OCH3)+, 100%]
A na l Calcd for C24H28O9 (460.48); C, 62.60; H 6.13, Found C, 62.4; H, 6.11
DL-2,4-Di-0-/7-methoxybenzyl-6-(methoxymethylidene)-l,3,5-0-methyIidene- 
cyclohexane-l,3,5/2,4-pentol (41)
Methoxymethyltriphenylphosphonium chloride (3.50g, 10.2mmol) was suspended in dry 
THF (lOmL) under N2 at 0°C. Potassium terf-butoxide (lO.lm L of a 1M solution in
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THF, 10.1 mmol) was added. The resulting orange suspension was allowed to reach 
room temperature and stirred for 1 h before cooling again to 0°C. A solution of ketone 
29 (2.14g 5.00mmol) in dry THF (lOmL) was added over 5 min. The mixture was 
refluxed for 2 h, after which its colour had darkened and TLC (ethyl acetate/hexane 1:1) 
showed the reaction to be complete, with the product at Rf 0.44. The mixture was 
allowed to cool and the solvent was removed by evaporation in vacuo. The orange 
residue was taken up in ether (lOOmL), the solution washed water then brine (50mL of 
each), dried (MgS04) and evaporated to give a clear brown oil. Purification by flash 
chromatography (ethyl acetate/pentane 2:3) gave the enol ether 41 as a white crystalline 
solid (2.12, 4.63mmol, 93%).
Mp: 110-111°C (from ethanol)
*H NMR (CDC13, 400 MHz) 8 3.67 (3H, s, =OCH3), 3.79 (3 H, s, OCH3), 3.80 (3 H, s, 
OCH3), 4.16 (1 H,ddd, J  = 3.4 Hz, 3.4 Hz, 1.2 Hz, inositol ring C-H), 4.21 - 4.23 (2 H, 
m, 2 x inositol ring C-H), 4.32 (1 H, appears as tt, J=  3.4 Hz, 1.5 Hz, C-3-H), 4.50, 4.58 
(2 H, ABq, J  = 11.9 Hz, 0 C //2C6H40Me), 4.51, 4.64 (2 H, ABq, J  = 11.6 Hz, 
0 C //2C6H40Me), 5.05 (1 H, ddd, J=  3.4 Hz, 1.5 Hz, 1.5 Hz, C -l-H  or C-5-H), 5.58 (1 
H, s, 0 3CH), 6.24 (1 H, s, =CtfOCH3), 6.79-6.87 (4 H, m C ^ O M e ) , 7.18-7.29 (4 H, 
m, Cfr^OM e).
13C NMR (CDC13, 100 MHz) 8 55.49 (q, 2 x OCH3), 60.47 (q, =CHOCH3), 66.98,
69.94, 72.10, 72.92, 73.29 (5 d, inositol ring C), 71.13 (t, 2 x OCH2C6H4OMe), 104.94 
(d, 0 3CH), 106.72 (s, C-6), 113.96, (d, 2 x C6H4OMe), 129.43 (d, 2 x C6H4OMe), 
130.35 (s, 2 x C6H40Me), 145.98 (d, =CHOCH3), 159.52 (s, 2 x C6H4OMe).
MS: m/z (+ve ion FAB, rel intensity) 335[ (M -C7H6OCH3)+, 1%], 121 [ (C7H6OCH3)+, 
100%].
MS: m/z (-ve ion FAB, rel intensity) 610 [(M+NBA)', 50%], 471(60), 291(100).
Anal. Calcd for C24H280 8 (456.49); C, 65.78; H 6.18, Found C, 65.6; H, 6.16
DL-3,5/4,6-Tetrahydroxy-3,5-di-0-/?-methoxybenzyl-cycIohex-l-ene-l-carbaldehyde
(42)
The enol ether 41 (l.OOg, 2.19mmol) was dissolved in THF (20mL) and 1M HC1 (2mL) 
was added. The solution was heated at reflux for 1 h and allowed to cool. The solution 
was stirred with 10% NaHC03 solution (5mL) for 5 min and the solvents were removed 
by evaporation in vacuo. The residue was taken up in dichloromethane (50mL), washed 
with water and brine (50mL of each), dried (MgSQ4) and evaporated in vacuo to give a
227
white solid which was purified by flash chromatography (ethyl acetate/dichloromethane 
1:5) giving the enal 42 (748mg, 1.80mmol, 82%). (A small amount of the formate 42a 
(~ 70mg) was also isolated as an oil).
Mp: 131-133°C (from ethyl acetate/hexane)
IR: Vc=o 1685cm'1
*H NMR (CDCI3, 270 MHz) 52.92 (1H, br s, D20  ex, OH), 3.55 (1 H, dd, 7 =  10.3 Hz,
7.3 Hz, C-5-H), 3.67 (1 H, br s, D20  ex, OH), 3.73 (1 H, br dd, D20  ex gives dd, J  =
10.3 Hz, 8.2 Hz, C-4-H), 3.80 (6 H, br s, 2 x OCH3), 4.26 (1 H, ddd (appears as dt), J  =
8.2 Hz, 2.4 Hz, 2.2 Hz, C-3-H), 4.68 (1 H, buried, C-6-H), 4.69, 4.82 (2 H, ABq, Jab =
11.4 Hz, CH2C6H40Me), 4.69, 4.99 (2 H, ABq, Jab = 11.0 Hz, CH2C6H4OMe), 6.54 
(1H, dd (appears as t), J  ~ 2 Hz, 1.5 Hz, C-2-H), 6.86-6.92 (4 H, m, C ^ O M e ) , ), 7.29- 
7.33 (4 H, m, C ^ O M e ) , 9.43 (1 H, s, CHO).
13C NMR (CDCI3, 68 MHz) 5 55.22 (q, 2 x OCH3), 70.90, 73.30, 77.45, 81.87 (4 d, 
inositol ring C), 72.99, 74.54 (2 t, OCH2Ar), 113.91 (d, C-3 and C-5 of p- 
methoxyphenyl rings), 129.64, 129.77 (2 d, C-2 and C-6 of p-methoxyphenyl rings),
130.24 (s, C-l of p-methoxyphenyl rings), 139.45 (s, C -l), 148.05 (d, C-2), 159.37,
159.43 (2 s, C-4 of /?-methoxyphenyl rings), 194.63 (d, conjugated C=0).
MS: m/z (+ve ion FAB, rel intensity) 413(1%), 121 [ (C7H6OCH3)+, 100%].
MS: m/z (-ve ion FAB, rel intensity) 567 [(M+NBA)', 100%], 292(60), 233(50), 
112(45).
Anal Calcd for C23H260 7 (414.46); C, 66.65; H 6.32, Found C, 65.4; H, 6.34
DL-4-O-FormyI-3,5/4,6-tetrahydroxy-3,5-di-0-/?-methoxybenzyIcyclohex-l-ene-l- 
carbaldehyde (42a)
‘H NMR (CDCI3, 270 MHz) 8  3.64 (1H, br s, OH), 3.68 (1 H, dd, J  = 10.5 Hz, 7.4 Hz, 
C-5-H), 3.79 (3 H, s, OCH3), 3.80 (3 H, s, OCH3), 4.38 (1 H, ddd (appears as dt), J  = 8.4 
Hz, 2.3 Hz, 2.0 Hz, C-3-H), 4.58, 4.63 (2 H, ABq, A n = 112 Hz, C ^ C e ^ O M e ) , 4.74 
(1 H, br m, C-6-H), 4.66,4.83 (2 H, ABq, A b = 11.1 Hz, C //2C6H4OMe), 5.02 (1 H, dd, 
J  = 10.5 Hz, 8.4 Hz, C-4-H), 6.56 (1 H, dd (appears as t), J  ~ 2 Hz, 1.5 Hz, C-2-H), 
6.83-6.92 (4 H, m, C ^ O M e ) , 7.22-7.28 (4 H, m, C ^ O M e ) , 8.11 (1 H, s, OCHO),
9.43 (1 H, s, CHO).
DL-5-IIydroxymethyl-l,3-di-0-/>-methoxybenzyl-cyclohex-5-ene-l,3/2,4-tetrol (43)
The enal 42 (414mg, l.Ommol) was dissolved in methanol (20mL) and THF (lOmL), 
and sodium borohydride (38mg, l.Ommol) was added. TLC (ethyl acetate) after 5 min
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showed that the reaction was complete with total conversion of enal (Rf  0.29) to a 
product with Rf 0.60. Water (5mL) was added and then the solvents were removed by 
evaporation in vacuo. The residue was taken up in ethyl acetate (50mL), washed with 
water (50mL) and brine (50mL) and dried (MgS04). Evaporation of solvents in vacuo 
gave a white solid which was recrystallised from ethyl acetate/hexane giving the allylic 
alcohol (380mg, 0.912mmol, 91%).
Mp: 142-145 (from ethyl acetate/hexane).
*H NMR (CDC13, 270 MHz) 52.34 (1 H, br t, J  ~ 6 HZ, D20  ex, CH20 H), 2.70-2.73 (2 
H, m, D20  ex, 2 x OH), 3.47 (1 H, dd, J  = 10.4 Hz, 7.9 Hz, C-3-H), 3.76 (1 H, ddd, J  =
10.3 Hz, 7.7 Hz, 2.0 Hz, D20  ex gives dd, J  = 10.3 Hz, 7.7 Hz, C-2-H), 3.80 (3 H, s, 
OCH3) , ), 3.81 (3 H, s, OCH3), 4.08 (1 H, m, C-l-H), 4.17 (2 H, br m, C H 2OH), 4.39 (1 
H, br m, D20  ex gives ddd, J  = 7.9 Hz, ~2 Hz, ~2 Hz, C-4-H), 4.65 (2 H, br s, 
C //2C6H4OMe), 4.76, 4.84 (2 H, ABq, 7ab = 11.2 Hz, C H 2C6H4OMe), 5.64 (1 H, br s, 
C-6-H), 6.87-6.91 (4 H, m, C ^ O M e ) , 7.26-7.33 (4 H, m, C ^ O M e ) .
13C NMR (d6-DMSO, 100 MHz) 5 55.13 (q, 2 x OCH3), 60.69 (t, C-7), 71.55, 74.59, 
79.41, 84.72 (4 d, C -l, C-2, C-3, C-4), 70.69, 73.52 (2 t, OCH2Ar), 113.41, 113.63 (2d, 
C-3 and C-5 of /?-methoxyphenyl rings), 120.25 (d, C-6), 129.23, 129.38 (2 d, C-2 and 
C-6 of p-methoxyphenyl rings), 131.13, 131.64 (2 s, C-l of /?-methoxyphenyl rings), 
141.30 (s, C-5), 158.58, 158.66 (2 s, C-4 of /7-methoxyphenyl rings).
MS: m/z (+ve ion FAB, rel intensity) 415(30), 295(10), 121 [[C7H6OCH3)+, 100%]
MS: m/z (-ve ion FAB, rel intensity) 582(100), 569(100), 415 [(M-H)', 60%]
Anal. Calcd for C23H2807 (416.47); C, 66.3; H 6.78, Found C, 66.4; H, 7.01
8.7 DL-6 -Deoxy-6 -hydroxymethyl-scy//0 -inositol-1,2,4-trisphosphate
DL-(l,3,5/2,4,6)-l,3-Di-0-benzyI-6-benzyloxymethyl-2,4-di-0-p-methoxybenzyl- 
cyclohexane-l,2,3,4,5-pentol (45)
To an ice-cold mixture of compound 34 (300mg, 0.427mmol) and 4A molecular sieves 
(2g) and THF (lOmL) under N2 were added borane-trimethylamine complex (190mg,
2.60 mmol) and freshly pulverised aluminium chloride (345mg, 2.59 mmol). The 
mixture was stirred at 0°C for 23 h, after which time TLC (ethyl acetate/hexane 1:1) 
showed the reaction to be complete with conversion of starting material (Rf  0.57) to a 
product (Rf 0 .49). Ether (50mL) was added followed by ice-water (50mL) and 1M HC1 
(lOmL). The organic layer was removed and the aqueous layer re-extracted with a 
further 50mL of ether. The combined organic extracts were washed with brine (lOOmL),
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dried (MgSCU) and evaporated under reduced pressure to give an oily residue. 
Purification by flash chromatography (dichloromethane/ethyl acetate 20:1) gave the 
alcohol 45 as a colourless oil which slowly solidified (195mg, 0.271mmol, 65%).
Mp 95-97°C (from hexane).
‘H NMR (CDC13, 270 MHz): S 1.67 (1 H, m, C-6-H), 2.66 (1 H, d, 7 = 2 .0  Hz, D20  ex., 
C-5-OH), 3.37 (1 H, dd, 7 = 9.2 Hz, 9.2 Hz, C-H), 3.49-3.85 (6 H, m, 4 x inositol C-H 
and C-7-H2), 4.41-4.96 (10 H, m, AB systems of C H 2C6H 5 and C ^C sfttO M e), 6.78- 
6.88 (4 H, m, C6f/4OMe) 7.18-7.36 (19 H, m, C (fl5 and C ^ O M e ) .
13C NMR (CDCI3, 68 MHz): 5 45.46 (d, C-6), 55.16 (q, 2 x OCH3), 65.65 (t, C-7),
69.48 (d, inositol ring CH), 73.06, 75.09, 75.35, 75.59 (4t, 5 x C H 2As),  77.44, 83.07, 
85.22, 85.92 (4d, inositol ring CH), 113.73, 113.93 (2d, C-3 and C-5 of p- 
methoxyphenyl rings), 127.40, 127.45, 127.53, 127.66, 127.78, 128.85, 128.33 (7d, 
C6H5 and Cef^OMe), 130.74 (s, 2 x C-l of p-methoxyphenyl rings), 138.27, 138.50, 
138.56 (3s, C6H5 ipso), 159.08, 159.26 (2s, C-4 of /7-methoxyphenyl rings).
MS: m/z (+ve ion FAB, rel intensity) 705[(M+H)+, 24%], 584[(M-PMB)+,28%], 
211(80), 121[(CH2C6H40Me)+, 100%].
MS: m/z (-ve ion FAB, rel intensity) 857 [(M+NBA)', 100%], 703 [(M -H)', 40%], 
470(78), 303(60), 140(80), 121(80).
Anal. Calcd for C ^ g O g  (704.86); C, 74.98; H 6.80, Found C, 74.7; H, 6.86
DL-(l,3,5/2,4,6)-l,3-Di-0-benzyI-6-benzyloxymethyl-cycIohexane-l,2,3,4,5-pentol
(46)
The alcohol 45 (200mg, 0.284mmol) was dissolved in ethanol (60mL) and 1M HC1 
(30mL) added. The mixture was heated at reflux for 5 h and then the solvents removed 
by evaporation under reduced pressure. The residue was dissolved in dichloromethane 
(50mL), washed with sat NaHCC>3 and brine (50mL of each) and evaporated to give an 
oily residue. Purification by flash chromatography (ethyl acetate/hexane 1:1) gave the 
triol as a white solid (115mg, 0.248mmol, 87%).
Rf  0.24 (ethyl acetate/hexane 1:1)
Mp: 93-95°C (from hexane)
*H NMR (CDCI3, 400 MHz): 8  1.70 (1 H, dddd, J  = 10.7 Hz, 10.7 Hz, 4.4 Hz, 2.4 Hz, 
C-6-H), 2.59 (1 H, d , J =  1.95 Hz, D20  ex., OH), 2.83 (1 H, br s, D20  ex., OH), 3.19 (1 
H, d, /  = 2.9 Hz, D20  ex, OH), 3.22 (1 H, dd, J  = 9.76 Hz, 9.28 Hz, C-3-H), 3.38-3.48 
(2 H, m, C -l-H  and C-4-H), 3.57-3.68 (3 H, m, C-2-H, C-5-H and C-7-Ha), 3.85 (1 H,
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dd, J  = 9.28 Hz, 2.4 Hz, C-7-Hb), 4.46, 4.50 (2 H, AB q, 7ab = 11.7 Hz, O C//2C6H5),
4.58, 4.78 (2 H, AB q, 7ab = 10.7 Hz, OC//2C6H5), 4.86 (2 H, s, O C//2C6H5), 7.24-7.38 
(15H, m, 3 x C6H5).
13C NMR (CDC13, 68 MHz): 8 44.92 (d, C-6), 66.60 (t, C-7), 70.58 (d, inositol ring 
CH), 73.25, 74.79, 74.83 (3t, CH2C6U5), 76.69, 77.05, 77.65, 81.88 (4d, inositol ring 
CH), 127.68, 127.75, 127.86, 127.92, 127.99, 128.39, 128.43, 128.54 (9d, C6H5), 
137.95, 138.40, 138.53 (3s, C6H5 ipso).
MS: m/z (+ve ion FAB, rel intensity) 465[(M+H)+, 6%], 181(15), 91 [(C7H7)+, 100%]. 
MS: m/z (-ve ion FAB, rel intensity) 617 [(M+NBA)', 80%], 463 [(M-H)', 100%].
Anal Calcd for C28H320 6 (464.56); C, 72.39; H 6.94, Found C, 72.3; H, 6.90
(l,3,5/2,4,6)-l,3,5-Tri-0-benzyl-6-hydroxymethyl-2,4-di-O-/?-methoxybenzyl- 
cyclohexane-l,2,3,4,5-pentol (47)
The fully-protected compound 34 (351mg, 0.5mmol) was suspended in dry toluene 
(2mL) and DIBALH (1.7mL of a 1.5 M solution in toluene, 2.55mmol) was added 
dropwise at 0°C. Stirring was continued at 0°C for 20 h after which TLC 
(chloroform/acetone 20:1) showed that starting material (Rf 0.38) had been almost 
completely converted to a major product (Rf 0.13). A minor product with Rf 0.26 was 
also present. Methanol (lOmL) was added (fizzing!) followed by 10% NaOH (lOmL). 
The mixture was stirred for 10 min and then the solvents removed by evaporation under 
reduced pressure. The residue was taken up in ethyl acetate (50mL), washed with water 
and brine (50mL of each) and dried (MgS04). Evaporation under reduced pressure gave 
a colourless oil, which was purified by flash chromatography (dichloromethane/ethyl 
acetate 10:1) giving the symmetrical alcohol 47 (252mg, 0.358mmol, 72%) as a white 
solid.
Mp: 118.5-120.5°C (from ethanol).*
‘H NMR (CDCh, 270 MHz): 50.91 (1 H, t, / =  5.6 Hz, D20  ex, CH2Ofl), 1.58 (1 H, br 
t, J  ~ 11 Hz, C-6-H), 3.42 (1 H, dd, J  = 10.8 Hz, 9.2 Hz, C -l-H  and C-5-H), 3.46 (1 H, t, 
J  = 9.0 Hz, C-3-H), 3.60 (1 H, dd, J  = 9.2 Hz, 9.0 Hz, C-2-H and C-4-H), 3.70 (2 H, dd, 
J  = 5.6 Hz, 2.4 Hz, D20 e x . gives d / =  2.4 Hz, C-7-H2), 3.78 (6 H, s, 2 x OCH3), 4.65,
4.91 (4H, AB q, / a b  =  110 Hz, C H2Ar), 4.80,4.85 (4 H, AB q, 7 a b  =  10.4 Hz, C H 2Ai) ,
* The crystals contained 0.5mole of EtOH per mole of 47, but a second *H NMR spectrum taken some 
months later showed that the ethanol had now disappeared.
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4.92 (2H, s, CH2C6H5), 6.82 (4H, d, J  = 8.6 Hz, C ^ O M e ) , 7.21 (4H, d, J  = 8.6 Hz, 
C ^ O M e ) , 7.26-7.40 (15H, m, C6H5).
13C NMR (CDCU, 68 MHz): S 45.56 (d, C-6), 55.25 (q, 2 x OCH3), 58.30 (t, C-7),
69.48 (d, inositol ring CH), 75.04, 75.44 (2t, 4 x C tf2Ar), 75.82 (t, OCH2Ar at C-5), 
76.66 (d, 2 x inositol ring CH), 83.30 (d, C-3), 85.88 (d, 2 x inositol ring CH), 113.81, 
(d, C-3 and C-5 of p-methoxyphenyl rings), 127.56, 127.63, 127.98, 128.27, 128.42,
128.58, 129.49 (7d, C6H5 and C6H4OMe), 130.72 (s, C-l of p-methoxyphenyl rings),
138.26, (s, 2 x C6H5 ipso), 138.68 (s, CeH5 ipso), 159.16(s, C-4 of p-methoxyphenyl 
rings).
MS: m/z (+ve ion FAB) 703[(M-H)+, 30%], 583[(M-PMB)+,50%], 211(80), 
121[(CH2C6H40Me)+, 100%].
MS: m/z (-ve ion FAB) 857 [(M+NBA)', 100%], 470(40), 289(45), 135(60), 140(80), 
121(50).
Anal. Calcd for C ^ g O g  (704.86); C, 74.98; H 6.86, Found C, 74.7; H, 6.86
(l,3,5/2,4,6)-l,3,5-Tri-0-benzyl-6-hydroxymethyl-cyclohexane-l,2,3,4,5-pentol (48)
The /7-methoxybenzyl protecting groups of the symmetrical alcohol 47 (200mg, 
0.284mmol) were cleaved using the same procedure as that for the symmetrical alcohol 
45. Purification by flash chromatography (ethyl acetate/hexane 1:1) gave the 
symmetrical triol 48 as a white solid (108mg, 0.232mmol, 81%).
Rf 0.46 (ethyl acetate/hexane 1:1)
Mp: 88-90°C (from hexane/ethyl acetate 10:1)
'H  NMR (C D C I3 , 270 MHz): 5 1.07 (1 H, t, J  = 5.5 Hz, D20  ex., CH2Ofl), 1-62 (1 H, tt, 
7 = 1 1  Hz, 3.8 Hz, C-6-H), 2.54 (2 H, d, J  = 2.2 Hz, D20  ex., C-2-OH, C-4-OH), 3.23 (1 
H, t, J  = 9.3 Hz, C-3-H), 3.38 (2 H, dd, J  = 11 Hz, 9.3 Hz, C-l-H  and C-5-H), 3.66 (2 H, 
ddd, J  = 9.3 Hz, 9.3 Hz, 2.2 Hz, D20  ex. gives dd, J  = 9.3 Hz, 9.3 Hz, C-2-H and C-4- 
H), 3.78 (2 H, dd, J  = 5.5 Hz, 2.8 Hz, D20  ex. gives d, J  = 2.7 Hz, C-7-H2), 4.74, 4.83 
(4 H, AB q, Jab = 11-4 Hz, 2 x OCH2C6H5), 4.87 (2 H, s, O C//2C6H5), 4.86 (2 H, s, 
OCH2C6R 5), 7.32-7.39 (15 H, m, 3 x C<f l 5).
I3C NMR (CDCI3, 68 MHz): <545.78 (d, C-6), 58.19 (t, C-7), 74.42, (t, 2 x CH2C6H5),
74.92 (t, CH2C6U5), 76.74 (d, 2 x inositol ring CH), 76.94, (d, 2 x inositol ring CH), 
82.37 (d, C-3), 127.86, 127.91, 127.97, 128.20, 128.57 (5d, C6H5), 138.24, (s, 2 x C6H5 
ipso), 138.47 (s, C6H5 ipso).
MS: m/z (+ve ion FAB, rel intensity) 465[(M+H)+, 2.3%], 181(10), 91 [(C7H7)+, 100%].
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MS: m/z (-ve ion FAB, rel intensity) 617 [(M+NBA)', 50%], 463 [(M-H)', 100%].
Anal. Calcd for C28H32O6 (464.56); C, 72.39; H 6.94, Found C, 72.1; H, 6.98.
DL-(l,3,5/2,4,6)-3,5-Di-0-benzyl-6-benzyloxymethyl-cyclohexane-l,2,3,4,5-pentoI
l,2,4-tris(dibenzylphosphate) (49)
To a solution of bis(benzyloxy)diisopropylaminophosphine (356mg, 1.03mmol) in dry 
dichloromethane (3mL) was added l//-tetrazole (144mg, 2.06mmol). The mixture was 
stirred at room temperature for 20min and then the triol 46 (80mg, 0.172mmol) was 
added, and stirring was continued for 30min. The mixture was cooled to -78°C, m- 
CPBA (200mg, 1.16mmol) was added, and the cooling bath was removed. The mixture 
was allowed to reach rt and then diluted with ethyl acetate (50mL). The clear solution 
was washed with 10% Na2SC>3, 1M HC1, sat. NaHCC>3 and brine (50mL of each) dried 
(MgSOzO and evaporated in vacuo giving an oily residue. Purification by column 
chromatography (chloroform acetone 10:1) afforded 49 (183mg, 0.147mmol, 85%) as a 
colourless oil which slowly crystallised.
Mp: 87.5 - 88.5°C (from hexane).
Rf  0.20 (chloroform/acetone 10:1)
‘H NMR (CDCI3, 400MHz): 8 1.93 (1 H, br t, J  = 10.7 Hz, C-6-H), 3.63 (1 H, dd, 7 =
8.9 Hz, 8.6 Hz, C-3-H or C-5-H), 3.71-3.77 (2 H, m, C-7-Ha and C-3-H or C-5-H), 3.84 
(1 H, dd, J  = 9.5 Hz, 2.1 Hz, C-7-Hb), 4.18, 4.44 (2 H, AB q, A n = 11.6 Hz, 
O C//2C6H5), 4.42 (1 H, half of AB system of O C//2C6H5), 4.53-5.07 (18 H, AB systems 
of OC772C6H5, C-l-H, C-2-H, C-4-H), 6.93-7.01 (6 H, m, CeH5), 7.08-7.26 (37H, m, 
CeHs), 7.39-7.41 (2 H, m, C ^ s ) .
I3C NMR (CDCI3, 100 MHz): 8 44.75 (d, C-6), 63.66 (t, C-7), 69.24, 69.29, 69.35, 
69.40, 69.71, 69.77 (6t, P(0)OCH2), 72.56, 73.90, 74.34 (3t, CHOCH2C6H5), 74.98, 
75.20, 78.86, 80.23, 81.84 (5d, inositol ring CH), 127.05, 127.41, 127.52, 127.61,
127.80, 127.91, 127.98, 128.02, 128.11, 128.18, 128.27, 128.33, 128.38, 128.47 (14d, 
C6H5), 135.77, 135.83, 135.90, 135.97, 136.03, 136.10 (6s, C6H5 ipso), 138.06, 138.20,
138.24 (3s, C6H5 ipso).
31P NMR (C D C I3 , 162 MHz, ^ -d eco u p led ): 5 -2 .1 2  (IP), -1.67(1P), -1.53(1P).
MS: m/z (+ve ion FAB, rel intensity) 1245 [(M+H)+, 65%], 271(10), 181(10), 91 
[(C7H7)+, 100%].
M S : m/z (-ve ion F A B , rel intensity) 1397 [ ( M + N B A ) ',  80%], 1153 [ ( M - C 7H 7) \  
100%], 277 [ (C 6H 5C H 20 )2P ( 0 ) 0 ' ,  100%].
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A na l Calcd for C70H71O 15P3 (1245.25); C, 67.52; H 5.75, Found C, 67.4; H, 5.64
DL-(l,3,5/2,4,6)-6-Hydroxymethyl-cyclohexane-l,2,3,4,5-pentol 1,2,4-trisphosphate 
(=  DL-6-Deoxy-6-hydroxymethyl-scy//o-inositol-l,2,4-trisphosphate 44)
The trisphosphate triester 49 (60mg, 48mmol) was deprotected as described for 
compound 15. Purification by ion-exchange chromatography on Q Sepharose Fast Flow 
Resin, as before gave the glassy triethyl ammonium salt of 44, which eluted between 450 
mM and 550 mM TEAB. Yield 34//mol, 71%
*H NMR (D20 , 400MHz): <5 1.47 (1 H, dddd, / =  11 Hz, 11 Hz, 2 Hz, C-6-H), 3.38 (1 
H, dd, J  = 9.5 Hz, 9.2 Hz, C-3-H), 3.48 (1 H, dd, /  = 11 Hz, 9.5 Hz, C-5-H), 3.68 (2 H, 
ABX, CH2), 3.80 (1 H, ddd, J  = 9.5 Hz, 9.2 Hz, 8.5 Hz, C-4-H), 3.87 (1 H, ddd, J  = 10.4 
Hz, 10.4 Hz, 10.4 Hz, C-l-H), 4.00 (1 H, ddd, J  = 9.2 Hz, 9.2 Hz, 9.2 Hz, C-2-H).
31P NMR (D20 , 162 MHz): 0.15 (IP, 7Hp = 10.0 Hz), 0.45 (IP, JHP = 8.1 Hz), 0.96 (7P, 
/ h p  = 9.0 Hz)
MS: m/z (+ve ion FAB, rel intensity) 102 [(C2H5)3NH+, 100%].
MS: m/z (-ve ion FAB, rel intensity) 867 [ (2M-H)\ 10%], 433 [(M-H)', 100%], 
159(10), 97 [H2P 0 4\  35%].
MS (accurate mass FAB'): m/z 432.9708 (M -H)' (calcd for C7H 16O 15P3', 432.9702)
8.8 a,c&-Trehalose 3,4,3',4'-tetrakisphosphate
4,6:4',6'-Di-0-benzylidene-a,a-trehalose (51)
This was prepared according to the procedure of Baer and Radatus.244 
a,a-Trehalose dihydrate (lO.Og, 26.4mmol) was dehydrated by heating a suspension in 
absolute ethanol (60mL) at reflux for 30min followed by evaporation of solvents in 
vacuo. The dry residue was dissolved in dry DMF (60mL) in a round-bottomed flask, 
and benzaldehyde dimethyl acetal (4.0mL, 27mmol) was added, together with a catalytic 
amount of /?-toluenesulphonic acid (250mg). The flask was fitted with an air condenser 
and the mixture was heated in an oil bath, with stirring, at 100°C for 10 min. The flask 
was then attached to a rotary evaporator for 5 min (bath temperature 60°C). The heating 
procedures in oil bath and on the evaporator were repeated twice, each time with the 
addition of fresh benzaldehyde dimethyl acetal (4.0mL and lm L respectively). By this 
time, no solid material remained and TLC (ethyl acetate/dichloromethane 3:1) showed 
total conversion to a product at Rf  0.4. Most of the DMF was removed by evaporation in
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vacuo to give a syrup, and toluene (60mL) was then added. Crystals began to form 
within a few minutes and were filtered off and washed with toluene. Further crops of 
crystals were obtained from the mother liquor by partial evaporation, addition of more 
toluene, and cooling in a refrigerator to 4°C. The combined crops were stirred with 10% 
sodium hydrogen carbonate solution for 20 min and then filtered off and washed 
successively with water and hexane. The product could be recrystallised by dissolving in 
boiling ethanol, followed by addition of hot water and slow cooling.* Considerable care 
was necessary to avoid the formation of an oil, but 51 was eventually obtained as 
colourless crystals of the hemihydrate (10.7g, 20.3mmol, 77%)
Mp:198-200°C (from ethanol/water) L i t260 195°C, L i t261 199-200°C.
[a ]D18 = +81 (c = 1, MeOH) (lit.260 +80.3, lit.244 +81.3).
'H  NMR (d6-DMSO, 270MHz): 8 3.36-3.50 (4 H, br m obscured by H2O, D2O ex gives 
dd, J  = 9.3 Hz, 3.7 Hz, C-2-H and C-2'-H, and dd J  = 9.3 Hz, 9.2 Hz, C-4-H and C-4'- 
H), 3.65 (2 H, br m, D20  ex gives dd, J  = 9.9 Hz, 9.9 Hz, C-3-H and C-3'-H), 4.00-4.15 
(4 H, m, C-6-H2 and C-6'-H2), 4.94 (2 H, d, J  = 3.8 Hz, C -l-H  and C-l'-H ), 5.26 (2 H, 
d, J  = 5.0 Hz, D20  ex, 2 x C -0H),  5.32 (2 H, d, J  = 5.9 Hz, D20  ex, 2 x C-OH),  5.54 (2 
H, s, C//Ph), 7.35-7.44 (10 H, m, aromatic H)
13C NMR (d6-DMSO, 68 MHz) 562.74, 69.86,72.36, 81.73 (4 d, C-2/2', C-3/3', C-4/4', 
C-5/5'), 68.69 (t, C-6/6'), 95.29 (d, C-l/1 '), 101.42 (d, CHPh), 126.90, 128.62, 129.46 
(3 d, C6H5), 138.20 (s, C6H5 ipso).
MS: m/z (+ve ion FAB, rel intensity) 1037 [(2M+H)+, 45%], 613(80), 519 [(M+H)+, 
100%], 251 [+ve fragment ion from cleavage of glycosidic bond, 45%].
MS: m/z (-ve ion FAB, rel intensity) 1202(30), 1123(40), 957(80), 684(100), 517 [(M - 
H)‘, 80%].
Regioselective Dibenzylation of 4,6:4/,6'-D i-0-benzyIidene-a,a'-trehalose
This was carried out according to Vicent et al.245
The tetrol 51 (2.00g, 3.46mmol) was placed in a dry three-neck flask, together with 
powdered molecular sieves (3A, lOg), dibutyltin oxide (2.40g, 4.82mmol) and dry 
acetonitrile (lOOmL). The mixture was stirred under N2 at 120°C for 24 h. Benzyl 
bromide (4.6mL, 38.6mmol) and Af-methylimidazole (0.60mL, 7.6mmol) were added, 
and stirring was continued at 110°C. TLC (chloroform/acetone 10:1) showed the
* 51 could be recrystallised far more easily from propan-2-ol. The crystals so formed contained 1 
equivalent of propan-2-ol, visible in the NMR spectra.
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reaction to be complete after 70 h, with products at Rf  0.22 and Rf  0.30. The mixture was 
allowed to cool, and filtered to remove the molecular sieves, which were washed with 
chloroform. The combined filtrate and washings were concentrated by evaporation in 
vacuo. Column chromatography of the residue (chloroform/acetone 10:1) gave first the 
2,3'-0-benzylated derivative 52 Rf  0.30 (785mg, 1.12mmol, 32%) and then the 
symmetrical 2,2'-0-benzylated product 53 (1.32g, 1.88mmol, 54%).
2,3'-Di-0-benzyl-4,6:4',6'-di-0-benzyIidene-a,a-trehalose (52)
Mp: 185-187°C (from ethyl acetate/hexane) (lit.245 syrup).
[a ]D19 = +88 (c = 1, CHC13 ) [lit32 [a]D = +76 (c = 1.1, CHC13)]
!H NMR (CDCI3, 270MHz): <52.38 (1 H, d, 7 = 5.1 Hz, C-2'-OH), 2.69 (1 H, d, 7 = 2.2 
Hz, C-3-OH), 3.50 (1 H, dd, 7 = 9.5 Hz, 9.3 Hz, C-4-H), 3.55 (1 H, dd, 7 = 9.3 Hz, 3.7 
Hz, C-2-H), 3.63-3.79 (4 H, m, C-2'-H, C-4'-H, C-6-Ha*, C-6'-Hax), 3.95 (1 H, dd, 7 =
9.2 Hz, 9.2 Hz, C-3'-H), 4.09-4.29 (5 H, m, C-3-H, C-5-H, C-5'-H, C-6-Heq, C-6'-Heq),
4.69-5.00 (4 H, 2 AB systems, PhCtf2), 5.17 (1 H, d, 7 =  3.8 Hz, C-l-H  or C-l'-H ), 5.19 
(1 H, d, 7= 3.8 Hz, C -l-H  or C-l'-H ), 5.51 (1 H, s, PhCH), 5.55 (1 H, s, PhC//), 7.23- 
7.52 (20 H, m, C ^ s )
13C NMR (CDCI3, 67.8 MHz): 562.71, 63.31 (2 d, CH), 68.84 (t, C-6 and C-6'), 70.35,
71.60 (2 d, CH), 73.30, 74.97 (2 t, OCH2C6H5), 78.61, 78.83, 81.23, 82.14 (4 d, CH), 
93.87, 95.38 (2 d, C-l-H  and C-l'-H), 101.28, 101.88 (2 d, PhCH), 126.12, 126.29, 
127.84, 127.92, 128.00, 128.05, 128.17, 128.26, 128.44, 128.65, 128.94, 129.16 (12 d, 
C6H5), 137.05, 137.36, 137.46, 138.32 (4 s, C6H5 ipso).
MS: m/z (+ve ion FAB, rel intensity) 699 [(M+H)+, 15%], 341[+ve fragment ion from 
cleavage of glycosidic bond, 4%], 91 [(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel intensity) 697 [(M-H)', 52%], 625(40), 612(45), 308(44), 
274(42).
2,2'-Di-0-benzyl-4,6:4',6'-di-0-benzyIidene-a,a-trehalose (53)
Mp: 196-199°C (from ethyl acetate/hexane) (lit.245 197-199°C).
[a ]D19 = +99 (c = 1, CHCI3 ) [lit32 [a]D = +90 (c = 2, CHC13)]
*H NMR (CDCI3, 400MHz): 52.57 (2 H, d, J  = 1.95 Hz, D20  ex., 3/3'-OH), 3.49 (2 H, 
dd, J  = 9.8 Hz, 9.8 Hz, C-4/4'-H), 3.54 (2 H, dd, J  = 9.3 Hz, 3.4 Hz, C-2/2'-H), 3.66 (2 
H, dd, / =  10.7 Hz, 10.3 Hz, C-6/6'-ax), 4.11 (2 H, dd, 7 =  10.3 Hz, 4.9 Hz, C-6/6'-eq),
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4.20-4.27 (4 H, m, simplifies on D20  shake, C-3/3'-H and C-5/5'-H), 4.75, 4.78 (4 H, 
ABq, Jab = 11.7 Hz, O C//2C6H5), 5.18 (2 H, d, /  = 3.4 Hz, C -l/l'-H ), 5.49 (2 H, s, 
PhCH), 7.25-7.48 (20 H, m, C ^ s ) .
13C NMR (CDC13, 67.8 MHz): 562.76 (d, 2 x CH), 68.84 (t, C-6/6'), 70.27 (d, 2 x CH), 
73.29 (t, 2 x OCH2C6H5), 78.95, 81.30 (2d, 4 x CH), 94.40 (d, C -l/l'-H ), 101.98 (d, 2 x 
PhCH), 126.46, 127.76, 127.97, 128.23, 128.62, 129.21 (6d, C6H5), 137.10, 137.57 (2s, 
4 x C6H5 ipso).
MS: m/z (+ve ion FAB, rel intensity) 1397[(2M+H)+, 30%], 1090(60), 830(65), 781(56), 
699 [(M+H)+, 20%], 341 [+ve fragment ion from cleavage of glycosidic bond, 40%], 
94(75).
MS: m/z (-ve ion FAB, rel intensity) 697 [(M -H )\ 20%], 625(60), 612(65), 308(70), 
274(60).
3,3'-Di-0-benzoyl-2,2'-di-(9-benzyl-4,6:4',6'-di-0-benzylidene-a,a-trehalose (54)
The symmetrical diol 53 (500mg, 0.716mmol) was dissolved in dry pyridine (4mL). A 
catalytic amount of DMAP (50mg) was added, followed by benzoyl chloride (0.19mL, 
1.64mmol). The mixture was stirred overnight at room temperature and then water 
(lm L) was added and stirring continued for a further lOmin. The solvents were removed 
by evaporation under reduced pressure. The residue was taken up in dichloromethane 
and washed with 0.1M HC1, sat. NaHCC>3 and brine (50mL of each) then dried over 
MgSC>4. Evaporation under reduced pressure gave a solid which was purified by flash 
chromatography (ethyl acetate/hexane 1:1) giving 54 (586mg, 0.646mmol, 90%) as a 
white solid.
Mp: 230-231°C (from ethyl acetate/hexane).
[ « ] d 20 = +78 (c =  1,CHC13 ).
‘H NMR (CDCI3, 400MHz): 53.68 (2 H, dd, J  = 10.3 Hz, 9.8 Hz, C-6/6'-H ») 3.73 (2 
H, dd, J  = 9.8 Hz, 9.8 Hz, C-4/4'-H), 3.86 (2 H, dd, J  = 9.8 Hz, 3.9 Hz, C-2/2'-H), 4.11 
(2 H, dd, J  = 10.3 Hz, 4.9 Hz, C-6/6'-Heq), 4.37 (2 H, ddd, J  = 9.8 Hz, 9.8 Hz, 4.9 Hz, 
C-5/5'-H), 4.62, 4.69 (4 H, ABq, Ab = 12.2 Hz, CH2Ph), 5.28 (2 H, d, J  = 3.9 Hz, C- 
l/l'-H ), 5.43 (2 H, s, CHPh), 5.92 (2 H, dd, J =  9.8 Hz, 9.8 Hz, C-3/3'-H), 7.17-7.46 (24 
H, m, C (fl5), 7.56 (2 H, t, J  = 7.3 Hz, O C (0)C Ji5 para), 8.05 (4 H, d, J  = 7.8 Hz, 
0 C(0 )C6^5 ortho)
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13C NMR (CDCI3, 67.8 MHz): S 62.95 (d, 2 x CH), 68.84 (t, C-6/6'), 71.65 (d, 2 x CH), 
72.64 (t, 2 x OCH2C6H5), 76.17, 79.55 (2d, 2 x CH), 94.79 (d, C -l/1 '), 101.61 (d, 2 x 
PhCH), 126.35, 127.91, 128.02, 128.25, 128.49, 128.84, 129.86 (7 d, C6HS) 130.17 (s, 2 
x 0 C (0 )C 6H5 ipso), 132.84 (d, 2 x 0C (0)C 6H5 para), 136.96, 137.20 (2s, C6H5 ipso),
165.09 (s, 2 x C=0).
MS: m/z (+ve ion FAB, rel intensity) 907 [(M+H)+, 60%], 445 [+ve fragment ion from 
cleavage of glycosidic bond, 60%], 323(80), 91 [(C7H7)+, 100%].
A nal Calcd for C54H50O13 (906.98); C, 71.51 H 5.56, Found: C, 71.6; H, 5.56.
Found: C, 71.6; H, 5.56. Calcd. for C54H50O13: C, 71.51; H, 5.56%
3,3'-Di-0-benzoyl-2,6,2',6'-tetra-0-benzyl-a,ct-trehalose (55)
To a solution of sodium cyanoborohydride in THF (14mL of a 1M solution) containing 
3A molecular sieves was added compound 54 (500mg, 0.551 mmol). The mixture was 
stirred under N2 at room temperature, and a solution of hydrogen chloride in dry ether 
was added dropwise until evolution of gas ceased. TLC (chloroform/acetone 10:1) 
showed the reaction to be complete with total conversion of starting material (/fy0.55) to 
a product at Rf 0.24. The mixture was diluted with dichloromethane (50mL), washed 
with water, sat. NaHCC>3 and brine (50mL of each) and dried over MgSC>4. Evaporation 
under reduced pressure gave an oil which was purified by flash chromatography to 
provide the symmetrical 55 as a white foam (404mg, 0.439mmol, 80%).
[a ]D25 = +158 (c = 1, CHCI3).
‘H NMR (CDCI3, 270MHz): 8  2.99 (2 H, d, J=  6.4 Hz, D20  ex. C-4/4'-OH), 3.59 (4 H, 
d AB q, 7ab ~ 11 Hz, C-6/6'-H). 3.69 (4 H, dd, J  = 9.8 Hz, 3.5 Hz, C-2/2'-H), 3.74, (2 
H, m, D20  ex. gives dd, J  = 9.7 Hz, 9.2 Hz, C-4/4'-H), 4.21 (2 H, ddd, J  = 10 Hz, 3.4 
Hz, 3.4 Hz, C-5/5'-H), 4.50 (4 H, AB s, OCH2C6H5), 4.57, 4.63 (4 H, AB q, J AB = 12.3 
Hz, OCH2C6H5), 5.35 (2 H, d, ]  = 3.5 Hz, C -l/l'-H ), 5.63 (2 H, dd, J  = 9.5 Hz, 9.5 Hz, 
C-3/3'-H), 7.14-7.19 (10 H, m, OfeCeffs), 7.24-7.29 (10 H, m, CH2C<fls) 7.45 (4 H, dd, 
J  = 7.9 Hz, 7.1 Hz, O C(P)Cffli meta), 7.59 (2 H, tt, 7 = 7.1 Hz, 1.5 Hz, 0 C(0 )C6«5 
para), 8.04 (4 H, dd, J  = 7.9 Hz, 1.5 Hz, O C(0)C(fl5 ortho)
13C NMR (CDC13, 67.8 MHz): 5 68.89 (t, C-6/6'), 69.38, 71.73, 72.52 (3 d, 6 x CH), 
73.64,75.22 ( 2 1, 4 x OCH2C6H5), 76.17 (d, 2 x CH), 93.45 (d, C -l/1 '), 127.60, 127.70,
127.83, 127.89, 128.33 (5d, C6H5), 129.76 (s, C(0)C6H5 ipso), 129.93 (d, 0C(0)C6H5
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ortho), 133.23 (d, OC(0)C6H5 para), 137.88, 136.99 (2 s, CH2C6H5 ipso), 167.14 (s, 2 x 
C=0).
MS: m/z (+ve ion FAB, rel intensity) 911 [M+, 40%], 537(80), 447 [+ve fragment ion 
from cleavage of glycosidic bond, 10%], 91 [(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel intensity) 1063 [(M+NBA-H)', 35%], 121 [(C 7 H 5 O 2 )’, 
100%].
A nal Calcd for C54H54O 13 (911.01) C, 71.19; H, 5.97; Found C, 71.0; H, 5.97. 
2,6,2',6'-Tetra-0-benzyl-a, a-trehalose (56)
Sodium hydroxide pellets (lOOmg, 2.5mmol) were added to a solution of 55 (400mg, 
0.439mmol) in methanol (25mL) and the mixture was heated at reflux for 30 min. TLC 
(chloroform methanol 5:1) showed complete conversion of starting material (Rf  0.82) to 
a product (Rf  0.50). The solution was allowed to cool and then neutralised by bubbling 
CO2 gas through it overnight. The solvents were removed by evaporation under reduced 
pressure and the solid residue was extracted with ethyl acetate (3 x 50mL). The 
combined extracts were washed with water (lOOmL), dried over MgSCU and evaporated 
to give an oil. Purification by flash chromatography (ethyl acetate) gave 56 (263mg, 
0.374mmol, 85%) as a white crystalline solid.
Rf  0.2 (ethyl acetate)
Mp: 135-137°C (from ethyl acetate/hexane).
[ « ] d 18 = +127 (c = 1, CHCl, ).
‘H NMR (CDCI3, 270MHz): <53.37 (2 H, dd, J  = 9.7 Hz, 3.1 Hz, C-2/2'-H), 3.53 (2 H, 
ddd, J  = 9.5 Hz, 9.5 Hz, ~5Hz, D20  ex gives dd, J  = 9.5 Hz, 9.5 Hz, C-4/4'-H), 3.52 - 
3.65 (4 H, m, C-6/6'-H2), 3.64, (2 H, br d, J -  5Hz, D20  ex., C-4/4'-OH), 4.04 (2 H, 
ddd, J  = 9.3 Hz, 9.3 Hz, 3.4 Hz, D20  ex gives dd, J  = 9.3 Hz, 9.3 Hz, C-3/3'-H), 4.10 (2 
H, ddd, J  = 9.5 Hz, 4 Hz, 3.4 Hz, C-5/5'-H), 4.20 (2 H, br d, 7 -  3.5 Hz, D20  ex, C-3/3'- 
OH), 4.44 - 4.66 (8 H, 2 x AB systems, 4 x O C//2C6H5), 5.12 (2 H, d, J  = 3.1 Hz, C- 
l/l'-H ), 7.22-7.27 (20 H, m, CHzCffls).
13C NMR (CDC13, 67.8 MHz): <5 69.31 (t, C-6/6'), 70.72, 71.28, 72.41 (3 d, 6 x CH), 
72.54,73.55 ( 2 1, 4 x OCH2C6H5), 78.09 (d, 2 x CH), 93.92 (d, C -l/1 '), 127.57, 127.66,
128.04,128.09, 128.30 (6 d, C6H5), 137.05,137.96 (2 s, 4 x CH2C6H5 ipso).
MS: m/z (+ve ion FAB, rel intensity) 703 [(M+H)+, 10%], 685(56), 433(24), 343 [+ve 
fragment ion from cleavage of glycosidic bond, 92%], 91 [(C7H7)+, 100%].
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MS: m/z (-ve ion FAB, rel intensity) 1404 [2M‘, 20%], 869(100), 855 [(M+NBA)', 
65%], 701 [(M -H)', 30%].
Anal. Calcd. for C40H64Ou: (702.80) C, 68.36; H, 6.60; Found: C, 68.2; H, 6.6.
2,6,2',6/-Tetra-0-benzyI-a,a-trehalose-3,4,3',4'-tetrakis(dibenzylphosphate) (57) 
To a solution of bis(benzyloxy)-Af,iV-diisopropylaminophosphine (550mg, 1.59mmol) in 
dry dichloromethane (2mL) was added 1/7-tetrazole (223mg, 3.18mmol). The mixture 
was stirred at room temperature for 10 min and then the tetrol 56 (140mg, 0.199mmol) 
was added. The mixture was stirred for a further 1 h, after which a 90 MHz 31P NMR 
spectrum showed signals at S 140.7 and 141.1 ppm (AB system 5/ Pp = 4.9Hz). The 
mixture was cooled to -78°C and m-CPBA (288mg, 1.67mmol) was added. The 
mixture was allowed to reach room temperature and then diluted with ethyl acetate 
(50mL). The solution was washed with 10% sodium sulphite solution, 1M HC1, sat. 
NaHCC>3 and brine (50mL of each), dried (MgS04) and evaporated in vacuo to give an 
oil. Purification by column chromatography (chloroform/acetone 10:1) gave 57 as a 
colourless oil (315mg, 0.181mmol, 91%).
Rf 0.26 (chloroform/acetone 10:1)
[«]D26 = +46 (c = 1, CHC13)
‘H NMR (CDCI3,400MHz): 8  3.28 (2 H, br d, J  ~ 11 Hz, C-6/6'-H), 3.47 (2 H, dd, J = 
11 Hz, 3.5 Hz, C-6/6'-H), 3.63 (2 H, dd, J  = 9.8 Hz, 3.7 Hz, C-2/2'-H), 4.21 (2 H, 
obscured by AB system, C-5/5'-H), 4.20, 4.37 (4 H, ABq, Jab = 11.9 Hz, 2 x 
OCtf2C6H5), 4.52, 4.60 (4 H, ABq, 7Ab = 11.9 Hz, 2 x  OCH2C6B 5), 4.70 (2 H, ddd, J  =
9.5 Hz, 9.5 Hz, 9.5 Hz, C-3/3'-H or C-4/4'-H), 4.84-5.13 (18 H, m, CH2OP AB systems 
and C-3/3'-H or C-4/4'-H), 5.16 (2 H, d, 7 =  3.7 Hz, C -l/l'-H ), 7.07-7.27 (60 H, m, 12 x 
C6H5).
I3C NMR (CDC13, 100 MHz): 8 67.34 (t, C-6/6'-H), 69.18 (t, / Cop = 5.5 Hz, 4 x 
CH2OP), 69.42 (t, Jcop = 5.5 Hz, 2 x CH2OP), 69.66 (t, Jcop = 5.5 Hz, 4 x CH2OP), 
69.69 (d, 2 x CH), 72.59 (t, 2 x OCH2C6H5), 73.05 (t, 2 x OCH2C6H5), 74.07 (d, 7Cop =
5.5 Hz, 3.7 Hz, C-3/3' or C-4/4'), 76.89 (d, 2 x CH), 78.39 (d, (d, 7Cop = 5.5 Hz, 3.7 Hz, 
C-3/3' or C-4/4'), 93.44 (d, C-l/1 '), 127.22, 127.33, 127.46, 127.59, 127.79, 127.88, 
127.93, 127.99,128.12,128.23, 128.28, 128.37 (12 d, C6H5), 135.69 (s, Jcop = 7.4 Hz, 2 
x POCH2C6H5 ipso), 135.89, 136.00, 136.12 (3 s, Jcop = 7.3 Hz, 6 x POCH2C6H5 ipso), 
137.33, 137.90 (2 s, 4 x OCH2C6H5 ipso).
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31P NMR (CDCI3, 162 MHz): 5 -1 .9 4  (2 P), -2.20(2 P).
MS: m/z (+ve ion FAB, rel intensity) 1744 [(M+H)+, 85%], 1654 (20), 459(40), 307(85), 
221(50), 91 [(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel intensity) 1742 [(M -H )\ 30%], 1652 [(M -C7H7)\ 80%], 277 
[((C6H5CH20 )2P 0 2) \  100%].
a,a-Trehalose 3,4,3',4'-tetrakisphosphate (50)
The trisphosphate triester 57 (135mg, HAfimoY) was deprotected as described for 
compound 15. Purification by ion-exchange chromatography on Q Sepharose Fast Flow 
Resin, as before gave the glassy triethylammonium salt of 50, which eluted between 500 
mM and 600 mM TEAB. Yield 50.5/zmol, 65%.
[a]o20 = +124 (c = 0.3, H2O, pH 5-6 , calculated for the free acid)
*H NMR (D20 , 400 MHz, pH 7) <5 3.54-3.61 (4 H, m, C-2/2'-H and C-6/6'-H), 3.67-
3.73 (4 H, m, C-5/5'-H and C-6/6'-H), 3.86 (2 H, ddd, J = 9.8Hz, 9.3Hz, 9.3Hz, C-4/4'- 
H), 4.36 (2 H, ddd, J  = 9.3Hz, 9.3Hz, 8.8Hz, C-3/3'-H), 5.03 (2 H, br s, C -l/l'-H ).
3IP NMR (D20 , 162 MHz, pH 7, 'H -coupled) 50.58 (2 P, d, J Hp = 8.9Hz, 3/3'-P), 0.99 
(2 P, d, Jm  = 10.1 Hz, 4/4'-P).
MS: m/z (+ve ion FAB) 255[((C2H5)3N+H +NBA), 85%], 102 [(C2H5)3N+H, 100%].
MS: m/z (-ve ion FAB) 1323 [ 2M \ 80%], 661 [ M \ 100%].
Accurate mass FAB': m/z 660.982 (M') calcd for C 12H25O23P4’, 660.974.
8.9 b-m yo-Inositol 1,3,4-trisphosphorothioate
DL-2,5,6-Tri-0-benzyI-/w-yo-inositol l,3,4-tris(dibenzylthiophosphate) (58)
To a solution of bis(benzyloxy)-7V,N-diisopropylaminophosphine (460mg, 1.33mmol) 
in dry dichloromethane (3mL) was added tetrazole (140mg, 2.00mmol). The mixture 
was stirred at rt for lOmins. The racemic triol 9 (lOOmg, 0.222mmol) was added and 
stirring continued for a further 30mins. Dry pyridine (3mL) and sulphur (lOOmg, 
3.13mmol) were added, and stirring continued for a further 18 h. The solvents were 
removed by evaporation under reduced pressure and the residue was purified by column 
chromatography (ethyl acetate/hexane 1:4) to give 58 (141mg, O.llOmmol, 50%) as an 
oil.
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*H NMR (CDCI3, 400MHz): 5 3.50 (1 H, dd, 7 9.4 Hz, 9.4 Hz, C-5-H), 4.11 (1H, dd, J
9.4 Hz, 9.4 Hz, C-6-H), 4.41-4.48 (2H, m, C-l-H  and C-3-H), 4.63-5.13 (19H, m, 
C H 2C6H 5 and C-2-H), 5.32 (1H, m, C-4-H), 6.98-7.30 (45H, m, CH2C6^ 5)
13C NMR (C D C I3 , 100 MHz): 8  69.60-70.34 (triplets showing 37cop coupling, 
overlapping, 6 x POCH2), 75.05, 75.60, 75.61 (3 t, CHOCH2C6H5), 76.46, 77.34, 78.07, 
78.14, 79.817, 80.67 (6 d, inositol ring Q  127.08, 127.16, 127.27, 127.34, 127.45,
127.80, 127.80, 127.87, 127.94, 128.09, 128.14, 128.22, 128.29, 128.36, 128.40, 
128.47, 128.53 (16d, C H ^ H s )  135.39-136.19 (singlets showing 37cop coupling, 
overlapping, 6 x P O C H ^ H s  ipso), 138.06, 138.29, 138.50 (3s, C O C H ^ H s  ipso).
31P NMR ( C D C I3 , 162MHz ) 566.91 (1 P, app. as sextet, 7hp = 9.5 Hz), 67.75(1 P, app. 
as sextet, 7hp = 10.0 Hz), 69.80(1 P, app. as sextet, 7hp = 9.5 Hz).
MS: m/z (+ve ion FAB, rel intensity) 1279[ (M+H)+, 1.6%], 181(80), 91[(CH2C6H5)+, 
100%]
MS:m/z (-ve ion FAB, rel intensity) 1277[ (M -H )\ 64%], 1185(25), 293 
[OP(S)(OCH2C6H5)2', 100%], 95(30).
Anal. Calcd for C69H69O 11S3P3 (1279.40); C, 64.78; H 5.44, Found C, 65.0; H, 5.45 
d l -myo-Inositol-1,3,4-trisphosphorothioate (59)
Compound 58 (90mg, lOpmol) was deprotected as described for compound 15 and 
purified by ion-exchange chromatography on Q Sepharose Fast Flow Resin, eluting with 
a gradient of triethylammonium bicarbonate buffer (0 to 1M), pH 8.0. The 
triethylammonium salt of 59 eluted between 800 mM and 930 mM. Yield 43^tmol, 
61%).
MS: m/z 466.887 (M -H )' (calcd for C6Hi4012P3S3\  466.886).
lH  NMR (D20 , 400MHz): 53.39 (1H, dd, 7 =  9.3 Hz, 9.3 Hz, C-5-H), 3.67 (1H, dd, 7 = 
9.8 Hz, 9.8 Hz, C-6-H), 4.00 (1H, ddd, 7 =  11.7 Hz, 9.8 Hz, 2.5 Hz, C-l-H), 4.10 (1H, 
ddd, 7 = 12.2 Hz, 9.8 Hz, 2.5 Hz, C-3-H), 4.34 (1H, br s, C-2-H), 4.35 (1H, ddd, 7 =
10.7 Hz, 9.8 Hz, 9.3 Hz, C-4-H).
31P NMR (D20 , 162 MHz): 546.02 (1 P, 7hp = 11.2 Hz), 48.16 (IP, 7HP = 11.7 Hz),
48.83 (IP , 7hp= 11.2 Hz).
MS: m/z (+ve ion FAB, rel intensity) 102 [(C2H5)3NH+, 100%].
MS: m/z (+ve ion FAB, rel intensity) 467 [(M-H)', 100%], 113 [H2PC>3S \ 10%].
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lL-2,5,6-Tri-0-benzyl-/wyo-inositol l,3,4-tris(dibenzylthiophosphate) (l-58)
To a solution of bis(benzyloxy)-A,Af-diisopropylaminophosphine (334mg, 0.966mmol) 
in dry dichloromethane (2mL) was added l//-tetrazole (135mg, 1.93mmol). The mixture 
was stirred at room temperature for 20 min and then the (+)-triol L-9b (72mg,
- j l
0.160mmol) was added, and stirring was continued for 30min. A P NMR spectrum 
now showed an AB system centred around <5p 141.2ppm (7ab = 3.7Hz) and a singlet at 
140.25ppm. Dry DMF (2mL) and dry pyridine(lmL) were added, followed by sulphur 
(46mg, 1.4mmol), and stirring was continued at rt for lOmin. 31P NMR now showed 3 
singlets around <5p 67ppm. No phosphite signals remained. The solvents were removed 
by evaporation under reduced pressure at room temperature. The residue was taken up in 
dichloromethane (50mL), washed with brine (50mL) and dried(MgS04). The solution 
was concentrated by evaporation under reduced pressure to a volume of about 20mL. 
This was left at 4°C overnight to crystallise out some of the excess sulphur, which was 
then filtered off. Purification by column chromatography (pentane/ethyl acetate 4:1) 
afforded L-58 (144mg, 0.113mmol, 71%) as a colourless oil.
[a]D18 = +1.6 (c = 1.2, CHC13).
Anal. Calcd for C w H a A ^ P a  (1279.40); C, 64.78; H 5.44, Found C, 65.0; H, 5.55 
NMR and mass spectroscopic data were identical to those for the racemic compound.
lL-l,3,4-myo-Inositol trisphosphorothioate (L-59)
L-58 (lOOmg, 78.2^mol) was deprotected as described for the racemic compound 59 
and purified by ion exchange chromatography as before. Yield 41/zmol, 52%).
[a]d22 = -1 4  ( c = 0.35, TEAB buffer, pH 8.0) Calculated for the free acid.
NMR and mass spectroscopic data were identical to those for the racemic compound. 
Accurate mass FAB': m/z 466.887 (M -H)' (calcd for C6H 14O 12P3S3', 466.886).




The triol 46 (75mg, 0.161mmol) was thiophosphorylated as described for compound L- 
59. Purification by column chromatography (pentane/ethyl acetate 5:1) afforded 61 
(163mg, 0.126mmol, 78%) as a colourless oil.
A na l Calcd for C70H71O12P3S3 (1293.43); C, 65.00; H 5.53, Found C, 65.0; H, 5.38
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*H NMR (CDCI3, 270MHz): 52.19 (1 H, m, C-6-H), 3.65 (2 H, ABX system (broad), 
C-7-H2), 3.89 (1 H, dd, J  = 10.9 Hz, 7.4 Hz, C-5-H), 4.00 (1 H, dd, J  = 4.7 Hz, 4.7 Hz, 
C-3-H), 4.18, 4.40 (2 H, AB q, /ab = 11.5 Hz, O C//2C6H5), 4.42 (1 H, half of AB 
system of OCtf2C6H5), 4.62-5.25 (18 H, AB systems of OCtf2C6H5, C-l-H , C-2-H, C-4- 
H), 7.04-7.32 (45 H, m, CeH5.
13C NMR (C D C I3 , 68 MHz): 5 43.90 (d, C-6), 64.69 (t, C-7), 69.59-70.04 (6t, 
P (0 )0 C H 2), 72.30, 72.74, 73.79 (3t, CHOCH2C6H5), 75.62, 76.45, 79.30, 81.74, 81.85 
(5d, inositol ring CH), 127.06, 127.18, 127.32, 127.37, 127.55, 127.76, 127.89, 127.97,
128.00, 128.07, 128.12, 128.15, 128.28, 128.31, 128.35, 128.39 (16d, C6H5), 135.59,
135.63, 135.71, 135.84 (4s, 6 x C6H5 ipso), 137.93, 138.29 (2s, 3 x C6H5 ipso).
31P NMR (CDCI3, 162 MHz): 567.76 (2P), 68.23 (IP).
MS: m/z (+ve ion FAB) 1293 [(M+H)+, 70%], 305(50), 271(10), 181(15), 91 [(C7H7)+, 
100%].
MS: m/z (-ve ion FAB) 1201 [(M -C7H7) \  80%], 293 [(C6H5CH20 )2P(0)S ', 100%].
DL-(l,3,5/2,4,6)-6-Hydroxymethyl-cyclohexane-l,2,3,4,5-pentol 1,2,4- 
trisphosphorothioate (=  DL-6-Deoxy-6-hydroxymethyl-scy//o-inositoI-l,2,4- 
trisphosphorothioate 60)
Compound 61 (90mg, 70pmo\) was deprotected as described for 15 and purified by ion- 
exchange chromatography on Q Sepharose Fast Flow Resin, eluting with a gradient of 
triethylammonium bicarbonate buffer (0 to 1M), pH 8.0. The triethylammonium salt of 
60 eluted between 880 mM and 1000 mM. Yield 45mmol, 64%)
Accurate mass FAB': m/z 480.9025 (M -H)' (calcd for C7Hi60i2P3S3', 432.9017).
‘H NMR (D2O, 400MHz): S  1.43 (1 H, br t, J  -  11 Hz, 9.2 Hz, C-6-H), 3.36 (1 H, dd, J  
= 9.3 Hz, 9.3 Hz, C-3-H), 3.47 (1 H, dd, J  = 10.3 Hz, 9.8 Hz, C-5-H), 3.62,3.62 (1 H, br 
d, /  = 12.2 Hz, C-7-Ha), 3.77 (1 H, br d, J  = 12.2 Hz, C-7-Hb), 3.94-4.08 (2 H, m, C -l- 
H, C-4-H), 4.27 (1 H, ddd, J  =11.7 Hz, 9.8 Hz, 9.3 Hz, C-2-H).
31P NMR (D20 ,  162 MHz): 46.47 (1 P, 7Hp = 9.9 Hz), 49.05 (1 P, 7Hp = 12.6 Hz), 50.50 
( 1 P ,7 h p =  11.9 Hz)
MS: m/z (+ve ion FAB) 102 [(C2H5)3NH+, 100%].
MS: m/z (-ve  ion FAB) 481 [(M -H)', 100%], 447(5), 385(5), 113 [H2P 0 3S \ 10%].
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8.11 scy//0 -Inositol 1,2,3,5-tetrakisphosphate
2,4-Di-O-/?-methoxybenzyI-l,3,5-0-methylidene-scy//0-inositol (63)
The ketone 29 (1.98g, 4.63mmol) was dissolved in a mixture of THF (20mL) and 
methanol (80mL). Sodium borohydride (430mg, 11.6 mmol) was added gradually and 
the mixture stirred at room temperature, for a further 30 min. TLC showed complete 
conversion to a product with Rf  0.44 (ethyl acetate/hexane 1:1). Water (lOOmL) was 
added and the product extracted with dichloromethane (3 x lOOmL). The combined 
organic phases were washed with brine and dried over MgSC>4. Evaporation of solvent 
under reduced pressure gave a white solid which was recrystallised from ethyl 
acetate/hexane to provide 63 (1.77g, 4.12 mmol, 89%).
Mp: 125-126°C (from ethyl acetate/hexane or ethanol).
‘H NMR (CDCI3, 270MHz): S 3.79 (6 H, s, 2 x OCH3), 4.10 (1 H, d, J  = 12.45 Hz, D20  
ex 6-OH), 4.34-4.42 (3 H, m, narrows on DzO ex, C-6-H and 2 x C-H), 4.43-4.48 (2 H, 
m, 2 x C-H), 4.56 (4 H, AB s, C tf2C6H5), 4.56 (1 H, m, buried, C-3-H), 5.49 (1 H, s, 
0 3CH), 6.77-6.84 (4 H, m, C ^ O M e ) , 7.08-7.16 (4 H, m, Q /^O M e).
I3C NMR (CDC13, 68 MHz): 555.15 (q, 2 x OCH3), 66.71, 68.73, 69.18, 72.85 (4 d, 6 x 
inositol ring C), 71.36 (t, 2 x CH2C6H40Me), 102.40 (d, 0 3CH), 113.83 (d, C-3 and C-5 
of p-methoxyphenyl rings), 129.56 (d, C-2 and C-6 of /?-methoxyphenyl rings), 129.72 
(s, C-l of p-methoxyphenyl rings), 159.42 (s, C-4 of p-methoxyphenyl rings).
MS: m/z (+ve ion FAB, rel intensity) 431 [(M+H)+, 1%], 309 (8%), 121 [ 
( C H 2C 6H 4 0 C H 3)+ , 100%].
Anal Calcd for C23H26O8, C, 64.18; H, 6.09%), Found: C, 63.9; H, 6.08.
1,3-Di-O-p-me thoxybenzy I-scy/Zo-inositol (64)
To a solution of 63 (l.Og, 2.32mmol) in methanol (50mL) was added 1M HC1 (5mL). 
The mixture was heated at reflux for 30 min after which TLC showed that most of the 
starting material (.K/0.48, ethyl acetate/ hexane 1:1) had been consumed. The heating 
source was removed and concentrated ammonia solution (lm L) was added. Stirring was 
continued for a further 30 min at room temperature and then the solvents were removed 
by evaporation in vacuo to give a solid residue which was extracted with hot ethyl 
acetate (5 x 50mL). Evaporation of the combined extracts, followed by crystallisation 
from methanol/ethyl acetate gave 64 (666mg, 1.58mmol, 68%).
Mp: 161-163°C (from ethyl acetate/methanol).
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*H NMR (d6-DMSO, 270MHz): 52.98-3.19 (5 H, m, C-l-H, C-3-H, C-4-H, C-6-H and 
C-5-H or C-2-H), 3.29 (1 H, m, D20  ex gives t, 7 = 9.2 Hz, C-2-H or C-5-H), 3.73 (6 H, 
s, 2 x OCH3), 4.70 (4 H, s, 2 x OC/72Ar), 4.84 (3 H, d, 7 = 3.5 Hz, D20  ex, 3 x OH), 
4.98 (1 H, d, 7 = 5.3 Hz, D20  ex, OH), 6.86 (4 H, d, 7 = 8.4 Hz, C ^ O M e ) , 7.34 (4 H, 
d, 7 = 8 .4  Hz, C ^ O M e ) .
13C NMR (de-DMSO, 68 MHz): 555.09 (q, 2 x OCH3), 73.43 (t, 2 x OCH2Ar), 73.67 
(d, inositol ring C), 73.79 (d, 2 x inositol ring C), 74.50 (d, inositol ring C), 82.95 (d, 2 x 
inositol ring C), 113.33 (d, C-3 and C-5 of p-methoxyphenyl rings), 129.27 (d, C-2 and 
C-6 of p-methoxyphenyl rings), 131.75 (s, C -1 of p-methoxyphenyl rings), 158.49 (s, C- 
4 of p-methoxyphenyl rings).
MS: m/z (+ve ion FAB, rel intensity) 419 [(M -H)+, 3%], 299 (12), 149 (15), 121 [ 
(CH2C6H4OCH3)+ , 100%].
MS: m/z (-ve ion FAB, rel intensity) 573 [(M+NBA)', 95%], 419 [(M-H)', 100], 291
(43), 118(32).
Anal. Calcd for C22H280 8 (420.46):C, 62.85; H, 6.71%, Found: C, 62.5; H, 6.69.
4,6-Di-0-p-methoxybenzyl-scy//0-inositol l,2,3,5-tetrakis[ bis(2-cyanoethyI)- 
phosphate] (65)
To a solution of bis(cyanoethoxy)-Af,jV-diisopropylaminophosphine (516mg, 1.90mmol) 
in dry dichloromethane (2mL) was added l//-tetrazole (267mg, 3.80mmol). The mixture 
was stirred at room temperature for 10 min and then the tetrol 64 (lOOmg, 0.238mmol) 
was added. The mixture was stirred for a further 1 h, after which a 31P NMR spectrum 
showed a complex pattern of signals around 141ppm. The mixture was cooled to -7 8 °C 
and m-CPBA (360mg, 2.09mmol) was added. The mixture was allowed to reach room 
temperature, and then diluted with ethyl acetate (50mL). The solution was washed with 
10% sodium sulphite solution, sat. N aHC03 and brine (50mL of each), dried (M gS04) 
and evaporated in vacuo to give an oil. Purification by column chromatography (ethyl 
acetate/ethanol 5:1) gave the tetrakisphosphate triester 65 as a colourless oil (237mg, 
0.202mmol, 85%).
’H NMR (CDCI3,400MHz): 52.36-2.58 (8 H, m, 4 x Cff2CN), 2.72 (4 H, br t, J  -  6 Hz, 
C tf2CN), 2.84 (4H, br t, 7 -  6 Hz, CH2CN), 3.80 (6 H, s, 2 x )CH3), 3.86 (2 H, dd, J  =
7.6 Hz, 7.6Hz, C-4/6-H), 3.97-4.47 (16 H, m, 8 x OCf/2CH2CN), 4.61-4.71 (4 H, m, C- 
1/3-H, C-2-H and C-5-H), 4.79 (4 H, AB system, Jab = 11.3 Hz, OCtf2Ar), 6.90 (4 H, d, 
J  = 8.5 Hz, C6# 4OMe), 7.39 (4 H, d, J  = 8.5 Hz, C ^ O M e ) .
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13C NMR (CDCI3, 100 MHz): <519.32 (t, / COp= 7.3 Hz, 4 x CH2CN), 19.55 (t, 7Co p =  9.2 
Hz, 2 x CH2CN), 19.70 (t, Jcop= 7.3 Hz, 2 x CH2CN), 55.34 (q, 2 x OCH3), 62.67 (t, 
/ c o p  = 5.6 Hz, 2 x OCH2CH2CN), 62.85 (t, 7COp =  3.6 Hz, 2 x OCH2CH2CN), 63.08 (t, 
/ c o p  = 5.5 Hz, 2 x OCH2CH2CN), 63.28 (t, 7cop =  5.5 Hz, 2 x OCH2CH2CN), 73.92 (t, 
2 x 0 CH2C6H40Me), 76.50, 77.27, (2 d, / c o p  unreadable, 3 x inositol ring C), 78.20 (d, 
inositol ring C-4/6), 78.60 (d, / c o p  = 7.4 Hz, C-5), 113.81 (d, C-3 and C-5 of p- 
methoxyphenyl rings), 116.66, 116.90, 117.12, 117.43 (4 s, 8 x CN), 128.93 (d, C-2 and 
C-6 of /?-methoxyphenyl rings), 129.35 (s, C-l of p-methoxyphenyl rings), 159.34 (s, C- 
4 of p-methoxyphenyl rings).
31P NMR (CDCI3, 162 MHz): -2 .79 (1 P), -3.11 (3 P).
MS: m/z (+ve ion FAB, rel intensity) 1165 [(M+H)+, 40%], 1043(60), 281(80), 121 [ 
(CH2C6H4OCH3)+ , 100%].
MS: m/z (-ve ion FAB, rel intensity) 1367(30), 1330(80), 1110(100),
203[((NCC2H5O)2PO2)', 45%].
scy//0-Inositol-l,2,3,5-tetrakisphosphate (62)
Compound 65 (lOOmg, 85.8^mol) was deprotected as described for 15, with the 
modification that the reaction was allowed to proceed for 5 min before quenching with 
methanol. Purification by ion-exchange chromatography on Q Sepharose Fast Flow 
Resin, eluting with a gradient of triethylammonium bicarbonate buffer (0 to 1M), pH 8.0 
gave the glassy triethylammonium salt of 62, which eluted between 670 mM and 780 
mM. Yield 61jUmol, 71%)
‘H NMR (D20 , 400 MHz, pH 4): <53.48 ( 2  H, dd, /  = 9.76 Hz, 8.55 Hz, C-4/6-H), 3.83 
( 1 H, dt, / =  8.85 Hz , 9.16 Hz, C-5-H), 3.90-4.02 ( 3 H, m, C-1/3-H and C-2-H).
3IP NMR (D20 , 162 MHz, pH 4): 50.11 ( 2 P, d, / Hp = 8.85 Hz, P-l and P-3), 0.38 ( 1 
P, d, / HP = 8.85 Hz), 0.53 (1  P, d, / Hp = 8.85 Hz).
MS: m/z (+ve ion FAB, rel intensity) 102 [ (C2H5)3NH+, 100%]
MS: m/z (-ve  ion FAB, rel intensity) 999 [(2M-H)', 80%], 499 [ (M -H ) ', 100%] 
Accurate mass FAB': m/z 498.919 (M -H)' calcd for C6H 15O 18P4 , 498.921.
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8.12 D- and L-m yo-Inositol 1,3,4,5-tetrakisphosphate
2-0 -[(-)-fi>Camphanoyl]-l,3,5-0 -methylidene-/7i_y0-inositol (66)
To a solution of myo-inositol orthoformate (27) (l.OOg, 5.26mmol) in dry pyridine 
(lOmL) was added (lS,4R)-(-)-o>-camphanic acid chloride (1.25g, 5.78mmol and a 
catalytic amount of DMAP (50mg). The solution was stirred for 30 min at room 
temperature, after which TLC (dichloromethane/ethyl acetate 2:1) showed conversion to 
a major product (Rf  0.26) and two minor products Cfy0.40 and 0.48). The solvents were 
removed by evaporation in vacuo and the residue was taken up in dichloromethane. 
(lOOmL), washed with 1M HC1 (50mL) and brine (50mL), dried (MgSCL). Evaporation 
in vacuo followed by purification using flash chromatography (dichloromethane/ethyl 
acetate 3:1) gave the 2-camphanate 66 (1.19g, 3.21 mmol, 61%) and smaller amounts of 
the 2,4- and 2,6-biscamphanates (see below).
Rf  0.26 (dichloromethane/ethyl acetate 2:1)
Mp: 241-250°C (from ethyl acetate)
'H  NMR (d6-DMSO, 400 MHz) 50.87, 1.02, 1.07 (9 H, 3 s, camph-CH3), 1.54-1.61 (1 
H, m, camph-CtL), 1.96-2.06 (2 H, m, camph-CfL), 2.40-2.47 (1 H, m, camph-CfD, 
4.16-4.20 (3 H, br m, C-4-H, C-5-H, C-6-H), 4.36 (2 H, br m, C-l-H  and C-3-H), 5.41 
(1 H, br s, C-2-H), 5.59 (1 H, br s, 0 3CH), 5.70 (2 H, br s, D20  ex, C-4-OH, C-6-OH)
13C NMR (ds-DMSO, 100 MHz) S 9.87, 16.64, 16.82 (3q, camph-CH3), 28.84, 30.72 (2 
t, camph-CTL), 54.88, 54.64 (2 s, camph-C), 65.20, 67.32, 69.99, 71.96 (4 d, inositol 
ring C), 91.40 (s, camph-C), 102.25 (d, O3CH), 167.22, 178.75 (2 s, 2 x camph C=0). 
MS: m/z (+ve ion FAB, rel intensity) 741 [ (2M+H)+ , 90%)], 371 [ (M+H)+ , 100%)], 
173 [(M-camphanate)+, 40%]
MS: m/z (-ve ion FAB, rel intensity) 536(100), 523 [ (M+NBA)- , 80% ], 416(30), 369 
[(M-H)", 40%], 197 [(camphanate)‘,30%].
Anal. Calcd for C 17H22O9 (370.36); C, 55.13; H 5.99, Found C, 55.1; H, 6.08
Bis[(-)-o>camphanate] Esters of my0-Inositol Orthoformate: Optimised Method
To a stirred suspension of rayo-inositol orthoformate 27 (2.00g, 10.5mmol) in dry 
dichloromethane (40mL) at 0°C were added triethylamine (3.3mL, 23.7mmol) and a 
catalytic amount of DMAP (80mg). A solution of (lS,4/?)-(-)-co-camphanic acid 
chloride (4.55g, 21.0mmol) in dry dichloromethane (lOmL) was added dropwise under 
N2 at 0°C. The cooling bath was removed after 15min and stirring continued for further
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45min, after which time almost no solid was present and TLC (dichloromethane/ethyl 
acetate 3:l)showed two major products at /?/0.32 and 0.23. The solvent was removed by 
evaporation in vacuo and the residue purified by flash chromatography 
(dichloromethane/ethyl acetate 4:1) giving first the 2,6-biscamphanate 67a (3.46g, 
6.28mmol, 60% yield) and secondly the 2,4-biscamphanate 67b ( 1.35g, 2.45mmol, 
23% yield).
lD-2,6-Di-0-[(-)-a>camphanoyl]-l,3,5-0-methylidene-fwy0-inositol (67a)
Rf 0.32 (dichloromethane/ethyl acetate 3:1); [oc]d = -15  (c = 1, C H C I3 ) , [a]r>26 = -21  (c 
= 1, DMF).
Crystals from ethyl acetate/hexane or propan-2-ol. Gradual melting with sublimation 
above 235°C with phase change to needles, melting at 274-275°C.
'H NMR (C D C I3 , 400 MHz) 5 1.00, 1.03, 1.09, 1.10, 1.12, 1.14 (18 H, 6 s, camph- 
CH3), 1.65-1.75 (2 H, m, camph-CH2), 1.92-2.03 (2 H, m, camph-CH2), 2.06-2.18 (2 H, 
m, camph-CH2), 2.41-2.56 (2 H, m, camph-CH2), 3.29 (1 H, d, /  = 6.8 Hz, D2O ex., 4- 
OH), 4.36 (1 H, dddd, appears as dq, J  = 4 Hz, 2 Hz, 2 Hz, 2 Hz, C-3-H), 4.43 (1 H, 
dddd, appears as dq, J  = 4 Hz, 2 Hz, 2 Hz, 2 Hz, C-l-H), 4.55 (1 H, dddd, appears as tt, 
7 = 4 Hz, 4 Hz, 2 Hz, 2 Hz, C-5-H), 4.66-4.68 (1 H, br m, C-4-H), 5.30 (1 H, ddd, 
appears as partially resolved dt, J -  2 Hz, 2 Hz, 1 Hz, C-2-H), 5.54 (1 H, d, J  = 0.98 Hz, 
O3CH), 5.63 (1 H, ddd, appears as dt, J  = 4 Hz, 4 Hz, 1.5 Hz, C-6-H). 
n C NMR (ds-DMSO, 100 MHz) 59.40,9.45, 15.93, 16.11, 16.18, 16.35 (6 q, camph- 
CHj), 28.22, 28.29, 30.21, 30.65 (4 t, camph-CH2), 53.91, 54.02, 54.26, 54.37 (4s, 
camph C), 64.28, 65.76, 68.14, 68.43, 69.38, 71.08 (6 d, inositol ring C), 90.67 (s, 2 x 
camph C), 102.05 (d, 0 3CH), 166.44, 166.16, 177.63 (3 s, 4 x camph C=0).
MS: m/z (+ve ion FAB, rel intensity) 1101 [ (2M+H)+ , 100%)], 687(60), 551 [ (M+H)+ 
, 80%)], 353 [(M-camphanate)+, 20%]
MS: m/z (-ve ion FAB, rel intensity) 1100[ 2M \ 40%], 989(80), 716(100), 703 [ 
(M +NBA)-, 75% ], 197 [(camphanate)\30%].
Anal. Calcd for C27H34Oi2 (550.56); C, 58.90; H 6.22, Found C, 58.7; H, 6.23
lD-2,4-Di-0-[(-)-to-camphanoyl]-l,3,5-0-methylidene-myo-inositol (67b)
Rf 0.23 (dichloromethane/ethyl acetate 3:1); [ « ] d 25 = +7 (c = 1, DMF).
Mp: 270-272°C (from DMF/water).
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JH NMR (d6-DMSO, 400 MHz) 50.86, 0.88, 1.01, 1.02, 1.05, 1.08 (18 H, 6s, camph- 
CH3), 1.52-1.61 (2 H, m, camph-CH2), 1.84-2.07 (4 H, m, 2 x camph-CH2), 2.38-2.47 (2 
H, m, camph-CH2), 4.23 (1 H, br s, C-H), 4.42 (3 H, br s, 3 x C-H), 5.32 (1 H, br s, C-2- 
H), 5.44 (1 H, br s, C-4-H), 5.73 (1 H, s, 0 3CH), 5.96 (1 H, d, J  = 3.36 Hz, D20  ex., C-
6-OH).
13C NMR (d6-DMSO, 68 MHz) 5 9.47,9.52, 16.13, 16.25, 16.44, 16.54 (6 q, camph- 
CH3), 28.28, 28.41, 30.31, (3 t, 4 x camph-CH2), 53.90, 54.07, 54.31, 54.41 (4 s, camph 
C), 64.46, 65.81, 67.95, 68.39, 68.87, 71.05 (6 d, inositol ring Q , 90.73, 90.86 (2 s, 
camph C), 102.12 (d, 0 3CH), 165.81, 166.57, 177.61 (3 s, 4 x camph C=0).
MS: m/z (+ve ion FAB, rel intensity) 1101 [ (2M+H)+ , 55%)], 687(65), 551 [ (M+H)+ , 
100%)], 353 [(M-camphanate)+, 30%]
MS: m/z (-ve ion FAB, rel intensity) 716(70), 703 [ (M+NBA)- , 40% ], 197 
[(camphanate)', 100%].
Anal. Calcd for C27H34Oi2 (550.56); C, 58.90; H 6.22, Found C, 58.6; H, 6.31 
Id-2,6-Di-0-[(-)-fi>camphanoyl]-myo-inositol (68a)
To a stirred suspension of Id-2,6-di-0-[(-)-cocamphanoyl]-1,3,5-O-methylidene-myo- 
inositol 67a (3.0g, 5.45mmol) in methanol (lOOmL) was added 1.0M HC1 (lOmL). The 
mixture was heated at reflux for 6 h, after which time TLC (CHCl3/MeOH 5:1) showed 
that almost all the starting material (Rf  0.76) had been converted to a major product (Rf  
0.40). The clear solution was allowed to cool, and then evaporated to dryness under 
reduced pressure, leaving a white residue which was purified by flash chromatography 
(CHCl3/MeOH 5:1) to give the tetrol 68a (2.58g, 4.77mmol, 88% yield).
Rf  0.23 (CHCl3/MeOH 5:1)
[«]d25 = -8  ( c =  l.D M F).
Mp: 211-213°C (from propan-2-ol)
‘H NMR (de-DMSO, 400 MHz) S 0.82, 0.87,0.96 (9 H, 3 s, 3 x camph-CH3), 0.99 (6H, 
s, 2 x camph-CH3), 1.03 (3 H, s, c camph-CH3), 1.48-1.58 (2 H, m, camph-CH2), 1.83-
2.05 (4 H, m, 2 x camph -CH2), 2.33-2.44 (2 H, m, camphanate-CH2), 3.22 (1 H, m, 
D20  ex. gives dd, J  = 9.28 Hz, 9.27 Hz, C-5-H), 3.38 (1 H, m, D20  ex. gives dd, J  = 
9.28 Hz, 9.27 Hz, C-4-H), 3.49 (1 H, m, D20  ex. gives dd, J  = 9.76 Hz, 2.93 Hz, C-3- 
H), 3.76 (1 H, m, after D20  ex. signal obscured by H20 , C-l-H), 4.98 (1 H, dd, J  = 
10.26 Hz, 9.76 Hz, C-6-H), 5.12 (1 H, d, J  = 4.88 Hz, D2Q ex., C-4-OH), 5.19 (2 H, br
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s, D20  ex., C-3-OH and C-5-0H), 5.34 (1 H, dd, J  = 2.45 Hz, 2.44 Hz, C-2-H), 5.41 (1 
H, d, / =  5.37 Hz, D20  ex., C-l-OH).
13C NMR (CDC13, 67.8 MHz) 59.60, 9.65, 16.15, 16.41, 16.59 (5 q, 6 x camph-CH3), 
28.48, 30.29 (2 t, 4 x camph-CH2), 53.99, 54.03, 54.37, 54.44 (4 s, 4 x camph-C), 67.02,
68.94, 72.08, 73.48, 75.80, 76.22 (6 d, inositol ring CH), 91.19, 91.38 (2 s, camph-C),
166.26, 178.10 (2 s, 4 x camph-C=0).
MS: m/z (+ve ion FAB, rel intensity) 1081 [(2M+H)+, 40%], 694(40), 677(80), 541 
[(M+H)+, 100%], 343 [(M-camphanate)+, 15%.
MS: m/z (-ve ion FAB, rel intensity) 1246(65), 1233 [(2M+NBA)', 10%], 1145(15), 
1079 [(2M-H), 45%], 979(80), 706(100), 693 [(M+NBA)', 70%], 539 [(M -H)', 28%], 
197 [(camphanate)', 60%].
A na l Calcd for C26H36Oi2.2H20  (576.60), C 54.2; H 6.99, Found C, 54.5; H, 6.89.
I d-2,4-Di-0-[(-)-G>camphanoyl]-myo-inositol (68b)
A solution of the alcohol 67b (520mg, 0.944mmol) in TFA (8mL) and water (2mL) was 
stirred at room temperature. After 40 h, TLC showed almost complete conversion to the 
tetrol. The solvents were removed by evaporation under reduced pressure. Water was 
added (lOmL) and removed by evaporation under reduced pressure. This procedure was 
repeated twice to remove residual TFA, and the dry solid white residue was purified by 
flash chromatography (chloroform/methanol 5:1) to give 68b (436mg, 0.807mmol, 
85%).
Rf  0.23 (CHCl3/MeOH 5:1)
[ « ] d 25 = +12 (c=  1, DMF).
Mp: 238-241°C (from DMF/water).
'H  NMR (ds-DMSO, 400 MHz) 50.87, (6 H, s, 2 x camph-CH3), 0.997, 1.00, 1.02, 1.11 
(12 H, 4 s, 4 x camph-CHj), 1.51-1.57 (2 H, m, camph-CH2), 1.87-2.03 (4 H, m, 2 x 
camph-CH2), 2.36-2.46 (2 H, m, camph-CH2), 3.25 (1 H, m, D20  ex. gives dd, J  = 9.46 
Hz, 9.16 Hz, C-5-H), 3.35 (1 H, m, D20  ex. gives dd, J  = 9.16 Hz, 9.15 Hz, C-6-H), 
3.49 (1 H, m, D20  ex. gives br d, J=  9.16 Hz, C-l-H), 3.74 (1 H, m, D20  ex gives br d, 
J  = 10.07 Hz, C-3-H), 5.03-5.13 (4 H, m, D20  ex. gives 1 H, dd, J  = 9.77 Hz, 9.46 Hz, 
C-4-H and 3 x OH), 5.37 (1 H, br s, C-2-H), 5.38 (1 H, br s, D20  ex, OH).
251
13C NMR (CDCI3, 100.4 MHz) 59.73, 16.37, 16.42, 16.59, 16.66 (5 q, 6 x camph-CH3), 
28.56, 28.62, 30.47 (3 t, 4 x camph-CH2), 54.11, 54.19, 54.53, 54.44 (3 s, 4 x camph-C), 
66.99, 69.18, 72.09, 73.24, 76.22, 76.39 (6 d, inositol ring CH), 91.27, 91.53 (2 s, 
camph-C), 166.38, 166.42, 178.21, 178.25 (4 s, 4 x camph-C=0).
MS: m/z (+ve ion FAB, rel intensity) 1081 [(2M+H)+, 45%], 694(50), 677(80), 541 
[(M+H)+, 100%], 343 [(M-camphanate)+, 10%.
MS: m/z (-ve ion FAB, rel intensity) 1246(60), 1145(15), 1079 [(2M-H), 50%], 
979(70), 706(100), 693 [(M + N B A )', 65%], 539 [(M-H)', 32%], 197 [(camphanate)', 
80%].
I d-2,6-Di-0-[(-)-fi>camphanoyl]-myo-inositol l,3,4,5-tetrakis[bis(2- 
cyanoethyI)phosphate] (69a)
The tetrol 68a (l.Og, 1.85mmol) was phosphitylated using bis(cyanoethoxy)-
1
diisopropylaminophosphine as described for the synthesis of 64. The P NMR spectrum 
of the intermediate tetrakisphosphite showed signals at 8 138.4 (IP, s,), 139.7 (IP, d, 
5JPP = 7.3 Hz), 141.3 (IP, d, 5/ PP = 7.3 Hz), 142.1 (IP, dd, 5/ PP = 7.3 Hz, 7.3 Hz ). 
Oxidation and work-up as before, followed by purification using flash chromatography 
(chloroform/methanol 5:1) afforded 69a (1.99g, 1.55mmol, 84%) as a brittle white 
foam.
[cc]d22 = -11 (c = 1, CHCI3).
‘H NMR (CDCI3, 400 MHz) 5 0.97, 1.05 (6 H, 2s, camph-CH3), 1.10 (6 H, s, 2 x 
camph-CH3), 1.13, 1.15 (6 H, 2s, camph-CH3), 1.71-1.76 (2 H, m, camph-CH2), 1.91-
2.05 (2 H, m, camph-CH2), 2.13-2.18 (1 H, m, camph-CH2), 2.24-2.30 (1 H, m, camph- 
CH2), 2.40-2.47 (1 H, m, camph-CH2), 2.51-2.58 (1 H, m, camph-CH2), 2.75-2.98 (16 
H, m, 8 x CH2CN), 4.32-4.46 (16 H, in, 8 x C7f2CH2CN), 4.66 (1 H, ddd, J = 9.46 Hz, 
9.46 Hz, 9.15 Hz, C-4-H or C-5-H), 4.73-4.86 (3 H, m, C-l-H , C-3-H and C-4-H or C- 
5-H), 5.54 (1 H, dd, J = 9.77 Hz, 9.76 Hz, C-6-H), 6.19 (1 H, br s, C-2-H).
13C NMR (CDC13, 100.4 MHz) 59.62, 9.73, 16.70, 16.73 (4 q, 6 x camph-CH3), 19.73 
(t, 8 x CH2CN), 28.80, 28.86, 30.65, 31.65 ( 4 1, camph-CH2), 54.81, 54.94, 55.0 (3 s, 4 
x camph-C), 63.09-63.55 (overlapping triplets showing 2Jcop coupling, 8 x POCH2),
69.9, 70.26, 71.94, 72.68, 74.83, 75.64 (6 d, inositol ring Q ,  90.95, 91.04 (2 s, camph­
or  117.12, 117.24, 117.34, 117.45 (4 s, 8 x CN), 166.24, 167.15, 177.81, 178.44 (4 s, 
camphanate-C=0)
31P NMR (CDC13, 162 MHz) 5 -3 .83 , -3.74, -3 .10, -2.85
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MS: m/z (+ve ion FAB, rel intensity) 1285 [(M+H)+, 100%], 1081 [(M -
( N C C 2H 50 )2P 0 2 ‘) +, 12%] 288(40), 169(45), 94(60).
MS: m/z (-ve ion FAB, rel intensity) 1450(50), 1437 [(M+NBA)', 25], 1230 [(M - 
CH2CH2CN+)\  100], 203 [(NCC2H50)2P02\  48%].




The tetrol 68b (380mg, 0.703mmol) was phosphitylated as described for 68a. A 3IP 
NMR of the intermediate tetrakisphosphite showed signals at 5 139.3 (IP, d, 5/pP = 6.7 
Hz), 139.5 (IP, s), 141.3 (IP, d, VPP = 7.9 Hz), 142.0 (IP, dd, VPP = 7.9 Hz, 6.7 Hz ). 
After oxidation and work-up as before, purification by flash chromatography 
(chloroform/methanol 10:1) afforded 69b (723mg, 0.563mmol, 80%) as a brittle white 
foam.
[a ]D20 = -6  (c=  1,CHC13).
*H NMR (CDC13, 400 MHz) 51.01, 1.03, 1.11, 1.12, 1.14, 1.17 (18 H, 6s, camph-CH3),
1.69-1.78 (2 H, m, camph-CH2), 1.92-2.06 (2 H, m, camph-CH2), 2.14-2.25 (2 H, m, 
camph-CH2), 2.43-2.58 (2 H, m, camph-CH2), 2.77-3.05 (16 H, m, 8 x C //2CN), 4.27- 
4.51 (16 H, m, 8 x C/72CH2CN), 4.70-4.87 (4 H, m, C-l-H, C-3-H, C-5-H, C-6-H), 5.61 
(1 H, dd, J=  9.77 Hz, 9.27 Hz, C-4-H), 6.15 (1 H, br s, C-2-H).
I3C NMR (C D C I3 , 100.4 MHz) 59.66, 16.70, 16.77, 16.86 (4 q, 6 x camph-CH3), 19.66,
19.73 (2 t, 8 x CH2CN), 28.80, 28.86, 30.93, 31.29 (4 t, camph-CH2), 54.55, 54.68, 
54.77, 54.93 (4 s, camph-C), 64.31-63.57 (overlapping triplets showing 2/ c o p  coupling, 
8 x POCH2), 69.70, 70.64, 72.29, 72.84, 74.40, 75.46 (6 d, inositol ring C), 90.87, 90.97 
(2 s, camph-C), 116.95, 117.08, 117.30, 117.35, 117.41, 117.46, 117.65 (7 s, 8 x CN), 
166.31, 166.82, 177.78, 178.35 (4 s, camph-C=0)
31P NMR (CDCI3, 109.4 MHz) 5-1 .84 , -2.05, -2.85, -3.01.
MS: m/z (+ve ion FAB, rel intensity) 1285 [(M+H)+, 100%], 288(30), 169(40), 94(50). 
MS: m/z (-ve ion FAB, rel intensity) 1450(50), 1437 [(M+NBA)', 30%], 1230 [(M- 
CH2CH2CN+)\  100%], 203 [(NCC2H50)2P02', 55%].




The fully-protected tetrakisphosphate 69a (2.00g, 1.56mmol) was placed into a thick- 
walled Pyrex lOOmL autoclavable bottle with a screw-cap and magnetic stirrer bead, 
followed by concentrated ammonia solution (50mL). The bottle was sealed and heated 
{Care!! Use a safety screen) in a water bath at 60°C for 6 hours. During this time the 
suspension first changed to a clear solution and then to a white suspension. The bottle 
was cooled in an ice bath and then the contents were transferred to a round-bottomed 
flask, together with aqueous washings. The mixture was evaporated to dryness under 
reduced pressure and the residue dissolved in de-ionised water (50mL). Dowex 50 resin 
(H+ form, previously well-washed with de-ionised water) was added to the stirred 
solution until the pH had fallen to approximately pH 2. The solution was then washed 
with dichloromethane (3 x 50mL) and ether (3 x 50mL) before titrating with 1M 
potassium hydroxide solution to pH 10. The solution was then lyophilised and the solid 
residue redissolved in the minimum volume of de-ionised water. Methanol (60mL) was 
added to precipitate the potassium salt which was separated by centrifugation, and the 
supernatant liquid discarded. The precipitate was redissolved in de-ionised water 
(20mL) and lyophilised to give the potassium salt of 70a (1.17g, 1.45mmol, 93% yield). 
[a]o22 = -3 .5  to -4 .0  (c = 2, H20 ) (potassium sa lt); Lit.98 -3 .5  for the potassium salt 
[a]o20 = -3  (c = 2, H20 )  (cyclohexylammonium salt); Lit.129 -2 .5  for the 
cyclohexylammonium salt.
*H NMR (D20 , 400 MHz) 5 3.71 (1 H, dd app. as t, /  = 9.8 Hz, 8.8 Hz, C-6-H), 3.77-
3.83 (2 H, m, C-l-H  and C-5-H), 3.87 (1 H, ddd app. as dt, J  = 9.3 Hz, 8.8 Hz, -2.5 Hz, 
C-3-H), 4.18 (1 H, ddd app. as q, J  = 9.8 Hz, 9.3 Hz, 9.3 Hz, C-4-H), 4.31 (1 H, dd app. 
as poorly resolved t, C-2-H).
13C NMR (D20 , 100 MHz) 5 73.40 (C-2), 74.74 (C-6), 76.47, 76.54 (C-l and C-3), 
78.77 (C-4), 80.51 (C-5).
31P NMR (D20 , 162 MHz) 53.07, 3.66, 3.94, 4.58.
MS: m/z (+ve ion FAB, rel intensity, cyclohexylammonium salt) 100 [C6Hi4N+, 100%] 
MS: m/z (-ve ion FAB, rel intensity, cyclohexylammonium salt) 999 [(2M-H)', 20%], 
499 [ (M -H ) ', 100%]
Accurate mass FAB': m/z 498.921 M' calcd for C6H 15O18P4 ,498.921.
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lL-my0-Inositol-l,3,4,5-tetrakisphosphate (70b)
The fully-protected L-trisphosphate 69b (600mg, 0.467mmol) was deprotected in the 
same way as described for 69a, and treated similarly to give the potassium salt of 70b 
(340mg, 0.422mmol, 90%).
[a]d22 = +3.5 to +4.0 (c = 2, H2O) (potassium salt)
129(Lit +2.6 for the cyclohexylammonium salt.
NMR and mass spectroscopic data were identical to those for the enantiomer 70a. 
Accurate mass FAB': m/z 498.925 M' calcd for C6H 15O 18P4", 498.921.
8.13 Alternative Route to D-mjw-Inositol 1,3,4,5-tetrakisphosphate
lD-2,6-Di-0-[(-)-a)-camphanoyl]-my0-inositol-l,3,4,5-tetrakis(dibenzylphosphate)
(71a)
To a solution of bis(benzyloxy)-Af,iV-diisopropylaminophosphine (765mg, 2.22mmol) in 
dry dichloromethane (4mL) was added l//-tetrazole (311 mg, 4.43mmol). The mixture 
was stirred at room temperature for 20min and then the tetrol 68a (150mg, 0.277mmol) 
was added. Stirring was continued for 30min, after which 31P NMR showed a complex 
pattern of signals around <5p 140ppm. The mixture was cooled to -78°C , m-CPBA 
(420mg, 2.44mmol) was added, and the cooling bath was removed. The mixture was 
allowed to reach room temperature and then diluted with dichloromethane (50mL). The 
clear solution was washed with 10% Na2SC>3, and sat. NaHCC>3 (50mL of each) dried 
(MgS04) and evaporated in vacuo. Purification of the residue by flash chromatography 
(chloroform/methanol 10:1) afforded 71a (377mg, 0.238mmol, 86%) as a colourless oil. 
[a ]D 21 = - 6  (c = 1, CHCI3).
‘H NMR (CDCI3, 270 MHz) 8 0.90 (3 H, s, camphanate-CH3), 0.95 (6 H, s, 2 x 
camphanate-CTL), 1.03 (3 H, s, camphanate-CTL), 1.05 (3 H, s, camphanate-CH3), 1.08 
(3 H, s, camphanate-CH3), 1.45-2.50 (8 H, m, 4 x camphanate-CTL), 4.17 (1 H, ddd, J  = 
10 Hz, 8 Hz, 2.5 Hz, C -l-H  or C-3-H), 4.26-4.38 (2 H, m, 2 x phosphorylated inositol 
ring C-H), 4.89-5.09 (17 H, m, 8 x CH2C6U5 and C-4-H) 5.59 (1 H, dd, J  = 9.8. Hz, 9.8 
Hz, C-6-H), 6.29 (1 H, dd, J=  2.5 Hz 2.5 Hz, C-2-H), 7.12-7.36 (40 H, m, 8 x C6H5).
13C NMR (CDC13> 68 MHz) <59.58, 16.40, 16.50, 16.77 (4 q, 6 x camph-CH3), 28.87 (t, 
2 x camph-CH3), 30.55, 31.14 (2 t, camph-CH3), 69.87, 70.34 (2 t, 8 x OCTLAr), 70.61,
71.63, 72.69, 75.15, 75.60 (5 d, 6 x inositol ring C), 90.87, 90.90 (2 s, 4 x camph-C),
127.84, 128.20, 128.28, 128.38, 128.57, 128.82 (6 d, C6H5), 135.29, 135.37, 135.48,
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135.58, 135.68, 135.77 (6  s, 8  x C6H 5), 165.48, 166.90 (2  s, 2 x c a m p h -C = 0 ) , 177 .66 ,
178.07 (2 s, 2 x c a m p h -C = 0 )
31P  N M R  (C D C I3, 109 M H z) 5 - 1 .0 4 ,  -0 .9 8 ,  - 0 .9 2 ,  -0 .6 1
M S: m/z (+ ve ion  F A B , rel in tensity ) 1581[(M + H )+, 80% ], 271(50), 181(16), 91 
[(C 7H 7)+, 100% ].
M S: m/z ( - v e  ion  F A B , rel in tensity ) 1746(80), 1732(40), 1489 [ (M -C 7H 7)",50% ], 277  [ 
(C 6H 50 )2 P 0 2 - , 100%  ]
Two-Stage Deprotection of 71a
A so lu tion  o f  71a (180m g, 1 14jumole) in  e th an o l/w a te r (4 :1 , 50m L ) w as h y d ro g en o ly sed  
at ro o m  tem p era tu re  o v e r P d /C  (10% , 200m g) at a  p re ssu re  o f  50  p .s.i. fo r 18 h. T h e  
suspension  w as filte red  th ro u g h  C elite  to  rem ove the ca ta ly st an d  then  sp lit in to  tw o  
portions. T h e  firs t p o rtio n  w as ad justed  to  pH  10 w ith  cy c lo h ex y lam in e  an d  then  
lyoph ilised  and  k ep t at -20°C  fo r la te r use. T h e  second  p o rtio n  w as d isso lv ed  in 
concen tra ted  am m o n ia  so lu tio n  and  stirred  a t 60°C  in a  sea led  co n ta in e r fo r 6  h. T h e  
so lu tion  w as a llo w ed  to  coo l and  w ashed  w ith  e th e r (25m L ). A 31P  N M R  at th is  stage  
w as ex trem ely  b road , du e  to  the p resence  o f  p a ram ag n etic  ions, and  sh o w ed  n o  detail. 
T he sam ple w as m ad e up  to  50m L  w ith  d e-io n ised  w a te r an d  p u rified  by  io n -ex ch an g e  
ch rom atography  on Q  S ep h aro se  F ast F low  R esin , e lu tin g  w ith  a  g rad ien t o f  
trie th y lam m o n iu m  b icarb o n a te  b u ffe r (0  to  1M ), pH  8.0. T h e  trie th y lam m o n iu m  salt o f  
70a elu ted  b e tw een  7 3 0  m M  and  850  m M . (M eth o d  n o t op tim ised ).
[a ] D 20 =  - 3  (c = 2, T E A B  buffer, p H  8 ) (trie th y lam m o n iu m  salt) L it129 - 2 .5 °  fo r  th e  
cy c lo h ex y lam m o n iu m  salt.
'H  N M R  (D 20 , 4 0 0  M H z) <53.73 (1 H , dd, 7  =  9 .8  H z, 9 .5  H z, C -6 -H ), 3 .8 6 -3 .9 3  (2 H , 
m , C - l -H  and  C -5 -H ), 3 .98  (1 H , ddd , J = 9 .8  H z, 9 .8  H z, 2 .4  H z, C -3-H ), 4 .2 4  (1 H , dd
7 - 2  H z, app. as p o o rly  re so lv ed  t, C -2-H ), 4 .28  (1H , ddd , 7  =  9.8 H z, 9 .5  H z, 9 .5  H z, 
C -4-H )
31P  N M R  (D 2O, 162 M H z, ^ -d e c o u p le d )  5 - 0 . 5 1 ,  -0 .3 4 ,  0 .08 , 0 .35  (no im p u ritie s  
v isib le).
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Appendix 1 Notes on Nomenclature
T h e  in o sito ls  are  cy c lo h ex an e-l,2 ,3 ,4 ,5 ,6 -h ex o ls . In d iv id u al in o s ito ls  are  d iffe ren tia ted  
b y  the  u se  o f  an ita lic ised  p re fix  and  hyphen. T h ere  are e ig h t p o ss ib le  d ia s te reo iso m eric  
in o sito ls , o f  w h ich  seven  are ach iral meso co m p o u n d s p o ssess in g  an  in te rn a l sy m m etry  
p lan e  (scyllo, myo, neo, epi, muco, cis, alio) and  the  e ig h th  (c /i/ro -in o sito l) is  ch ira l. T h e  
sy m m etry  p lan e  m ay  n o t be  o bv ious in alio-inosito l, in  th a t the  in d iv id u a l c h a ir  fo rm s 
a re  ch ira l, b u t ch a ir-in v ers io n  leads to  the  enan tiom er.
muco cis alio
A s s ig n m e n t o f  L o c a n ts  (P o s itio n a l N u m b e rs ) 262
L o can ts  are  assigned  to  the  carb o n  atom s o f  the  ring . T h e  su b stitu en ts  above th e  p lan e  o f  
th e  rin g  co n stitu te  a  set, and  th o se  be lo w  the  p lan e  an o th e r set. L o w e s t lo c a n ts  are 
re la ted  to  on e  set o f  su b stitu en ts  acco rd ing  to  a  sequence  o f  c r ite ria  w h ich  are ap p lied  
su ccessiv e ly  un til a  d ec is io n  is reached:
(i) to  th e  su b stitu en ts  co n sid e red  as a  num erica l series, w ith o u t reg a rd  to  co n fig u ra tio n ;
(ii) i f  on e  se t o f  su b stitu en ts  is m ore  nu m ero u s than  the  o th er, to  the  m o re  num ero u s;
(iii) i f  th e  se ts  are eq u a lly  n u m ero u s and  one o f  th em  can  b e  d en o ted  by  lo w er n um bers, 
to  th a t set;
(iv ) to  su b stitu en ts  o th e r th an  u n m o d ified  hydroxy l groups;
(v) to  th e  su b stitu en t f irs t in  a lphabe tica l order;
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(v i) — fo r m eso -co m p o u n d s only— to those  p o sitio n s th a t lead  to  an  L ra th e r th an  a  D 
d esig n a tio n  w hen  the  absolute configuration rule is ap p lied  to  th e  lo w es t-n u m b ered  
a sy m m etric  carb o n  a to m  (see  below ).
N o te : L o w est nu m b ers are th o se  that, w hen  co n sid ered  as a  s ing le  ascen d in g  series, 
co n ta in  th e  lo w er n u m b er a t the  firs t p o in t o f  d iffe ren ce , e.g . 1 ,2 ,3 ,6  is lo w er than
T h ese  c rite ria  are  generally  app licab le  to  cyc lito l n o m en c la tu re . F o r 
u n su b s titu ted  in o sito ls , on ly  c rite ria  (ii) and  (vi) are requ ired . A p p lica tio n  o f  th ese  
c r ite ria  to  m yo-inosito l, fo r exam ple , g ives the n u m b erin g  show n  b e lo w , in  w h ich  the  
ax ia l h y d ro x y l g ro u p  is d esig n ated  as the  2-position .
Derivatives of Inositols
T h e  n u m b erin g s o f  the  p a ren t in osito ls  are re ta in ed  fo r deriva tives. W ith in  th is 
fram ew o rk , c rite ria  (iv) and  (v) are u sed  to  dec ide  b e tw een  a lte rna tives. T h ese  arise  
b ecau se  (a) in several o f  the  p aren t inosito ls  (scyllo, neo, muco, cis, chiro) th ere  are  tw o 
o r m o re  fu lly  eq u iv a len t s tarting  po in ts  (re la ted  by  a  C„ sym m etry  ax is) fo r the 
n u m b erin g , th a t m ay  n o t be  eq u iv a len t in  the deriva tives, and  (b) c rite rio n  (v i) does no t 
app ly  to  ch ira l d eriv a tiv es  o f  in osito ls  h av ing  a sym m etry  p lan e  {scyllo, myo, neo, epi, 
muco, cis, alio). T h e  app lica tion  o f  c rite ria  (iv) an d  (v) to  a  p a ir  o f  en an tio m ers  g ives 
each  a  p a ir  o f  m irro r-re la ted  p o sitio n s  o f  th e  sam e num bering . T yp ica lly , one 
en an tio m er w ill be  n u m b ered  c lo ck w ise , the o ther an ti-c lockw ise .
Absolute Configuration Rule262
T h e ab so lu te  co n fig u ra tio n  o f  each  en an tio m er is sp ec ified  by  m ak in g  a  vertical F isch er 
p ro jec tio n  o f  the  s tru c tu re  w ith  C - l  a t the  top  and  w ith  C -2  an d  C -3 on  the fro n t ed g e  o f  
the ring . T h e  co n fig u ra tio n  is then  desig n ated  D i f  the hydroxy l g roup  o f  the low est- 
n u m b ered  s te reo g en ic  cen tre  (o r o th er su b stitu en t i f  no  h ydroxy l g roup  is p resen t) 
p ro jec ts  to  th e  righ t, an d  as L- i f  it p o in ts  to  th e  left:
Above plane









1 D-myo-inositol 1 ,3 ,4-trisphosphate 1 L-ch/ro-inositol 2 ,3 ,5-trisphosphate
p
For myo-inositol derivatives, this rule has the consequence that derivatives numbered 
anticlockwise have the prefix D -, and clockwise numbering leads to the L - prefix:
The mere absence of a prefix D , L or D L indicates that the compound has a meso- 
configuration (e.g. Ins(l,3 ,4 ,6 )P4) and should therefore not be omitted. However, see 
below.
R e la x a tio n  o f  L o w est L o c a n t R u le
may be relaxed, so that a compound that by this rule belongs to the 1l  series may be 
given the I d  numbering if this shows the relationships that the author wishes to stress. 
For example, in the metabolic conversion:
lD-rayo-inositol 1,3,4-trisphosphate —> lL-myo-inositol 1,6-bisphosphate,
it may not be obvious that the step is simply a hydrolysis at C -l, but this is immediately
apparent if the conversion is written as:
lD-m yo-inositol 1,3,4-trisphosphate —» lD-m yo-inositol 3,4-bisphosphate.
T h e  S y m b o l In s
The recommendation also allows that Ins should be taken to mean wyo-inositol with 
the numbering of the I d  configuration unless other prefixes are explicitly added. Thus, 
lD-myo-inositol 1,4,5-trisphosphate may be symbolised as Ins(l,4,5)P3. In this thesis, D -
OH
D-/T7yo-lns ( 1 ,3 ,4)P 3
oh
L-myo-lns(1,3,4)P3
A more recent recommendation263 allows that, when necessary, the lowest-locant rule
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an d  L -prefixes are o ften  used , even  w hen  no t s tric tly  req u ired , an d  th e  lo w est lo can t ru le  
ap p lied , so  as to  em p h asise  p articu la r ste reochem ica l re la tio n sh ip s , e .g .





h o \ « ^ ^ o p o 3
OPO 2 -











[ Criteria (ii) and (vi) ]
2 Allocate lowest numbers to phosphate groups within this framework:
ho 2 -
I O P O 3 6 
H 0 - \ ^ ^ ^ 0 2P 0 3
OPO-
myo-inositol 1,4,5-trisphosphate
3 Determine absolute configuration:
[ Criterion (iv) ]
Criterion (vi) no longer 
applies, and therefore 
direction of numbering 
changes to give lowest 
locants.




Appendix 2 X-Ray Crystallography Data for 67a
Note: The labelling scheme for atoms in 6 7 a  is that given in Figure 7.7a.
A crystal of approximate dimensions 0.3 x 0.3 x 0.3 mm was used for data 
collection.
Crystal data: C27H340 12, M  = 550.54, Monoclinic , a = 6.755(1), b = 
31.139(2), c = 7.035(1) A , )3 = 117.800(10)°, U = 1309.0(3) A3, space group P2„  
Z  = 2, Dc = 1.397 gem 3, (fiMo-KJ = 0.110 mm'1, F(000) = 584. Crystallographic 
measurements were made at 293(2)° K o n a  CAD4 automatic four-circle 
diffractometer in the range 2.61<0<21.93 . Data (1795 reflections) were 
corrected for Lorentz and polarization but not for absorption.
In the final least squares cycles all atoms were allowed to vibrate 
anisotropically. Hydrogen atoms were included at calculated positions where 
relevant, except in the case of H1A which was located in the penultimate 
difference Fourier and refined at a distance of 0.96 A  from 04. Examination of the 
supramolecular structure revealed that the lattice is dominated by one 
dimensional linear polymers parallel to the a axis as a consequence of hydrogen 
bonding. Typically, H1A (attached to 04) interacts with 0 8  of the molecule 
generated via the operator -1+x, y, z. [H1A-08, 2.14(3) A; 04-H1A-08, 157(6) *].
The solution of the structure (SHELX86)1 and refinement (SHELX93)2 
converged to a conventional [i.e. based on 1326 with Fo>4a(Fo)] R1 =0.0318 
and wR2 = 0.0755. Goodness of fit = 1.029. The max. and min. residual densities 
were 0.185 and -0.175 eA '3 respectively.
1. Sheldrick G.M., Acta Cryst., A46, 467-73, 1990.
2. Sheldrick G.M., J.Appl.Cryst., 1995 (In preparation.)
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Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [l>2cr(l)]
R indices (all data)
Absolute structure parameter 











a = 6.755(1 )A
b = 31.139(2)A beta = 117.80(1)" 




0.110 mm ‘1 
584
0.3 x 0.3 x 0.3 mm 
2.61 to 21.93°.
-7<=h<=0; 0<=k<=32; -6<=l<=7 
1795
1638 [R(int) = 0.1331]
Full-matrix least-squares on F2
1 6 3 0 /2 /3 6 2
1.029
R1 =0.0318 wR2 = 0.0755 
R1 =0.0593 wR2 = 0.1193 
- 1(2 )




Fc’ =kFc[1 +0.001 xFc!X3/sin(6)]” ‘
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic 
displacement parameters (A2 x 103) U(eq) 
is defined as one third of the trace of the orthogonalized Uij tensor.
Atom X y z U(eq)
0(1) -255(8) 5365(2) 10997(6) 64(1)
0(2) -3838(8) 5078(2) 9334(7) 66(1)
0(3) -3254(8) 5782(2) 8695(7) 67(1)
0(4) -4273(7) 5171(1) 3953(6) 63(1)
0(5) -518(6) 4652(1) 6815(6) 48(1)
0(6) -2121(7) 4025(1) 6876(6) 53(1)
0(7) 1069(6) 4373(1) 4277(5) 43(1)
0(8) 3352(6) 4304(2) 2804(6) 51(1)
0(9) 903(7) 5933(2) 8669(6) 59(1)
0(10) 74(11) 6264(2) 5571(7) 98(2)
0(11) 2818(8) 6933(2) 7690(7) 64(1)
0(12) 3831(9) 7625(2) 8288(9) 85(2)
C(1) 200(9) 5224(2) 9282(8) 48(2)
0(2) -1127(10) 4817(2) 8392(9) 47(2)
0(3) -3592(10) 4924(2) 7521(9) 50(2)
0(4) -4433(10) 5285(2) 5835(9) 57(2)
0(5) -2947(11) 5670(2) 6852(10) 57(2)
0(6) -517(10) 5572(2) 7602(9) 50(2)
0(7) -2541(14) 5444(2) 10204(11) 69(2)
0(8) -1083(8) 4243(2) 6232(8) 39(1)
0(9) -298(8) 4062(2) 4734(8) 38(1)
0(10) 2196(9) 4135(2) 3469(8) 41(2)
0(11) 1597(8) 3669(2) 3509(8) 41(1)
0(12) -848(9) 3647(2) 1708(9) 46(1)
0(13) -2145(9) 3925(2) 2538(9) 50(2)
0(14) 1270(8) 3672(2) 5553(8) 38(1)
0(15) 3405(9) 3763(2) 7640(9) 49(2)
0(16) 187(10) 3265(2) 5859(9) 51(2)
0(17) 3192(10) 3353(2) 3352(9) 53(2)
0(18) 1041(12) 6256(2) 7500(10) 58(2)
0(19) 2430(10) 6610(2) 8982(9) 46(2)
C(20) 3356(11) 7301(2) 8881(11) 60(2)
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C (21) 3306(9) 7199(2) 10961(10) 50(2)
C(22) 5365(10) 6905(2) 12144(11) 63(2)
C(23) 47 40(10) 6494(2) 10779(11) 62(2)
C(24) 1349(9) • 6868(2) 10101(9) 48(2)
C(25) -901(11) 7066(3) 8529(13) 77(2)
C(26) 1091(12) 6630(2) 11874(10) 64(2)
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C (19)-C (24)-C (25) 113 .0 (5)
C (19)-C (24)-C (26) 115 .4(5)
C (25)-C (24)-C (26) 109 .4(5)
C( 19 )-C (24)-C (21) 91 .5 (4 )
C (25)-C (24)-C (21) 112 .9(5)
C (26)-C (24)-C (21) 113 .7(5)
268
Table 4. Anisotropic displacement parameters (A2 x 103)
The anisotropic displacement factor exponent takes the form: 
-2 pi2 [ h2 a* 2 U11 + ... + 2 h k a* b* U12 ]
Atom U11 U22 U33 U23 U13 U12
0 (1) 89(4) 60(3) 44(2) -5(2) 34(2) -10(3)
0 (2) 87(3) 63(3) 72(3) -13(2) 58(3) -14(3)
0(3) 90(3) 54(3) 69(3) -5(3) 48(3) 6 (2)
0(4) 63(3) 73(3) 43(2) -3(2) 17(2) -9(2)
0(5) 54(2) 47(3) 52(2) -1(2) 33(2) -6(2)
0 (6) 58(3) 50(3) 59(3) 0(2) 35(2) -12(2)
0(7) 44(2) 43(3) 46(2) 5(2) 25(2) -4(2)
0 (8) 47(2) 56(3) 55(2) 8(2) 30(2) -5(2)
0(9) 82(3) 49(3) 46(2) -4(2) 30(2) -19(2)
0 (10) 155(5) 93(4) 45(3) -4(3) 48(3) -51(4)
0 (11) 95(3) 51(3) 66(3) -5(2) 55(3) -19(2)
0 (12) 116(4) 58(3) 100(4) 5(3) 68(3) -20(3)
C(1) 52(3) 47(4) 45(3) -4(3) 21(3) -5(3)
C(2) 60(4) 47(4) 42(3) 0(3) 30(3) -5(3)
C(3) 56(4) 54(4) 49(3) -3(3) 31(3) -6(3)
0(4) 51(4) 70(5) 51(4) -5(4) 24(3) 3(3)
0(5) 76(5) 49(4) 45(3) 0(3) 27(3) 0(3)
0 (6) 66(4) 46(4) 40(3) -4(3) 25(3) -12(3)
0(7) 102(6) 67(5) 54(4) -12(4) 51(4) -8(5)
0 (8) 31(3) 41(4) 38(3) 2(3) 11(3) -3(3)
0(9) 36(3) 47(4) 34(3) 6(2) 18(3) -5(3)
0 (10) 29(3) 59(4) 31(3) 5(3) 10(3) -1(3)
0 (11) 36(3) 47(4) 40(3) 0(3) 20(3) -2(3)
0 (12) 41(3) 56(4) 38(3) -3(3) 17(3) -10(3)
0(13) 30(3) 73(4) 37(3) 7(3) 7(3) -6(3)
0(14) 32(3) 49(4) 33(3) 7(3) 14(3) -5(3)
0(15) 36(3) 59(4) 45(3) 9(3) 13(3) -2(3)
0(16) 54(4) 57(4) 50(3) 10(3) 30(3) -4(3)
0(17) 49(4) 59(4) 56(3) 2(3) 29(3) -3(3)
0(18) 89(5) 54(5) 51(4) 1(3) 49(4) -11(4)
0(19) 57(4) 43(4) 46(3) -2(3) 31(3) -13(3)
C(20) 67(4) 50(4) 76(5) 2(4) 43(4) -5(4)
0 (21) 53(4) 47(4) 60(4) -3(3) 34(3) -4(3)
C(22) 42(4) 60(5) 74(4) -9(4) 15(3) 0(3)
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C (23) 55(4) 52(4) 86(5) 3(4) 38(4) 8 (3 )
C (24) 43(3) 53(4) 48(3) 2(3) 21(3) -1 (3)
C (25) 51(4) 88(6) 87(5) 6(4) 28(4) 12(4)
C (26) 76(5) 70(5) 61(4) -3(4) 4 5 (4 ) -14(4)
C (27) 101(6) 58(5) 82(5) -21(4) 51(5) -10(4)
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Table 5. Hydrogen coordinates ( x 104) and isotropic 
displacement parameters (A2 x 103)
Atom X y z U(eq)
H(1 A) -5099(95) 4921(13) 3199(94) 75
H(1) 1802(9) 5165(2) 9848(8) 58
H(2) -696(10) 4607(2) 9556(9) 57
H(3) -4499(10) 4665(2) 6931(9) 60
H(4) -5987(10) 5356(2) 5455(9) 69
H(5) -3418(11) 5909(2) 5831(10) 68
H(6) -285(10) 5479(2) 6390(9) 60
H(7) -2772(14) 5536(2) 11418(11) 82
H(12A) -976(9) 3760(2) 370(9) 55
H(12B) -1394(9) 3353(2) 1477(9) 55
H(13A) -2822(9) 4171(2) 1613(9) 60
H(13B) -3297(9) 3761(2) 2668(9) 60
H(15A) 4108(35) 4018(7) 7471(23) 74
H(15B) 4413(28) 3524(6) 7971(33) 74
H(15C) 3034(12) 3804(12) 8789(16) 74
H(16A) -31(58) 3295(5) 7107(36) 77
H(16B) 1144(29) 3023(3) 6047(59) 77
H(16C) -1232(29) 3219(7) 4616(27) 77
H(17A) 2730(38) 3066(2) 3459(64) 79
H(17B) 4671(15) 3402(8) 4500(39) 79
H(17C) 3195(51) 3387(9) 1998(28) 79
H(22A) 6697(10) 7036(2) 12208(11) 76
H(22B) 5623(10) 6844(2) 13594(11) 76
H(23A) 5787(10) 6437(2) 10224(11) 75
H(23B) 4678(10) 6248(2) 11590(11) 75
H(25A) -1385(46) 7261(14) 9288(22) 116
H(25B) -1992(26) 6843(3) 7885(66) 116
H(25C) -734(24) 7220(15) 7428(53) 116
H(26A) -49(56) 6415(10) 11243(12) 96
H(26B) 676(76) 6830(3) 12665(48) 96
H(26C) 2485(26) 6496(13) 12828(44) 96
H(27A) 3189(87) 7497(3) 13490(41) 115
H(27B) 1840(44) 7745(9) 11319(34) 115
H(27C) 4460(47) 7769(9) 12524(73) 115
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Appendix 3 3,P NMR Titration of Ins(l,3,4,5)P4
A preliminary 3IP NMR titration for D-70a indicates a complex micro-protonation 
process due to interactions of the phosphate groups. A slight upfield shift is observed for 
PI on deprotonation, an effect also observed for Ins(l,4 ,5 )P3 .189 However it is clear that 
the behaviour of P4 is very different from that of P4 in Ins(l,4 ,5 )P3 . Further experiments 
are in progress.











. *O OO O o













1) S im p so n , P. B .; C h alliss , R. A . J.; N ahorsk i, S. R . Trends Neurosci. 1995 ,18, 299 -306 .
2) M en n iti, F . S .; B ird , G . S. J.; G lennon , M . C .; O bie , J. F .; R o ssie r, M . F .; P u tn ey  Jr., J. 
W . Molecular and Cellular Neurosciences 1992, 3, 1-10.
3) C lap h am , D . E . Cell 1995, 80, 259-268.
4 ) B errid g e , M . J. Ann. N. Y. Acad. Sci 1995, 766, 31-43.
5) S tuck i, J. W .; S om ogy i, R . Biochim. Biophys. Acta 1994,1183, 4 5 3 -4 7 2 .
6) K im , S .; L ak h an i, V .; V osta , D . J.; S harara , A. I.; F itz , J. G .; H uang , L .-W .; P e ters , K.
G .; K in d m an , L . A. J. Biol. Chem. 1995, 270, 5266-5269 .
7 ) C h o i, O . H .; K im , J. H .; K inet, J. P. Nature (London) 1996, 380, 634 -636 .
8) B errid g e , M . J. Mol. Cell. Endocrinol. 1994, 98, 119-124.
9) G u , Q .-M .; S ih , C. J. J. Am. Chem. Soc. 1994,116, 7 4 81-7486 .
10) G alio n e , A . Mol. Cell. Endocrinol. 1994, 98, 125-131.
11) V u, C. Q .; L u , P .-J.; C hen , C .-S .; Jacobson , M . K. J. Biol. Chem. 1996, 271, 47 4 7 - 
4754 .
12) M eszaro s, L .; B ak , J.; C hu , A . Nature (London) 1993, 364, 76 -79 .
13) K im , H . Y .; T h o m as, D .; H an ley , M . R . Mol. Pharmacol. 1996, 49, 360 -364 .
14) W o jc ik iew icz , R. J. H . J. Biol. Chem. 1995, 270, 11678-11683.
15) M atsu m o to , M .; N ak ag aw a, T .; Inoue, T .; N agata , E .; T an ak a , K .; T ak an o , H .; M inow a, 
O .; K uno , J.; S ak ak ib ara , S .; Y am ada, M .; Y onesh im a, H .; M iy aw ak i, A .; F u k u u ch i, Y .; 
F u ru ich i, T .; O kano , H .; M ik o sh ib a , K .; N oda, T. Nature (London) 1996, 379, 168-171.
16) B lo n d e l, O .; T ak ed a , J.; Janssen , H .; Seino , S.; B ell, G . I. J. Biol. Chem. 1993, 268, 
11356-11363 .
17) B lo n d e l, O .; M o o d y , M . M .; D ep ao li, A . M .; S harp , A . H .; R oss, C. A .; S w ift, H .; B ell, 
G . I. Proc. Natl. Acad. Sci. USA 1994, 91, 7777-7781 .
18) Jo sep h , S. K. Cell. Signal. 1996, 8 , 1-7.
19) K han , A . A .; S te iner, J. P .; K lein , M . G .; S chneider, M . F .; S nyder, S. H . Science 1992, 
2 5 7 , 815-818 .
273
20) K h an , A . A .; S te iner, J. P .; S nyder, S. H. Proc. Natl. Acad. Sci. USA 1992, 89, 2 8 4 9 - 
2853 .
21) M o n k aw a , T .; M iyaw ak i, A .; S ug iyam a, T .; Y onesh im a, H .; Y a m a m o to -H in o , M .; 
F u ru ich i, T .; S aru ta , T .; H asegaw a, M .; M ikosh iba , K . J. Biol. Chem. 1995,270, 14700- 
14704.
22) Jo sep h , S. K .; L in , C .; P ierson , S .; T hom as, A. P .; M aran to , A . R . J. Biol. Chem. 1995, 
270, 2 3 3 10-23316 .
23) W atras , J.; M oraru , I.; C osta , D . J.; K indm an, L. A . Biochemistry 1994, 33, 14359- 
14367.
24) B errid g e , M . J. Biochem. J. 1995, 312, 1-11.
25 ) H o th , M .; P enner, R . Nature (London) 1992, 355, 353 -356 .
26) R an d riam am p ita , C .; T sien , R . Y. Nature (London) 1993, 364, 809 -8 1 4 .
27) P arek h , A . B .; T erlau , H .; S tiihm er, W . Nature (London) 1993, 364, 814 -818 .
28) T h o m as, D .; H an ley , M . R. J. Biol. Chem. 1995, 270, 6 4 2 9 -6 4 3 2 .
29) D eL isle , S.; B londel, O .; L ongo , F . J.; S chnabel, W . E .; B ell, G . I.; W elsh , M . J. Am. J. 
Physiol. Cell. Physiol. 1996, 39, C 1255-C 1261 .
30) C lem en ti, E .; M artin i, A .; S tefan i, G .; M eldo lesi, J.; V o lp e , P . Eur. J. Pharmacol.- 
Molecular Pharmacology Section 1995, 289, 23-31.
31) P o tte r, B . V . L .; L am p e , D . Angew. Chem. Int. Ed. Engl. 1995, 34, 1933-1972.
32) T ak ah ash i, M .; T anzaw a, K .; T ak ah ash i, S. J. Biol. Chem. 1994, 269, 369 -372 .
33) W o rley , P. F .; B araban , J. M .; S upattapone , S.; W ilso n , V . S.; S n y d er, S. H . J. Biol. 
Chem. 1987, 262, 12132-12136.
34) W este rd u in , P .; W illem s, H . A . M .; van  B oeckel, C . A . A . Tetrahedron Lett. 1990, 31, 
6 919-6 9 2 2 .
35) W illem s, H . A . M .; V een em an , G . H .; W este rdu in , P. Tetrahedron Lett. 1992, 33, 
2 075-2 0 7 8 .
36) K o z ik o w sk i, A . P.; O g nyanov , V . I.; C hen , C .; K urian , P.; C rew s, F . T . Tetrahedron 
Lett. 1993, 34, 219-222.
274
37) G u illem ette , G .; L aM o n tag n e , S.; B ou lay , G .; M ou illac , B . Mol. Pharmacol 1989, 35, 
339-344 .
38) B ezp ro zv an n y , I.; O ndrias, K .; K aftan , E .; S toyanovsky , D . A .; E hrlich , B . E . M ol Biol 
Cell 1993, 4, 347-352 .
39) B ro w n , G .R ., Sayers, L .G ., K irk , C .J., M ichell, R .H ., M ich elan g eli, F. Biochem. J.
1992, 282, 309-312 .
40 ) S ayers, L . G .; M ichelangeli, F. Biochem. Biophys. Res. Commun. 1993 ,197, 1203- 
1208.
4 1 ) S ayers, L . G .; M ichelangeli, F. Biochim. Biophys. Acta 1993,1152, 177-183.
4 2 ) R ich ard so n , A .; T ay lo r, C. W . J. Biol. Chem. 1993, 268, 11528-11533.
43 ) D reef, C . E .; Jansze , J .-P .; E lie , C. J. J.; van  der M arel, G . A .; van  B o o m , J. H . 
Carbohydr. Res. 1992, 234, 37-50 .
4 4 ) G aw ler, D . J.; P o tte r, B . V . L .; G igg , R .; N ahorsk i, S. R . Biochem. J. 1991, 276, 163- 
167.
4 5 ) L iu , C .; A l-H afid h , J.; W estw ick , J.; P o tte r, B . V . L . Bioorg. Med. Chem. 1994, 2, 253- 
257.
46 ) K o z ik o w sk i, A . P.; F auq , A . H .; W ilcox , R. A .; C h alliss , R. A. J.; N ah o rsk i, S. R. / .  
Med. Chem. 1994, 37, 868-872.
4 7 ) S afrany , S. T .; W ilco x , R. A .; L iu , C .; D ubreu il, D .; P o tte r, B . V . L .; N ah o rsk i, S. R. 
Mol. Pharmacol. 1993, 43, 499 -503 .
4 8 ) A l-H afid h , J.; M ills, S. J.; L am pe , D .; L iu , C .; P o tte r, B . V . L .; W estw ick , J. Br. J. 
Pharmacol. 1994,112 S, 4 3 5 P
4 9 ) M ills , S. J.; R iley , A . M .; M urp h y , C. T .; B u llock , A . J.; W estw ick , J.; P o tte r, B . V . L. 
Bioorg. Med. Chem. Lett. 1995, 5, 203-208 .
50 ) F auq , A . H .; Z aid i, J. H .; W ilco x , R . A .; V arvel, G .; N ahorsk i, S. R .; K o z ik o w sk i, A .
P .; E m eu x , C . Tetrahedron Lett. 1996, 37, 1917-1920.
51) B ird , G . S. J.; P u tney  Jr., J. W . J. Biol Chem. 1996, 271, 6766 -6 7 7 0 .
52) H u g h es, P. J.; M ich ell, R . H . Curr. Opin. Neurobiol. 1993, 3, 383 -400 .
53) Irv ine , R . F. Biochem. Soc. Trans. 1995, 23, 27-35 .
275
54) L u , P .-J.; S h ieh , W .-R .; C hen, C .-S . Biochem. Biophys. Res. Commun. 1996, 220, 637- 
642.
55) H aw k in s, P. T .; P oyner, D. R .; Jackson , T. R .; L etcher, A . J.; L ander, D . J.; Irv ine , R. F. 
Biochem. J. 1993, 294, 929-934 .
56) M en n iti, F. S .; O liver, K . G .; P u tney  Jr., J. W .; S hears, S. B . Trends. Biol. Sci. 1993,18, 
53-56 .
57) F alck , J. R .; R eddy , K. K .; Y e, J.; Saady , M .; M io sk o w sk i, C .; S h ears , S. B .; T an , Z.; 
S afrany , S. J. Am. Chem. Soc. 1995,117, 12172-12175.
58) V an w ey en b erg , V .; C om m uni, D .; D 'S an tos, C. S.; E m eu x , C . Biochem. J. 1995, 306, 
429-4 3 5 .
59) C o m m u n i, D .; V anw eyenberg , V .; E m eu x , C. Cell. Signal. 1995, 7, 6 4 3 -6 5 0 .
60) L ee , S. Y .; S im , S. S.; K im , J. W .; M oon , K. H .; K im , J. H .; R hee, S. G . J. Biol. Chem. 
1990, 265, 9434-9440 .
61) L in , T .-A .; L in , T .-N .; H e, Y. Y .; H su , C. Y .; S un, G . Y. Biochem. Biophys. Res. 
Commun. 1992,150, 626-629.
62) d a  S ilva , C . P .; E m m rich , F.; G use, A . H . J. Biol. Chem. 1994, 269, 12521-12526 .
63) S afrany , S. T .; W ilcox , R. A .; L iu , C .; P o tte r, B . V. L .; N ah o rsk i, S. R . Ear. 
J.Pharmacol.-Molecular Pharmacology Section 1992, 226, 265 -272 .
64) S afrany , S. T .; S aw yer, D . A .; N ahorsk i, S. R .; P o tter, B . V . L. Chirality 1992, 4, 415- 
422 .
65) C hung , S .-K .; M oon , S .-H . Carbohydr. Res. 1994, 260, 39-50 .
66) C rax to n , A .; A li, N .; S hears, S. B . J. Biol. Chem. 1995, 305, 4 9 1 -498 .
67) V an  D ijk en , P .; de H aas, J .-R .; C rax ton , A .; E m eu x , C .; S hears, S. B .; van  H aastert, P.
J. M . J. Biol. Chem. 1995, 270, 29724-29731 .
68) L iu , C .; P o tte r, B. V . L . Tetrahedron Lett. 1994, 35, 1605-1608.
69) W ilco x , R . A .; W h ith am , E. M .; L iu , C .; P o tte r, B . V . L .; N ah o rsk i, S. R . FEBS Lett. 
1993, 336, 261-211.
70) K o z ik o w sk i, A . P .; F auq , A. H .; W ilco x , R. A .; N ah o rsk i, S. R . J. Org. Chem. 1994,
59, 2279-2 2 8 1 .
71) V erjan s, B .; M oreau , C .; E m eu x , C. Mol. Cell. Endocrinol. 1994, 98, 167-171 .
276
72) L ax m in aray an , K . M .; M atza ris , M .; S peed , C. J.; M itch e ll, C. A . J. Biol. Chem. 1993, 
268, 4 9 6 8 -4 9 7 4 .
73) L ax m in aray an , K . M .; C han , B . K .; T etaz, T .; B ird , P. I.; M itchell, C . A . J. Biol. Chem. 
1994,269, 17305-17310.
74) A ttree , O .; O livos, I. M .; O kabe, I.; B ailey , L. C .; N elson , D . L .; L ew is , R . A .; M cln n es , 
R . R .; N u ssb au m , R . L . Nature (London) 1992, 358, 239 -242 .
75) Z h an g , X .; Jefferson , A . B .; A u e th av ek ia t, V .; M ajeru s , P. W . Proc. Natl. Acad. Sci. 
USA 1995, 92, 4 853-4856 .
76 ) N ye, K . E .; R iley , G. A .; P in ch in g , A. J. Clin. Exp. Immunol. 1992, 89, 89-93.
77 ) M en g u b as, K .; Jab b ar, S. A . B .; N ye, K . E .; W ilk es , S .; H o ffb ran d , A . V .; 
W ick rem asin g h e , R. G . Leukaemia 1994, 8 , 1718-1725.
78 ) Jack so n , S. P .; S ch o en w aeld er, S. M .; M atzaris , M .; B ro w n , S.; M itch ell, C. A . EMBO 
J. 1995,14, 4490-4 5 0 0 .
79 ) M cP h erso n , P. S .; G arcia , E . P .; S lepnev , V. I.; D av id , C .; Z hang , X .; G rabs, D .; Sossin , 
W . S .; B au erfe in d , R .; N em oto , Y .; D e C am illi, P. Nature (London) 1996, 379, 353-357 .
80) F o w ler, C . J.; E rik sso n , A. Cell. Signal. 1992, 4, 723 -725 .
81) F o w ler, C. J.; B ran n stro m , G .; A h lg ren , P. C .; F lo rva ll, L .; A k erm an , K. E . O. Biochem. 
J. 1993, 289, 853-859.
82) S afrany , S. T .; M ills , S. J.; L iu , C .; L am pe, D .; N o b le , N . J.; N ah o rsk i, S. R .; P o tte r, B . 
V . L . Biochemistry 1994, 33, 10763-10769.
83) L am pe , D .; L iu , C .; P o tter, B . V . L . J. Med. Chem. 1994, 37, 907 -912 .
84) K o z ik o w sk i, A . P .; O gnyanov , V . I.; C hen , C .; F auq , A . H .; S afrany , S. T .; W ilcox , R. 
A .; N ah o rsk i, S. R . J. Med. Chem. 1993, 36, 3035-3038 .
85) A b d u llah , M .; H u g h es, P. J.; C rax to n , A .; G igg , R .; D esa i, T .; M arecek , J. F .;
P restw ich , G . D .; S hears, S. B . J. Biol. Chem. 1992, 267, 2 2 3 4 0 -2 2 3 4 5 .
86) H an sen , C . A .; V o n  D ahl, S.; H u d d e ll, B .; W illiam so n , J. R . FEBS Lett. 1988, 236, 53- 
56.
87) H u g h es, P. J.; K irk , C. J.; M ich ell, R . H. Biochim. Biophys. Acta 1994 ,1223, 57-70 .
88) S tephens, L . Biochem. Soc. Trans. 1995, 23, 207 -221 .
277
89) V lah o s, C . J.; M atter, W . F .; H ui, K . Y.; B row n, R . F. J. Biol. Chem. 1994, 269, 5241- 
5248.
90) W ard , S. G .; M ills , S. J.; L iu , C .; W estw ick , J.; P o tte r, B . V . L . J. Biol. Chem. 1995, 
270, 12075-12084.
91) Irv ine , R . F .; L etcher, A . J.; L ander, D . J.; B erridge , M . J. Biochem. J. 1986, 240, 301- 
304.
92) P o lo k o ff, M . A .; B en cen , G. H .; V acca, J. P .; D eS o lm s, S. J.; Y o u n g , S. D .; H u ff, J. R . 
J. Biol. Chem. 1988, 263, 11922-11927.
93) S trup ish , J.; C ooke, A. M .; Potter, B . V . L .; G igg , R .; N ah o rsk i, S. R . Biochem. J. 1988, 
253, 901 -905 .
94) Irv ine , R . F .; M oor, R . M .; P ollock , W . K.; S m ith , P. M .; W reg g e tt, K . A. Phil. Trans. 
R. Soc. Lond. Ser. B 1988, 320, 281-298 .
95) O zak i, S .; K ohno , M .; N akah ira , H .; B unya , M .; W atan ab e , Y . Chem. Lett. 1988, 77-80 .
96) B o eh m , M . F .; P restw ich , G. D . Tetrahedron Lett. 1988, 29 , 5217-5 2 2 0 .
97) G ou, D .-M .; C hen , C .-S . Tetrahedron Lett. 1992, 33, 721 -724 .
98) G ou , D .-M .; L iu , Y .-C .; C hen , C .-S . Carbohydr. Res. 1992, 234, 51-64 .
99) P ayne, R. 1992, P erso n a l C om m unica tion .
100) P o tte r, B . V . L .; N ahorsk i, S. R. In  Drug Design for Neuroscience', K o z ik o w sk i, A . P. 
E d .; R av en  P ress: N ew  Y ork , 1993; pp  383-416.
101) N ah o rsk i, S. R .; P o tte r, B . V. L . In  New Leads and Targets in Drug Research', 
K ro g sg aard -L arsen , P ., C hristenesen , S. B ., K ofod , H . E ds.; M u n k sg aard : C o p en h ag en , 
1992; pp  211-223 .
102) M o h r, F . C .; H ershey , P. E . C .; Z im anyi, I.; P essah , I. N . Biochim. Biophys. Acta 1993, 
1147, 105-114.
103) S tep h en s, L . R .; H aw k in s, P. T .; D ow nes, C. P. Biochem. J. 1989, 262, 7 2 7 -7 3 7 .
104) W o n g , N . S .; B ark er, C . J.; M orris, A . J.; C rax to n , A .; K irk , C . J.; M ich e ll, R . H . 
Biochem. J. 1992, 286 ,459-468 .
105) W ilco x , R . A .; N ah o rsk i, S. R .; Saw yer, D . A .; L iu , C .; P o tte r, B . V . L . Carbohydr. 
Res. 1992, 234, 237-246 .
106) L am p e , D .; P o tte r, B . V . L . Tetrahedron Lett. 1993, 34, 2 3 6 5 -2 3 6 8 .
278
107) K o z ik o w sk i, A . P .; O gnyanov , V . I.; F auq , A . H .; N ah o rsk i, S. R .; W ilcox , R . A . J. 
Am. Chem. Soc. 1993,115,4 4 2 9 -4 4 3 4 .
108) S eew ald , M . J.; A ksoy , I. A .; P ow is, G .; F auq , A . H .; K o z ik o w sk i, A . P. J. Chem. Soc. 
Chem. Commun. 1990, 1638-1639.
109) S afran y , S. T .; W o jc ik iew icz , R . J. H .; S trup ish , J.; N ah o rsk i, S. R .; D u b reu il, D .; 
C leo p h ax , J.; G ero , S. D .; Potter, B . V . L. FEBS Lett. 1991, 278, 252 -256 .
110) W ilco x , R . A .; C h alliss , R. A . J.; L iu , C .; P o tte r, B . V . L .; N ah o rsk i, S. R. Mol. 
Pharmacol. 1993, 44, 810-817.
111) W ilco x , R . A .; C halliss , R . A . J.; B audin , G .; V ase lla , A .; P o tte r, B . V . L .; N ah o rsk i, 
S. R . Biochem. J. 1993, 294, 191-194.
112) C u llen , P. J.; Irv ine , R. F .; D aw son , A . P. Biochem. J. 1990, 271, 549 -553 .
113) G aw ler, D . J.; P o tte r, B. V . L .; N ahorsk i, S. R. Biochem. J. 1990, 272 , 519-524 .
114) L o o m is-H u sse lb ee , J. W .; C ullen , P. J.; D re ik h au sen , U . E .; Irv ine , R . F .; D aw so n , A. 
P. Biochem. J. 1996, 314, 811-816.
115) Irv ine , R. F .; C u llen , P. J. Curr. Biol. 1993, 3, 540-543 .
116) L iickhoff, A .; C lapham , D . E. Nature (London) 1992, 355, 356 -358 .
117) Irv ine , R. F .In  Advances in Second Messenger and Phosphoprotein Research', P u tney  
Jr., J. W . E d .; R av en  P ress: N ew  Y ork, 1992; p p  161-186.
118) C u llen , P. J.; H su an , J. J.; T ruong , O .; L etcher, A. J.; Jack so n , T . R .; D aw so n , A . P .; 
Irv ine , R . F. Nature (London) 1995, 376, 527-530 .
119) C u llen , P. J.; D aw so n , A . P .; Irv ine , R. F. Biochem. J. 1995, 305, 139-143.
120) C u llen , P. J.; C hung , S .-K .; C hang , Y .-T .; D aw so n , A . P .; Irv ine , R . F. FEBS Lett. 
1995, 358, 240 -242 .
121) S ch iav o , G .; G m ach l, M . J. S .; S tenbeck , G .; S o llner, T . H .; R o th m an , J. E . Nature 
(London) 1995, 378, 733-736 .
122) B illin g to n , D . C .; B aker, R . J. Chem. Soc. Chem. Commun. 1987, 1011-1013 .
123) M eek , J. L .; D av id so n , F .; H obbs Jr, F. W . J. Am. Chem. Soc. 1988,110, 2317-2 3 1 8 .
124) D eS o lm s, S. J.; V acca , J. P .; H uff, J. R . Tetrahedron Lett. 1987, 2 8 ,4 5 0 3 -4 5 0 6 .
279
125) B illin g to n , D . C .; B aker, R .; K u lagow sk i, J. J.; M aw er, I. M .; V acca , J. P .; D eS o lm s,
S. J.; H u ff, J. R . J. Chem. Soc. Perkin Trans. 1 1989, 1423-1429.
126) D reef, C . E .; T u in m an , R. J.; E lie , C . J. J.; van  d er M are l, G . A .; van  B o o m , J. H . Reel. 
Trav. Chim. Pays-Bas 1988,107, 395-397.
127) F a lck , J. R .; A bda li, A. Bioorg. Med. Chem. Lett. 1993, 3, 717 -720 .
128) W a tan ab e , Y .; F u jim o to , T .; S h inohara , T .; O zak i, S. J. Chem. Soc. Chem. Commun. 
1991, 428-4 2 9 .
129) B au d in , G .; G lanzer, B . I.; S w am inathan , K. S.; V ase lla , A . Helv. Chim. Acta 1988,
77, 1367-1378.
130) L ee , H . W .; K ish i, Y. J. Org. Chem. 1985, 50, 4402-4 4 0 4 .
131) B illin g to n , D . C . The inositol phosphates: chemical synthesis and biological 
significance’, V C H : W ein h e im , 1993;
132) T eg g e , W .; D en is , G . V .; B allou , C. E. Carbohydr. Res. 1991, 277 , 107-116.
133) Z h en g , J.; C ah ill, S. M .; L em m on , M . A .; F u shm an , D .; S ch lessin g er, J.; C o w b u m , D . 
J. Mol. Biol. 1996, 255, 14-21.
134) S haw , G. Bioessays 1996,18, 35-46.
135) H arlan , J. E .; H a jduk , P. J.; Y oon, H . S.; F esik , S. W . Nature (London) 1994, 371, 
168-170.
136) L em m o n , M . A .; F erguson , K. M .; O 'B rien , R .; S ig ler, P. B .; S ch lessin g er, J. Proc. 
Natl. Acad. Sci. USA 1995, 92, 10472-10476.
137) H y v o n en , M .; M ac ias, M . J.; N ilges, M .; O schk ina t, H .; S araste , M .; W ilm an n s , M . 
EMBO J. 1995,14, 4676 -4 6 8 5 .
138) C ifu en tes , M . E .; D e lan ey , T .; R ebecch i, M . J. J. Biol. Chem. 1994, 269, 1945-1948.
139) F erg u so n , K. M .; L em m o n , M . A .; S ch lessinger, J.; S ig ler, P . B . Cell 1995, 83, 1037- 
1046.
140) L ip k o w itz , K. B .; P eterson , M . A. J. Comp. Chem. 1993,14, 121-125.
141) E ssen , L .-O .; P erisic , O .; C heung , R .; K atan , M .; W illiam s, R . L . Nature (London) 
1996, 380, 595-602 .
142) P o iro t, E .; B o u rd o n , H .; C hretien , F .; C hap leur, Y .; B erth o n , B .; H illy , M .; M au g er, J.- 
P .; G u illo n , G . Bioorg. Med. Chem. Lett. 1995, 5, 569-572 .
280
143) D esa i, T .; G igg , J.; G igg , R .; Payne, S. Carbohydr. Res. 1992, 225 , 209-228 .
144) G igg , J.; G igg , R .; P ayne, S.; C onan t, R. Carbohydr. Res. 1985,142, 132-134.
145) G igg , J.; G igg , R .; P ayne, S.; C onant, R. J. Chem. Soc. Perkin Trans. 1 1987, 4 23-429 .
146) N ash ed , M . A .; A nderson , L. Tetrahedron Lett. 1976, 3 503-3506 .
147) N ag ash im a , N .; O hno, M . Chem. Lett. 1987,1987, 141-144.
148) V acca , J. P .; D eS o lm s, S. J.; H uff, J. R .; B illing ton , D . C .; B aker, R .; K u lag o w sk i, J. 
J.; M aw er, I. M . Tetrahedron 1989, 45, 5679-5702 .
149) G igg , J.; G igg , R .; P ayne, S.; C onan t, R . J. Chem. Soc. Perkin Trans. 1 1987, 2411 - 
2414.
150) F a ttah , J.; T w y m an , J. M .; D obson , C. M . Magn. Reson. Chem. 1992, 30, 606-615 .
151) S te iner, T .; H inrichs, W .; S aenger, W .; G igg , R. Acta Cryst. 1993, B49, 708 -718 .
152) B riggs, A . P. J. Biol. Chem. 1922, 53, 13-16.
153) F ein , A .; P ayne , R .; C orson , D . W .; B erridge , M . J.; Irv ine , R . F. Nature (London) 
1984,311, 157-160.
154) B row n , J. E .; R ub in , L. J.; G halay in i, A . J.; T arver, A . L .; Irv ine , R . F .; B errid g e , M .
J.; A n d erso n , R . E . Nature (London) 1984, 311, 160-162.
155) P ayne , R .; C orson , D . W .; Fein , A .; B erridge , M . J. J. Gen. Physiol. 1986, 8 8 , 127- 
142.
156) P ayne , R .; P o tte r, B . V. L . J. Gen. Physiol. 1991, 97, 1165-1186.
157) H u g h es, P. J.; Shears, S. B . J. Biol. Chem. 1990, 265, 9 869-9875 .
158) S hears, S. B . In Advances in Second Messenger and Phosphoprotein Research', P u tney  
Jr., J. W . E d .; R av en  P ress: N ew  Y ork , 1992; pp  63-92 .
159) H ira ta , M .; W atan ab e , Y .; Y osh ida, M .; K oga, T .; O zak i, S. J. Biol. Chem. 1993, 268,
19260-19266 .
160) B illin g to n , D . C . Chem. Soc. Rev. 1989,18, 83-122 .
161) P o tte r, B . V . L. Nat. Prod. Reps. 1990, 7, 1-24.
162) D esa i, T .; G igg , J.; G igg, R .; P ayne, S.; P enades, S. Carbohydr. Res. 1992, 234, 1-21.
163) S hvets , V . I.; K lyashch itsk ii, B. A .; S tepanov , A . E .; E v stig n eev a , R . P. Tetrahedron 
1973, 29, 331-340 .
164) B aker, G . R .; B illing ton , D. C .; G ani, D . Tetrahedron 1991, 47, 3895-3 9 0 8 .
165) B illin g to n , D . C .; B ak er, R .; K ulagow ski, J. J.; M aw er, I. M . J. Chem. Soc. Chem. 
Commun. 1987, 314-316 .
166) G arig ap ati, V . R .; R oberts , M . F. Tetrahedron Lett. 1993, 34, 769 -772 .
167) A neja , R .; A neja , S .; Pathak , V. P.; Ivanova, P. T . Tetrahedron Lett. 1994, 35, 60 6 1 - 
6062.
168) L in d o n , J. C .; B aker, D. J.; W illiam s, J. M .; Irv ine , R. F . Biochem. J. 1987, 244, 591 - 
595.
169) O zak i, S .; K ondo , Y .; S h io tan i, N .; O gasaw ara , T .; W atan ab e , Y. J. Chem. Soc.Perkin 
Trans. 1 1992, 729-737 .
170) W o jc ik iew icz , R. J. H. J. Biol. Chem. 1995, 270, 11678-11683.
171) O 'R o u rk e , F .; M atthew s, E .; Feinstein , M . B . Biochem. J. 1995, 312, 4 9 9 -5 0 3 .
172) P arys, J. B .; D e S m edt, H .; M issiaen , L .; B o o tm an , M . D .; S ienaert, I.; C as tee ls , R. 
Cell Calcium 1995,17, 239-249 .
173) N u n n , D . L .; T ay lo r, C. W . Biochem. J. 1990, 270, 227 -232 .
174) K alinosk i, D . L .; A ld inger, S. B .; B oyle, A . G .; H uque, T .; M arecek , J. F .; P re s tw ich , 
G . D .; R estrep o , D . Biochem. J. 1992, 281, 449 -456 .
175) W o rley , P. F .; B araban , J. M .; S upattapone, S .; W ilso n , V . S .; S nyder, S. H . J. Biol. 
Chem. 1987, 262, 12132-12136.
176) L u b ell, A .; G onzalez , R .; R ana, R. S. FASEB J. 1995, 9, A 1308
177) de B o n t, H . B . A .; van  B oom , J. H .; L iskam p , R . M . J. Reel. Trav. Chim. Pays-Bas 
1990,109, 27-28 .
178) Ito , H .; M o to k i, Y .; T aguch i, T .; H anzaw a, Y. J. Am. Chem. Soc. 1993,115, 8 835- 
8836.
179) R iley , A . M .; Jenk ins, D . J.; P o tter, B . V . L . J. Am. Chem. Soc. 1995,117, 3 3 0 0 -3 3 0 1 .
180) H ira ta , M .; Y anaga, F .; K oga, T .; O gasaw ara , T .; W a tan ab e , Y .; O zak i, S. J. Biol. 
Chem. 1990, 265, 8404-8407 .
282
181) H am b lin , M . R .; P o tter, B . V . L .; G igg , R . J. Chem. Soc. Chem. Commun. 1987, 626- 
627.
182) C ooke, A . M .; P o tte r, B . V. L .; G igg , R. Tetrahedron Lett. 1987, 25 , 2305-2308 .
183) W ilco x , R. A .; C halliss, R . A . J.; T raynor, J. R .; F auq , A . H .; O g nyanov , V . I.; 
K o z ik o w sk i, A . P .; N ahorsk i, S. R . J. Biol. Chem. 1994, 269, 26815 -2 6 8 2 1 .
184) F errie r, R . J.; S tuz , A . E . Carbohydr. Res. 1990, 205, 283-291 .
185) C h en ed e , A .; P o th ie r, P .; S o llogoub , M .; F a irb an k s, A . J.; S inay , P. J. Chem. Soc. 
Chem. Commun. 1995, 1373-1374.
186) W illco ck s, A . L .; S trup ish , J.; Irv ine , R. F .; N ah o rsk i, S. R . Biochem. J. 1989, 257, 
297-300 .
187) N o b le , N . J.; D u b reu il, D .; P o tte r, B . V . L. Bioorg. Med. Chem. Lett. 1992, 2, 4 7 1 - 
476.
188) L iu , C .; P o tte r, B . V. L. Tetrahedron Lett. 1994, 35, 8457-8460 .
189) S chm itt, L .; B ortm an n , P.; S ch lew er, G .; S p iess, B . J. Chem. Soc. Perkin Trans. 1 
1993, 2 257-2263 .
190) P ine , S. H .; Shen , G . S.; H oang , H. Synthesis 1991, 165-167.
191) K u lag o w sk i, J. J. Tetrahedron Lett. 1989, 30, 3869-3872 .
192) A k iyam a, T .; S h im a, H .; O hnari, M .; O kazak i, T .; O zak i, S. Bull. Chem. Soc. Jpn. 
1993, 6 6 , 3760-3767 .
193) V edejs , E .; M eier, G . P .; S noble , K . A . J. / .  Am. Chem. Soc. 1981,103, 2 8 23-2831 .
194) S h ing , T . K . M .; T ai, V . W .-F .; T am , E. K . W . Angew. Chem. Int. Ed. Engl. 1994, 33, 
2 3 12-2313 .
195) S uam i, T . Adv. Carbohydr. Chem. Biochem. 1990, 48, 21 -90 .
196) Isoga i, A .; S akuda, S.; N akayam a, J.; W atan ab e , S .; S u zu k i, A . Agric. Biol. Chem. 
1987, 51, 2 2 77-2279 .
197) H o rto n , D .; W eck erle , W . Carbohydr. Res. 1975, 44, 227 -240 .
198) C ooper, D . B .; Inch , T. D .; L ew is, G . J. J. Chem. Soc. Perkin Trans. 1 1974, 1043- 
1048.
283
199) G o ren s te in , D . G .; R ow ell, R. J. Am. Chem. Soc. 1979,101, 4 9 25-4928 .
200) G o ren ste in , D . G .; R ow ell, R .; F ind lay , J. J. Am. Chem. Soc. 1980,102, 5 0 77-5081 .
201) S ch u ltz , C .; M etsch ies , T.; G erlach , B .; S tad ler, C .; Jas to rff, B . Synlett 1990, 163-165.
202) D reef, C . E .; E lie , C. J. J.; H oogerhou t, P .; van  d er M arel, G . A .; van  B o o m , J. H . 
Tetrahedron Lett. 1988, 29, 6513-6516 .
203) Y u, K .-L .; F raser-R eid , B. Tetrahedron Lett. 1988, 29 , 979-982 .
204) T aira , K .; K ofen , L .; G orenste in , D . G . Tetrahedron 1986, 42, 229 -238 .
205) L an k h o rs t, P. P.; C .H aasnoo t, A . G .; E rke lens, C .; A ltona, C, J. Biomol. Struct. Dyn. 
1984, 7, 1387
206) N ob le , N . J.; C ooke, A. M .; P o tter, B . V. L. Carbohydr. Res. 1992, 234, 177-187.
207) Y eag le , P. L .; H utton , W . C .; M artin , R. B . J. Am. Chem. Soc. 1975, 97, 71 7 5 -7 1 7 7 .
208) S chm itt, L .; S ch lew er, G .; S piess, B . Biochim. Biophys. Acta 1991, 1075, 139-140.
209) S chm itt, L .; B ortm ann , P.; S p iess, B .; S ch lew er, G . Phosphorus,Sulfur,and Silicon 
1993, 76, 147-150.
210) L in d o n , J. C .; B aker, D . J.; F arran t, R . D .; W illiam s, J. M . Biochem. J. 1986, 233, 
275-277 .
211) T ak ah ash i, M .; K agasak i, T .; H osoya, T .; T ak ah ash i, S. / .  Antibiot. 1993, 46, 1643- 
1647.
212) T ak ah ash i, S.; K inosh ita , T .; T akahash i, M . J. Antibiot. 1994, 47, 95 -100 .
213) W ilco x , R . A .; S afrany , S. T .; L am pe , D .; M ills , S. J.; N ah o rsk i, S. R .; P o tte r, B . V . L. 
Eur. J. Biochem. 1994, 223, 115-124.
214) O zak i, S .; W atanabe , Y. In  Inositol Phosphates and Derivatives - Synthesis, 
Biochemistry, and Therapeutic Potential', R eitz , A . B . E d .; A m erican  C h em ica l S ocie ty : 
W ash in g to n , D C , 1991; p p  43-65.
215) L u , P .-J.; G ou, D .-M .; Shieh , W .-R .; C hen , C .-S . Biochemistry 1994, 33, 11586- 
11597.
216) B aker, R .; C arrick , C .; L eeson , P. D .; L en n o n , I. C .; L iv erto n , N . J. J. Chem. Soc. 
Chem. Commun. 1991, 298-300.
217) C o le , A . G .; G ani, D . J. Chem. Soc. Chem. Commun. 1994, 1139-1141.
284
218) L iu , C .; T hom as, N . F.; P o tte r, B . V. L. J. Chem. Soc. Chem. Commun. 1993, 1687- 
1689.
219) F au q , A . H .; K oz ikow sk i, A . P .; O gnyanov , V . I.; W ilco x , R . A .; N ah o rsk i, S. R . J. 
Chem. Soc. Chem. Commun. 1994, 1301-1302.
220) C lasso n , B .; G aregg , P. J.; H elland , A .-C . J. Carbohydr. Chem. 1989, 8, 543 -551 .
221) G areg g , P. J.; H u ltberg , H .; W allin , S. Carbohydr. Res. 1982,108, 97 -101 .
222) L u b in eau , A .; L em oine, R. Tetrahedron Lett. 1994, 35, 8795-8796 .
223) D eN in n o , M . P.; E tienne, J. B .; D up lan tier, K . C. Tetrahedron Lett. 1995, 36, 669- 
672.
2 24) Ito , Y .; N u n o m u ra , S.; S h ibayam a, S.; O gaw a, T. J. Org. Chem. 1992, 57 , 1821-1831.
225) T ak an o , S., A k iyam a, M ., Sato , S., and  O gasaw ara, K. Chem.Lett. 1983, 1593-1596.
226) P o itras , M .; B ern ier, S.; B oulay , G .; F ourn ier, A .; G u illem ette , G . Eur. J. Pharmacol. 
1993, 244, 203-210.
227) O gaw a, S.; Iw asaw a, Y .; Suam i, T. Chem. Lett. 1984, 355-356 .
228) C zo lln er, L .; B aud in , G .; B em et, B .; V asella , A . Helv. Chim. Acta 1993, 76, 1013- 
1025.
229) M u lle r, J.; B o ile r, T .; W iem k en , A . Plant Science 1995,112, 1-9.
230) B esra , G . S .; B o lto n , R. C .; M cN eil, M . R .; R idell, M .; S im pson , K . E .; G lu sh k a , J.; 
van H a lb eek , H .; B ren n an , P. J.; M inn ik in , D . E. Biochemistry 1992, 31, 9 8 3 2 -9 8 3 7 .
231) W a llace , P. A .; M in n ik in , D . E. Carbohydr. Res. 1994, 263, 43 -59 .
232) W allace , P. A .; M inn ik in , D . E .; R idell, M . J. Chem. Soc. Chem. Commun. 1994, 329- 
330.
233) W esse l, H . P .; T schopp , T . B .; H osang , M .; Iberg , N . Bioorg. Med. Chem. Lett. 1994, 
4, 1419-1422.
2 34) B lazq u ez , M . A .; L agunas, R .; G ancedo , C .; G ancedo , J. M . FEBS Lett. 1993, 329, 51- 
54.
2 35) R o n n o w , T. E . C . L .; M eldal, M .; B ock , K . Carbohydr. Res. 1994, 260, 323 -328 .
2 36) T are lli, E .; W h eeler, S. F . Carbohydr. Res. 1994, 261, 25-36 .
285
237) D u d a , C . S.; S tevens, E . S. J. Am. Chem. Soc. 1993,115, 8487-8488 .
238) D o w d , M . K .; R eilly , P. J.; F rench , A . D . J. Comp. Chem. 1992,13, 102-114.
239) W ei, A .; K ish i, Y. J. Org. Chem. 1994, 59, 88-96.
240) C ano , F. H .; de P az, J. L. G .; F oces-F oces, C .; J im en ez -B arb ero , J.; M artin -L o m as,
M .; P en ad es, S .; V icen t, C. Tetrahedron 1993, 49, 2109-2114 .
241) Jen k in s , D . J.; P o tte r, B . V. L . J. Chem. Soc. Chem. Commun. 1995, 1169-1170.
242) W ilco x , R. A .; E m eu x , C .; P rim rose, W . U .; G igg , R .; N ah o rsk i, S. R . Mol. 
Pharmacol. 1995, 47, 1204-1211.
243) M o itessie r, N .; C hristian , A . L .; C hap leur, Y .; H um eau , C . Tetrahedron Lett. 1995, 36, 
8023-8026 .
244) B aer, H . H .; R ad atu s, B. Carbohydr. Res. 1984,128, 165-174.
245) V icen t, C .; M artin -L om as, M .; P enades, S. Carbohydr. Res. 1989,194, 308 -314 .
246) D esa i, T .; G igg , J.; G igg , R . Carbohydr. Res. 1996, 280, 209 -221 .
247) R estrep o , D .; T ee ter, J. H .; H onda, E .; B oyle , A . G .; M arecek , J. F .; P res tw ich , G . D .; 
K a lin o sk i, D . L. Am. J. Physiol. 1992, 263, C 667-C 673 .
248) R iley , A . M .; M ills, S. J.; P o tter, B . V . L. Phosphorus,Sulfur,and Silicon 1996, 111,
71.
249) P itte t, D .; S ch legel, W .; L ew , D . P .; M onod , A .; M ayr, G . W . J. Biol. Chem. 1989,
264, 18489-18493 .
2 50) M ills , S. J.; S afrany , S. T .; W ilcox , R. A .; N ahorsk i, S. R .; P o tte r, B . V . L . Bioorg. 
Med. Chem. Lett. 1993, 3, 1505-1510.
251) H ira ta , M .; N aru m o to , N .; W atanabe, Y .; K anem atsu , T .; K oga, T .; O zak i, S. Mol. 
Pharmacol. 1994, 45, 271-276 .
252) K o z ik o w sk i, A . P .; F auq , A . H .; W ilcox , R. A .; N ah o rsk i, S. R . Bioorg. Med. Chem. 
Lett. 1995, 5, 1295-1300.
253) T an ak a , T .; T am atsu k u ri, S.; Ikehara , M . Tetrahedron Lett. 1986, 27 , 199-202 .
254) B an n w arth , W .; T rzec iak , A . Helv. Chim. Acta 1987, 70, 175-186.
286
255) M u rp h y , C . T .; B u llock , A . J.; L ind ley , C. J.; M ills, S. J.; R iley , A . M .; P o tte r, B . V.
L .; W estw ick , J. Mol. Pharmacol. 1996, in  press.
256) R iley , A . M .; P ayne, R .; P otter, B . V. L. J. Med. Chem. 1994, 37, 3 9 1 8 -3 9 2 7 .
257) G use, A . H .; G o ldw ich , A .; W eber, K .; M ayr, G . W . J. Chromatogr. B 1995, 672, 189- 
198.
258) D reef, C. E .; van  d er M arel, G. A .; van B oom , J. H . Reel. Trav. Chim. Pays-Bas 1987, 
106, 161-162.
2 59) G igg , J.; G igg , R .; P ayne, S.; C onan t, R. J. Chem. Soc. Perkin Trans. 1 1987, 1757- 
1762.
2 60) H an essian , S .; P lessas, N . R. J. Org. Chem. 1969, 34, 1035-1044.
2 61) H ou g h , L .; M unroe , P. A .; R ichardson , A . C. J. Chem. Soc. (C) 1971, 1090-1094 .
262) IU P A C -IU B  Pure Appl. Chem. 1974, 37, 285-297.
263) N C -IU B  Biochem. J. 1989, 258, 1-2.
287
